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ABSTRACT 
There is a high prevalence of co-morbid anxiety disorders in patients with 
chronic obstructive pulmonary disease (COPD). Although co-morbid anxiety 
impacts negatively upon health-related quality of life, physical functioning and 
healthcare utilisation, anxiety disorders remain significantly under recognised 
and undermanaged. One reason for this may be the lack of a validated disease-
specific patient-reported screening tool and outcome measure. Existing scales 
may be limited by their inclusion of somatic items, which may overlap with 
symptoms of COPD or the side-effects of medications.  
This thesis aimed to develop a novel non-somatic self-report anxiety scale that 
can be used to screen for anxiety disorders and assess the severity of anxiety in 
patients with COPD. The Anxiety Inventory for Respiratory disease (AIR) was 
developed using a mixed methods approach to item development that 
incorporated both emic (interviews with 14 COPD patients) and etic (review of 
extant anxiety scales) perspectives to generate 16 novel items scored using a 
Likert-type response set. Patients and clinicians were involved in the 
development of the AIR to ensure that the scale is user-friendly and clinically 
relevant. Qualitative findings from the interviews also provide a unique insight 
into the experience of anxiety from the patients’ perspective and support the 
non-somatic format of the AIR. 
The draft 16-item AIR was completed by 88 patients with COPD and refined 
through rigorous item and factor analysis. Six items were removed to create the 
final 10-item AIR (score range 0-30). The reliability and validity of the AIR were 
examined in a sample of 56 COPD outpatients. The AIR proved to have excellent 
internal consistency in all phases (Cronbach’s α = 0.92-0.95) and test-retest 
reliability (Intraclass correlation coefficient = 0.81). The AIR also demonstrated 
high convergent validity with the Hospital Anxiety and Depression Scale 
(Spearman’s rho correlation = 0.91) and was able to discriminate between 
patients with and without anxiety disorders (p<0.001). Confirmatory factor 
analysis found that a two-factor model containing two intercorrelated factors 
(general anxiety and panic) provided the best fit. The AIR was able to accurately 
screen for anxiety disorders. The area under the curve (AUC) for the AIR based 
on the Patient Health Questionnaire anxiety screener was 0.96. A cut-off score 
of 15 produced a sensitivity of 0.93 and a specificity of 0.98.  
Although further research is required to validate the AIR in larger clinical 
populations, the findings presented in this thesis support the use of the scale as 
a reliable and valid marker of anxiety in patients with COPD. The AIR is also a 
promising screening tool for anxiety disorders, particularly panic disorder and 
generalised anxiety disorder in patients with COPD. 
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Chapter 1 : INTRODUCTION TO STUDY 
 
“A crust eaten in peace is better than a banquet partaken in anxiety.” 
Aesop 
 
1.1 BACKGROUND TO THE STUDY 
 
Chronic obstructive pulmonary disease (COPD) is a preventable, progressive 
condition that is characterised by a decline in lung function. The National 
Institute of Clinical Excellence (NICE, 2010: 5) defines COPD as:  
 
“… characterised by airflow obstruction. The airflow obstruction is usually 
progressive, not fully reversible and does not change markedly over several 
months.”  
 
Chronic airflow obstruction in COPD is caused by both obstruction and 
destruction of alveoli and the small airways. This results in a mixture of chronic 
bronchitis and emphysema, the relative contributions of which vary between 
individuals (Rabe, 2007). Alongside the changes in lung function, patients with 
COPD exhibit a number of common symptoms including exertional 
breathlessness, chronic cough, regular sputum production, and a chronic 
wheeze (Global Initiative for Chronic Lung Disease; GOLD, 2011). 
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The classification and diagnosis of COPD is usually undertaken with spirometry, 
which provides a simple descriptor of pathological changes. Post-
bronchodilator measures of forced expiratory volume in one second (FEV1) and 
forced vital capacity (FVC) enable the classification of COPD into categories e.g., 
mild, moderate, severe and very severe (see Table 1.1). Despite slight variations 
in wording, the British, American and European respiratory bodies define mild 
COPD as the ratio of FEV1 to FVC being < 0.7 and the FEV1 being ≥80% of the 
predicted value (Celli & MacNee, 2004; GOLD, 2011; NICE, 2010). 
 
Table 1.1: Classification of COPD according to ATS/ERS, GOLD and NICE 
guidelines 
 
  ATS/ERS (Celli & 
MacNee, 2004) 
GOLD (2011) NICE (2010) 
Post bronchodilator 
FEV1/FVC 
FEV1% 
Predicted 
 
Severity of airflow obstruction 
<0.7 ≥80% Mild  Grade 1- Mild Grade 1- Mild 
<0.7 50-79% Moderate Grade 2- 
Moderate 
Grade 2- 
Moderate 
<0.7 30-49% Severe Grade 3- 
Severe 
Grade 3- 
Severe 
<0.7 <30% Very severe Grade 4- Very 
severe 
Grade 4- Very 
severe 
ATS, American Thoracic Society; ERS, European Respiratory Society; GOLD, Global Initiative for 
Chronic Lung Disease; NICE, National Institute for Clinical Excellence; FEV1, Forced expiratory 
volume in one second; FVC, Forced vital capacity 
 
It is generally assumed that there is a significant under-diagnosis of COPD 
worldwide and, as a result, many individuals live with undetected lung disease. 
One reason for this is that the disease is not usually recognised until it is 
clinically apparent and moderately advanced (Pauwels & Rabe, 2004). In 
England and Wales some 900,000 people have diagnosed COPD, but it is 
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estimated that the true figure might be 1.5-3 million, allowing for under-
diagnosis (Devereux, 2006; Healthcare Commission, 2006). It is estimated that 
24 million Americans may have impaired lung function, whilst less than half of 
this number (10 million) report a physician diagnosis of COPD (Mannino et al., 
2002). 
 
The prevalence of COPD varies between 2% and 10% globally (Pauwels & Rabe, 
2004). A large population-based study from Spain found that COPD was present 
in 9.1% of a sample of over 4000 men and women aged 40-69 years. Of those 
identified with COPD, 78% had not been previously diagnosed and only 49% of 
patients with severe COPD, 12% of patients with moderate COPD, and 10% of 
patients with mild COPD were receiving treatment (Peña et al., 2000). The 
prevalence of COPD also appears to increase with age. A study from the USA 
found that the prevalence of moderate COPD increased from 7.2% in people 
aged 45-54 years to 22.9% in those aged 75 years and older (Mannino et al., 
2002). 
 
Traditionally, COPD has been more common in men than in women. Data from 
Spain suggest that the prevalence of COPD was 14.3% in men compared to 3.9% 
in women (Peña et al., 2000). Despite this, the prevalence of COPD in women 
has been gradually increasing during the past few decades (0.8% in 1990) and 
is continuing to rise. In contrast, the incidence of COPD in men is thought to 
have plateaued (Devereux, 2006). The World Health Organisation (WHO) have 
proposed that increased tobacco use by women in high-income countries, 
alongside the increased exposure to indoor air pollution (such as fuel for 
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cooking and heating) in low-income countries, has resulted in COPD affecting 
men and women almost equally (WHO, 2011). Data from the USA demonstrated 
that in 2000, the number of women dying from COPD surpassed the number of 
men dying for the first time (Mannino et al., 2002). Recent evidence indicates 
that COPD may now be more common in women than in men (National Health 
Interview Survey, 2007). 
 
COPD is a major cause of mortality worldwide. The 2002 World Health Report 
identifies COPD as the fifth leading cause of death in the world, killing over 2.6 
million people in 2001 (WHO, 2002). This figure is predicted to rise with some 
experts forecasting that COPD will be the third leading cause of death 
worldwide by 2020 (Murray & Lopez, 1997). In the USA, the number of women 
who died from COPD increased by 182% between 1980 and 2000 whilst in men 
this figure rose by just 13% (Mannino et al., 2002). 
 
The increase of mortality in COPD contrasts with that of other chronic diseases 
including cardiovascular diseases and stroke. For example, in the USA the death 
rate of COPD increased by 102.8% between 1970 and 2002, whilst coronary 
heart disease and stroke reduced by 52.1% and 63.1% respectively (Jemal et al., 
2005). In the UK, 27,700 people died of COPD in 2004, a figure higher than that 
of all types of cancer (except respiratory cancers), and third only to ischaemic 
heart disease and cerebrovascular disease (WHO, 2009).  
 
There is a significant morbidity associated with COPD. In particular, COPD has a 
major burden in terms of disability and ill health. The burden of COPD on the 
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population is often measured in terms of a disability-adjusted life year (DALY). 
This represents the number of years lost due to ill health, levels of disability and 
early death. Worldwide, COPD is expected to rise from the 12th leading cause of 
DALYs in 1990 to become the fifth leading cause of DALYs by 2020 (Lopez & 
Murray, 1998). Additionally, although only a small proportion of patients with 
COPD are admitted to hospital each year, one in every eight emergency hospital 
admissions in the UK is for COPD. This makes COPD the second largest cause of 
emergency hospital admissions and one of the most costly conditions treated by 
the National Health Service (NHS) in the UK (British Lung Foundation, 2007). 
 
COPD seldom occurs in isolation and often co-exists with other chronic diseases 
(Fabbri et al., 2008). Co-morbidities in COPD may be due to systemic 
inflammation, shared risk factors, or the sequelea of COPD e.g., reduced physical 
activity (Fabbri et al., 2008; GOLD, 2011). Perhaps unsurprisingly for a chronic 
smoking-related disease, COPD commonly co-occurs with a number of other 
diseases that share tobacco smoke as a risk factor. There is growing evidence 
that the systemic inflammation caused by cigarette smoking may also cause 
some of the most common co-morbidities in patients with COPD, including 
cardiovascular, liver, pancreatic, muscle and bone disease (Fabbri et al., 2008). 
Data from the recent National COPD Audit indicate that 77% of inpatients 
admitted for COPD had one or more medical conditions in addition to their 
COPD (Royal College of Physicians, British Thoracic Society & British Lung 
Foundation, 2008). 
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Psychiatric disorders are amongst the most common and disabling co-
morbidities among patients with COPD. Recent data suggest that almost half of 
all patients with COPD (49%) might have a co-morbid psychiatric disorder 
(Laurin et al., 2007). The most common psychiatric co-morbidities are mood 
disorders (including depression) and anxiety (including panic), which affect 
about 17% and 46% of patients respectively. In addition, a quarter of patients 
with COPD may have two or more psychiatric disorders, with 14% having both 
a mood and anxiety disorder (Laurin et al., 2007).  
 
Anxiety may be defined as an apprehensive anticipation of danger or stressful 
situations associated with excessive feelings of dysphoria or somatic symptoms 
of tension. Symptoms of anxiety include feelings of restlessness, difficulty 
concentrating, muscle tension, fatigue, irritability and sleep disturbance. Panic 
is characterised by a sudden onset of physical symptoms including 
breathlessness, chest pains and trembling sensations, alongside psychological 
symptoms that include intense fear, fear of dying and detachment (American 
Psychiatric Association, APA, 2000; Speilberger et al., 1983). 
 
Although anxiety and depression frequently co-occur and overlap in their 
symptomology, they may be considered as specific psychiatric conditions, 
particularly under a nosological medical classification system such as DSM-IV-
TR (APA, 2000). Anxiety can generally be distinguished from depressive states 
as it is characterised by vasomotor responsiveness, as well as panic attacks, 
derealisation and perceptual dysfunctions. Depression, however, is 
characterised by a general negative affect associated with a loss of interest and 
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pleasure, hopelessness, emotional withdrawal and excessive fatigue (Gelenberg, 
2000). A major difference between anxiety and depression is that the emotional 
pattern of anxiety is future oriented and predictive of threat, whilst depressive 
responses are tied to imminent or past events which have a direct bearing on 
self-esteem (Dobson, 1985). 
 
Two of the most prevalent and recognisable anxiety disorders in patients with 
COPD are generalised anxiety disorder (GAD) and panic disorder (PD) with or 
without agoraphobia, which affect up to 33% and 41% of patients respectively 
(Dowson et al., 2004). In contrast, the prevalence of GAD among community-
based older adults is between 1-7%, whilst the prevalence of PD (with or 
without agoraphobia) is between 0.1 and 2% (Kirmizioglu et al., 2009; 
Wolitzky-Taylor et al., 2010). Estimates of anxiety prevalence based on 
threshold scores on self-report anxiety scales suggest that clinically significant 
symptoms of anxiety may be present in up to 74% of patients with COPD 
(Yohannes et al., 2010). 
 
Despite the high prevalence of anxiety disorders in patients with COPD, there 
has been surprisingly little focus upon anxiety within the literature. This is also 
the case among the general elderly population, where anxiety remains less well 
studied than other psychiatric disorders such as depression (Pachana et al., 
2007). Findings from a recent study by Kunik and colleagues (2005) indicate 
that anxiety is less recognised than depression in patients with COPD. Kunik et 
al. (2005) found that 43% of patients with a depressive disorder had been 
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previously diagnosed, compared to only 29% of patients with an anxiety 
disorder. 
 
There is growing evidence to suggest that co-morbid anxiety in patients with 
COPD impacts negatively on a number of key measurable outcomes including 
functional status, health related quality of life (HRQoL) and healthcare 
utilization (e.g., Felker et al., 2010; Gudmundsson, 2006; Kim et al., 2000). 
Anxiety may also be a major predictive factor for increased hospital admissions 
for acute exacerbation of COPD (AECOPD) in the elderly (Yohannes et al., 
2000a). Anxiety also has a significant emotional impact in patients with COPD. 
Qualitative accounts from patients with COPD indicate that co-morbid anxiety is 
associated with intense fear, inextricable breathlessness and near-death 
experiences (Bailey, 2001; Bailey 2004; Barnett, 2005). However, remarkably 
little is known about how patients with COPD experience anxiety, particularly 
which symptoms are most common and how these interact with respiratory 
disease.  
 
The “gold standard” diagnosis of anxiety is through psychiatric interview with a 
qualified practitioner, yet this is often impractical due to the time-consuming 
nature of the interview. Therefore, routine screening for anxiety is typically 
undertaken using specifically designed scales, which can identify patients who 
may have clinically significant symptoms of anxiety requiring further 
investigation. Current clinical guidelines for COPD, such as those from the 
American College of Chest Physicians (ACCP; Maurer et al., 2008) and Global 
Initiative for chronic Obstructive Lung Disease (GOLD, 2011) advocate routine 
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screening for anxiety. Yet, although there are a number of anxiety screening 
scales in existence, co-morbid anxiety remains poorly recognised and 
undermanaged (GOLD, 2011; Kunik et al., 2005; NCCCC, 2010; Roundy et al., 
2005). For example, Kunik and colleagues found that among 204 patients with 
COPD and clinically significant anxiety or depression, only 31% were receiving 
treatment. Furthermore, only 46% of patients with severe anxiety or 
depression were receiving treatment (Kunik et al., 2005). In another chart 
review of 102 patients with COPD, only 47% of patients with a clinical anxiety 
disorder were identified and followed by primary care providers or mental 
health providers (Roundy et al., 2005). 
 
Researchers and clinicians who recognise the need to identify patients with 
clinically significant anxiety and/or to measure anxiety levels to monitor 
interventions, have called for a reliable and easily administered screening and 
measurement tool (Cheung et al., 2012, Kunik et al., 2005). However, as Jain and 
Lolak asserted in 2009, the most appropriate “gold standard” anxiety screening 
instrument for patients with COPD was yet to be identified. The majority of 
anxiety screening instruments that are used in clinical practice and within 
research settings have been developed in and for young healthy populations. 
Few scales have been specifically developed for use in elderly populations and 
none have been developed specially for patients with COPD where there is a 
lack of standardisation of appropriate markers (Gudmundsson et al., 2005). 
Clinical guidelines recommend scales such as the Hospital Anxiety and 
Depression Scale-Anxiety (HADS-A; Zigmond & Snaith, 1983), Beck Anxiety 
Inventory (BAI; Beck et al., 1988) and Depression Anxiety Stress Scales (DASS; 
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Lovibond & Lovibond, 1995) for measuring and screening anxiety in patients 
with COPD. However, these scales, although popular within COPD-related 
research and clinical practice, have a number of documented shortcomings that 
may make them unsuitable for use in patients with chronic somatic disease, 
particularly COPD. 
 
Perhaps the most important and widely recognised limitation of these scales is 
their inclusion of somatic items. The NCCC (2011), among others (e.g., Jain & 
Lolak, 2009), recognise that there is a significant potential overlap between 
symptoms of COPD and the somatic symptoms of anxiety (e.g., breathlessness, 
heart palpitations). However, recommended extant scales include a number of 
somatic items. For example, the BAI contains a total of 21 items, of which 14 
reflect the somatic symptoms of anxiety. Although somatic symptoms are a key 
component in the diagnosis of anxiety, their inclusion in anxiety scales leads to 
the possibility of false positives when used for screening purposes in patients 
with somatic disease. Findings from Ferguson et al. (2006) provide some 
support for the utility of somatic items of the BAI for measuring anxiety in 
patients with COPD, yet many experts still question the validity of somatic items 
for measuring and screening anxiety in this patient group (Jain & Lolak, 2009; 
Mikkelsen et al., 2004; NCCC, 2011).  
 
There are also questions relating to the content of extant scales, particularly 
regarding their symptom coverage. This is likely to be a result of the theoretical 
considerations that underpin each scale. The DASS, for example, is designed to 
distinguish between symptoms of anxiety and depression and therefore focuses 
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on symptoms that are unique to each disorder. Items measuring symptoms such 
as tension and irritability are omitted as they relate to both anxiety and 
depression (McDowell, 2006). Whilst this strengthens the scale in terms of its 
power to discriminate between psychiatric conditions, its use as a general 
screening and measuring tool for anxiety is limited as common symptoms of 
anxiety are not included (McDowell, 2006). 
 
Often, ‘off-the-shelf’ tools may be inappropriate or suboptimal (DeVellis, 2003; 
Redding et al., 2006). Few extant anxiety scales have been validated (in a 
limited fashion) in COPD populations and their recommended use in patients 
with COPD is based primarily upon psychometric data from healthy populations 
or patients with other diseases. The high prevalence and under recognition of 
co-morbid anxiety in patients with COPD indicates (alongside the other barriers 
to recognition) that a reliable and valid screening tool and anxiety marker is 
needed. This would have clinical utility by acting as a screening tool and anxiety 
marker in clinical practice, but also as an outcome measure for research. 
 
The aim of this research, therefore, was to develop a novel scale to act as a 
marker and screener for anxiety in patients with COPD. The scale addresses 
some of the documented limitations of existing scales by containing only 
somatic items and by being developed specifically for patients with COPD. 
According to Kunik et al. (2007) the goal of an effective screening instrument is 
to maximise recognition of patients with clinically significant symptoms. 
Therefore, a screening tool for anxiety in patients with COPD should have a high 
sensitivity (Jain & Lolak, 2009). To achieve this goal, it is important that the 
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scale contains items that are relevant to the patient, yet also recognises those 
whose symptoms reach a level where management is required. Therefore, this 
research sought to include patients in the development of a scale, both in terms 
of eliciting patients’ experiences to identify appropriate anxiety symptoms (to 
ensure item coverage) and in the design of the scale (to ensure user-
friendliness). This approach is advocated by guidelines that guide the 
development of patient reported outcome measures (PROMs; American Food 
and Drug Administration; FDA, 2009)  
 
1.2 AIM OF THE STUDY 
 
The aim of the study was to develop a non-somatic anxiety scale that can be 
used as a marker of anxiety in patients with COPD and also screen for GAD and 
PD. 
 
1.3 RESEARCH OBJECTIVES 
 
Three research objectives were developed to guide this study: 
 
1. To explore the experience of anxiety in patients with COPD and to 
develop potential scale items based on both patients’ experiences of 
anxiety and the content of extant anxiety scales. 
2. To develop a novel and user-friendly non-somatic scale that can be used 
as a screening tool and as a marker of anxiety in patients with COPD. 
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3. To establish the reliability, validity and clinical utility of the novel scale 
in a clinical population of patients with COPD. 
 
1.4 OUTLINE OF THESIS 
 
Chapter 1 has discussed the background to the study and has outlined the aims 
of the research. 
 
Chapter 2 provides a detailed overview of anxiety in patients with COPD. The 
chapter begins by providing an introduction to the psychological and medical 
models of anxiety. It then proceeds to review the prevalence of clinically 
relevant symptoms of anxiety and anxiety disorders in patients with COPD, and 
summarises the aetiology, risk factors, impact and management of co-morbid 
anxiety in patients with COPD. Finally, the chapter critically reviews issues 
relating to anxiety markers and screening, with a specific focus on the strengths 
and limitations of existing self-report anxiety scales. 
 
Chapter 3 critically discusses self-report ratings scales and the key 
considerations in scale development, particularly issues surrounding reliability 
and validity. A comprehensive review of the scale development process is also 
provided and consideration is given to the theory that drives the scale 
development process of the current research. 
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Chapter 4 presents the research methodology. The chapter discusses the 
conceptual framework of the research and outlines the research design. Ethical 
considerations are also discussed within this chapter. 
 
Chapter 5 describes Phase 1 of the research; an item development process that 
incorporated both emic and etic perspectives to develop a pool of novel items 
for the anxiety scale. 
 
Chapter 6 describes Phases 2 and 3 of the research. In Phase 2 of the research 
the original pool of items was condensed using statistical techniques to create 
the final scale. In Phase 3, the reliability, validity and clinical utility of the new 
scale were examined in a clinical sample of patients with COPD. 
 
Chapter 7 discusses the findings from the three phases of research and 
considers the strengths and limitations of the research.  
 
Chapter 8 contains the summary, clinical and theoretical implications, 
recommendations for future research and conclusion.  
 
1.5 SUMMARY OF CHAPTER 1 
 
It is clear from the outset that COPD is a common condition with a growing 
global prevalence. Anxiety disorders are amongst the most common co-
morbidities in patients with COPD and have a significant deleterious impact on 
HRQoL and healthcare utilisation if untreated. However, anxiety disorders are 
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both under detected and undermanaged in patients with COPD. Although 
existing anxiety scales have been recommended to detect and monitor anxiety 
in this patient group, there are a number of documented limitations, 
particularly their inclusion of somatic items. Therefore, the primary aim of the 
current research is to develop a novel disease-specific non-somatic anxiety 
scale to screen and act as a marker of anxiety in patients with COPD. 
 
The following chapter explores co-morbid anxiety in patients with COPD and 
focusses upon the prevalence and relevance of anxiety disorders. Existing 
anxiety scales that are used in clinical and research settings are also critically 
discussed. 
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Chapter 2 : CO-MORBID ANXIETY IN PATIENTS WITH 
COPD 
 
“Worry is a thin stream of fear trickling through the mind. If encouraged, it cuts a 
channel into which all other thoughts are drained.” 
Arthur Sommers Roche 
 
2.1 INTRODUCTION 
 
In line with the aim and objectives of this thesis, the following chapter gives a 
concise overview of issues relating to co-morbid anxiety disorders in patients 
with COPD. First, a general introduction to anxiety in both a clinical and 
psychological context is provided. Second, the prevalence of clinically 
significant symptoms of anxiety and specific anxiety disorders among patients 
with COPD are examined. Third, a review of the aetiology and pathophysiology 
of co-morbid anxiety is presented, and key theories relating to the mechanisms 
of anxiety in patients with COPD are explored. Fourth, in order to outline the 
relevance of anxiety disorders in patients with COPD, the impact of anxiety 
upon key health outcomes in patients with this condition are evaluated. Fifth, 
the recommended management of co-morbid anxiety in patients with COPD is 
examined. Finally, the detection of anxiety in this patient group is explored and 
key anxiety scales and screening tools are critically evaluated.  
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2.2 ANXIETY: AN OVERVIEW 
 
Anxiety is a universal human experience and refers to a variety of concepts, 
including a mental state, a drive, a response to a particular situation, a 
personality trait, the cause of behaviour, and a psychiatric disorder (McDowell, 
2006). Thus, the diverse nature of anxiety ensures that providing a definition in 
a clinical sense is complicated. Perhaps the most widely recognised clinical 
definition of anxiety is provided in the Diagnostic and Statistical Manual of 
Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR) which considers 
anxiety to be: 
 
“… apprehensive anticipation of future danger or misfortune accompanied by a 
feeling of dysphoria or somatic symptoms of tension.” (APA, 2000: 820) 
 
This definition alludes to the multi-faceted nature of anxiety and the emotional, 
somatic and behavioural symptoms that can present. Keedwell and Snaith 
(1996) provide a more detailed definition of anxiety in a clinical context that 
further highlights the complex nature of the construct: 
 
“The term encompasses a specific mood equivalent to fear, feelings of insecurity 
and apprehensive anticipation, content of thought dominated by disaster or 
personal incompetence, increased arousal or vigilance, a sense of respiratory 
constriction leading to hyperventilation and its consequences, muscular tension 
causing pain, tremor and restlessness, and a variety of somatic discomforts based 
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upon over activity of the autonomic nervous system” (Keedwell & Snaith, 1996: 
177). 
 
Although Keedwell and Snaith (1996) include the term fear in their definition, 
fear may be considered to be an emotion that is related to the response to 
immediate danger i.e., fight or flight, that occurs after exposure to a stimulus. 
Anxiety on the other hand, is considered to be apprehension over potential 
future danger; a future-oriented state (McDowell, 2006). 
 
The symptoms of anxiety broadly fall within two categories: non-somatic and 
somatic. Non-somatic symptoms of anxiety include an affective response often 
characterised by feelings of apprehension or arousal, a behavioural response 
such as situational avoidance or pacing, and a cognitive response that often 
includes memory problems or confusion. Somatic anxiety is characterised by a 
physiological response of hyperarousal, often involving symptoms such as 
sweating, heart palpitations or breathlessness. A recent study by Simms et al. 
(2012) explored the anxiety symptoms reported by 5433 primary care patients 
from 14 countries as recorded in the WHO’s Collaborative Study of 
Psychological Problems in General Health Care (Üstün & Sartorius, 1995). The 
authors found 25 core anxiety symptoms representing a range of somatic and 
non-somatic symptoms (see Table 2.1).  
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Table 2.1: Anxiety symptoms identified by Simms et al. (2012) 
Non-somatic Somatic 
Mentally tense Difficulty swallowing/felt as if choking 
Difficulty concentrating because of worry Trembly or shaky 
Might lose control of self Lump in throat 
Nervous or anxious Aware of heart pounding or racing 
Unusually restless Feeling of tightness in the chest 
Difficulty relaxing Feel muscles are tense 
Felt unreal Feel dizzy or light-headed 
Feeling worried Difficulty with breathing 
Afraid that something terrible might happen Hot or cold sweats 
Trouble falling asleep because of worry Dry mouth 
Continually irritable Discomfort or pain in chest or belly 
Easily startled  
Fears of crowds, traveling, leaving home  
Sudden situational fear/anxiety  
 
 
Whilst all people experience anxiety to some degree, most do not develop long-
term anxiety disorders. Chronic, persistent or severe anxiety are typically 
classified, in terms of a medical approach, into one of the specific anxiety 
disorders (PD or GAD, for example), such as those proposed by the DSM-IV-TR 
criteria (APA, 2000) or International Classification of Diseases-10 (ICD-10; 
WHO, 1992). This categorical system allows clinicians to decide whether or not 
to treat the patient. However, McDowell (2006) posits that psychologists, in 
contrast to medical doctors, typically take a dimensional approach to anxiety, 
which treats the associated symptoms of anxiety on a continuum of severity. 
This distinction is characterised by the two styles of measurement: the medical 
model of dichotomous case or non-case, categorised by a clinical diagnosis, and 
the psychological model of ordinal markers of symptom severity, often 
undertaken using scales and questionnaires. 
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2.2.1 MARKERS OF ANXIETY 
 
The experience of anxiety is composed of intricate interactions between 
cognitive, emotional and physiological experiences (Barlow et al. 1996). These 
cognitive, emotional and physiological changes are linked by their expression of 
a state of hypervigilance which is the cardinal indicator of anxious mood and 
behaviour (Eysenck, 1992). It has been suggested that the mechanisms 
underlying anxiety are closely related to the fear response, a biological process 
which rapidly detects environmental threat and responds accordingly e.g., in 
the “flight or fight” response (Lang et al. 2000). This response involves the 
recruitment and coordination of cognitive, motor, autonomic and endocrine 
systems (Lang et al. 2000). As a result, anxiety can be expressed in multiple 
systems that are linked together in a neural network (Lang, 1988). Anxiety can 
therefore be identified through a variety of markers including through the 
cognitive-language system (e.g., expressions of worry), through the motor-
behavioural system (e.g., avoidance behaviours or decreased activity), and 
through physiological systems which may include markers such as elevated 
heart rate or increased activity in the amygdala (see for example Roth, 2005).  
The following section provides an overview of the psychophysiological 
mechanisms associated with anxiety and identifies the specific markers of 
anxiety that underly the non-somatic approach to anxiety markers chosen in 
this thesis. 
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Non-somatic markers of anxiety include cognitive, emotional and behavioural 
components. Broadly speaking, cognitive anxiety involves the apprehensive 
anticipation of future danger and the mental pre-occupation over an anxiety-
inducing event (APA, 2000; Barlow et al. 1996). Thus cognitive anxiety can be 
detected using the cognitive-language system through subjective markers such 
as feelings of worry, rumination and irritability, for example (APA, 2000). 
Anxiety may also have an emotional involvement, with anxiety leading to 
feelings of fear, sadness and helplessness, associated with a reduced ability to 
effectively cope with the situation at hand (Barlow et al. 1996). Obvious 
behavioural manifestations of anxiety include avoidance and escape and both 
may be considered as indirect markers of anxiety that have been conceptualised 
as coping strategies (McLean & Woody, 2000). Escape involves fleeing from the 
scene when confronted with a fear stimulus, becoming avoidance when specific 
situations are associated with the fear stimulus and avoided in anticipation 
(McLean & Woody, 2000).  The cognitive and emotional distress of anxiety is 
often accompanied by a somatic physiological activation (arousal) response 
whose features can be explained as preparation for physical activity (Roth, 
2005). This physiological response occurs through stimulation of the 
sympathoadrenal and endocrine systems.  
 
The activation of the sympathetic division of the autonomic nervous system 
occurs when noradrenaline and norepinephrine release in the brain, triggered 
by anxiety-eliciting events causes an upregulation of sympathetic functions. It 
has been proposed that the ascending noradrenergic system originating from 
the locus ceruleus is the core around which feeling of anxiety are organised 
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(Redmond & Huang, 1979). Some LC neurons project to the paraventricular 
nucleus (PVB) in the hypothalamus and activate the hypothalamic-pituitary-
adrenal (HPA) axis triggering the stress response associated with increased 
anxiety (Steimer, 2002). Other LC neurons project to other key structures 
involved in the anxiety response including the amygdala (which plays an 
important role in fear-response), pre-frontal cortex, the bed nucleus of the stria 
terminalis (thought to be important in free-floating anxiety), the hippocampus, 
the periaqueductal gray, the hypothalamus, the thalamus and the nucleus 
tractus solitarius (Steimer, 2002; Stein, 2003). 
 
In addition to the acute autonomic response, a long-term stress response occurs 
involving the hypothalamic-pituitary-adrenal (HPA) axis, whose purpose is to 
increase the amount of usable energy in the body. The hypothalamus releases 
adrenocorticotropic hormone (ACTH) which stimulates the adrenal cortex to 
synthesize and release glucocorticoids (e.g., cortisol and cortisone) into the 
bloodstream (Graeff, 2007). Glucocorticoids cause the breakdown of 
triglycerides, glycogen and protein into usable forms of energy such as free fatty 
acids, glucose and amino acids.  
 
Neurological and endocrine responses which accompany anxiety result in a 
number of physiological markers of anxiety including increased sweating, heart 
rate, blood pressure, dilation of the pupils, trachea, and bronchi  and increased 
respiratory rate (Gelenberg, 2000; Rosen & Shulkin, 1998). However, in anxiety, 
the absence of a ‘real’ threat renders these physiological changes a source of 
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great discomfort, contributing to further anxiety and impairing social 
functioning (Barrett & Armony, 2006). 
 
The autonomic response to anxiety has been widely studied and it has been 
proposed that changes in the sympathetic branch of the autonomic nervous 
system may be a key element in the development of anxiety disorders 
(Berntson et al. 1998). However, the relationships between anxiety and 
autonomic function are far from simple and this is likely to be a reflection of the 
diversity of anxiety disorders, the complex nature of central autonomic control 
and multiple neural systems and processes involved in anxiety states (Bernston 
et al. 1998). A recent review by Graeff (2007) highlights that anxiety (GAD) and 
panic (PD) are pathologically distinct and that specific neurobiological systems 
are involved in each disorder. While GAD activates both the HPA and 
sympathoadrenal axis, panic attacks appear to cause significant sympathetic 
activation, but have little effect on the HPA axis. 
 
The pathophysiology of specific anxiety disorders is complex and is thought to 
involve abnormalities in a variety of systems including neurochemical, 
neuroendocrine, neurophysiological and neuroanatomical systems. PD is 
characterised by mild to moderate baseline levels of chronic anxiety which have 
been associated with abnormalities in cerebral blood flow and glucose 
metabolism in the hippocampus and parahippocampal gyrus, although the 
direction of this regional asymmetry is still contended (see Charney & Drevets, 
2002 for a thorough review). Similarly, chemically induced PAs in laboratory 
settings have identified increased cerebral blood flow in the anterior insula, 
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anteromedial cerbrellum and the midbrain (Charney & Drevets, 2002). Other 
findings indicate that morphometric and morphological abnormalities in the 
temporal lobe may also exist in patients with PD (Ontiveros et al. 1989; Uchida 
et al. 2003). The neurobiology of GAD may involve a number of 
neurotransmitters and systems including the gamma-aminobutyric acid 
(GABA)/benzodiazepine complex, norepinephrine, serotonin, cholecystokinin, 
contricotropin-releasing factor, the HPA axis, and neurosteroids (see Connor & 
Davidson, 1998 for a review).  
 
The pharmacotherapy for anxiety disorders is focussed primarily on two drug 
groups: benzodiazepines and selective serotonin reuptake inhibitors 
(SSRIs)/serotonin and noradrenaline reuptake inhibitors (SNRIs). 
Benzodiazepines bind to specific sites on the γ-aminobutyric acid (GABA)-
receptor, thus potentiating the effect of the inhibitory neurotransmitter GABA. 
SSRIs inhibit the reuptake of serotonin at the presynaptic membrane by the 
serotonin (5-HT), thus increasing synaptic concentration of the 
neurotransmitter, whilst SNRIs inhibit the reuptake of both serotonin and 
nonadrenaline (Koen & Stein, 2011). Traditional approaches to GAD and PD 
management have advocated the use of benzodiazepans (e.g., diazepam) and 
antidepressants (e.g., impipramine and trazodone) for first line medical 
management (Connor & Davidson, 1998). However, there is growing evidence 
to support the efficacy and tolerability of SSRIs (e.g., fluoxetine and citalopram) 
for GAD and PD amongst other anxiety disorders, although there remains 
significant debate regarding optimal dosing, dependence , duration of use and 
discontinuation syndrome (Koen & Stein, 2011).  Despite these limitations, 
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Benzodiazepines, continue to play an important role in the treatment of anxiety 
disorders, particularly because of their efficacy and rapid onset of action. 
2.2.2 STATE AND TRAIT ANXIETY 
 
Evolving definitions of anxiety in the 1950s and 60s led to the development of 
the idea that anxiety is a multidimensional concept, which exists as two distinct 
entities: state and trait anxiety (Cattell and Scheier, 1958; Spielberger et al., 
1966). Cattell and Scheier (1958) were the first to distinguish between state 
and trait anxiety using factor analytical techniques. They describe trait anxiety 
as an enduring disposition and state anxiety as a temporary and changeable 
phenomenon. Trait anxiety involves a tendency to react to certain situations in 
a certain manner, to experience anxious symptoms in non-threatening 
situations, and to be vulnerable to stress. State anxiety, on the other hand, is a 
discrete response to a specific threatening situation and involves transitory 
unpleasant feelings such as worry, apprehension and tension, often associated 
with a physiological arousal response (McDowell, 2006; Spielberger et al., 
1966).  
 
People with high trait anxiety are assumed to be prone to experience state 
anxiety. However, work by Endler and colleagues (1991; 2001) posits that trait 
and state anxiety are also multidimensional (see Figure 2.1). Endler et al. 
(1991) conducted a factor analysis (FA) to clarify the empirical relationship 
between state and trait anxiety and identified four distinct aspects of trait 
anxiety: social evaluation, physical danger, ambiguous situations and daily 
routines. In addition, they identify two facets of state anxiety: cognitive-worry 
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and autonomic-emotional.  Social evaluation trait anxiety measures an 
individual’s predisposition to experience an increase in state anxiety in 
situations when one is being observed by others. Physical danger relates to 
situations where one may be physically hurt. Ambiguous trait anxiety refers to 
situations which are new to an individual. Finally, daily routines trait anxiety is 
related to situations that involve an individual’s daily routines and are 
innocuous (Endler et al., 1991; 2001). 
 
 
Figure 2.1: Multidimensionality of state and trait anxiety. Reproduced with 
permission from Endler & Kocovski (2001) 
 
 
According to the multidimensional state-trait anxiety model, for an increase in 
state anxiety to occur, the threatening situation must be congruent with the 
corresponding dimension of trait anxiety. In other words, levels of state anxiety 
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are dependent upon both the person (trait anxiety) and the stressful stimulus 
(Endler et al., 2001). For example, an individual with high physical danger trait 
anxiety would interact with a physical danger situation by reporting high state 
anxiety. However, it is posited that the interactions do not occur between other 
dimensions of the trait anxiety. Therefore, for example, high physical danger 
trait anxiety would not result in elevated state anxiety in a social evaluation 
situation (Endler et al., 1991; 2001). 
 
2.2.2 COGNITIVE THEORIES OF ANXIETY 
 
In keeping with cognitive theories of anxiety, biases in information processing 
play a key role in the aetiology and maintenance of anxiety disorders. According 
to attentional control theory (ACT) (Eysenck et al. 2007), anxiety disrupts the 
balance between the goal-driven or stimulus-driven systems. The goal directed 
attentional system is managed by expectations, knowledge and current goals 
and represents top-down attentional control. The stimulus-driven system, on 
the other hand, represents bottom-up attentionial control which is guided by 
behaviourally relevant salient sensory events (Corbetta & Shulman, 2002). 
Eysenck and colleagues (2007) propose that anxiety modulates the balance 
between the two systems leading to an increase in influence from the stimulus-
driven attentional system and a decreased influence of the goal-directed 
attentional system.  
 
ACT suggests that anxiety affects processing efficiency to a greater extent than 
performance effectiveness due to the effects of anxiety on the attentional 
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control of inhibition, updating and shifting functions. A key assumption of ACT 
is that anxiety increases the allocation of attention to threat-laden stimuli, 
reducing attentional focus on the current task unless it is threat-laden. As a 
result, anxious individuals preferentially allocate attentional resources to 
threatening stimuli such as worrisome thoughts (e.g., meta-worry) or external 
threatening distractions (Eysenck et al. 2007). 
 
Eysenck’s earlier theory of anxiety (Eysenck, 1997) states that the level of 
anxiety experienced by an individual depends on the amount of attention given 
to the external environment, one’s own physiological activity, one’s own 
behaviour, and negative cognitions about future threats. Individuals with high 
trait anxiety are thought to exhibit attentional (e.g., attending to threat-laden 
rather than neutral stimuli) and interpretive (e.g., interpreting ambiguous 
stimuli or situations in a threatening fashion) biases. However, as Derakshan et 
al. (2007) asserts, some individuals may exhibit different attentional bias that 
leads them to avoid negative states in a repressive coping style. Such individuals 
demonstrate low levels of trait anxiety (measured by self-report) and high 
defensiveness, yet there are clear discrepancies between their self-report trait 
anxiety and objectively measured physiological and behavioural indicators. 
These individuals may be considered to be repressing their subjective 
experience of anxiety, despite tendencies to respond physiologically and 
behaviourally in a manner suggestive of high levels of perceived threat 
(Weinberger, 1990). Repressors show biases indicating that they avoid 
attending to threat-laden stimuli when presented concurrently with neutral 
stimuli. They also tend to interpret ambiguous stimuli and situations in a non-
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threatening fashion and avoid retrieving threatening information (Derakshan et 
al. 2007). Another key assumption underlying the repressive coping style is that 
these avoidant processes exist in relation to both external and internal stimuli, 
such as their own physiology, behaviour and emotion-related cognitions 
(Derakshan et al. 2007).  
 
Previous work by Weinberger, Schwartz and Davidson (1979) has identified 
four groups of individuals based on their self-reported trait anxiety (in this case 
the Taylor Manifest Anxiety Scale) and defensiveness (measured using the 
Marlowe-Crowne Social Desirability Scale; Crowne & Marlowe, 1964). The four 
groups were: 1) low-anxious (low on trait anxiety and low on defensiveness); 2) 
repressors (low on trait anxiety and high on defensiveness); 3) high anxious 
(high on trait anxiety and low on defensiveness); and 4) defensive high anxious 
(high on trait anxiety and high on defensiveness). Weinberger (1990) asserts 
that repressors report lower relative self-reported anxiety than physiological or 
behavioural anxiety because they are self-deceivers, as opposed to deceiving 
others. Therefore, these individuals avoid experiencing anxiety on a conscious 
level. The attentional and interpretative biases of these individuals may explain 
these differences. For example, high anxious individuals may have selective 
attentional biases which lead them to attend to threat-laden stimuli and 
interpretative biases that lead them to interpret ambiguous stimuli in a 
threatening manner. Conversely, repressors may have selective attentional 
biases that lead them to avoid attending to threat-laden stimuli and 
interpretative biases that lead them to avoid interpreting ambiguous stimuli in 
a threatening manner, thus “protecting” them from consciously experiencing 
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anxiety (Derakshan et al. 2007; Derakshan & Eysenck, 1999; Derakshan & 
Eysenck, 2001). 
 
In an attempt to explain the discrepancies in reported anxiety and objective 
markers of anxiety, Derakshan and co-workers (2007) proposed a vigilance-
avoidance theory. The key assumption of this theory is that there are two 
successive stages on processing when repressors are exposed to self-relevant 
threats. The first stage (vigilance) is a rapidly occurring stage which involves 
automatic and non-conscious processes and is thought to produce behavioural 
and physiological anxiety responses. The second stage (avoidance) incorporates 
avoidant cognitive biases which are important in producing low self-reported 
anxiety. Thus, repressors are thought to make use of avoidance cognitive biases 
after some processes indicating that a stimulus poses a self-relevant threat 
(Derakshan et al. 2007). 
 
The repressive coping style is of particular concern in the detection and 
management of anxiety as small or no correlations are found between self-
reported, physiological and behavioural anxiety (Eysenck, 1997). However, 
when repressors are removed from these analyses, the expected relationships 
between the markers are found. This might suggest that repressors could be 
missed when screening using self-report scales where patients are asked to 
report the severity of their symptoms. This may be of particular concern in 
some chronic diseases where repressors may form a large part of the 
population. Previous studies have identified a high rate of repressors among 
patients with chronic respiratory diseases including lung cancer and asthma 
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(Prasertsri et al. 2011, Gonzalez-Freire et al. 2010). The repressive coping style 
is associated with poor prognosis, a reluctance to seek social support and 
engage with psychotherapy (Phipps & Steele, 2002). High rates of defensive 
high anxious individuals have also been identified amongst other chronic 
disease populations, particularly in chronic lower back pain and chronic fatigue 
syndrome (Creswell & Chalder, 2001; Lewis et al. 2012). The defensive high 
anxious coping style has also been associated with detrimental health, 
particularly via increased endorphin levels in the brain which can lead to 
imunocompetence (Jamner et al. 1988). 
 
2.2.3 TYPES OF ANXIETY DISORDER 
 
In terms of a medical perspective, excessive anxiety is a central symptom of a 
number of psychological disorders, particularly the clinical anxiety disorders. 
Seven types of anxiety disorder are defined by the most recent DSM-IV-TR 
(APA, 2000) criteria: PD with or without agoraphobia; agoraphobia without a 
history of PD; social phobia; specific phobia; GAD; obsessive-compulsive 
disorder (OCD), and post-traumatic stress disorder (PTSD). The following 
section provides a brief description of the DSM-IV-TR anxiety disorders and 
their corresponding symptoms and features. 
 
2.2.3.1 Panic disorder (PD) with or without agoraphobia 
 
The central feature of PD is the occurrence of panic attacks (PA) which are 
defined as discrete periods of intense fear or discomfort. DSM-IV-TR (APA, 
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2000) criteria for PA require that four of the 13 symptoms listed in Table 2.2 
must be present during the attack. 
 
Table 2.2: Symptoms of panic attack according to DSM-IV-TR (APA, 2000) 
1 Shortness of breath and smothering sensations 
2 Choking 
3 Palpitations are accelerated heart rate 
4 Chest discomfort or pain 
5 Sweating 
6 Dizziness, unsteady feelings or faintness 
7 Nausea or abdominal distress 
8 Depersonalisation or derealisation 
9 Numbness or tingling sensations 
10 Flushes or chills 
11 Trembling or shaking 
12 Fear of dying 
13 Fears of going crazy or doing something uncontrolled 
 
For a diagnosis of PD to be confirmed, the PAs must have been recurrent and 
unexpected and at least one of the attacks must have been followed by 1 month 
or more of: persistent concerns about having additional attacks; worry about 
the implications of the attack or its consequences, or a significant change in 
behaviour related to the attacks (APA, 2000). PD with agoraphobia refers to PA 
that are followed by pervasive avoidance behaviours, especially avoidance of 
public places or other “unsafe” situations (Rachman, 2004). 
 
2.2.3.2 Agoraphobia without a history of panic disorder (PD) 
 
Agoraphobia refers to a fear of being in public places from which escape might 
be difficult. The symptoms are similar to phobic anxiety disorders, however, 
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symptoms such as depression and depersonalisation are found more often in 
agoraphobia than in other phobias (Gelder et al., 1996). Although many 
situations might trigger agoraphobic cognitions, three common themes prevail: 
distance from home, overcrowding and confinement. Individuals with this 
particular anxiety disorder typically experience panic-like symptoms that are 
often sub-clinical in intensity (APA, 2000). 
 
2.2.3.3 Social phobia 
 
Social phobia is characterised by inappropriate anxiety experienced in 
situations in which the individual is observed and could, therefore, be criticised 
(Gelder et al., 1996). This particular phobia it typified by avoidance of social 
situations, particularly behaviours such as avoiding conversations or entering 
social environments e.g., meetings, canteens etc. Two common physiological 
symptoms of social phobia are trembling and blushing (APA, 2000).  
 
2.2.3.4 Specific phobia 
 
In a similar vein to social phobia, individuals who experience specific phobia 
demonstrate inappropriate anxiety to a specific object or situation. The fear that 
accompanies specific phobias are especially intense and persistent. Common 
phobias include fear of spiders, flying or dentists (Gelder et al., 1996; Rachman, 
2004). 
 
2.2.3.5 Generalised anxiety disorder (GAD) 
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Symptoms of GAD are, as the name indicates, not restricted to or strongly 
predominating in any particular set of circumstances (Gelder et al., 1996). The 
cardinal signs of GAD are worry and apprehension, which are prolonged and 
difficult to control, motor tension, such as restlessness or inability to relax, and 
autonomic hyperactivity, such as sweating or dry mouth (see Table 2.3). Other 
symptoms include sleep disturbance (both trouble falling asleep and staying 
asleep), poor concentration and irritability (Gelder et al., 1996). For a diagnosis 
of GAD to be given, symptoms must have occurred more days than not for a 
period of at least 6 months (APA, 2000). According to DSM-IV-TR criteria, the 
worries that underlie GAD are not focussed upon specific elements such as 
being embarrassed in public (social phobia)or being contaminated (OCD). 
Rather, worries are often widespread, possibly relating to issues such as 
finances or health, or minor matters such as household chores or being late for 
appointments (APA, 2000).   
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Table 2.3: Symptoms of GAD according to Gelder et al. (1996) 
Symptom category Symptom sub-category Symptom 
Psychological  Fearful anticipation 
  Irritability 
  Sensitivity to noise 
  Restlessness 
  Poor concentration 
  Worrying thoughts 
Physical Gastrointestinal Dry mouth 
  Difficulty swallowing 
  Epigastric discomfort 
  Excessive wind 
  Frequent or loose motions 
 Respiratory Constriction in the chest 
  Difficulty inhaling 
  Overbreathing (breathlessness) 
 Cardiovascular Palpitaions 
  Discomfort in chest 
  Awareness of missed beats 
 Genitourinary Frequent or urgent micturition 
  Failure of erection 
  Menstrual discomfort 
  Amenorrhoea 
 Neuromuscular system Tremor 
  Prickling sensations 
  Tinnitus 
  Dizziness 
  Headache 
  Aching muscles 
Sleep disturbance  Insomnia 
  Night terror 
Other symptoms  Depression 
  Obsessions 
  Depersonalisation 
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2.2.3.6 Obsessive compulsive disorder (OCD) 
 
OCD is characterised by obsessional thinking and compulsive behaviour, as well 
as anxiety, depression and depersonalisation (APA, 2000). There are a number 
of obsessional and compulsive symptoms including obsessional thoughts (often 
unpleasant words, ideas or beliefs), obsessional images (unpleasant imagined 
scenes), obsessional ruminations (often in the form of internal debates), 
obsessional doubts (such as concerns that actions may not have been completed 
e.g., turning off gas or locking the door), and obsessional rituals (such as 
washing hands or turning lights on and off multiple times). Anxiety is a key 
symptom of OCD and can be both reduced or elevated following obsessional 
actions (Gelder et al., 1996). 
 
2.2.3.7 Post-traumatic stress disorder (PTSD) 
 
PTSD consists of multiple symptoms that include anxiety, elevated arousal, 
avoidance and fear (Rachman, 2004). The term denotes an intense and often 
prolonged reaction to an intensely distressing experience, such as a natural 
disaster, or violent event. Alongside the anxiety that is common in PTSD, 
individuals experience intrusions that include flashbacks and distressing 
dreams, and exhibit avoidance behaviours such as avoiding reminders of the 
original event (Gelder et al., 1996; Rachman, 2004). 
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2.2.4 DEPRESSION AND ANXIETY 
 
Anxiety has long been recognised as a prominent symptom of many psychiatric 
disorders, especially depression. It was not until the last part of the nineteenth 
century that anxiety disorders were classified separately from other disorders 
of mood (Gelder et al., 1996). Anxiety and depression frequently co-occur, with 
epidemiological studies suggesting that the two disorders co-present 
approximately 40% to 75% of the time (Clark, 1989). The USA National Co-
morbidity Survey found that among patients diagnosed with major depression 
there is a 3-fold to 8-fold increased likelihood that the patient is also suffering 
from a co-morbid anxiety disorder (Kessler et al., 1996). The prevalence of 
anxiety and depression in patients with COPD shows a similar picture. Kunik 
and colleagues found that anxiety and depression co-occurred in 26% of 
patients with either an anxiety or depressive disorder (Kunik et al., 2005). In 
addition, Yohannes and co-workers (2000a) found that 37% of patients with 
depression also had co-morbid clinical anxiety. 
 
Diagnostically, the DSM-IV-TR categorises mixed anxiety-depressive disorder as 
the presence of anxiety and depressive symptoms of equal intensity that do not 
occur to the extent that justifies a diagnosis if considered separately (APA, 
2000). However, patients may have clinically relevant symptoms that meet the 
criteria for either a depression or anxiety diagnosis. Hirschfeld (2001) suggests 
that co-occurring anxiety and depression typically present as one of four clinical 
presentations: (1) a clinical anxiety disorder with subsyndromal levels of 
depression, (2) major depression with subsyndromal levels of anxiety, (3) both 
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clinical anxiety disorder and major depression, and (4) subsyndromal mixed 
anxiety-depression.  
 
Several theories have been proposed to explain the overlap of anxiety and 
depression and their frequent co-occurrence (Shankman & Klein, 2003). One 
explanation is that anxiety disorders and depression share common symptoms. 
For example, sleep disturbance and fatigue are considered to be symptoms of 
both GAD and major depressive disorder (MDD; APA, 2000). Another possibility 
is that anxiety and depression share a single underlying, general negative mood, 
rather than existing as separate dimensions (Feldman, 1993).  
 
More recently, a number of models have been proposed that expand on 
Feldman’s (1993) general negative mood theory (cf. Shankman & Klein, 2003): 
the tripartite model (Clark & Watson, 1991); the approach-withdrawal model 
(Davidson, 1998), and the valence-arousal model (Heller & Nitschke, 1998). Of 
these models, Clark and Watson’s tripartite model is perhaps the most widely 
acknowledged, finding general acceptance particularly within adult psychiatry 
(e.g., Marshall et al., 2003). The model proposes that there are three underlying 
dimensions for anxiety and depression (see Figure 2.2). The first dimension is a 
higher order factor of general distress or negative affect, which is posited to be 
common to both anxiety and depression and is characterised by aversive 
emotional states such as sadness, anger and fear. The second dimension is 
positive affect, which represents positive emotional states such as feeling 
happy, enthusiastic and energetic. According to Clark and Watson (1991), 
patients with depression can be distinguished from those with anxiety in that 
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they have low positive affect, such as feelings of anhedonia or sluggishness. 
Finally, the third dimension is that of autonomic arousal, which represents 
physiological symptoms such as breathlessness or dizziness and is believed to 
be specific to anxiety disorders. This model helps to explain the co-occurrence 
of anxiety and depression, with both disorders sharing the dimension of 
negative affect, depression characterised by low positive affect, and anxiety – 
particularly panic – characterised by high autonomic arousal.  
 
 
 
 
 
 
 
Figure 2.2: Tripartite model of anxiety and depression (Clark & Watson, 
1991) 
 
2.2.5 SUMMARY 
 
Anxiety is a complex, ambiguous and multidimensional construct that has been 
defined in many ways; however, it is typified by feelings of apprehension and 
physiological arousal. Further ambiguity is provided by the evident overlap 
between anxiety and depression which frequently co-occur. Anxiety can be 
identified through a variety of markers including through the cognitive-
language system the motor-behavioural system and through physiological 
Low positive 
affect 
Negative 
affect 
Autonomic 
arousal 
Depressive symptoms Anxiety symptoms 
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systems. Anxiety may be subdivided into state anxiety (transient and situation 
specific) and trait anxiety (enduring and multidimensional). Individuals who 
have a trait predisposition to a specific stimulus are likely to experience 
elevated situational-specific state anxiety. The dimensional model of anxiety, 
favoured by psychologists treats anxiety as a continuum, whilst the medical 
model of anxiety categorises anxiety into various clinical anxiety disorders, as 
exemplified by the DSM-IV-TR. Specific anxiety disorders include PD, GAD, 
agoraphobia without PD, specific and social phobia, OCD and PTSD.  
 
2.3 PREVALENCE OF ANXIETY IN PATIENTS WITH COPD 
 
There is little consensus on the prevalence of anxiety in patients with COPD. For 
example, recent literature reviews indicate that clinically significant symptoms 
of anxiety may be present in between 2 and 96% of patients with COPD (Brenes, 
2003; Hynninen et al., 2005; Mikkelsen et al., 2004; Yohannes et al., 2010). It is 
likely that diverse reports on the prevalence of anxiety are a reflection of a mix 
of limiting factors, such as the use of a range of diagnostic procedures (including 
various  screening tools and interview schedules), the populations sampled 
(e.g., inpatient and outpatient samples) and the heterogeneity of patient 
samples (such as variations in age, sex, disease severity etc.).  
 
Although numerous studies have reported on the prevalence of anxiety in 
COPD, many of these have utilised self-report anxiety scales which identify 
‘likely’ cases of clinical anxiety based on symptom severity, rather than 
diagnosis. Such studies are able to give an insight into the severity of symptoms 
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experienced by patients with COPD, but cases of likely anxiety are based upon 
cut-off scores, often varying even when using the same self-report scale. For 
example, studies which include the HADS-A as a screener for likely clinical 
anxiety, report a range of cut-off scores (e.g., Cleland et al., 2007; Gudmundsson 
et al., 2005; Xu et al., 2008). This is discussed in greater detail in section 2.8.1 on 
‘Extant scales.’ 
 
In contrast to self-report scales, psychiatric interviews are able to give a more 
reliable diagnosis of clinical anxiety. Psychiatric interviews are usually carried 
out using a structured clinical interview that is based on robust psychiatric 
diagnostic criteria such as the DSM-IV-TR (APA, 2000) or the ICD-10 (WHO, 
1992). Psychiatric interviews allow an in-depth understanding of the patient’s 
symptoms and therefore enable the specific classification of psychiatric 
disorders. Table 2.4 provides a summary of studies that report on the 
prevalence of clinical anxiety or specific anxiety disorders in patients with 
COPD.  
 
In studies that report the overall prevalence of clinical anxiety, reports vary 
considerably, ranging from 10-55% (Aghanwa & Erhabor, 2001; Vögele & von 
Leupoldt, 2008). Similar rates have been reported in both inpatient (10-55%) 
and outpatient samples (13-46%) indicating that high incidence cannot be 
explained solely by the presence of an exacerbation-related hospitalisation and 
is more likely to be an enduring disease-related phenomenon (Vögele & von 
Leupoldt, 2008). It is unclear why reported prevalence rates for anxiety 
disorders in patients with COPD range so considerably. One factor may be the 
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heterogeneity of the samples, particularly in terms of age and sex. For example, 
in the ten studies included in this literature review, the mean age of participants 
ranged from 48.5 to 73.0 years (Aydin & Ulusahin; Yohannes et al., 2000a). The 
majority of studies also included mainly male samples. Five studies contained 
samples which were >70% male whilst only two studies had roughly equal 
ratios of males and females (Laurin et al., 2007; Yohannes et al., 2000a). Finally, 
although all studies included psychiatric diagnosis, the psychiatric classification 
and interview format varied between studies. The majority of studies 
incorporated a nosological DSM or ICD diagnostic criteria, yet one study 
(Yohannes et al., 2000a) utilised a computerised syndromal classification.  
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Table 2.4: Study characteristics for diagnosed anxiety prevalence  
         Specific anxiety disorders 
Study Country N Age 
(years) 
Male 
(%) 
Participants Interview 
schedule 
Diagnostic 
tool 
Prevalence 
of clinical 
anxiety (%) 
GAD 
(%) 
PD 
(%) 
Specific 
phobia 
(%) 
Social 
phobia 
(%) 
OCD 
(%) 
PTSD 
(%) 
Aghanwa & 
Erhabor 
(2001)  
Nigeria 30 62.9  
± 9.6 
83 Inpatients - ICD-10 10 - - - - - - 
Aydin & 
Ulusahin 
(2001)  
Turkey 38 48.5  
± 9.4 
100 Inpatients CIDI DSM-IV-TR 16 16 0 - - - - 
Dowson et 
al. (2004) 
New 
Zealand 
39 71.3  
± 7.2 
41 Inpatients - DSM-IV-TR - 33 41 - - - - 
Karajgi et 
al. (1990) 
USA 50 64.9  
± 9.7 
62 Outpatients SCID DSM-III-R 16 - 8 - - - - 
Kunik et al. 
(2005) 
USA 204 65.9  
± 10.7 
96 Outpatients 
(pre-
screened) 
SCID DSM-IV-TR - 19 6 13 2 1 7 
Kühl et al. 
(2008)  
Germany 143 67.0  
± 9.5 
78 Outpatients - ICD-10 - 6 8 - - - - 
Laurin et 
al. (2007)  
Canada 116 67.0  
± 8.0 
47 Outpatients ADIS-IV DSM-IV-TR 46 19 21 27 11 2 1 
Vögele & 
von 
Leupoldt 
(2008)  
Germany 20 62.2  
± 10.0 
70 Inpatients F-DIPS DSM-IV-TR 55 - 40 10 5 - - 
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         Specific anxiety disorders 
Study Country N Age 
(years) 
Male 
(%) 
Participants Interview 
schedule 
Diagnostic 
tool 
Prevalence 
of clinical 
anxiety (%) 
GAD 
(%) 
PD 
(%) 
Specific 
phobia 
(%) 
Social 
phobia 
(%) 
OCD 
(%) 
PTSD 
(%) 
Yellowlees 
et al. 
(1987) 
Australia 50 65.0  
± 9.9 
64 Inpatients - DSM-III 34 10 24 - - - 2 
Yohannes 
et al. 
(2000a) 
UK 137 73.0 50 Outpatients GMS AGECAT 18 - - - - -  
GAD: generalised anxiety disorder; PD: panic disorder; OCD: obsessive-compulsive disorder; PTSD: post-traumatic stress disorder; ICD-10: International 
Classification of Diseases-10; CIDI: Composite International Diagnostic Interview; DSM: Diagnostic and Statistical Manual of Mental Disorders; USA, United States of 
America; SCID: Structured Clinical Interview for DSM; ADIS-IV: Anxiety Disorders Interview Schedule for DSM-IV; F-DIPS: Diagnostisches Interview für Psychische 
Störungen–Forschungsversion; UK, United Kingdom; Geriatric Mental State Schedule  
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Specific anxiety diagnoses including GAD, PD (with and without agoraphobia), 
specific phobia and social phobia are particularly prevalent and appear to occur 
at a greater rate among patients with COPD compared with the general 
population (Pirkola et al., 2005; Wolitzky-Taylor et al., 2010). For example, 
between 6% and 33% of patients with COPD appear to suffer from GAD (Aydin 
& Ulusahin, 2001; Downson et al., 2004; Kunik et al., 2005; Kühl et al., 2008; 
Laurin et al., 2007; Yellowlees et al., 1987), compared to 1-7% of community-
based older adults (Wolitzky-Taylor et al., 2010).  
 
The prevalence of PD (see Table 2.4) also appears to be noticeably higher in 
patients with COPD than among the general population. Studies indicate that 
between 0% and 41% of COPD patients may have PD (Aydin & Ulusahin, 2001; 
Dowson et al., 2004). In three recent studies with large sample sizes (n=116-
204), prevalence of PD (with or without agoraphobia) was found to be 6-21% 
(Kühl et al., 2008; Kunik et al., 2005; Laurin et al., 2007). In contrast, the 
prevalence of PD (with or without agoraphobia) among older adults is between 
0.1 and 2% (Kirmizioglu et al., 2009; Wolitzky-Taylor et al., 2010). 
 
Kunik and colleagues (2005) conducted a detailed study of specific anxiety 
diagnoses in patients with COPD in which patients who demonstrated 
significant anxiety on the BAI (total score ≥16) underwent a secondary 
structured clinical interview to establish a psychiatric diagnosis. Their results 
indicated that specific phobia was the second most prevalent anxiety disorder 
(behind GAD), affecting 13% of pre-screened COPD patients. Other studies also 
report a high prevalence of phobic anxiety disorders among this patient group 
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including specific phobia (prevalence of 10-27%) and social phobia (prevalence 
of 5-11%; Laurin et al., 2007; Vögele & von Leupoldt, 2008). 
 
Among elderly populations, phobias are the most prevalent psychiatric disorder 
after cognitive disorders (Wittche & Fehm, 2001). Specific phobia is thought to 
occur in up to 10% of older people, and social phobia, although less prevalent, is 
believed to affect up to 6% of older people (Wolitzky-Taylor et al., 2010). The 
prevalence of phobic anxiety disorders in patients with COPD is higher than 
among healthy age-matched samples but it is not clear why this might be. It is 
possible that a high prevalence of specific phobia and social phobia is due to 
increased self-consciousness and embarrassment (due to overt signs of their 
respiratory disease e.g., breathlessness, sweating or use of ambulatory oxygen), 
or increased sensitivity to situations of perceived danger (e.g., being without 
medication or becoming acutely breathless (Arnold et al., 2007; Willgoss et al., 
2011).  
 
Anxiety disorders including PTSD and OCD are less prevalent than other anxiety 
disorders in patients with COPD. The prevalence of OCD and PTSD is 
approximately 1-2% in patients with COPD (Laurin et al., 2007; Yellowlees et 
al., 1987) and is similar to that found among the general elderly population 
(0.1-3.5%; Wolitzky-Taylor et al., 2010). It is not clear why the prevalence of 
certain anxiety disorders (GAD, PD and phobias) is higher in patients with COPD 
whilst rates of PTSD and OCD remain normal. One reason may be that unlike 
GAD, PD and phobias, PTSD and OCD do not share common aetiological features 
with COPD. PTSD often originates from a specific traumatic event, whilst OCD 
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typically has an early onset (beginning in adolescence early adulthood). 
Therefore, it is unlikely that the risk of developing these specific disorders will 
be elevated with the development of COPD.  
 
Even conservative estimates of anxiety prevalence in patients with COPD are 
generally higher than that found in the general population or matched healthy 
controls (Aghanwa & Erhabor, 2001; Pirkola et al., 2005). Aghanwa and 
Erhabor (2001) compared the prevalence of clinical anxiety among COPD 
patients to matched clinical comparisons including hypertensive patients and 
healthy controls (see Table 2.5). Patients with COPD and hypertension 
displayed a similar incidence of anxiety (10%) that was significantly higher 
than among patients with no major health issues (3%). Other studies indicate 
that the prevalence of clinical anxiety is significantly higher in COPD patients 
than among individuals with other diseases including chronic orthopaedic 
disease and those with recently diagnosed tuberculosis (Aydin & Uluşahin, 
2001; Vögele & von Leupoldt, 2008). Finally, one study found comparable 
prevalence of PD and GAD in patients with COPD and their spouses. Kühl et al. 
(2008) found that 8% of patients with COPD had PD and/or agoraphobia 
compared to 5% of spouses. In addition, 6% of patients with COPD had GAD 
compared to 7% of spouses. 
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Table 2.5: Prevalence of clinical anxiety in COPD compared to comparison 
groups 
Study Populations compared Prevalence of 
clinical anxiety (%) 
Aghanwa & Erhabor (2001) COPD (n=30) 10 
 Hypertensives (n=30) 10 
 Healthy controls (n=30) 3 
Aydin & Ulusahin (2001) COPD (n=38) 16 
 Recently diagnosed TB (n=42) 2 
 Defaulted TB (n=38) 3 
 Multi-drug resistant TB (n=39) 15 
Vögele & von Leupoldt (2008) COPD (n=20) 55 
 Chronic orthopaedic disease (n=20) 20 
COPD, chronic obstructive pulmonary disease; TB, tuberculosis 
 
In addition to studies exploring prevalence rates through psychiatric diagnosis, 
there are numerous studies providing estimations of anxiety prevalence based 
on the severity of anxiety symptoms as identified in self-report scales. Table 2.6 
presents a non-exhaustive list of reported anxiety prevalence from major 
studies published during the last few decades. Among these studies are a 
number of multi-centre trials that permit large samples to be recruited (e.g., Xu 
et al., 2008). However, even among large homogenous samples of patients with 
COPD, estimated prevalence of clinical anxiety varies markedly. For example, in 
a recent study exploring the impact of anxiety and depression on 
hospitalisations and exacerbations, Xu and colleagues (2008) report that 10% 
of COPD patients had likely clinical anxiety at baseline as identified using the 
HADS-A (total score ≥11). In comparison, a similar study by Gudmundsson et al. 
(2005) which also incorporated the HADS-A found that 41% of the sample were 
likely cases of clinical anxiety (based on a cut-off score of ≥8). It is likely that the 
variation in HADS-A cut-off score is at least partly responsible for the disparity 
69 
 
in prevalence estimates between these studies and highlights the difficulty in 
establishing a benchmark prevalence figure. 
 
The diverse prevalence estimates for anxiety among patients with COPD may be 
explained, in part, by the various scales and cut-off scores that have been used. 
A number of self-report anxiety scales have been used to report the prevalence 
of likely clinical anxiety in patients with COPD, including the HADS-A, the BAI 
and the State-Trait Anxiety Inventory (STAI; Spielberger et al., 1983). It is also 
evident that the cut-off scores used to distinguish a case of likely clinical anxiety 
are not consistent. For example, studies that utilise the HADS-A to report likely 
anxiety prevalence have used a variety of cut-off scores, ranging from 8 to 11 
(e.g., Cleland et al., 2007; Gudmundsson et al., 2005; Xu et al., 2008). 
Generalising these findings to the wider COPD population should, therefore, be 
carefully considered. 
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Table 2.6: Prevalence of likely anxiety in patients with COPD 
Study Country N Screening 
tool 
Prevalence 
(%) 
Bosley et al. (1996) UK 76 HADS 28 
Cleland et al. (2007) UK 110 HADS 33 
Di Marco et al. (2006)  Italy 202 STAI 19 
Dowson et al. (2001) New Zealand 79 HADS 50 
Engström et al. 
(1996) 
Sweden 68 HADS 13 
Funk et al. (2009) Austria 122 HADS 49 
Gudmundsson et al. 
(2005) 
Sweden, Norway, Finland, 
Iceland, Denmark 
406 HADS 41 
Gurney-Smith et al. 
(2002) 
UK 30 HADS 53 
Kim et al. (2000) USA 43 BAI 33 
Lewis et al. (2007) UK 182 HADS 25 
Sutton et al. (1999) USA 37 HADS 57 
Walke et al. (2007) USA 74 ESAS 32 
Withers et al. (1999) UK 95 HADS 29 
Xu et al. (2008) China 491 HADS 10 
HADS, Hospital Anxiety and Depression Scale, STAI, State-trait Anxiety Inventory; BAI, Beck 
Anxiety Inventory; ESAS, Edmonton Symptom Assessment System. 
 
2.3.1 SUMMARY 
 
Although it is difficult to reach a consensus on the prevalence of anxiety in 
patients with COPD, it is clear that it is more common in this condition than 
among both the healthy population, and among patients with other chronic 
diseases. Even the most conservative estimates of anxiety prevalence from 
studies that utilise psychiatric interviews suggest that anxiety disorders, 
especially GAD, PD, and phobias, are common in patients with COPD. 
 
Amongst the most prevalent anxiety disorders are PD and GAD, which appear to 
be considerably more common among patients with COPD than in the general 
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population. Although the prevalence of phobic anxiety disorders also appears to 
be high in patients with COPD, it is evident that these disorders are also among 
the most common in healthy elderly patients. The prevalence of OCD and PTSD 
do not appear to be significantly elevated in patients with COPD. 
 
2.4 AETIOLOGY AND PATHOPHYSIOLOGY OF ANXIETY IN PATIENTS WITH COPD 
 
Although there are a number of theories that attempt to explain the elevated 
levels of anxiety in patients with COPD, the exact aetiology of anxiety in this 
patient group remains poorly understood. Muller et al. (2005) suggests that the 
elevated levels of anxiety in patients with chronic medical conditions are a 
result of four possible associations: a physiological consequence of the medical 
disorder; a psychological reaction to the experience of living with the medical 
disorder; a side effect of treatment, or a chance occurrence. Broadly speaking, 
theories explaining the elevated anxiety in patients with COPD mirror those 
posited by Muller and colleagues. It is likely, however, that the association 
between anxiety and COPD is both multifactorial and bidirectional (Jain & Lolak, 
2009). 
 
There is growing evidence for a physiological explanation of anxiety in COPD 
that can be explained by the presence and severity of dyspnoea. For example, 
recent brain imaging studies have found that the affective dimension of 
dyspnoea is processed in areas of the brain that are also activated by sensations 
of fear of anxiety (Carrieri-Kohlman et al., 2010; LeDoux, 2003; von Leupoldt et 
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al., 2009). This adds support to the notion that there might be a common 
aetiology between anxiety and symptoms of COPD such as dyspnoea.   
 
Dyspnoea is a central symptom in both COPD and anxiety (particularly PAs) and 
Klein (1993) proposes that PAs in patients with respiratory disease are often a 
result of a false suffocation alarm. As panic can be reliably induced in laboratory 
settings, it has been the focus of a great deal of psychophysiological research. 
Klein (1993) found that increasing brain CO2 and lactate in the laboratory were 
both indicators of potential asphyxiation that can lead to a false suffocation 
alarm and, therefore, to PAs. This may explain why PAs are so common in 
patients with COPD, who often have elevated pCO2. More recently, Beck and 
colleagues (1999; 2000) found that hypoxia, another indicator of potential 
suffocation, has a panicogenic response.  
 
The majority of research exploring the association between anxiety and COPD is 
focussed upon PAs and PD and a number of theoretical (and often 
contradictory) models have been proposed to explain this relationship. Within 
this field, the most widely accepted model is the cognitive model of panic 
proposed by Clark (1986). According to Clark’s model (Figure 2.3), a PA results 
when ambiguous bodily sensations are interpreted as imminently catastrophic, 
creating a positive feedback loop (Livermore et al., 2012). Catastrophic 
thoughts may be misinterpretations or over-interpretations of symptoms, and 
are often applied to shortness of breath in patients with COPD. There is growing 
evidence for the cognitive model of panic, supported by studies which 
demonstrate that although all patients with COPD experience shortness of 
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breath, it is those with catastrophic misinterpretations who experience 
heightened symptoms of panic and elevated prevalence of anxiety disorder 
(Livermore et al., 2010; 2012). 
 
 
 
 
 
 
 
 
Figure 2.3: Clark’s cognitive model of panic (adapted from Clark, 1986)  
 
 
An opposing model to that proposed by Clark is Ley’s ‘dyspneic-fear’ theory 
(1989). This model was an adaptation on an earlier hyperventilation theory of 
panic (Ley, 1985) and was based on findings questioning the role of 
catastrophic cognitions in panic, namely that catastrophic cognitions follow 
fear, that some patients experience panic without fearful cognitions, and that 
patients experience panic attacks during non-dreaming stages of sleep (Margraf 
et al., 1987; Rachman et al., 1987; Wolpe & Rowan, 1988).  The ‘dyspneic-fear’ 
model suggests that catastrophic cognitions follow fear and, therefore, that fear 
is a direct response to the sensation of respiratory distress (i.e., dyspnoea-fear). 
This hyperventilatory theory of panic posits that patients with COPD 
misinterpret the severity of their dyspnoea and that their fear of breathlessness 
Internal/external trigger 
Perceived threat 
Anxiety 
Physical/cognitive 
symptoms 
Misinterpretation 
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leads to a heightened state of psychological arousal. One of the criticisms of the 
‘dyspneic-fear’ model is that it is specific to those patients who experience what 
Ley (1992) labels Type I/classic or hyperventilatory panic attacks and not to 
those experiencing anticipatory panic attacks (Type II), or cognitive panic 
attacks (Type III). Carr et al. (1992) examined the application of the ‘dyspneic-
fear’ model in patients with asthma and PD and found that the model applies to 
patients with asthma (and no PD), but not to those individuals with only PD. 
The authors recommend that the cognitive model of panic is a better 
explanation of panic than the ‘dyspneic-fear’ model for patients with PD. 
Porzelius et al. (1992), and more recently Livermore et al. (2012), offer support 
for the cognitive model of panic by suggesting that ratings of catastrophic 
cognitions, but not dyspnoea, differentiate panickers from nonpanickers among 
patients with COPD. Furthermore, findings suggesting that actual respiratory 
function and perceived breathlessness do not affect levels of anxiety lend 
weight to the argument that elevated anxiety is a result of negative cognitions 
and symptom perception, rather than actual or perceived respiratory distress 
(Vögele & von Leupoldt, 2008).  
 
The exact mechanism/link between respiratory impairment, hyperinflation and 
anxiety is unclear.  It is possible that the rapid breathing response of a panic 
attack in patients with obstructive lung disease may also elevate (precipitate) 
dyspnoea through hyperventilatory mechanisms. As respiratory rate increases 
due to anxiety or increased respiratory demand (e.g., during exercise or an 
AECOPD), expiratory airflow obstruction causes an insufficient ability to exhale. 
This imbalance between inhalation and exhalation may lead to air trapping and 
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hyperinflation of the lungs, an increased work of breathing and a sense of 
greater effort to breathe. This may contribute to increased   respiratory distress 
and dyspnoea, which further feeds the dyspnoea-anxiety cycle. In addition, the 
sensation of an unsatisfying (insufficient) breath and the discomfort caused by 
hyperinflation can directly cause anxiety in patients who experience 
hyperventilation in the context of obstructive lung disease (Neuman et al., 
2006). The deleterious effect of anxiety and severe shortness of breath in COPD 
patients may discourage them from performing daily activities and engage in 
social interaction in fear of triggering further anxiety and embarrassment. 
 
Yohannes (2008) and NICE (2010) assert that the chronic and progressive 
nature of COPD may lead to increased anxiety. For example, patients with COPD 
may endure frequent AECOPD and hospitalisations that can be a source of 
stress and anxiety for both patients and their families. In addition to the 
physiological and psychological associations between anxiety and COPD, there 
also appears to be a link between anxiety and COPD medications. For example, 
common medications such as albuterol, salmeterol, oral corticosteroids and 
theophylline can cause anxiety, especially among patients with long-term usage 
(Cantor & Jacobson, 2003; Shanmugam et al., 2007). Common medications used 
in the management of COPD may have anxiogenic properties and also stimulate 
sympathetic responses. For example, commonly prescribed medications such as 
β-agonists can mimic the actions of sympathetic adrenergic stimulation acting 
through β-adrenoceptors. This explains the common side-effects of β-agonists 
which include increased heart rate, palpitations and sweating (Katon et al. 
2004). 
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2.4.1 SUMMARY 
 
The interactions between anxiety and COPD are far from clear. There is a 
limited but growing evidence base to indicate that a physiological pathway 
exists between dyspnoea and anxiety, or that COPD-related medications may 
elevate anxiety levels. Other theories focus upon the catastrophic 
misinterpretation of symptoms and the link between dyspnoea and fear. In all 
cases, current empirical evidence supporting these theories remains limited 
and unpersuasive. However, it is generally accepted that the aetiology of anxiety 
in patients with COPD is multifaceted and complex. 
 
2.5 RISK FACTORS FOR ANXIETY IN PATIENTS WITH COPD 
 
Few studies have explored the risk factors for anxiety among patients with 
COPD. Due to a lack of long-term epidemiological studies that specifically seek 
to establish risk-factors, it is difficult to gain a detailed understanding of the 
most important risks for developing anxiety. However, several cross-sectional 
studies have explored the characteristics of patients with COPD who experience 
anxiety and have attempted to identify the most likely risk-factors.  
 
The greatest focus of existing research has been upon the possible link between 
COPD severity and anxiety risk. In a study exploring the characteristics of COPD 
patients, Wagena and colleagues (2005) found no significant difference in 
psychological distress between patients according to their COPD severity 
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(based on GOLD categorisation). This finding has been supported by other 
studies exploring the relationships between anxiety and disease severity based 
on lung function (Engström et al., 1996; Gudmundsson et al., 2006). In contrast, 
Downson et al., (2001) found that patients with impaired lung function were at 
greater risk of developing anxiety. Also, Felker and colleagues (2010) found 
patients with very severe COPD were at more than three times the risk of 
having a clinical anxiety or depressive disorder (Felker et al., 2010).  Studies 
exploring the subjective experience of COPD severity suggest that patients with 
worse perceived symptoms of COPD are at higher risk of anxiety (Cleland et al., 
2007).  
 
There is clearer evidence that sex may impact upon the risk of experiencing 
anxiety. Several studies have found that women with COPD are at greater risk of 
experiencing psychological distress, including anxiety than their male 
counterparts (Di Marco et al., 2006; Gudmundsson et al., 2006; Laurin et al., 
2007). This is consistent with the elevated risk of anxiety among elderly women 
living in the community (Schoevers et al., 2003). Gudmundsson and colleagues 
found that in a multi-centre sample of 416 patients, 47% of women had 
clinically significant levels of anxiety (HADS-A total score ≥8), compared to 34% 
of men (p=0.009). It is not clear why there is a higher prevalence of anxiety 
among women, although it has been suggested that women may be more 
susceptible to the negative effects of COPD upon health status (Antonelli-Incalzi 
et al., 2003). 
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Age may also be a contributing factor to the risk of developing anxiety. Cleland 
et al. (2007) found that anxiety (HADS-A total score ≥11) was more prevalent in 
patients who were younger than 60 years old, irrespective of COPD severity. 
The authors postulate that increased susceptibility to anxiety in younger COPD 
patients may be because they cope less well with the enforced lifestyle changes 
that are associated with COPD (Cleland et al., 2007). In contrast to these 
findings, a large study by Gudmundsson and colleagues (2006) found no 
association between anxiety and age in patients with COPD.  
 
Smoking history and current smoking status also appear to be relevant. 
Gudmundsson et al., (2006) found that patients who currently smoked had a 
higher prevalence of anxiety than non-smokers (54% vs. 37%, p<0.01). 
Smoking is the most significant risk factor for developing COPD and high levels 
of anxiety have been identified as an important risk factor for adolescents 
starting to smoke (Patton et al., 1996; GOLD et al., 2011). It is likely, therefore, 
that those patients who develop COPD as a result of smoking have higher levels 
of anxiety when they begin to smoke (Hill et al., 2008). In addition, smoking is 
increased in patients with anxiety, so anxiety may be considered to be an 
aetiological factor in COPD (Lasser et al., 2000). 
 
Other factors that are thought to elevate the risk of anxiety in patients with 
COPD include those patients who have low satisfaction in their marital 
relationships, patients who demonstrate poor disease coping strategies, and 
patients with low levels of social support (Ashmore et al., 2005; McCathie et al., 
2002). 
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2.5.1 SUMMARY 
 
Although a number of potential factors have been identified that may increase 
the risk of anxiety in patients with COPD, the evidence remains ambiguous. The 
most consistent finding is that females and individuals who smoke may have an 
elevated risk of anxiety. The role of factors such as COPD severity and age are 
less clear. Further epidemiological studies that explore the long-term natural 
history of COPD and anxiety are needed to clarify the most important risk 
factors. 
 
2.6 IMPACT OF CO-MORBID ANXIETY IN PATIENTS WITH COPD 
 
Psychological distress may reduce an individual’s ability to cope with the 
physical symptoms of disease, which in turn may lead to further debility and 
worsening of psychological distress (van Ede, 1999). It is evident that the 
presence of co-morbid anxiety has a multifaceted impact upon patients with 
COPD. The following section will explore both subjective and objective 
outcomes associated with untreated co-morbid anxiety in patients with COPD. 
 
Several studies have found that co-morbid anxiety has a negative influence 
upon HRQoL (Cully et al., 2006; Giardino et al., 2010). Giardino and colleagues 
(2010) conducted a large multicentre study on 1828 patients with emphysema 
and found that anxiety was inversely associated with HRQoL as measured by 
the St George’s Respiratory Questionnaire (SGRQ; Jones et al., 1991). According 
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to Cully et al. (2006), the impact of anxiety on HRQoL can be extensive, affecting 
outcomes such as physical functioning, general health, pain, and disease-specific 
outcomes, such as mastery of illness and symptoms of dyspnoea. 
 
It also appears that anxiety may have a deleterious role on the physical 
functioning of patients with COPD. Eisner et al. (2010) found that patients with 
anxiety (≥9 on the HADS-A) had worse submaximal exercise performance on 
the 6-minute walk test and a greater risk of self-reported functional limitations. 
Likewise, Kim and colleagues (2000) conducted regression modelling to explore 
the role of anxiety in functional impairment and found that anxiety, as identified 
on the BAI, had a significant negative impact on functional ability reported on 
the Short Form-36 Health Survey (SF-36; Ware & Sherbourne, 1992).  
 
Two large, long-term follow-up studies by Xu et al. (2008) and Gudmundsson et 
al. (2005, 2006) have explored the impact of anxiety in patients with COPD on 
healthcare utilisation, specifically the role of exacerbations and related 
hospitalisations. Xu et al. followed 491 patients with COPD for 1 year and found 
that patients with a score of ≥11 on the HADS-A experienced exacerbations that 
lasted almost twice as long as those without anxiety (adjusted incidence rate 
ratios, IRR: 1.92: 95% CI; 1.04-3.54). However, those patients with clinically 
significant symptoms of anxiety did not have longer hospital stays. 
Gudmundsson and colleagues (2005, 2006) also followed a large group of 
patients (n=416) over a 1-year period and found that patients with low health 
status (SGRQ score >60) and higher anxiety (measured with the HADS-A) had 
an increased risk of rehospitalisation (hazard ratio, HR: 1.76; 95% CI, 1.16-
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2.68). Likewise, Yohannes et al. (2000a) retrospectively found that the presence 
of an anxiety disorder was a major factor related to the frequency of COPD-
related hospitalisations. 
 
Other studies have found that the risk of exacerbations is also increased in 
patients with COPD and anxiety. For example, Eisner et al. (2010) found that 
patients with COPD and anxiety (≥9 on the HADS-A) had a higher longitudinal 
risk of AECOPD (HR: 1.39; 95% CI, 1.01-1.90). However, Laurin et al. (2011) 
asserts that although the presence of anxiety may infer an increased risk of 
exacerbation in patients with COPD, there is little evidence to indicate that 
these exacerbations lead directly to hospitalisations. Rather, the exacerbations 
reported are usually symptom-based rather than event-based (i.e., ending in a 
hospitalisation). This is supported to some extent by an earlier study by Laurin 
and colleagues (2009) that followed patients with COPD for 2 years. Their 
results indicate that patients with a psychiatric diagnosis, as identified with a 
structured clinical interview, had a significantly higher rate of exacerbations 
treated in an outpatient setting, but no difference in the rate of exacerbations 
treated in inpatient settings. 
 
It is not clear why patients with COPD and co-morbid anxiety may be at a 
greater risk of exacerbations and related healthcare utilisation. COPD patients 
with anxiety often have lower self-efficacy, functional limitations and poor 
health behaviours that may lead to inadequate disease-management and place 
them at a higher risk of exacerbations (Burgess et al., 2005; Kunik et al., 2005; 
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Laurin et al., 2009). However, the interactions underpinning this relationship 
are far from clear and require further investigation.  
 
There have been few qualitative studies exploring the experience of living with 
COPD, and none that have specifically focussed upon the subjective experience 
of anxiety. However, there is some evidence to suggest that alongside the 
negative impact on measurable health outcomes, co-morbid anxiety also has a 
significant emotional impact. One qualitative study found that patients with 
COPD and symptoms of anxiety experience feelings of intense fear and 
vulnerability, especially at night (Shackell et al., 2007). It has also been 
suggested that because of the inextricable link between dyspnoea and anxiety, 
that patients with COPD experience repeated “shadow-of-death” moments – 
periods of extreme panic with thoughts associated with death (Bailey, 2001).   
 
2.6.1 SUMMARY 
 
Although research exploring the impact of co-morbid anxiety in patients with 
COPD is still evolving, there is growing evidence to suggest that the impact is 
multifaceted. Anxiety appears to impact negatively upon HRQoL, as well as 
functional activities and exercise performance. The impact on healthcare 
utilisation is less clear, but it is evident that although anxiety may or may not 
lead to an increase in hospitalisations, it does increase the likelihood of 
symptom-based exacerbations and also increases the duration of 
hospitalisations and risk of readmission. Finally, although there is a paucity of 
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research exploring the subjective experiences of anxiety in patients with COPD, 
there may be a significant and lasting emotional impact.   
 
2.7 MANAGEMENT OF ANXIETY IN PATIENTS WITH COPD 
 
Despite the high prevalence of anxiety disorders in patients with COPD, recent 
reports indicate that only 31% of patients with clinical anxiety or depression 
are receiving treatment (Kunik et al., 2005). Although there is a growing 
research base exploring the management of co-morbid anxiety in patients with 
COPD, recent reviews have identified that the current state of evidence remains 
insufficient to support treatment guidelines (Cafarella et al., 2012; Usmani et al., 
2011). Management approaches are focussed upon treatment strategies that 
cover three broad areas: pharmacological approaches, pulmonary 
rehabilitation, and psychological interventions. The following section will 
explore these three approaches and the corresponding evidence base relating to 
their efficacy in patients with COPD. 
 
2.7.1 PHARMACOLOGICAL INTERVENTIONS 
 
Pharmacological interventions are regularly used in the treatment of a variety 
of anxiety disorders including PD and GAD (Cafarella et al., 2012) and are 
recommended as the first-line approach to treating anxiety in patients with 
COPD (NICE, 2010). However, there is a dearth of high quality research 
supporting the pharmacological management of anxiety in COPD. For example, 
a recent Cochrane review exploring pharmacological treatments for anxiety 
84 
 
specifically in patients with COPD found only four studies (n=40) exploring the 
efficacy of selective serotonin reuptake inhibitors (SSRIs), tricyclic 
antidepressants (TZAs) and azapirones (Usmani et al., 2011). Due to poor study 
quality (e.g., small sample size and short follow-up periods), meta-analyses 
have not been undertaken (Usmani et al., 2011).  
 
The most persuasive evidence supports the use of SSRIs for managing anxiety. 
Studies exploring the efficacy of SSRIs for treating anxiety have found small but 
non-significant reductions in anxiety symptoms (e.g., Eiser et al., 2005). 
However, sample sizes lack statistical power (n=28) and therefore these results 
have limited application. Despite unconvincing evidence supporting its efficacy, 
pharmacotherapy appears to be as commonly used to treat anxiety in patients 
with COPD, as in other chronic disease groups (Cafarella et al., 2012).  
 
2.7.2 PULMONARY REHABILITATION 
 
The benefits of pulmonary rehabilitation (PR) in patients with COPD have been 
widely documented and include improvements in HRQoL, exercise tolerance, 
fatigue and dyspnoea (see Lacasse et al., 2007 for an extensive review). There is 
also growing evidence to support the role of PR in reducing symptoms of 
anxiety (Coventry & Hind, 2007). A recent systematic review and meta-analysis 
indicates that PR, incorporating exercise, education and social support, leads to 
a significant reduction in anxiety in patients with COPD (Coventry & Hind, 
2007). Findings from three studies comparing PR to standard care found a 
standard mean difference (SMD) in anxiety symptoms of -0.33 (95% CI: -0.57 to 
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-0.09, p=0.008) in favour of PR (Emery et al., 1998; Griffiths et al., 2000; Güell et 
al., 2006). 
 
PR programmes usually involve a combination of goal setting, exercise training, 
education and psychosocial support (Nici et al., 2006). Although the various 
components may all have an important role both individually, or in 
combination, the multifaceted nature of PR makes it unclear which aspects of 
the PR programme have the greatest impact upon anxiety.  
 
Exercise may facilitate the release of endogenous opiates and may also have a 
desensitising effect on anxiety symptoms such as dyspnoea and 
hyperventilation (Emery et al., 2008; Yohannes et al., 2010). Exercise-induced 
dyspnoea can be readily confused with anxiety-induced dyspnoea, so exercise 
allows patients to experience these symptoms in safety, often under the 
supervision of the rehabilitation coordinator such as a physiotherapist or 
exercise practitioner. This helps patients to learn to distinguish between 
physical and emotional symptoms and become desensitised to dyspnoea 
(Emery et al., 2008). A second proposed mechanism is that exercise causes 
increased temperature in specific brain regions, such as the brain stem, which 
may result in feelings of relaxation (Raglin & Morgan, 1981). Finally, findings 
from patients with chronic heart failure suggest that exercise may lead to 
additional psychosocial benefits, such as increased social support and quality of 
life (Wielenga et al., 1998). 
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Güell et al. (2006) found a significant reduction in anxiety in COPD patients who 
underwent a PR programme with a considerable exercise component, alongside 
breathing training techniques and disease education. However, few studies 
have specifically examined the role of exercise in the PR programme. A single, 
outdated study by Cockcroft et al. (1982) found that patients who underwent a 
controlled exercise programme demonstrated ‘psychological improvement’ that 
was non-significant.  
 
The role of the educational component of PR in ameliorating anxiety has been 
examined in even less detail. Educational components usually involve symptom 
management (such as lung clearance techniques), information about 
medications, disease education, and advice on relaxation techniques (Nici et al., 
2006). In their systematic review of the efficacy of PR, Coventry and Hind 
(2007) conclude that it is unlikely that an education component alone can 
reduce anxiety. However, education remains an important and complementary 
aspect of the PR programme which may help patients to understand the 
benefits of PR and to improve self-efficacy (Yohannes et al., 2010). Kunik and 
colleagues (2008) found that a COPD education intervention resulted in similar 
reductions in anxiety symptoms as a cognitive behavioural therapy (CBT) 
intervention. The authors postulate that anxiety may be reduced through the 
social interaction and support that occurs during educational sessions (Kunik et 
al., 2008). 
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2.7.3 PSYCHOLOGICAL INTERVENTIONS 
 
NICE guidelines advocate the role of psychological interventions for patients 
with diagnosed anxiety (NICE, 2011). The content of psychological intervention 
can vary from low-intensity interventions such as individual non-facilitated or 
guided self-help and psycho-educational groups, to high-intensity interventions 
such as CBT or applied relaxation (NICE, 2011). 
 
A recent systematic review examining the efficacy of CBT in managing anxiety 
in patients with COPD found only limited evidence supporting this approach 
(Coventry & Gellatly, 2008). The authors conclude that there is some limited 
evidence that CBT, when combined with exercise and education reduces anxiety 
in patients with COPD (Coventry & Gellatly, 2008). A lack of consistency in the 
use of anxiety scales (e.g., HADS, STAI, SCL-90) and the use of small sample sizes 
ensure that it is difficult to conduct robust and sufficiently powered reviews of 
this management approach.  
 
Since the publication of Coventry and Gellatly’s systematic review in 2008, two 
randomised controlled trials have been conducted that explore the efficacy of 
CBT in patients with COPD (Hyninnen et al., 2010; Kunik et al., 2008). Kunik and 
colleagues (2008) compared an intervention of group CBT, consisting of eight 1-
hour sessions, with a control intervention of eight 1-hour COPD education 
sessions in sample of 238 predominantly male (96%) patients with stable 
COPD. Both interventions led to a clinically significant reduction in anxiety as 
measured on the BAI. More recently, Hyninnen et al. (2010) conducted a 
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randomised controlled trial (n=51) comparing a 7-week intervention of 2 
hours/week of CBT to a control group who received enhanced normal care 
(consisting of a 5-10 minute telephone call with a clinician every two weeks). A 
significant reduction in anxiety score (mean change of 4.8 on the BAI) was 
reported in the CBT group post-treatment, which remained at 6-months follow-
up. No change in anxiety was reported in the control group who received 
enhanced normal care.   
 
A recent systematic review and meta-analysis explored psychologically based 
interventions in patients with COPD, including individual and group CBT, 
psychotherapy, stress management and progressive muscle relaxation 
(Baraniak & Sheffield, 2011). The authors analysed eight studies and found a 
small but significant combined reduction in anxiety (r = -0.27; CI: -0.42 to -0.14) 
when compared to standard treatment groups that included interventions such 
as PR or COPD education (Baraniak & Sheffield, 2011). However, when studies 
that included non-treatment controls were pooled and analysed, no significant 
reduction in anxiety was found. 
 
2.7.4 SUMMARY 
 
There remains a paucity of evidence on which to base recommendations for one 
type of management intervention. Although pharmacological interventions are 
recommended for managing patients with GAD and PD and are endorsed as a 
first line treatment approach in patients with COPD (Cafarella et al., 2012; NICE, 
2010), there is evidence to suggest that patients with COPD are often reluctant 
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to take additional medication (Yohannes et al., 2001). In addition, caution 
should be taken when prescribing medicines such as tricyclic antidepressants, 
mirtazapine and benzodiazepines as there is an increased risk of respiratory 
centre depression and associated respiratory failure (Cafarella et al., 2012).  
This indicates that a non-pharmacological approach to management is perhaps 
most appropriate for patients with COPD. However, although there is some 
emerging evidence in favour of non-pharmacological approaches such as PR 
and CBT, further research is needed to explore the effects of these interventions 
on large cohorts with minimal dropout rates. 
 
2.8 DETECTION OF ANXIETY IN PATIENTS WITH COPD 
 
GOLD (2011) and NICE (2010) guidelines recommend that all newly diagnosed 
COPD patients should undergo a detailed medical assessment, including the 
assessment of anxiety symptoms. The NICE (2010) guidelines for COPD also 
indicate that clinicians should be alert to the presence of anxiety in their 
patients. However, these COPD-specific guidelines fail to recommend clear 
strategies for identifying anxiety in this patient group. Although NICE (2011) 
guidelines on the management of GAD and PD (with and without agoraphobia) 
recommend that a formal diagnosis of anxiety should be undertaken using a 
structured clinical interview, this is not always practical. Therefore, it is 
recommended that COPD patients seen in clinical settings are screened using 
self-report screening tools (Maurer et al., 2008). In clinical settings a two-step 
approach is often incorporated in which patients are first screened using brief, 
inexpensive scales. Those patients who screen positive for anxiety usually 
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undergo a more thorough assessment to confirm diagnosis with a clinical 
interview (Vodermaier & Millman, 2011). 
 
There are a number of barriers to the detection of anxiety in patients with 
COPD. These typically fall into patient- or clinician-level barriers. Patient-level 
barriers to anxiety detection include the stigma associated with mental illness 
which may lead patients with anxiety to exaggerate somatic complaints instead 
of acknowledging emotional problems, the reluctance to disclose anxiety 
symptoms, and the confusion or masking that may occur in physical symptoms. 
Clinician-level barriers include the lack of a standardised assessment approach 
for patients with COPD, the lack of a disease-specific screening tool, the poor 
utilisation and uptake of existing screening tools, lack of confidence, skills and 
knowledge of anxiety symptoms and disorders, and the stigma of mental illness 
(Kunik et al., 2005; Maurer et al., 2008; Yohannes et al., 2010).  
 
Such barriers may help to explain why in one recent study exploring the 
prevalence of anxiety disorders in patients with COPD, less than a third (29%) 
of patients with a clinical anxiety disorder had received a physician’s diagnosis 
(Kunik et al., 2005).  
 
In clinical practice and research settings, monitoring of anxiety symptoms and 
screening of anxiety disorders is typically undertaken using self-report anxiety 
scales. The following section focuses specifically on these scales and critically 
discusses their use in patients with COPD. 
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2.8.1 EXTANT ANXIETY SCALES 
 
A number of different scales have been utilised for the measurement and 
screening of anxiety symptoms and disorders in patients with COPD. Within this 
section, I critically review six scales that have been either recommended by 
clinical guidelines for COPD, are widely utilised in COPD-related research, 
and/or are validated for use in patients with COPD (see Table 2.7). A summary 
of the scales’ psychometric properties is provided, with a focus on reliability 
and validity. Also, where appropriate, recommended cut-off values of will be 
discussed in order to assess the clinical utility of these scales to screen for 
anxiety disorders.  
 
Table 2.7: Comparison of reviewed anxiety scales 
Scale Number 
of items 
Administered by 
(duration) 
Application Partially 
validated in 
COPD 
Recommended 
by 
BAI 21 Self or 
interviewer (5 
min) 
Outcome 
measure & 
screener 
Yes ACCP 
DASS 42 Interviewer (10 
min) 
Outcome 
measure 
No ACCP 
GAI 20 Self or 
interviewer (5-10 
min) 
Outcome 
measure & 
screener 
Yes - 
HADS 14 Self (2-5 min) Outcome 
measure & 
screener 
Yes GOLD, ACCP 
STAI 40 Self (10 min) Outcome 
measure & 
screener 
No - 
TMAS 28/50 Self (10-15 min) Research No - 
COPD, Chronic Obstructive Pulmonary Disease; BAI, Beck Anxiety Inventory; ACCP, American 
College of Chest Physicians; DASS, Depression Anxiety Stress Scales; GAI, Geriatric Anxiety 
Inventory; HADS, Hospital Anxiety and Depression Scale; GOLD, Global initiative for chronic 
Obstructive Lung Disease; STAI, State-Trait Anxiety Inventory; TMAS, Taylor Manifest Anxiety 
Scale. 
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2.8.1.1 Beck Anxiety Inventory (BAI) 
 
Beck and colleague’s (1988) inventory is a self-report instrument that was 
specifically designed to minimize confounding symptoms with depression and 
avoid the nonspecific dimension of negative affect. The scale contains 21 items, 
with 14 items reflecting somatic symptoms of anxiety and panic. The BAI is 
recommended by the ACCP as a viable screening tool for use in COPD patients 
(Maurer et al., 2008). A few studies have utilised the BAI in COPD-related 
research (e.g., Kim et al., 2000; Kunik et al., 2008), yet the scale remains one of 
the most common instruments for measuring anxiety in general medical 
research (Piotrowski, 1999). 
 
Items are presented as a list of symptoms with respondents asked to rate on a 
four-point scale how much they have been bothered by each symptom in the 
preceding week. Scores range from 0-63. Beck and Steer’s (1990) manual 
suggests that a cut-off point of ≤9 indicates normal levels of anxiety; 10-18 
mild-moderate levels of anxiety; 19-29 moderate-severe levels of anxiety, and 
30-63 severe levels of anxiety.  
 
The reliability of the BAI appears to be very high. A review by McDowell (2006) 
found 16 studies reporting Cronbach’s α for internal consistency of 0.86 to 0.94 
across a range of populations, including elderly medical outpatients, psychiatric 
patients and healthy populations. Test-retest reliability for the BAI is reported 
to be 0.73 for one-week and 0.67 for 11 days (Fydrich et al., 1992).  
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The factor structure of the BAI has been explored by Hewitt and Norton (1993) 
and Creamer et al. (1995) with both studies finding a two factor solution: one 
factor of cognitive symptoms and a second factor representing somatic 
symptoms. McDowell (2006) reviewed studies reporting on the convergent 
validity of the BAI and found correlation coefficients of 0.44-0.68 with the STAI 
and 0.47-0.67 with the Hamilton Anxiety Rating scale for Anxiety. Steer et al. 
(1994) explored whether the BAI could distinguish between elderly medical 
patients (without psychiatric disease) and psychiatric outpatients to establish if 
the high number of somatic symptoms in the BAI may lead to false-positives. 
Although the BAI performed generally well in discriminating between groups, 
the authors note that six of the somatic items did not distinguish between 
medical patients and psychiatric patients.  
 
Although Beck and co-workers (1988) claim that the BAI can be used both as a 
screening tool for anxiety disorders and as an outcome measure for anxiety 
symptoms, others contend that the BAI is not a marker of anxiety in general but 
rather a marker of symptoms of panic (Cox et al., 1996). The BAI appears to 
have good face validity for symptoms of PAs, querying 10 of the 14 symptoms 
listed in DSM-IV-TR classification (APA, 2000). However, it has limited face 
validity for detecting GAD, as it does not include worry-type symptoms that are 
integral to a DSM-IV-TR diagnosis (Leentjens et al., 2008). This assertion is 
supported by a recent FA, which suggests that the strongest quality of the BAI is 
to assess panic symptomology (Leyfer et al., 2006). Leyfer and colleagues 
(2006) conclude that whilst the BAI has achieved significant discriminant 
validity for detecting patients with PD, it has sacrificed construct validity for 
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assessing overall anxiety. This is probably because Beck and co-workers (1988) 
deliberately excluded items which may overlap with depression, particularly 
symptoms associated with GAD (e.g., restlessness, irritability or fatigue). Cox 
and colleagues (1996) argue that the BAI is compromised as a tool for 
identifying general anxiety and should be considered a marker of panic. 
 
2.8.1.2 Depression Anxiety Stress Scale (DASS) 
 
The DASS (Lovibond & Lovibond, 1995) was designed to test for emotional 
disturbance as part of a broad clinical assessment and contains three subscales 
relating to depression, anxiety and stress. The scale contains 42 negatively 
worded statements (14 for each subscale) and has a four-point response format, 
which ranges from “did not apply to me at all” (0) to “applied to me very much, or 
most of the time” (3), with a high score indicating worse distress. The anxiety 
subscale contains four smaller sections relating to autonomic arousal (5 items), 
skeletal musculature effects (2 items), situational anxiety (3 items), and 
subjective experience of anxious affect (4 items). A 21-item version of the scale 
is also available (Lovibond & Lovibond, 1995).  
 
The DASS has not been validated in patients with COPD, yet the AACP (Maurer, 
2008) recommend the scale for use in this clinical population. A search of the 
literature on PubMed identifies a single study (Moore & Zebb, 1998), which has 
utilised the DASS in patients with COPD.  
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Although the DASS was not designed to screen for specific DSM or ICD 
diagnoses, the authors suggest that based on percentiles derived from a 
normative sample of students, scores of 0-77 represent normal states, 78-86 
represent mild disorder, 87-94 represent moderate disorders, 95-97 represent 
severe disorders, and 98-100 represent extremely severe distress (Lovibond & 
Lovibond, 1995). Nieuwenhuijsen and colleagues (2003) report an optimal cut-
off score of five on the anxiety subscale for detecting clinical anxiety disorders. 
 
A review exploring the reliability of the DASS has found that α internal 
consistency coefficients for the anxiety subscale are generally very high, ranging 
from α=0.84-0.92 (McDowell, 2006). In addition, two-week test-retest 
correlations were 0.79 for a mixed sample of outpatients (Brown, 1997). 
However, a recent Rasch analysis of the 21-item DASS in patients with chronic 
back pain indicates that although the depression subscale performs strongly 
(demonstrating good model fit), the anxiety and stress scales are not internally 
consistent enough to be used for individual anxiety assessment and are only 
suitable for assessing groups of patients (Parkitny et al., 2012). Previous Rasch 
analyses have also found poor model fit for the DASS anxiety subscale and 
recommend removal of items to achieve model fit (Shea et al., 2009). 
 
The validity of the DASS has been investigated by several studies whose 
findings support the three-factor structure originally proposed by the scale’s 
developers (e.g., Brown et al., 1997; Nieuwenhuijsen et al., 2003). However, 
there is some evidence of cross-loadings or poor fit on the anxiety subscale. For 
example, one study found that item 9 “I found myself in situations that made me 
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so anxious I was most relieved when they ended” loaded moderately on both the 
anxiety and stress factors (Brown et al., 1997). Similarly, items 30 “I feared that 
I would be ‘thrown’ by some trivial but unfamiliar task,” and 25 “I was aware of 
the action of my heart in the absence of physical exertion (e.g., sense of heart rate 
increase, heart missing a beat)” have been found to load equally onto both 
anxiety and stress factors (Brown et al., 1997; Nieuwenhuijsen et al., 2003). 
Finally, item 19 “I perspired noticeably (e.g., hands sweaty) in the absence of high 
temperatures or physical exertion” appears to load primarily onto the stress 
factor (Nieuwenhuijsen et al., 2003). Studies exploring the concurrent validity 
of the DASS demonstrate high correlations with the BAI (0.83) but low 
correlations with the STAI (0.44) (Antony et al., 1998; Brown et al., 1997). 
 
The DASS focuses on discriminating between anxiety and depression rather 
than providing comprehensive coverage of these constructs. Therefore, it omits 
several common symptoms of anxiety and depression that may be useful in case 
detection e.g., sleeping difficulties, tiredness and irritability. According to 
McDowell (2006), the omission of non-specific items from the DASS may have 
increased specificity at the expense of sensitivity. However, Nieuwenhuijsen et 
al. (2003) found that an optimal cut-off score of 5 resulted in a high sensitivity 
(0.92) but a poor specificity (0.40), thus leading to a high percentage of false 
positives. The DASS may be a valuable tool in initial screening due to its high 
sensitivity for detecting clinical disorders, but further investigations are needed 
to confirm the presence or absence of a clinical disorder for those who screen 
positive. According to Nieuwenhuijsen and colleagues (2003), for every 100 
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patients that are screened using the DASS, 66 will screen positive for an anxiety 
disorder, yet only 19 will actually prove to have a disorder.   
 
2.8.1.3 Geriatric Anxiety Inventory (GAI) 
 
The GAI (Pachana et al., 2007) is a recently developed scale which was designed 
specifically for use in older populations. It was designed to minimise fatigue by 
being brief, minimise symptom overlap of medical conditions by excluding 
somatic items, and utilises a dichotomous scoring format for ease of use in 
patients with mild cognitive impairment. The GAI is a 20-item scale consisting 
of statements with an agree/disagree response format. Respondents are asked 
to reflect on the previous week when answering the items. 
 
Although the GAI has only recently been developed, there are some early data 
relating to the scale’s reliability and validity. Pachana and colleagues (2007) 
report a Cronbach’s α for internal consistency to be 0.91 and 1-week test-retest 
reliability of 0.91 in a geriatric psychiatric sample. Other studies exploring the 
psychometric properties of the GAI in patients with Parkinson’s disease have 
found a Kuder-Richardson coefficient of 0.95 (Matheson et al., 2012), whilst 
Cheung and colleagues (2012) report a Cronbach’s α of 0.92 in patients with 
COPD.  
 
Pachana et al. (2007) demonstrated that the GAI correlated significantly with a 
number of extant scales including the BAI and STAI. The optimal cut-off score 
for identifying patients with an anxiety disorder was found to be 8/9, which 
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correctly classified 78% of patients with a sensitivity of 73% and a specificity of 
80%. However, a study exploring the sensitivity and specificity of the GAI in 
detecting anxiety disorders in older patients with COPD has recently been 
undertaken that found a significantly lower cut-off score of 2/3. This correctly 
identified 80% of the sample with a sensitivity of 86% and a specificity of 78% 
(Cheung et al., 2012).  
 
Although Pachana and co-workers (2007) claim the original GAI is 
unidimensional in nature, they present no empirical data to support this 
assertion. In response, a study exploring the psychometric properties of the 
Spanish version of the GAI found three factors: cognitive symptoms, arousal-
related symptoms, and, perhaps surprisingly considering the conceptual model 
of the scale, a factor containing somatic symptoms (Márquez-González et al., 
2012). Four of the items of the GAI loaded predominantly onto the somatic 
factor indicating that the GAI may indeed have a confounding somatic element. 
Item 7 “I often feel like I have butterflies in my stomach”, item 12 “I get an upset 
stomach due to my worrying”, and item 18 “I sometimes feel a great knot in my 
stomach”, all had factor loadings of >0.7 which suggests that these stomach-
related items do not fit the non-somatic model of anxiety originally proposed by 
Pachana and co-workers (2007). 
 
2.8.1.4 Hospital Anxiety and Depression Scale (HADS) 
 
The HADS (Zigmond & Snaith, 1983) was designed as a self-assessment scale for 
detecting clinically significant anxiety and depression in outpatients. It is widely 
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used in general medical settings and is the most frequently utilised scale in the 
COPD literature. A recent review exploring the prevalence of anxiety symptoms 
in patients with COPD found nine studies that utilised the HADS-A as a 
screening tool (Yohannes et al., 2010). The HADS-A has also been mentioned by 
the ACCP (Maurer et al., 2008) and GOLD (2011) for screening anxiety in COPD 
populations. 
 
The HADS contains 14 items covering both anxiety and depression, with 
patients asked to recall their experiences during the past week. The anxiety 
component of the HADS (the HADS-A) contains seven items: three items 
referring to fear or panic and four items referring to generalised anxiety. Scores 
range from 0-21 for the anxiety subscale. A major innovation in the 
development of the HADS was the deliberate exclusion of symptoms that might 
arise from the somatic aspects of illness. This ensured that the scale (in theory) 
is not be confounded by physical symptoms of illness or disease (Martin et al., 
2005). 
 
Zigmond and Snaith (1983) originally proposed a cut-off score of ≥8 as a 
possible case of anxiety, and ≥11 for a definitive case. More recently, Bjelland 
and colleagues (2002) and Bunevicious et al. (2007) report that a score of ≥9 
represents the optimal cut-off point for clinically significant symptoms of 
anxiety. However, Bunevicious et al. (2007) also found that the optimal cut-off 
points varied depending on the type of anxiety disorder being screened. For 
example, the optimal cut-off point for patients with PD was ≥11 yet the score 
was ≥9 for phobias and GAD. Other studies have demonstrated that optimal cut-
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off points in older patients with COPD may be considerably lower, perhaps as 
low as ≥4 (Cheung et al., 2012). 
 
The internal consistency of the HADS is generally moderate-high with reported 
Cronbach’s α for the anxiety subscale of 0.76-0.93 in patients with chronic 
disease (Bjelland et al., 2002). Quintana et al. (2003) demonstrated a 
Cronbach’s α of 0.86 for both the anxiety and depression subscales. Test-retest 
reliability has been reported as 0.84 at two weeks, 0.73 at two to six weeks, and 
0.70 at >6 weeks (Herrmann, 1997). 
 
The validity of the HADS has been extensively tested. In terms of factorial 
validity, the majority of studies have found a two-factor structure for the scale, 
corresponding to “anxiety” and “depression” (Bjelland et al., 2002; Quintana et 
al., 2003). However, other studies have found a three-factor solution indicative 
of the tripartite model of anxiety and depression (Clark & Watson, 1991; 
Dunbar et al., 2000).  
 
Although there is consistent support of the HADS for the purposes of clinical 
screening of anxiety disorders and assessment of the severity of anxiety 
symptoms, there is growing concern regarding the scale’s validity and reliability 
in populations with illness and disease (Martin, 2005). In particular, Martin 
highlights that if the bi-dimensionality of the HADS is not supported, or found to 
be compromised in certain clinical populations, then the scale cannot be 
concluded to reliably and accurately measure the two domains of anxiety and 
depression. A review of the HADS by Bjelland et al. (2002) supported the use of 
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the HADS in a range of settings (including primary care, acute care and 
psychiatric populations), yet only 11 of the 20 studies they review support a bi-
dimensional factor structure. A more recent review that focussed on studies 
from the year 2000 onwards found that only seven of 22 studies report a bi-
dimensional structure (Martin, 2005). The majority of contemporary studies 
report a 3-factor structure, yet one study by Karimova and Martin (2003) found 
that in a sample of pregnant women (n=100) there were 4-5 factors underlying 
the HADS. In addition, even among those studies who report a bi-dimensional 
structure, there were a number of instances where items loaded onto the 
‘wrong’ factor (Martin, 2005). 
 
Quintana et al. (2003) explored the psychometric properties of the Spanish 
version of the HADS on a large sample of patients (n=685) that included 
patients with diseases such as COPD, asthma and Crohn’s disease. FA revealed 
that across the entire sample, anxiety and depression items loaded well onto 
the corresponding anxiety and depression factors. However, among the COPD 
sample, there was evidence of cross-loadings between factors. Item 2 on the 
HADS-A “I get a sort of frightened feeling as if something awful is about to 
happen” loaded more onto the depression factor than the anxiety factor. In 
addition, item 5 on the HADS-Depression (HADS-D) “I have lost interest in my 
appearance” loaded evenly onto both the anxiety (0.46) and depression (0.48) 
factors. Other studies exploring the factor structure of the HADS-A suggest that 
item 4 “I can sit at ease and feel relaxed” is particularly prone to cross-loading. 
For example, studies in patients with musculoskeletal disease and cancer have 
found item 4 loaded considerably higher on the depression factor than the 
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anxiety factor for which it was designed (Boermeester & Berard, 1998; Pallant 
& Bailey, 2005). 
 
Researchers have also questioned whether the HADS represents the two factors 
of “anxiety” and “depression” that was conceptualised by the scale’s designers. 
For example, Johnston et al. (2000) explored the factor structure of the HADS in 
patients with somatic disease such as myocardial infarction and stroke and 
found a 2-factor solution that they label “psychological” and “somatic”. Although 
the majority of the items loaded primarily onto the “psychological” factor, item 
4 on the anxiety subscale demonstrated a split loading between “psychological” 
(0.42) and “somatic” (0.37). Two items on the depression subscale also showed 
split loadings (item 1 “I still enjoy the things I used to enjoy” and item 6“I look 
forward with enjoyment to things”). The authors suggest that item 4 on the 
HADS-A, as well as a poorly performing item on the HADS-D; item 4 “I feel as 
though I am slowed down”, are both items that are likely to be influenced by 
patients’ physical conditions. This may question the non-somatic nature of the 
HADS. 
 
There is also growing evidence that the structure of the HADS-A may not be 
unidimensional in patients with chronic disease. Studies utilising Rasch 
analyses of the HADS-A in patients with COPD and cancer have found some 
misfit to the unidimensional model. Tang and colleagues (2008) demonstrated 
that item 7 “I get sudden feelings of panic” was a mute item on the Chinese 
version of the HADS-A among a sample of patients with COPD. Additionally, the 
study found that items 2 and 6 “I feel restless as if I have to be on the on the 
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move” were of borderline misfit. A Rasch analysis by Smith et al. (2006) in a 
sample of cancer patients found additional evidence that item 6 did not fit the 
unidimensional model. 
 
Martin (2005) concludes that due to improvements in FA techniques, notably 
the increased use of confirmatory factor analysis (CFA), the majority of 
contemporary studies exploring the factor structure of the HADS support a tri-
dimensional structure. This three-factor structure supports the ‘tripartite’ 
model of anxiety and depression proposed by Clark and Watson (1991) that 
includes ‘negative affect’, ‘autonomic anxiety’, and ‘anhedonic depression’. 
When the tripartite model is applied to the HADS, it is suggested that the seven 
anxiety items are split between negative affectivity (four items) and autonomic 
anxiety (three items). Dunbar et al. (2000) conducted CFA on the HADS and 
found that items 2 “I get a sort of frightened feeling as if something awful is about 
to happen”, 5 “I get a sort of frightened feeling like butterflies in the stomach”, and 
7 “I get sudden feelings of panic” loaded onto the autonomic anxiety factor (see 
Figure 2.4). Martin (2005) argues that the autonomic anxiety component of the 
HADS-A would be sensitive to the somatic aspects of experience, which 
accompany illness and disease. Therefore, there may be considerable source of 
contamination in the scale due to physical symptoms that can negatively 
influence the accuracy of case detection.  
 
104 
 
 
Figure 2.4: Hierarchical factor structure of the HADS based on the 
‘tripartate’ model (Reproduced with permission from Dunbar et al., 2000) 
 
2.8.1.5 State Trait Anxiety Inventory (STAI) 
 
The STAI (Spielberger et al., 1983) is a 40-item scale measuring transient and 
enduring levels of anxiety. The first 20 items assess situational or state anxiety 
with respondents asked to indicate “How you feel right now, that is, at this 
moment.” The second 20 items refer to underlying or trait anxiety for which 
respondents are asked to indicate “How you generally feel.” The time frame for 
the state questions is “right now”, which may yield problems when assessing 
patients with PD outside the context of a PA (Leentjens et al., 2008). Each item 
on the STAI is scored on a four-point scale and totals for the trait and state 
subscale range from 20-80. 
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The STAI is used frequently within the COPD research, both as an outcome 
measure (e.g., Paz-Diaz et al., 2007) and as a screening tool (e.g., Kvaal et al., 
2001). It is also the most commonly used anxiety scale in contemporary medical 
research (Piotrowski, 1999). Reliability for the scale is generally good. 
McDowell (2006) reviewed a number of studies exploring the internal 
consistency of the STAI, the majority of which were in healthy student 
populations, and found Cronbach’s α of between 0.83 and 0.95 for the state 
scale and 0.67 and 0.95 for the trait scale. Predictably, test-retest scores for the 
state scale are lower than those for the trait scale. For example, McDowell 
(2006) reports 30-day retest values ranging between 0.71-0.75 for the trait 
scale and 0.34-0.62 for the state scale.  
 
To assess the validity of the scale, Vagg and colleagues (1980) conducted a 
factor analytic study of the STAI and found a four-factor structure that 
distinguished between state and trait anxiety and between positively and 
negatively worded items. However, a Rasch analysis in the mid-1980s showed 
that a number of items on both the state and the trait scales did not meet the 
scaling criteria and that there was inadequate coverage at the low end of the 
anxiety continuum (Tenenbaum et al., 1985). More recently, it has been 
suggested that the STAI is not specific to anxiety. Rather, McDowell (2006) 
suggests that that the STAI correlates more highly with depression scales than 
with anxiety scales such as the BAI.  
 
Results from a FA conducted by Bieling et al. (1998) suggest that the trait part 
of the STAI does not assess ‘pure’ anxiety, but rather includes items that reflect 
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depression and general negative affect. The authors found a hierarchical factor 
structure with a principal factor representing negative affect and two secondary 
factors reflecting anxiety (items representing rumination, worry and disturbing 
thoughts) and depression (items representing dysphoric mood and negative 
self-appraisal). A more recent FA found poor fit for the two-factor model and 
instead proposed a five-factor model: a 10-item anxiety factor containing three 
related sub-factors (restlessness, self-confidence and worry), a four-item 
unsuccessfulness factor and a six-item happiness factor (Caci et al., 2003). 
 
Kvaal and colleagues (2005) assessed the state subscale of the STAI in screening 
for anxiety disorders among stable geriatric patients. Their results suggest that 
the optimal cut-off score is 54/55, with a sensitivity of 0.82 and a specificity of 
0.88.  
 
The STAI contains a high number of items for a self-report scale. However, 
Leentjens and colleagues (2008) argue that some of the symptoms of anxiety 
disorders such as GAD, PD and phobias, such as fatigue, concentration and 
irritability, are not represented in the state scale, limiting the face and content 
validity of the STAI as a generic marker of anxiety.  
 
2.8.1.6 Taylor Manifest Anxiety Scale (TMAS) 
 
The TMAS is a little used scale that was originally designed for selecting 
patients for inclusion in psychological experiments. It has subsequently been 
used to assess anxiety as a general personality trait and not for assessing 
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anxiety as a clinical entity. This limits the use of the TMAS as a clinical screening 
tool or research outcome tool. However, one group of researchers exploring 
exercise tolerance and oxygen therapy in patients with COPD have utilised 
Taylor’s (1953) scale as a marker of anxiety status (Borak et al., 1991; 1996; 
1998). 
 
The TMAS exists as 50-item or 28-item versions and consists of statements with 
a true and false scoring system. Scores range from 0-50 or 0-28 depending on 
the version used.  Reliability estimates based on Kuder-Richardson coefficients 
were 0.78 and 0.84 in Iranian college students (Hojat & Shapurian, 1986). 
Taylor’s (1953) original paper reported test-retest correlations of 0.89 over a 3-
week period, 0.82 over five months and 0.81 over 9-17 months. In terms of 
validity, the TMAS does not correlate well with other assessments of anxiety 
(Siegman, 1956). Factor analyses have also found inconsistent results. For 
example, one study of graduate students by Livneh and Redding (1986) found 
18 factors with eigenvalues above one, whilst another study reported a five-
factor solution (Moore et al., 1984). 
 
2.8.2 COMMENTARY ON EXTANT SCALES 
 
Whilst all of the scales discussed above appear to offer generally high reliability 
and validity, there are a number of issues which may limit their practicality in 
screening and assessing markers of anxiety in clinical populations, especially 
those with chronic somatic disease such as COPD. In the following section, the 
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limitations of extant scales in these populations are summarised, with a 
particular focus upon their use in patients with COPD. 
 
2.8.2.1 Somatic focus 
 
Although some extant scales have been designed specifically to omit somatic 
anxiety symptoms, it is evident that none have so far achieved this goal. Both 
the HADS and the GAI were based on a cognitive model of panic, yet results 
from CFAs reveal that each scale contains items that load onto somatic factors. 
Scales such as the BAI, DASS, STAI and TMAS include somatic items in varying 
proportions. The BAI is heavily weighted towards somatic markers of anxiety 
and contains 14 somatic items out of a total of 21.  
 
The fact that extant anxiety scales assess somatic markers of anxiety is not a 
problem in the majority of settings. On the contrary, somatic symptoms are key 
considerations for the diagnosis of a range of anxiety disorders. For example, 
GAD is characterised by fatigue and muscle tension, whilst PD is characterised 
by PAs that are dominated by somatic symptoms including palpitations, 
breathlessness and sweating (APA, 2000). However, these anxiety symptoms 
mirror the common symptoms experienced by patients with COPD and may 
confound the diagnosis of anxiety. According to Hill et al. (2008), anxiety scales 
that contain somatic items such as breathlessness and fatigue are likely to 
overestimate the prevalence of anxiety (i.e., create false positives), since some 
symptoms may be associated with the primary respiratory component. Coffman 
(2002) adds that further confusion can be caused by the side effects of 
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medications. For example, bronchodilators used by patients with COPD can 
cause tremor, palpitations and insomnia, which can be associated with 
symptoms of anxiety. Without a formal psychiatric interview, it is difficult to 
establish to the cause of somatic symptoms and therefore scales containing 
somatic items may have a limited clinical utility in this population. 
 
2.8.2.2 Coverage of anxiety symptoms 
 
In an effort to distinguish between anxiety and depression, both the BAI and the 
DASS focus upon symptoms which are specific to anxiety. The DASS omits items 
relating to shared symptoms of anxiety and depression such as fatigue, tension 
and irritability. Likewise, to discriminate between the two types of psychiatric 
disorders, the BAI focuses upon psychophysiological symptoms of anxiety 
which can help to distinguish between anxiety and depression. The scale 
focuses upon symptoms of hyperarousal such as inability to relax, heart 
palpitations and tremor. Subsequently, those patients with high levels of 
cognitive anxiety may be underrated, whilst those exhibiting high levels of 
somatic symptoms may be overrated (McDowell, 2006). 
 
The strong correlations between both the DASS and BAI and depression scales 
means that it is likely that there is a common underlying negative factor. 
Therefore, it is impossible to separate anxiety and depression completely 
(McDowell, 2006). It is possible, however, that efforts to discriminate between 
anxiety and depression have resulted in scales that do not cover the full range of 
anxiety symptoms. For example, Cox et al. (1996) argue that the somatic-
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dominated BAI represents somatically laden panic rather than more general 
(cognitive) symptoms of anxiety. It is posited that both the DASS and the BAI 
assess markers of the majority of anxiety disorders with the exception of GAD 
(McDowell, 2006). 
 
Scales such as the HADS appear to cover a more general range of symptoms, 
including items relating to fatigue and irritability, but this can lead to cross-
loading between anxiety and depression factors. Factor analysis of the HADS 
demonstrates that there is a general negative affect factor underlying the scale 
and this, in theory, may limit the specificity of the HADS for detecting and 
discriminating between anxiety disorders and depression.   
 
2.8.2.3 Factor structure and loadings 
 
There appear to be many inconsistencies relating to factor structures of extant 
scales, which place doubts on the construct validity of these instruments. FA is 
often used to test the theoretical basis of the scale in an attempt to see if the 
scale measures what it purports to measure (DeVellis, 2003).  FA of the HADS, 
GAI, STAI and TMAS all reveal contrasting factor structures to those intended by 
the authors. This places serious doubts on whether the scales really are 
assessing markers of anxiety in the way that they were conceptualised. 
 
Studies exploring the BAI and the DASS have demonstrated a consistent factor 
structure, but these scales appear to be prone to cross loadings between factors, 
thus questioning their construct validity. For example, both the BAI and DASS 
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appear to contain items that are designed to assess anxiety, yet load 
predominantly onto a depression factor. This also seems to be the case for the 
HADS. Specifically, cross loadings between anxiety and depression factors 
appear to be particularly evident among patients with COPD (Quintana et al., 
2003).  
 
2.8.2.4 Validation in patients with COPD 
 
Perhaps the most important limitation to the clinical utility of existing anxiety 
scales is that few have been validated in patients with COPD. This is an 
especially important consideration as scales may perform very differently 
between clinical populations and identical item/scale performance cannot be 
assumed between groups (DeVellis, 2003). For example, the majority of extant 
anxiety scales were developed for general use e.g., HADS for use in medical 
outpatients.  
 
Of the six scales that have been recommended for use, or are frequently used in 
patients with COPD, only the BAI, GAI and the HADS have been validated (in a 
limited fashion) in this patient group (Cheung et al., 2012; Kunik et al., 2005; 
2007). However, no studies have specifically sought to explore the reliability or 
validity of these anxiety scales in patients with COPD. Cheung and colleagues 
(2012) and Kunik et al., (2005; 2007) have explored the ability of the GAI, HADS 
and BAI to screen for the anxiety disorders in patients with COPD.  
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Although the HADS is recommended by NICE and AACP guidelines and is likely 
to be the most commonly used scale among clinicians and researchers working 
with patients with COPD, Cheung and colleagues (2012) suggest that there is 
sufficient doubt in its ability to screen anxiety disorders accurately in older 
populations (particularly those with COPD) for it not to be recommended for 
clinical or research purposes. 
 
2.8.2.5 Summary 
 
It is clear that although all of the scales reviewed have promising reliability and 
validity in general medical populations, or in the populations they were 
designed for, few, with the exception of the BAI, GAI and HADS have been 
partially validated in patients with COPD. The ability of these three scales to 
screen for clinical anxiety in patients with COPD demonstrates that none have 
particularly high sensitivity. In addition to the lack of validation in patients with 
COPD, all of the scales reviewed have limitations in one or more key areas, 
including the inclusion of somatic items, selective symptom coverage and 
questionable factorial validity. 
 
The purpose of a screening tool is to identify those patients who are in need of 
further psychiatric examination. Identifying high numbers of false positives is 
costly, both financially, and in terms of wasted time for the clinician and the 
patient. A scale that can efficiently screen patients for anxiety is characterised 
by a high sensitivity, which ensures that all individuals with an anxiety disorder 
are identified (Lalkhen & McCluskey, 2008). 
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2.9 SUMMARY OF CHAPTER 2 
 
In addition to defining anxiety in both a medical and psychological context, this 
chapter has reviewed the prevalence, aetiology, pathophysiology, impact, risk 
factors, management and detection of anxiety in patients with COPD. 
 
It is evident that co-morbid anxiety in patients with COPD remains poorly 
understood. Yet, clinical anxiety disorders, particularly GAD and PD are highly 
prevalent in patients with COPD and occur at a greater rate than among age-
matched healthy populations and patients with other chronic disease.  Although 
there are a number of competing theories that attempt to explain the elevated 
prevalence of anxiety in this patient group, there is likely to be a multifactorial 
and potentially, a bidirectional relationship. Patients who are female and who 
continue to smoke appear to have an elevated risk of anxiety. The impact of 
unmanaged co-morbid anxiety in patients with COPD is multifaceted and 
includes reduced HRQoL, exercise tolerance and ability to perform activities of 
daily living (ADL). There is also some evidence to suggest that untreated co-
morbid anxiety increases healthcare utilisation in patients with COPD. 
 
Although there is little evidence to support a single management approach, 
there is emerging evidence that non-pharmacological treatments such as PR 
and psychological interventions can be efficacious in reducing symptoms of 
anxiety in patients with COPD. However, the lack of a standardised assessment 
tool, along with the poor quality of existing clinical trials limit the extrapolation 
of these findings to the wider COPD population. 
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This chapter also reviewed those scales that are recommended for clinical use, 
or have been used in COPD-related research. Although six extant scales were 
reviewed, there are limitations to the application of these scales for use in 
patients with COPD. In particular, extant scales are limited by potentially 
confounding somatic items, partial symptom coverage, unclear factor structure 
and lack of validation in this patient group.  
 
The absence of a validated tool and the questionable suitability of existing tools 
for assessing and screening anxiety in patients with COPD suggests that a new 
tool that is specifically designed for this purpose has considerable clinical 
utility. Although anxiety may be recognised through cognitive-language 
markers, motor-behavioural markers and physiological markers, this thesis 
focuses on both cognitive-language and motor-behavioural markers. One 
reason for omitting reference to physiological markers of anxiety is that these 
markers are often confused or attributed to other underlying medical 
conditions in primary care settings (Gelenberg, 2000). A focus on cognitive or 
behavioural symptoms enables a more accurate diagnosis in patients who have 
complex medical conditions which are typified by somatic symptoms. 
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Chapter 3 : SELF-REPORT RATINGS SCALES AND 
CONSIDERATIONS IN SCALE DEVELOPMENT 
 
 
“There are two possible outcomes: if the result confirms the hypothesis, then 
you’ve made a measurement. If the result is contrary to the hypothesis, then you’ve 
made a discovery.” 
Enrico Fermi 
 
3.1 INTRODUCTION 
 
In Chapter 2, the relationship between co-morbid anxiety and COPD was 
reviewed. It is evident that co-morbid anxiety has a significant impact upon 
patients, yet it remains under recognised and undertreated. In terms of 
detecting anxiety in patients with COPD, clinical guidelines advocate the role of 
reliable and valid self-report ratings scales. This chapter will explore self-report 
psychiatric ratings scales and their clinical use. Following this, key factors in the 
development of self-report scales are explored in detail, including 
considerations in item content and scale structure, concepts of reliability and 
validity, and the scale development process. 
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3.2 SELF-REPORT RATINGS SCALES IN PSYCHIATRY 
 
Scientific progress depends upon accurate measurement and instruments used 
in clinical and research settings must be both reliable and unambiguous in what 
they claim to measure (Keedwell & Snaith, 1996). Yet, it is only during the past 
60 or so years, that measurement has become a routine part of healthcare 
research and practice (Blais & Baer, 2010). Measurement of psychiatric 
disorders involves an understanding of both signs and symptoms as markers of 
the disorder. Signs may be considered to be objective findings that are observed 
by the clinician, such as restlessness, whereas symptoms are subjective 
experiences that are reported by the patient e.g., feeling nervous (Kessler et al., 
2000). Self-report rating scales are designed to be instruments that quantify 
patients’ subjective experiences and aid the clinician in identifying, quantifying 
and tracking changes in these important but not directly observable markers 
(Blais & Baer, 2010). 
 
Self-report scales typically fall into two groups: screening scales, and symptom-
rating scales. Screening scales are designed to identify the presence or absence 
of a specific disorder, such as a personality disorder, and provide a dichotomous 
outcome (i.e., case or non-case). In comparison, symptom-rating scales are 
designed to quantify the severity of symptoms. This may involve assessing the 
severity of symptoms in a pre-diagnosed disorder, or monitoring of sub-clinical 
symptoms (Blais & Baer, 2010). Although rating scales quantify symptom 
severity, many also report cut-off scores that can be used to indicate possible 
clinical disorders in a dichotomous fashion. 
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Self-report scales have become increasingly popular since the 1940s due to a 
growing need for reliable and valid outcome measures for both research and 
clinical practice. In addition, Kessler et al. (2000) suggest that there are a 
number of important practical benefits to self-report scales. First, they are 
relatively inexpensive to develop and distribute. Second, the continuous 
measurement approach is better suited to the understanding of diverse 
symptoms than a dichotomous clinician judgement. Third, the psychometric 
properties of self-report scales are easier to record than clinician judgement. 
 
Self-report scales fulfil, if developed appropriately, many of the criteria that are 
required from an outcome measure. For example, a survey of Canadian 
clinicians found high levels of agreement that outcome measures used in clinical 
practice should have the following characteristics: brevity, simplicity, ease of 
scoring, reliability, validity and sensitivity to change (Bellamy et al., 1998). 
 
Although self-report scales have a number of strengths that make them suitable 
for both clinical and research settings, there are a number of factors which 
influence their effectiveness and application. These fall under two main 
categories: response distortions and psychometric properties. Response 
distortions refer to response styles (such as acquiescence bias, extreme and 
central tendency responding) and response sets (such as social desirable 
responding), whereas psychometric properties refer principally to reliability 
and validity. These factors will be discussed in detail in sections 3.4 ‘Reliability 
and validity’ and 3.5 ‘Processes in scale development’. 
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3.3 SCALE DEVELOPMENT THEORY 
 
3.3.1 INTRODUCTION 
 
The following section explores the two distinct approaches to scale 
development that are utilised by researchers: classical test theory (CTT) and 
item response theory (IRT). Within this section, a brief overview of each 
approach is given. The strengths and limitations of these two competing 
theories are then discussed and a justification of the theory that guides this 
thesis is provided.  
 
3.3.2 CLASSICAL TEST THEORY 
 
Throughout the 20th Century, scale development was dominated by the classical 
measurement model, also known as CTT (Novick, 1966; Spearman, 1904). CTT 
assumes that items within a scale are comparable indicators of an underlying 
construct or latent variable, that is, not directly observable and not constant 
(DeVellis, 2003). The latent variable is the cause of how a person will respond 
to an item. For example, a measurement of depression may consist of multiple 
items such as “I feel sad” or “My life is joyless”, which relate to the latent variable 
of depression. An individual’s response to these items is largely determined by 
how they are feeling at that time (DeVellis, 2003). 
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According to CTT, a participant’s response to each item on a scale (the observed 
score) is thought to consist of both a “true” score and some random error. In a 
perfectly reliable scale, where all error has been removed, the true score is 
equal to the observed score. The more error there is in a scale, the worse the 
reliability will be (Redding et al., 2006). Figure 3.1 demonstrates the path 
diagram for the relationship between the variables according to classical 
theory. In the diagram, D is the latent variable “depression”, X1 through X4 
stands for the items in the scale, and e1 through e4 stand for measurement 
errors for each item.  
 
 
 
 
 
 
 
 
Figure 3.1: Path diagram illustrating relationships between variables 
according to Classical Test Theory (CTT) 
 
3.3.3 ITEM RESPONSE THEORY 
 
Although CTT has served the scale development and measurement community 
for the most of the last century, IRT has seen an exponential growth in recent 
decades (Fan, 1998). IRT comprises a set of generalised linear models and 
e1 X1 
e2 X2 
D 
e3 X3 
e4 X4 
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statistical tests that connect observed responses to a respondent’s location on 
an unmeasured underlying “latent” trait (Hays et al., 2000).  IRT, as the name 
implies, focuses on the theory of the item, rather than test-level focus of CTT. 
IRT is also known as modern test theory, and although the roots of IRT can be 
traced back to Louis Thurstone’s work in the 1920s (Thurstone, 1925), it did 
not become widely used until the 1980s when access to personal computers 
allowed psychometricians to conduct the complex mathematical modelling 
required.  
 
In IRT, each item’s relationship to the latent variable is assessed and reliability 
is not enhanced by redundancy (as in CTT), but by identifying better items. 
Whereas items in CTT are designed to be very similar to each other and to tap 
into the underlying variable in the same way, items in IRT are designed to tap 
different degrees or levels of the attribute (DeVellis, 2003).  
 
IRT assumes that a scale is undimensional and, therefore, that only a single 
latent trait is influencing item responses. The correspondence between the 
predicted response (i.e., probability of success) to an item and the latent trait is 
known as an item-characteristic curve that takes an S-shape (see Figure 3.2).  
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Figure 3.2: Item characteristic curve showing the relationship between the 
location on the latent train and the probability of answering the item 
correctly 
 
3.3.4 STRENGTHS AND LIMITATIONS OF CLASSICAL TEST THEORY AND ITEM 
RESPONSE THEORY 
 
IRT was developed to resolve some of the limitations of CTT. One of the most 
important limitations of CTT is that norms used for interpretation of the test 
scores are sample specific. In contrast, IRT is sample independent. Another 
limitation of CTT is that in order to examine an item’s performance, it is 
necessary for a respondent to complete all items on a scale. In contrast, IRT 
techniques model the relationship between the latent trait and each individual 
item (Reid et al., 2007).  
 
The theoretical advantages of IRT mean that it is increasingly becoming 
accepted as the preferred approach for scale development. However, there are a 
number of small, but practically relevant limitations of IRT. The first limitation 
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is that IRT requires large sample sizes. Hambleton and Jones (1993) 
recommend that samples of at least 500 respondents are needed to conduct 
IRT. In comparison, CTT can be applied to much smaller samples, perhaps a few 
hundred respondents or fewer. This makes CTT especially useful when there 
are limitations in time and recruitment. CTT also has advantages over IRT in 
that the simplicity of the model and its assumptions make CTT an attractive 
alternative to the complex and expensive software required for IRT (Fan et al., 
1998; Hambleton & Jones, 1993). CTT trades complexity for simplicity, whereas 
IRT focusses upon the precision of items within a scale (DeVellis, 2003) 
 
Although there is increasing acceptance of IRT for scale construction, 
developers in clinical settings continue to adopt CTT approaches. According to 
DeVellis (2003) the two approaches are comparable in many situations, 
especially if the aim is to produce a scale with non-hierarchical items. In CTT, 
the assumption is that each item is a roughly equal parallel indicator of the 
underlying latent variable. This assumption fits well when measuring 
characteristics such as attitudes, beliefs and mood states, particularly when 
utilising Likert-type scaling. In contrast, IRT is a more suitable for measuring 
hierarchical responses in which non-consistent measurement such as Guttman 
or Thurstone scaling is used. In these cases, each item represents a specific level 
of the attribute being measured (DeVellis, 2003). 
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3.3.5 CHOICE OF THEORY UNDERPINNING THE CURRENT RESEARCH 
 
The current research follows tradition and adopts a CTT approach to scale 
development. This decision was guided primarily by issues relating to sample 
size. The author and supervisory team agreed that it was unlikely that this 
research project would be able to recruit >500 respondents, particularly those 
from a clinical setting. In addition, the availability of statistical software at the 
University meant that CTT would be a more viable approach.  
 
There is empirical evidence to suggest that although IRT might be theoretically 
more robust, CTT and IRT may yield similar outcomes. For example, Fan et al. 
(1998) conducted an empirical comparison of CTT and IRT and found that the 
results between approaches were comparable. In particular, the degree of 
invariance of item statistic across samples, usually considered to be 
theoretically superior in IRT, also appeared to be comparable.    
 
3.4 RELIABILITY AND VALIDITY 
 
3.4.1 INTRODUCTION 
 
In order to be useful for both research and clinical application, a scale must be 
both reliable and valid (DeVellis, 2003). Reliability minimises random error 
whilst validity minimises systematic error. In order to be valid, a score must 
have adequate reliability, yet a reliable score does not necessarily have to be 
valid. Thus, reliability is usually established prior to validity (Corcoran & Fisher, 
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2000).  The following section discusses these two important psychometric 
properties in the context of scale development.  
 
3.4.2 RELIABILITY 
 
Reliability is a fundamental issue in psychological measurement and is 
concerned with random error in measurement (McDowell, 2006). Scale 
reliability or internal consistency may be defined as the proportion of variance 
attributable to the true score of the latent variable (DeVellis, 2003). Internal 
consistency is a measure of to what extent items in a scale are correlated with 
each other and therefore that items are all measuring (i.e., are manifestations 
of) the same thing (DeVellis, 2003). Internal consistency is usually calculated 
with Cronbach’s coefficient α (Cronbach, 1951), a measure of the average inter-
correlations within a scale. Cronbach’s α is defined as: 
 
 
 
Where s2i  are the estimates of the variances of the n items and s2sum is variance 
of the sum of all items. The calculated α is a number between zero and one, with 
one representing an instrument with ‘perfect’ internal consistency (Streiner & 
Norman, 2003).  
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There is no absolute answer regarding what level of α is adequate as the 
purpose of the measurement influences the standard of measurement required 
(McDowell, 2006). For example, a scale used in a clinical setting to make 
important health decisions requires higher internal consistency than a scale 
measuring multifaceted attitude constructs. According to Nunnally (1978), α 
should be above 0.70 to indicate a high level of internal consistency. Streiner 
and Norman (2003) argue that an α higher than 0.90 might indicate some 
redundancy of items but other psychometricians recommend that α of 0.90 
should be targeted, especially for scales designed for clinical use (Kline, 2000). 
 
Other types of reliability should also be considered during scale development. 
Split-half reliability provides a second test of internal consistency and is 
achieved by randomly splitting the scale in half and calculating the correlation 
between the scores for each half of the scale (Kline, 2000). Split-half reliability 
is usually calculated using Guttman’s split-half coefficient. 
 
Temporal stability can also be computed by having the same sample of 
participants complete the same scale on more than one occasion. This measure 
of test-retest reliability enables the measurement of how constant scores 
remain from one occasion to another (DeVellis, 2003). The rationale underlying 
this approach to reliability is that if a measure truly reflects a meaningful 
construct, it should therefore assess the construct comparably on two separate 
occasions (DeVellis, 2003). Of course, the time interval between these two 
occasions will depend on the underlying construct being assessed and can vary 
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considerably. Streiner and Norman (2003) suggest that a time interval of 
between 2 and 14 days is usual for calculating temporal stability in 
psychological testing.  
 
Test-retest reliability is commonly calculated using the Pearson or Spearman’s 
rank correlation coefficient. However, as McDowell (2006) points out, this 
approach can seriously exaggerate the impression of reliability as it ignores 
many of the mismatches between scores by only measuring the relationships of 
the relative standings between the scores. Therefore, McDowell (2006) advises 
the use of the intraclass correlation coefficient (ICC) which measures the 
consistency of the subjects’ actual scores on the two ratings.  
 
Research by Bland and Altmann in the 1980s highlighted that basic correlation 
coefficients were inappropriately being used to compare measurement tools in 
medical journals (Altman & Bland, 1983; Bland & Altman, 1986). They argued 
that rather than measure correlations, which are likely to be high in most tools 
that are designed to measure similar constructs, that differences between the 
measurements should be plotted against the mean scores. This can also be 
applied when comparing one measure over time (i.e., temporal stability) and 
allows the limits of agreement to be calculated. According to Bland and Altman 
(1986), a reliable scale should have 95% of the differences lying between SD of -
2 and +2. Rankin and Stokes (1998) assessed the use of ICC and Bland and 
Altman tests and recommended that neither test alone provides sufficient 
information and, therefore, suggested that both tests should be used.  
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3.4.3 VALIDITY 
 
Establishing a high level of reliability is an important step in scale development, 
but it is not sufficient on its own. Alongside reliability, the scale developer 
should also consider issues of validity. A scale “… is said to be valid if it measures 
what it claims to measure” (Kline, 2000; 17). This is an important consideration, 
as although a scale may have proven reliability (i.e., respondents get the same 
score each time they complete the scale), there needs to be additional evidence 
that the scale is measuring what we believe it measures.  
 
Traditional approaches to defining validity have adopted a ‘trinitarian’ 
perspective which divides validity into ‘three Cs’: content validity, criterion 
validity, and construct validity (Landy, 1986). However, Landy (1986) argues 
that validation processes are not so much directed towards the integrity of tests 
(where the attributes of a test e.g., the three types of validity, are ticked off in a 
checklist fashion) as they are directed toward the inferences that can be made 
about the attributes of the people who have produced the test scores. 
Establishing validity, therefore, can be seen as a process of hypothesis testing 
that is limited only by the imagination of the scale developer and their ability to 
develop experiments to test their hypotheses. This modern approach to validity 
testing provides a problem to the scale developer in that the wider social 
science community continue to grade validity based on the traditional 
‘trinitatian’ approach. Therefore, the author will comply with convention and 
describe validity under the headings of content, criterion and construct validity. 
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3.4.2.1 Content validity 
 
Content validity can be defined as “… the extent to which a specific set of items 
reflects a content domain.” (DeVellis, 2003: 49). Kline (2000) and DeVellis 
(2003) argue that content validity is easiest to evaluate when the domain is well 
defined. This is more difficult to establish when a scale measures attitudes and 
beliefs as it is challenging to determine the range of potential items and 
whether the sample of items is representative (DeVellis, 2003). This process is 
subjective and typically involves asking experts to review items to establish 
content that might have been omitted but should be included.  
 
Alvan Feinstein (1987) proposed an extension to content validity which he 
termed “sensibility”. Sensibility is an underlying principle in the area of 
clinimetrics and refers to the clinical appropriateness of a scale. This can be 
divided into five main topics, which can be assessed subjectively: the purpose of 
the scale (clinical function and justification), the overt format of the scale 
(comprehensibility, clarity), face validity (aimed at the right area), content 
validity (representative of the domain), and ease of usage (time and effort 
required to complete). 
 
Perhaps the least persuasive yet still highly desired type of validity is face 
validity. That is, do the items appear on the surface to be measuring what they 
actually are? (Streiner & Norman, 2003). This is particularly important in self-
report scales because, as Streiner and Norman (2003) state, “If the item appears 
irrelevant, then the respondent may very well object to it or omit it, irrespective of 
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its possibly superb psychometric properties” (pp.66). Although this appears to be 
similar to content validity in that this is essentially a subjective appraisal of 
general acceptability (Gregory, 2003), some experts advocate that scale 
developers consider face validity during the early stages of the scale 
development process (DeVellis, 2003; Streiner & Norman, 2003). According to 
Nevo (1985), face validity should be judged by the respondent and not by the 
scale developer. Whilst it is important that the scale appear valid, face validity 
alone is insufficient to demonstrate that the scale is measuring what it claims to 
measure. 
 
3.4.2.2 Criterion validity 
 
Criterion validity is concerned with demonstrating the accuracy of a scale. This 
can be established by demonstrating an empirical association between the scale 
and some other measure of the same construct, ideally, a ‘gold standard’ which 
has already been used and accepted in the field (Streiner & Norman, 2003). 
There are two main forms of criterion validity: concurrent validity and 
predictive validity. In concurrent validity, the new scale is correlated with the 
criterion measure, which are both completed at the same time. In contrast, 
predictive validity assesses the ability of the new scale to predict future changes 
in relevant variables (Streiner & Norman, 2003). 
 
Concurrent validity can be used to measure the degree of agreement between 
the two measures based on the correlation between their total scores. In 
addition, when a ‘gold standard’ produces a dichotomous outcome e.g., a 
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medical diagnosis, a threshold score can be calculated that demonstrates how 
well the new scale distinguishes between groups (i.e., those with a particular 
diagnosis and those without).  
 
Two types of error can occur when calculating a threshold or cut-off score: the 
test may fail to identify patients who have the condition, or it may falsely 
classify people without the condition as having it. The term “sensitivity” refers 
to the proportion of the people with the condition (positives) who are correctly 
identified by the scale, while “specificity” refers to the proportion of people 
without the condition (negatives) who are correctly identified by the scale 
(McDowell, 2006). An increase in sensitivity is almost always accompanied by a 
decrease in specificity. Therefore, the aim of the scale developer is to calculate 
the score which provides the best balance between sensitivity and specificity. 
Given that cut-off scores affect the number of false positives and false negatives, 
the choice of score will have both clinical and economic consequences . A higher 
rate of false negatives leaves a number of patients unrecognized who are likely 
in need of support, whereas an elevated level of false positives may lead to an 
increase in unnecessary healthcare costs (Vodermaier & Millman, 2011). 
 
A common approach to determining a cut-off score is to plot true-positives 
(sensitivity) against false-positive results (1-specificity) for each potential cut-
off score in a scale forming a curve known as the receiver operating 
characteristic (ROC; McDowell, 2006; Streiner & Norman, 2003). The curve (see 
Figure 3.4a) illustrates the trade-off between sensitivity and specificity and the 
area under the curve (AUC) indicates the amount of information provided by 
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the test. An AUC of 0.5 (the diagonal line in Figure 3.4a) indicates that the test is 
no better than simply guessing whether a person has the condition or not. 
However, values above 0.5 indicate that the scale has merit as a screening tool. 
According to Swets (1988) values between 0.5-0.7 represent poor accuracy, 
values between 0.7-0.9 have some use as a diagnostic tool, and values of ≥0.9 
indicates a highly accurate tool. A ROC curve can also be used to measure the 
diagnostic characteristics of several tools at once (see Figure 3.4b). In this 
example, the curve with the largest AUC (scale B, i.e., the curve closest to the top 
left of the graph) has the best diagnostic properties in terms of sensitivity and 
specificity.  
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a. 
 
b. 
 
Figure 3.3: Example of ROC curve for a) a single scale, and b) comparison 
between two scales 
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3.4.2.3 Construct validity 
 
Construct validity (Cronbach & Meehl, 1955) can be defined as “… the extent to 
which a measure ‘behaves’ the way that construct it purports to measure should 
behave with regard to established measures of other constructs.” (DeVellis, 2003: 
53). Establishing construct validity is an on-going process of empirically testing 
whether a measure behaves as it is should according to theoretical 
assumptions. As Kline (1979: 11) asserts, in order to test construct validity, “…a 
number of hypotheses are set up that would be tenable if the test were valid.” 
There is no single proof of construct validity, so a scale developer should 
systematically build an evidence base to support the adequacy of the scale 
(McDowell, 2006). This process typically involves testing multiple a priori 
hypotheses to support the behaviour of the scale based on the conceptual 
definition of the construct. Each supportive study serves only to strengthen 
what Cronbach and Meehl (1955) term the “nomological network”. According to 
Cronbach and Meehl (1955) this network includes the theoretical framework 
for what you are trying to measure, an empirical framework for how you are 
going to measure it and the specification of linkages found between the 
theoretical and empirical frameworks. 
 
One hypothesis that may be tested is whether the scale correlates well with 
other scales that purport to measure similar constructs. This is known as 
“convergent validity”. Conversely, a second hypothesis may state that the scale 
will not correlate with other scales that measure unrelated phenomena, a 
process known as “divergent validity” or “definition by exclusion” (Kline, 2000). 
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McDowell (2006) argues that as this process is one of empirical hypothesis 
testing, the scale developer should always declare what level of correlation is 
adequate prior to testing.  
 
Another method for establishing construct validity is to determine group 
differences, this is also known as “known-groups validation” (DeVellis, 2003). In 
this method, the scores of groups, who, according to the conceptual model are 
expected to perform differently, can be compared using statistical procedures. 
For example, a scale which purports to measure ADL could be tested on two 
groups (e.g., a healthy group vs. a group with chronic lower back pain). 
Significant differences in scores would disprove the null hypothesis that the 
scale fails to differentiate between them (McDowell, 2006).  
 
Construct validity can also be tested by proving the ability of a scale to detect 
change that actually occurs (McDowell, 2006; Streiner & Norman, 2003). For 
example, scores on a scale measuring pain would be expected to change if a 
sample of patients are given pain medication. This element of construct validity 
is especially important in scales that are designed to be used in a clinical 
research setting as knowing the responsiveness of an instrument is valuable in 
calculating the power of a study and the sample size required. 
 
Finally, construct validity may be established through the use of statistical 
analysis to determine whether there is an underlying conceptual structure of a 
scale. Confirmatory factor analytical procedures are usually undertaken to 
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define underlying scale structure. This is discussed in detail in the succeeding 
section (‘Statistical tests for scale development’). 
 
3.4.4 SUMMARY 
 
Reliability and validity are two important concepts in scale development. 
Reliability may be defined in terms of internal consistency (i.e., internal 
reliability) and temporal stability (i.e., test-retest reliability). Validity is a more 
complex measure which can be established throughout the scale development 
process. In the early stages of scale development, content validity and face 
validity can be established. Criterion validity can be established by comparing a 
new scale against gold standard measures and exploring the screening 
properties of the scale. Finally, construct validity can be measured through 
empirically testing a priori hypotheses, including the scale’s conceptual factor 
structure, know-groups validity and convergent validity. 
 
3.5 PROCESSES IN SCALE DEVELOPMENT 
 
3.5.1 INTRODUCTION 
 
Within the following section, the processes of scale development are explored. 
This is principally focussed on the initial item development process, where 
decisions on item writing and scale format are made, and the subsequent item 
selection and validation process which involves quantitative approaches that 
are concerned with establishing reliability and validity of the scale. 
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3.5.2 ITEM DEVELOPMENT 
 
The first phase of the scale development process can be separated into several 
sub-phases that have a shared objective of developing an internally consistent 
scale. Integral to this process is what Rowan and Wulff (2007: 461) describe as 
the “predevelopment stage” – defining the latent variable that is to be measured 
through a thorough review and understanding of existing literature (DeVellis, 
2003; Redding et al., 2006). 
 
Following this, a development phase can begin where a pool of scale items are 
developed. For many researchers, simply “borrowing” items from existing 
scales is adequate when developing item pools and generating new scales 
(Morizot et al., 2007; Yesavage & Brink, 1983). For example, Zhang and Yu 
(1998) developed a pool of items for their life satisfaction scale by selecting 
those that already existed in a previous scale.  However, Comrey (1988) does 
not recommend this procedure as it requires that all the needed items in the 
right form be available in the pool. According to Comrey (1988), items must 
meet two criteria: a) they must have been written specifically to measure the 
same construct, and b) they must satisfy a statistical criterion of relatedness by 
correlating with each other sufficiently to define an item factor in a FA of items 
after they have been written. In order to achieve these criteria, it is usually 
necessary to develop some new items. 
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The development of a scale is dominated by quantitative data and analyses, 
however, an increasing number of scale developers have incorporated a 
qualitative phase of exploratory work in the scale development process (e.g., 
Jones et al., 2009b; Michalak et al., 2010; Okuyama et al., 2000; Ushiro, 2009). 
Qualitative inquiry can be especially useful to scale development researchers in 
that the validity of the quantitative research can be enhanced by first being 
grounded in real life situations through having interviews from an open 
perspective (Rowan and Wulff, 2007). Qualitative inquiry in the early stages of 
scale development may also “serve as a vehicle for us to see if there may be some 
yet unexplored or untapped areas of the topic in questions (or new informants) 
that could yield specific new items” (Rowan and Wulff, 2007: 451).  
 
In writing the item pool, it is important to pilot as many items as possible, but 
this needs to be balanced with the demand that are placed upon the respondent. 
Kline (2000) recommends that twice the number of items that are anticipated 
in the final scale are included in the item pool. To minimise random error and 
enhance reliability, items need to be interpreted in a consistent manner, 
therefore, wording and clarity of items is important. Developers should avoid 
exceptionally lengthy items and consider reading difficulty level at which the 
items are written (DeVellis, 2003). A readability formula such as the Flesch 
Reading Ease Score (Flesch, 1948) which predicts the difficulty of text based on 
average word and sentence length and number of syllables can help to avoid 
confusing items. According to DeVellis (2003), a reading level between the fifth 
and seventh grades (equivalent to Year 6 in the UK i.e., age 10-11 years) is an 
appropriate target for instruments that will be used in the general population. 
138 
 
In addition, face validity and content validity can be enhanced at this stage by 
collaborating with experts in the field and with respondents who represent the 
population that the scale is being defined for. 
 
Another key consideration is deciding upon response and scaling formats. 
There have been a multitude of scaling methods using within health-related 
research including Thurstone, Guttman and visual analogue scaling (Streiner & 
Norman, 2003). However, by far the most common are Likert scales (Likert, 
1952). Their popularity may be a result of the fact that they are relatively 
simple to construct, easily analysed and are familiar to most respondents (Kline, 
2000). Likert scaling presents the respondent with a declarative statement, 
followed by response options that indicate varying levels of agreement or 
endorsement to an attitude or experience (DeVellis, 2003). An example of a 
Likert response format for an item is as follows: 
 
I am generally a happy person. 
Strongly Agree    Moderately Agree    Moderately Disagree    Strongly Disagree 
 
There are a number of important decisions to be made regarding the number of 
response options and their wording, and these have received considerable 
debate within the literature (e.g., DeVellis, 2003; Kline, 2000). However, it is 
generally assumed that response options to be worded so as to have roughly 
equal intervals with respect to agreement or endorsement and that greater 
numbers of response options will improve scale reliability by increasing 
discrimination between individuals.  
139 
 
 
DeVellis (2003) recommends that validation items should be included at this 
stage to provide information about convergent and discriminant validity. 
However, Worthington and Whittaker (2006) recommend that this is not done, 
in order to keep questionnaire length short and reduce the burden on 
respondents. 
 
Considerations relating to the potential for response bias should also be 
considered at this stage of the scale development process. Two common biases 
of acquiescence bias and social desirability bias are suggested to reduce the 
validity of a scale. Acquiescence bias is the tendency to give a positive (or 
consistent) response to an item regardless of its content or the direction of the 
wording (Locker et al., 2007). Social desirability bias, on the other hand, is the 
unconscious tendency to give a socially acceptable response (Locker et al., 
2007).  
 
In order to minimise acquiescence bias, scale developers frequently include 
both positively and negatively worded items. The theory underlying this 
approach is that the change in item structure will result in the respondent 
giving more careful consideration to their response (Bowling, 2009). Although 
this strategy is a generally accepted practice, research exploring the construct 
validity of the Zung Self-rating Depression Scale (SDS; Zung, 1965) and the STAI 
challenges this convention (Schotte et al., 1996). These findings indicate that 
significant differences exist in mean scores between negatively and positively 
worded items, and that factor structures of the scales demonstrate negative and 
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positive factors. Strategies for predicting the extent of acquiescence bias and 
social desirability bias include using uncorrelated items to estimate response 
styles and estimating response styles from existing questionnaires (Chami-
Castaldi et al., 2008).  
 
Extreme and central tendency responding are also a potential issue in scale 
validity. Extreme responding refers to the tendency of the respondent to favour 
the endpoints or extreme categories of the scale response set 
disproportionately (Naemi et al., 2009). Rasch analyses indicate that 
approximately 30% of scale respondents are ‘extreme responders’ (Austin et al., 
2006).  Extreme responding is the opposite of central tendency responding in 
which respondents tend to favour the mid-point of the response set (Naemi et 
al., 2009). One strategy for reducing central tendency is to have a ‘forced 
response’ e.g., an even number of responses with no midpoint (DeVellis, 2003). 
This approach is useful in attitudinal scaling where there is often a clear neutral 
standpoint, but less so in self-report symptom scales in which the midpoint is 
usually a middle value of symptom severity. Strategies to reduce extreme 
responding are less clear. As extreme responses are more likely to occur in 
smaller response sets, one possibility is to increase the number of response 
options available to respondents. However, there is the danger that response 
sets can be too long, thus presenting the respondent with categories that are 
not meaningful (Chami-Castaldi et al., 2008). 
 
Once an item pool has been developed, it should then be reviewed by a group of 
experts who are knowledgeable in the content area (DeVellis, 2003). This will 
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enhance content validity of the scale and ensure that items fully represent the 
defined construct. Expert opinion may also be sought on the wording and clarity 
of the items. However, as discussed previously, respondent input may be more 
valuable in assessing issues of face validity and therefore the scale developer 
may consider their input at this stage.  
 
3.5.3 STATISTICAL TESTS FOR SCALE DEVELOPMENT 
 
After establishing a final pool of items, these can then be assessed statistically to 
establish which items are consistent with the latent variable and which items 
should be removed. In CTT, two types of statistical procedures are involved: 
Item analysis and FA (Nunnally, 1978). Item reduction through item analysis 
and FA is a complex, iterative and subjective process (Cabrera-Nguyen, 2010). 
Worthington and Whittaker (2006: 808) suggest that refining an item pool is a 
“… dynamic process of examination and revision, followed by more examination 
and revision, ultimately leading to a tentative rather than a definitive outcome.” 
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3.5.3.1 Item analysis 
 
Prior to item analysis, the item pool should be completed by a sample of 
respondents. DeVellis (2003) recommends that this be a representative sample 
of the target population and argues the case for large samples in order to reduce 
standard error by reducing the systematic variance (Worthington & Whittaker, 
2006). Nunnally (1978) suggests that the sample should be large enough to 
eliminate subject variance and advocates samples of >300 respondents, and 
preferably over 1,000. However, Kline (2000) argues that as long as a sample is 
representative of the target population, a sample of ~100 respondents is 
sufficient. In practice, robust item analysis has been performed on sample sizes 
well below the 300 recommended. Practical implications such as time 
constraints, financial constraints, and access to sufficiently large populations, 
mean that sample sizes of below 100 respondents are common and acceptable 
(Okuyama et al., 2000). 
 
As discussed previously in section 3.4.2 ‘Reliability’, producing an internally 
consistent scale is at the heart of the scale development process. This can be 
achieved through distributing the pool of items to a large and representative 
sample and selecting a set of highly intercorrelated items using item analysis 
(DeVellis, 2003). Nunnally (1978) advocates that item analysis be carried out in 
the early stages of scale development to refine the item pool prior to additional 
statistical procedures such as FA. The aim of item analysis is to select those 
items which demonstrate desirable characteristics which can increase 
reliability and produce a homogenous test (Kline, 2000). Desirable 
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characteristics for items include those which contribute to the internal 
consistency (Cronbach’s α), those with high item-total correlations, those with 
high variance, and those which have a mean score close to the centre of the 
range of possible scores (Kline 2000). 
 
Each item in a scale should measure what the test measures and this can be 
calculated using item-total correlations (Kline, 2000). Items can be selected or 
removed based on how they perform compared to other items in the scale. A 
corrected item-total correlation provides the correlation between the item 
score and the total score, without that item included. If the correlation is low 
then it can be assumed that that particular item is not measuring the same thing 
that the rest of the scale is measuring and can therefore be removed. 
 
Another attribute that is desirable in an item, is that it has relatively high 
variance (DeVellis, 2003). If all respondents answer an item the same way then 
this will not discriminate between individuals and the variance will be zero. As 
DeVellis (2003: 94) states “… an item that does not vary cannot covary.” 
Therefore, a range of responses is required to ensure that an item can 
differentiate between respondents. Similarly, it is desirable that the mean score 
for an item is near the centre of the possible range. If the mean is at the extreme 
end of possible scores then it may indicate that the item is worded poorly and 
does not allow for a range of possible responses. 
 
Finally, the internal consistency can be maximised by selecting items which 
positively contribute to α. Those items which lower the overall α value can be 
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highlighted based on the ‘α if item deleted’ statistic. Removal of these items will 
result in more reliable scale (DeVellis, 2003). However, it is worth noting that 
removing an item for a negligible improvement in α may not be desirable if the 
scale developer feels that the item ‘taps’ into a particularly important aspect of 
the latent variable. 
 
3.5.3.2 Factor analysis 
 
Factor analysis (FA) is a statistical technique that investigates whether items in 
a scale are linearly related to a smaller number of unobservable factors. FA 
enables the scale developer to determine how many latent variables underlie a 
set of items and also to help define what these latent variables may represent. 
Furthermore, FA can help minimise systematic error by checking for the 
unidimensionality of the scale (DeVellis, 2003). FA is at the heart of questions of 
validity and provides a diagnostic tool to evaluate whether the data are in line 
with the theoretically expected structure of the unobserved construct and 
thereby to determine if the scale has measured what it purports to measure 
(Matsunaga, 2010).  
 
As with item analysis, issues regarding minimum sample size for FA have 
received considerable discussion in the literature (Worthington & Whittaker, 
2003). There are two main risks to samples that are too small: (1) patterns of 
covariance may not be stable, as chance can influence correlations among items 
when the ratio of participants to items is low, and (2) the development sample 
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may not adequately represent the intended population (DeVellis, 2003; 
Worthington & Whittaker, 2006). 
 
There are no strict guidelines for the minimum sample size needed for FA, 
although a number of criteria are recommended. Most guidelines suggest that 
sample size should be based upon the number of variables included in the 
analysis, with more variables requiring larger sample sizes. However, there is 
little agreement within the literature on what this ratio of sample size to 
variables should be. For example, Gorsuch (1983) recommends that there 
should be at least 5 respondents to each measured variable, whilst Nunnally 
(1978) suggests that a ratio of 10 respondents to each variable is more suitable. 
Costello and Osborne (2005) examined various respondent-item ratios and 
found that ratios of 2:1 produced correct solutions just 10% of the time, 
whereas ratios of 5:1 and 10:1 produced correct solutions 40% and 60% of the 
time respectively.  
 
MacCallum et al. (1999) argue that minimum sample size is influenced 
considerable by the extent to which factors are overdetermined (i.e., how many 
variables there are for each factor) and the level of the communalities of the 
measured variables. MaCallum et al. (1999) advises that when factors are 
overdetermined by a ratio of 4:1 and communalities are high (mean >0.7) then 
accurate FA can be conducted on samples as small as 100. Therefore, it is 
generally accepted that the stronger the data is, the lower the sample size needs 
to be for FA.  
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Whilst sample sizes of over 100 are recommended by most guidelines (Fabrigar 
et al., 1999; MacCallum et al., 1999), studies have demonstrated good FA 
recovery on considerably smaller data sets. For example, studies by Barrett and 
Kline (1981) and Arrindell and van der Ende (1985) demonstrate good 
recovery in samples of n=48 (respondent-item ratio of 3:1) and n=78 
(respondent-item ratio of 3.9:1) respectively. MacCallum and colleagues 
conducted a large Monte Carlo study exploring the impact of sample size on FA 
and found communalities were an important factor in successful analysis. In 
studies that had communalities of >0.6, acceptable solutions were 
demonstrated 100% of the time in sample sizes of n=60. Unfortunately, 
communalities cannot be calculated in the development stage but they can be 
used as an important post hoc indicator of whether sample size was adequate 
(MacCallum et al., 1999). 
 
Although minimum sample size remains a debated issue, sampling adequacy 
statistics can be calculated prior to FA to ensure that the data is suitable for FA. 
It is recommended that the Kaiser-Meyer-Olkin (KMO) equation and Bartlett’s 
test of sphericity care calculated to test data suitability (Cabrera-Nguyen, 2010; 
Worthington & Whittaker, 2006). The KMO statistic varies between 0 and 1. A 
value of 0 indicates a diffusion in the pattern of partial correlations and the sum 
of correlations, making FA inappropriate. In contrast, a value of close to 1 
indicates that the FA should yield distinct and reliable factors (Field, 2005). 
Bartlett’s test of sphericity tests the null hypothesis that the variables are 
uncorrelated, thus a significant finding rejects the hypothesis and indicates that 
the data is suitable for FA (Field, 2005). 
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There are two distinct methods of FA: exploratory factor analysis (EFA) and 
CFA. These play different roles in scale development with EFA used for theory-
building and scale refinement, and CFA primarily used for theory-testing 
(Matsunaga, 2010). The focus of this section will be on EFA for the purposes of 
early scale development.  The role of CFA will be discussed in the later section 
(3.5.4) exploring scale validation procedures.  
 
Before discussing the role of EFA, it is worth exploring the two closely related 
but often-confused analysis approaches that fall under the rubric of EFA: 
principal components analysis (PCA) and true FA. Both PCA and FA involve the 
transformation of a number of (possibly) correlated variables into a smaller 
number of uncorrelated (PCA) or correlated (FA) variables known as principal 
components or factors (Wang et al., 2009). The main conceptual differences 
between PCA and FA are that in PCA the aim is to account for as much of the 
total variance as possible, whilst the aim of FA is to try to explain the 
covariances or correlations among the variables. Also, PCA is generally used to 
reduce the data into a smaller number of components, while FA is used to 
understand what constructs underlie the data (Wang et al., 2009).  
 
Although these two approaches are both regularly used within scale 
development, both empirical research and analysis guidelines recommend the 
use of FA over PCA (Costello & Osborne, 2005; Worthington & Whittaker, 2006). 
Costello and Osborne (2005) conducted a large study comparing PCA and FA on 
over 24,000 data sets. Although the two approaches produced similar results, 
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the authors found that PCA overestimated the variance accounted for by 16.4% 
compared to FA and also produced over-inflated item loadings. The authors 
conclude that FA produces more generalizable and reproducible results as it 
does not inflate the variance estimates. Boyle (1985: 51) summarises the 
general attitude towards the superiority of FA by suggesting that “Use of 
principal components is elegant, but would seem psychologically meaningless in 
view of the common factor model.” 
 
EFA assesses the construct validity during the initial development of a scale and 
is applied to a set of items to examine the underlying dimensionality of the item 
set (Worthington & Whittaker, 2006). The primary aim of EFA is that it allows 
the scale developer to identify items that do not measure an intended factor or 
simultaneously measure multiple factors. These could be poor indicators of the 
desired construct and can therefore be eliminated from further consideration 
(Worthington & Whittaker, 2006). 
 
EFA begins with the premise that one latent variable (or factor) containing all of 
the items is all that is required and then assesses how much of the association 
among individual items that single concept can explain. If it appears that one 
latent variable has not accounted for all the covariation between the items, the 
analysis rejects the initial premise and identifies a second latent variable that 
explains some of the remaining covariation among items. This process 
continues until the amount of covariation that the set of factors has not 
accounted for is acceptably small (DeVellis, 2003). 
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A large number of factors will usually emerge following EFA (usually the same 
number of factors as items), yet many of these factors will only explain a small 
amount of the variance. The scale developer must therefore decide how many 
factors to retain. Factors are typically retained based on eigenvalues (the 
amount of information captured by a factor) or by visual interpretation of a 
scree plot (Field, 2005; O’Rourke et al., 2005). Kaiser’s (1960) criterion dictates 
that all factors with an eigenvalue greater than one should be retained as they 
represent a substantial amount of variation. However, Cattell (1966) 
recommends that a graph is plotted (the scree plot) which compares each 
eigenvalue (y-axis) against the factor (x-axis) with which it is associated (see 
Figure 3.4). According to Cattell (1966) the cut-off point for selecting factors 
should be at the point of inflexion (the arrow in Figure 3.4) of this curve. 
Costello and Osbourne (2005) argue that using Kaiser’s criterion alone is 
inadequate. Therefore, in practice, the majority of scale developers employ a 
combination of these two methods to ensure that all relevant factors are 
retained (Field, 2005; O’Rourke et al., 2005). 
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Figure 3.4: Example of scree plot with point of inflexion highlighted 
 
Once the number of factors to be retained have been decided, the scale 
developer can then explore the loadings of each item onto each factor. If more 
than one factor is identified then the data must be rotated. If the factor axes are 
rotated, the loading of a variable on one factor is maximized while its loading on 
the other factors is minimized, thereby making the factor structure easier to 
interpret. The two main forms of rotation available are orthogonal rotation and 
oblique rotation. Orthogonal rotation is used when the factors are not believed 
to be correlated, whilst oblique rotation enables factor correlations to be 
explored (Kline, 2000). Those scales that have a clear single-factor structure do 
not require rotation. 
 
The final stage of EFA is to interpret the retained factors. In cases where the 
latent variables have been defined a priori, there is no need to define the factor. 
Point of 
inflexion 
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However, often it is necessary to explore items loading strongly onto a 
particular factor to “… provide a window into the nature of the factor in question” 
(DeVellis, 2003; 126).  
 
3.5.4 SCALE VALIDATION 
 
The final stage of the scale development process is validation. As Robins et al. 
(2001: 160) asserts, validation is an on-going process and “…one never validates 
a scale but rather provides progressively more evidence for a particular 
interpretation of the scale.”  
 
According to the FDA’s (2009) guidance on PROMs, a scale can only be 
considered a credible measure if it has been validated in the target population. 
Therefore, scale validation procedures typically involve establishing validity, 
including criterion and construct validity in a clinical sample that is 
representative of the population it has been designed for use in.  
 
One of the key aspects of construct validity that can be explored in the scale 
validation phase is the confirmation of the factor structure through CFA using 
structural equation modelling (SEM; Redding et al., 2006). CFA is used to test an 
existing theory, usually to evaluate or confirm the extent to which the 
researcher’s hypothesised model (typically that produced by prior EFA) is 
replicated in the sample data. It can also be used to assess the extent to which 
one model fits the data better than an alternative model (Worthington & 
Whittaker, 2006).  
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CFA typically involves specifying the hypothesised model using SEM software 
and then exploring the fit of the data to the model. Software programmes such 
as AMOS can be used to model factors and variables on the predetermined 
model (see Figure 3.5). Model fit is then assessed using a number of indices 
which establish how well the model fits the data. These include absolute model 
fit indices such as Chi-square test statistic or Goodness-of-Fit Index (GFI), 
incremental fit indices such as Normed Fit Index (NFI) or Non-normed Fit Index 
(NNFI)/Tucker-Lewis Index (TLI), and predictive fit indices, such as the 
Bayesian Information Criterion (BIC; Worthington & Whittaker, 2006). There 
are various recommendations for the cut-off values for each of these fit indices 
(e.g., Hu & Bentler, 1999) and these are discussed in Chapter 6 (section 
6.4.3.4.4.3) of this thesis. If poor model fit is found in CFA then researchers are 
able to modify and retest models based on modification indices. However, it is 
important to note that such modifications should always be guided by theory 
(Worthington & Whittaker, 2006).  
 
 
 
 
 
 
 
 
Figure 3.5: Example single factor CFA model 
Item 1 
Item 2 
Item 3 
Item 4 
e 
e 
e 
e 
Factor 
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As with the sample size considerations discussed in the previous section on EFA 
(Section 3.4.3.2), there are no strict guidelines for CFA. Kline (2005) 
recommends a minimum sample size of 100 participants. However, it is 
generally accepted that a 5:1 ratio of participants to number of parameters is 
needed (Bentler & Chou, 1987; Worthington & Whittaker, 2006).  
 
3.6 SUMMARY OF CHAPTER 3 
 
This chapter has summarised some of the key considerations relating to the 
development of self-report scales. The thesis is guided by a CTT approach to 
scale development which is sample dependent and assumes that items within 
the scale all measure an underlying latent variable. This theory was chosen over 
the modern approach of IRT due to limitations in the potential sample size and 
the availability of complex statistical software. However, empirical evidence 
support the use of CTT, especially when representative clinical samples can be 
incorporated in scale development procedures. 
 
At the heart of scale development is the need to establish the reliability and 
validity of a scale. Reliability refers to both internal consistency (internal 
reliability) and temporal stability (test-retest reliability), whereas validity is 
traditionally measured under three criteria: content validity (that items reflect 
the domain being measured), criterion validity (the accuracy of the scale) and 
construct validity (the behaviour of the scale). 
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Scale development is an iterative process which typically follows a sequential 
course which begins with developing a conceptual model for the scale. 
Following item writing, in which important decisions are made regarding the 
wording of items, their appropriateness in the target population and the 
development of a response set and format, the item pool is tested on specific 
clinical sample. Statistical procedures guide the refinement of the new scale. 
Both item analysis and EFA can be incorporated to establish the initial internal 
consistency and latent structure of the scale prior to finalisation. The final stage 
of validation is an on-going process of evidence gathering in which a priori 
hypotheses regarding the scale’s theoretical performance are tested in 
representative samples. This typically involves comparison with extant 
measures, establishing screening properties, testing temporal stability and 
confirming the factor structure through CFA. 
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Chapter 4 : METHODOLOGY 
4.1 INTRODUCTION 
 
The purpose of this study was to develop a novel non-somatic anxiety scale to 
measure and screen COPD patients for anxiety. The research aims outlined in 
Chapter 1 guided the choice of research design for this study. The research 
consisted of three phases that are described in the following chapter. This 
chapter will outline and justify the chosen research methodology and 
conceptual framework guiding this research. An overview of the methods 
employed in each phase is also presented. 
 
4.2 CONCEPTUAL FRAMEWORK 
 
This study utilised a pragmatic sequential mixed methods approach to scale 
development that integrated qualitative and quantitative data into a single 
study (Durham et al., 2011; Johnson & Onwuegbuzie, 2004; Morrow et al., 2011; 
Onwuegbuzie et al., 2010) and was based broadly upon the scale development 
steps recommended by DeVellis (2003) and Redding et al. (2006).  
 
The following section will give an overview of mixed methods and specifically 
discuss how the pragmatic philosophy can influence the selection and mixing of 
research methods. Mixed methods approaches to scale development will be 
explored and the chosen research design will be justified.  
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Mixed methods is a relatively new approach, which have evolved from the 
‘mono method era’ during which researchers adopted a purely quantitative or 
qualitative approach to research (Armitage, 2007).  Traditionally, researchers in 
the social sciences fell into two opposing worldviews or paradigms. Tashakkori 
and Teddlie (1998) adopt the terms “positivist” and “constructivist” to describe 
the traditional objectivist scientific endeavours of the positivist researchers and 
the subjective multiple realities of the constructivists.  
 
In this long-running debate, the incompatibility of quantitative and qualitative 
research was stressed in terms of the fundamentally opposing worldviews, 
ontology (the nature of reality and whether it exists) and epistemology (how it 
is possible to know about reality; Glogowska, 2011). The mixed methods design 
blends the positivist/post-positivist and constructivist paradigms and is 
considered to be the ‘third paradigm’ (Glogowska, 2011). ‘Mixed methods 
research’ is increasingly becoming the standard terminology for research that 
involves both qualitative and quantitative research. However, it is still 
sometimes referred to as ‘multi methods’ or ‘mixed methodology’ research 
(Glogowska, 2011).  
 
A key strength in mixed methods is that a combination of the qualitative and 
quantitative frameworks allows more potential support than can be achieved by 
using either qualitative or quantitative methods in isolation (Bryman, 2007). A 
mixed methods design was chosen for this study as the integrated analysis of 
both qualitative and quantitative data allow the experiences of the patient to 
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complement the robust statistical analysis which typifies the scale development 
process (Mahoney et al., 1995; Onwuegbuzie et al., 2010). 
 
This research is guided by the philosophical underpinnings of pragmatism. 
Pragmatism is a relatively recent philosophy that allows the mixing of both 
quantitative and qualitative methodologies and emerged as a challenge to the 
mono method era in the early 1960s, termed by Tashakkori and Teddlie (1998) 
as “Paradigm Wars”. Pragmatists consider the research question as central to 
the choice of approach (Creswell, 2009) and therefore, this “what works” tactic 
(Armitage, 2007) enables the researcher to address questions that do not sit 
comfortably within a purely quantitative or qualitative approach to research 
design and methodology. According to Johnson and Onwuegbuzie (2004) a 
pragmatic approach should mix research methods in ways that offer the best 
opportunities for answering important research questions. 
 
Pragmatism is an attractive philosophy to the scale developer because it is 
grounded in real life practice and enables a freedom of choice that allows the 
researcher to choose the methods, techniques, and procedures that best meet 
their needs and purposes, and to make decisions on which methods can be used 
to maximise the validity and reliability of a scale (Clark & Watson, 1995; 
Creswell, 2009). The review of scale development in Chapter 3 makes it clear 
that the development of a scale is dominated by quantitative methods such as 
item and factor analysis. It has been suggested, however, that using quantitative 
methods alone for developing scales is often insufficient (Steckler et al. 1992). 
This may be because certain factors that define a ‘good’ scale, including face 
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validity and content validity, are subjective in nature and thus lend themselves 
to qualitative inquiry. To achieve the dual purpose of a robust, reliable and valid 
scale that is also grounded in ‘real life’ experience, a pragmatic decision can be 
made to ‘mix’ methods by including both qualitative and quantitative methods 
in complementary ways (Mahoney et al,. 1995). 
 
There are a number of mixed method approaches to scale development and 
these vary in their complexity and in the relative mix of both qualitative and 
quantitative methods. Writing shortly after the present research commenced, 
Onwuegbuzie and colleagues (2010) present a comprehensive 10-phase 
approach that mixes quantitative and qualitative methods throughout the scale 
development process. Such an approach involves numerous stages of research 
and crossover analysis and lends itself to the development of poorly understood 
or complex, multifaceted constructs. As anxiety is a relatively well-understood 
concept, with many extant scales already in existence, this research 
incorporates a more simplistic mixed methods approach to scale development 
that incorporates an additional qualitative phase to aid in the initial item 
development process (Morrow, 2011).  
 
In the early stages of scale development, mixed methods research permits the 
use of qualitative methods to help conceptualise the construct of interest and to 
identify behaviours that underlie the construct prior to the substantive 
quantitative methods that seek to address issues of reliability and validity 
(Durham et al., 2011; Kline, 2000; Mahoney et al., 1995; Onwuegbuzie et al., 
2010). As a result, there is increasing evidence of the use of mixed methods in 
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scale development, particularly in studies that seek to develop health-related 
scales. A number of studies have now been published that utilise a pragmatic 
mixed methods approach to item development that integrates both emic 
(qualitative data) and etic (such as literature review) perspectives (Bova et al., 
2006; Durham et al., 2011; Mahoney et al., 1995; Onwuegbuzie et al., 2010). 
 
Many guidelines for developing scales discuss the role of conducting literature 
reviews to aid in item development (e.g., DeVellis, 2003; Streiner & Norman, 
2003). However, there is little specific guidance concerned with generating 
potential items using qualitative methods. Rowan and Wulff (2007) argue that 
this may be because scale development is still dominated by quantitative 
methods and therefore little attention is paid to the origin of items, as long as 
they prove to be reliable and valid. Nevertheless, an increasing number of scale 
developers have incorporated a qualitative phase of exploratory work in the 
item development process (Jones et al., 2009b; Michalak et al., 2010; Okuyama 
et al., 2000; Ushiro, 2009).  
 
Qualitative inquiry can be especially useful to scale development researchers in 
that the validity of the quantitative research can be enhanced by first being 
grounded in real life situations through collecting qualitative data (e.g., 
interviews, focus groups or textual sources) from an open perspective 
(Mahoney et al., 1995; Padgett, 1998; Rowan and Wulff, 2007). Qualitative 
inquiry in the early stages of scale development may also enable the researcher 
to see if there are unexplored or untapped areas of the topic in question (or new 
informants) that could yield specific new items (Rowan and Wulff, 2007). There 
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is also a growing acceptance among scale developers that items should be 
derived from the words used by patients to describe their own symptoms or 
experiences (Yorke et al., 2010), thus improving scale fidelity (Collins et al., 
2006). Examples of qualitative methods used in item development include 
interviews or focus groups with participants from the target population (Jones 
et al., 2009b; Okuyama et al., 2000), families and carers (Michalak et al., 2010) 
and experts in the field e.g., clinicians or academics (Jones et al., 2009b; 
Michalak et al., 2010; Okuyama et al., 2000). 
 
The benefits of integrating qualitative data in the early stages of item 
development are particularly significant for this research because although 
anxiety is a relatively well-defined construct, it is not known whether people 
with COPD experience anxiety that is similar to those without the disease 
(Maurer et al., 2010). Therefore, it was decided that a qualitative study that 
explored the experience of anxiety symptoms from the patients’ perspective 
would enhance the item writing process.   
 
4.3 RESEARCH DESIGN 
 
Comrey (1988), DeVellis (2003), and more recently Redding et al. (2006), 
provide practical guidelines for developing reliable and valid measurement 
scales and collectively advocate a sequential process. DeVellis’ (2003) eight 
steps and Comrey’s (1988) and Redding et al. (2006) five steps, share a mutual 
belief that there are three main phases (often consisting of multiple studies) in 
scale development: a primary phase of initial item generation, a secondary 
161 
 
phase of item reduction, and a third phase of on-going scale validation. This 
approach has been adopted by scale developers in a range of social science 
settings (e.g., Bova et al., 2006; Okuyama et al., 2000; Ushiro, 2009; Yesavage & 
Brink, 1983). 
 
This research followed the iterative scale development process proposed by 
DeVellis (2003) and Redding et al. (2006) which integrated a contemporary 
mixed methods approach to item development and was followed by the 
‘classical’ quantitative scale refinement approach   (Mahoney et al., 1995; 
Morrow et al., 2011; Padgett, 1998; Rowan & Wulff, 2007).  
 
Figure 4.1 illustrates the three-phase scale development process used in this 
research. The first phase involved conceptualising and defining the construct 
and writing items. This phase incorporated a mixed methods approach which 
integrated both emic (qualitative interviews) and etic (quantitative review of 
extant scales) perspectives. The second phase involved refining the scale using 
quantitative analysis procedures. In the third phase, the resultant scale was 
validated through quantitative analysis. 
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Figure 4.1: The three phase sequential mixed methods approach to scale 
development used in the present study 
 
The three phases of research reflect the scale development stages proposed by 
both DeVellis (2003) and Redding et al. (2006). Table 4.1 illustrates how each 
phase corresponds to the proposed guidelines. 
 
 
Literature review 
Patient interviews 
Item writing 
Refining scale 
Validation of scale 
Phase 1 
Quantitative + 
Qualitative 
Phase 2 
Quantitative 
Phase 3 
Quantitative 
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Table 4.1: Phases of research and their corresponding steps according to 
DeVellis (2003) and Redding et al. (2006) 
 
 Stage of process according to guidelines 
Phase of research DeVellis (2003) Redding et al., (2006) 
Phase 1 Step 1 – Determine what is to be 
measured 
Step 1 – Define construct 
Step 2 – Generate an item pool Step 2 – Write items 
Step 3 – Determine the format 
for measurement 
 
Step 4 – Have initial item pool 
reviewed by experts 
Step 3 – Pilot test & exploratory 
work 
Step 5 – Consider inclusion of 
validation items (N/A) 
 
Phase 2 Step 6 – Administer items to 
development sample 
Step 4 – Field testing & 
exploratory work 
Step 7 – Evaluate the items  
Step 8 – Optimise scale length  
Phase 3  Step 5 – Confirm, analyses, 
cross-validation 
 
 
The following paragraphs provide a brief description of the three research 
phases and the procedures that were involved. Detailed descriptions of each 
phase, including the specific methods employed are discussed in Chapters 5 and 
6. 
 
The first phase of the study generated a pool of potential items that were 
grounded in both etic and emic perspectives. A strategic review of the literature 
(see Chapter 2) was conducted to confirm the need for a new tool (Jones et al., 
2009b). Following this, a purposive literature review (etic perspective) was 
conducted which identified extant anxiety scales. A list of items was identified 
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and these were then subjected to both thematic and content analysis to derive 
key themes. In addition, qualitative interviews were conducted with patients 
with COPD (emic perspective) to explore the experience of anxiety, 
conceptualise anxiety in this research context, and, specifically, to elicit 
descriptions of anxiety symptoms. Using the themes identified from the review 
of extant scales, a thematic and content analysis was conducted on qualitative 
data to identify themes. The themes generated from the etic and emic 
perspectives were used to write a list of items. The wording, content and 
readability of these items were then checked by an expert reference group 
made up of patients and clinicians. The qualitative interviews also allowed an 
in-depth exploration of the first-hand experiences of anxiety in patients with 
COPD. Data were analysed using a thematic network approach which enabled 
basic themes, organising themes and global themes to be generated. 
 
In the second phase of the study, the pool of items generated in Phase 1 was 
completed by a clinical sample of inpatients and outpatients. These data were 
then subjected to item analysis and EFA to establish the scale’s reliability, to aid 
in item reduction and to explore the factor structure of the scale. Following 
statistical analysis, a final scale was developed; the Anxiety Inventory for 
Respiratory Disease (AIR). Finally, the scale was rated by patients to establish: 
how easy the scale was to complete, how helpful the scale was in reflecting their 
experiences, and how easy the scale was to understand. 
 
In the third phase of the study, the AIR was completed on two occasions by a 
clinical sample of outpatients to determine its reliability (internal consistency 
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and temporal stability) and validity. The respondents also completed a battery 
of scales to determine the criterion validity and construct validity of the new 
scale. A sub-sample of these respondents also underwent a clinical psychiatric 
interview to aid in establishing sensitivity and specificity properties of the AIR. 
The data from phase 3 were also subjected to CFA to confirm the factor 
structure of the AIR.  
 
4.4 SETTING 
 
This research was conducted in the North Western boroughs of Greater 
Manchester where COPD appears to be particularly prevalent and has a 
significant impact upon healthcare utilisation and resources. According to the 
British Lung Foundation’s Missing Millions report (2007), Manchester faces the 
sixth greatest challenge from COPD in the UK and the fourth greatest in 
England. People in Manchester are 40% more likely to be admitted to hospital 
through COPD than the UK average. The report highlights that those individuals 
who are at risk of future hospital admission with COPD live mostly in 
socioeconomically deprived areas such as those covered by the two NHS trusts 
which participated in the current research: Pennine Acute Hospitals NHS Trust 
and Tameside Hospital NHS Foundation Trust. Even though Manchester is 
experiencing a period of unprecedented and continued economic growth, it still 
has high and enduring levels of deprivation and unemployment is a major issue 
(British Lung Foundation, 2007).  
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4.5 ETHICAL CONSIDERATIONS 
 
This research received approval from the Lancaster NHS National Research 
Ethics Service (NRES) committee (see Appendix 1) and the Manchester 
Metropolitan University (MMU) research ethics committee (see Appendix 2). A 
number of factors were taken into account during the planning of this research. 
These are discussed below along with steps that were taken to minimise 
potential issues.  
 
4.5.1 RISKS, BURDENS AND BENEFITS FOR RESEARCH PARTICIPANTS 
 
In Phase 1, participants discussed themes relating to anxiety, panic and general 
mental health that may have been potentially distressing. However, 
understanding the experiences of the patient was a key objective of this 
research and it was felt that a first-hand account of the experience as told by the 
participant was the best way to achieve this. To minimise any possible distress, 
participants were able to take breaks from or terminate an interview at any 
time. In addition, if the author was concerned about the participant's anxiety 
then their GP was contacted with permission of the participant (see Appendix 3 
for example GP letter).  
 
There was also the potential that the interview process would provide an 
additional inconvenience to participants in terms of a time burden. Participants 
were required to give up to 2 hours of their time for the interview process 
(including introductions, gaining consent etc.). To minimise this burden 
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interviews were conducted at the participant’s home (if requested) so that no 
travel time or expense was incurred. Also, participants were free to choose a 
day and time which best suited them. The decision to interview patients in their 
own home may have been seen as an intrusion by some participants. In such 
cases an alternative interview location was arranged which was accessible to 
the participant; a local outpatient clinic.  
 
Participants who had severe respiratory disease may have become breathless 
during the interviews. In such cases, participants were given the opportunity to 
take frequent breaks throughout the interview process. In cases of severe 
breathlessness, interviews could be postponed to another date or split over a 
number of days. In all cases the participant was consulted on this prior to and 
during the interview.  
 
In Phases 2 and 3, participants completing the draft scale may have experienced 
some emotional distress as the items included topics relating to fear and worry. 
In order to minimise distress, the GP of the participant was contacted by letter 
(with permission) if the author was concerned about the participant's anxiety. 
 
In Phase 3, participants were posted follow-up scales to be completed two 
weeks after recruitment. There may have been a time burden associated with 
the completion of the scales, so to minimise this participants were given 7 days 
in which to complete and return the scales. A pre-paid envelope was also 
provided to minimise further inconvenience and costs to the participant. 
 
168 
 
Although there were no direct benefits to participating in this research, it was 
hoped that the findings could be used to improve the care of patients with COPD 
in the future. 
 
4.5.2 RECRUITMENT AND INFORMED CONSENT 
 
In Phase 1, all potential participants were recruited in person by the author 
who explained the research and answered any questions related to the study. In 
Phase 2, potential participants were recruited by the author or a trained 
research assistant. In Phase 3, participants were recruited either by postal 
invitation or in person by the author. 
 
All potential participants were given a Participant Information Sheet and 
Informed Consent Form corresponding to that phase of the research. These are 
detailed in Chapters 5 and 6, with example forms provided in appendices 4, 5, 8, 
9, 12 and 13. All participants were given 24 hours to decide whether they 
wished to participate in the research. Written informed consent was obtained 
by either the author or the research assistant.  
 
4.5.3 CONFIDENTIALITY AND ANONYMITY 
 
All information collected during this research was anonymised with a unique 
code that was only known to the author. The following procedures were also 
implemented to ensure confidentiality and anonymity: 
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 Personal details were encrypted and stored on a computer protected 
with a firewall. The computer was also kept in a locked room which was 
only accessible to PhD students. 
 Data contained on paper was locked in a filing cabinet which was only 
accessible to the author. 
 All direct quotes were anonymised using pseudonyms. 
 All audio recording devices were kept in a locked storage area and were 
wiped clean of data once the files had been transferred and encrypted on 
the computer. 
 Access to data at the University was restricted to the author. All 
information was password protected and kept on computers protected 
by a firewall. 
 
4.6 SUMMARY OF CHAPTER 4 
 
This chapter detailed the methodology of the current research. The conceptual 
framework of the research was guided by the philosophical underpinnings of 
pragmatism and a mixed methods research design was chosen to incorporate 
both emic and etic perspectives during item development. The research consists 
of three phases: item development (qualitative and quantitative), scale 
refinement (quantitative) and scale validation (quantitative), and follows a 
classical approach to scale development described by DeVellis (2003) and 
Redding et al. (2006). Finally, a number of ethical concerns were considered 
and efforts to minimise participant risks and burden and to maximise benefits, 
confidentiality and anonymity were explored. 
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The next chapter describes Phase 1 of the research in which emic and etic 
perspectives were integrated to develop a pool of potential items for the new 
anxiety scale. In addition, detailed experiences of anxiety were explored from 
the patients’ perspective. 
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Chapter 5 : PHASE 1 – ITEM DEVELOPMENT 
5.1 INTRODUCTION 
 
This chapter will outline the mixed methods approach to item development in 
the present study (DeVellis, 2003; Redding et al., 2006). According to Keedwell 
and Snaith (1996), the first step in developing a scale for clinical use is to 
develop a pool of items that are relevant to the patients for which the scale is 
designed. The primary goal of Phase 1 of the research, therefore, was to develop 
items that were grounded in the experience of anxiety from the patients’ 
perspective.  
 
An inductive approach to item development was used, with potential items 
developed by combining two distinct approaches. First, a review of extant 
anxiety scales was undertaken (Phase 1.1) which permitted a thorough 
exploration of the content of existing items and enabled the full coverage of 
non-somatic anxiety symptoms. The second approach involved developing 
content for items de novo through a qualitative study of patients’ experiences of 
anxiety (Phase 1.2). Exploration of the experience of anxiety can aid in 
conceptualising the construct and confirming the need for a new scale. As has 
been outlined in the previous chapter (Chapter 4), this mixed methods 
approach to item development enables enhanced scale validity and fidelity, and 
ensures that the item pool covers all aspects of the construct. 
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5.2 PHASE 1 AIMS 
 
5.2.1 PRIMARY AIMS 
 
1. To develop a pool of representative items that will contribute towards 
developing a scale to measure and screen for anxiety in patients with 
COPD. 
 
5.2.2 SECONDARY AIMS 
 
2. To gain a deeper understanding of the experience of living and coping 
with anxiety in patients with COPD. 
3. To explore the need for a new anxiety scale for patients with COPD. 
 
5.3 PHASE 1.1: REVIEW OF EXISTING ANXIETY SCALES 
 
5.3.1 INTRODUCTION 
 
This initial study was designed to explore the symptoms of non-somatic anxiety 
present in extant anxiety scales. Therefore, existing anxiety scales were 
analysed and categorised according to their content. 
 
5.3.2 PHASE 1.1 AIMS 
 
The specific aims of Phase 1.1 were: 
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a) To identify non-somatic anxiety symptoms from extant anxiety scales. 
b) To explore the symptom coverage of extant anxiety scales 
 
5.3.3 METHODS 
 
A multi-database literature search of Ovid MEDLINE (R), Embase, CINAHL and 
PsychINFO was conducted to identify extant anxiety scales. Databases were 
searched from their inception to 30 April 2010. The search terms were 
“anxiety/ OR panic”, AND “scale/ OR inventory/ OR instrument/ OR test/ OR 
index/ OR questionnaire/ OR checklist.” The inclusion criteria for reviewed 
scales were those that: (1) can be completed as self-report instruments, (2) 
assess state anxiety or panic (including GAD and PD) in clinical settings, (3) 
contain multiple items, (4) are available and validated in English, and (5) have 
documented reliability and validity in clinical populations. Scales were excluded 
if they were: (1) designed to assess other specific anxiety disorders such as 
PTSD or specific phobia; and (2) designed to assess for severity of pre-
diagnosed anxiety disorders, for example, Panic Disorder Severity Scale – Self 
Report (PDSS-SR; Houck et al., 2002).  
 
The full texts of all relevant scales were accessed and the published versions of 
scales were retrieved by the author. This enabled a list of items contained 
within extant scales to be collated. A psychiatrist was also approached to check 
for any scales used in UK clinical practice that had been missed in the literature 
search. The following data were extracted from retrieved scales: 
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 Timeframe  
 Item wording 
 Response set  
 Scoring options 
 
Items were examined for general symptom themes and inductively coded using 
an open coding framework. In accordance with the aims set out in Chapter 1, 
somatic items were excluded from the pool of items. In addition, sleep-related 
items were excluded from the item pool because of the documented overlap 
between anxiety, symptoms of COPD and the side-effects of medication 
(Shackell et al., 2007). Finally, items that were unrelated to GAD or PD were 
excluded. Following coding, items were categorised according to content and 
the frequency of their occurrence was calculated. The categorisation and coding 
process was discussed with the supervisory team as well as with the 
psychiatrist. 
 
5.3.4 RESULTS 
 
A total of 14 self-report anxiety scales were identified which covered a range of 
anxiety-related symptoms (see Table 5.1). The majority of scales were 
measurement tools, however, one scale – the Generalised Anxiety Disorder-7 
(GAD-7; Spitzer et al., 2006) – was designed primarily as screening tool for GAD, 
but can also be used for measurement purposes.  
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Table 5.1: Characteristics of reviewed anxiety scales used in Phase 1.1 
 
Scale Type of scale No of anxiety 
items 
Timeframe  Type of response 
option 
No of response 
options 
Score 
range 
Beck Anxiety Inventory (BAI; Beck et al., 1988) Measurement 21 7 days Likert 4 0-63 
Cognitive-Somatic Anxiety Questionnaire (CSAQ; 
Schwartz et al., 1978) 
Measurement 14 - Likert 5 14-70 
Depression Anxiety Stress Scale (DASS; 
Lovibond & Lovibond, 1995) 
Measurement 14 7 days Likert 4 0-42 
Generalised Anxiety Disorder-7 (GAD-7; Spitzer 
et al., 2006) 
Measurement 
&screening tool 
7 14 days Likert 4 0-21 
Geriatric Anxiety Inventory (GAI; Pachana et al., 
2007)  
Measurement 20 7 days Agree/disagree 2 0-20 
Goldberg Anxiety and Depression Scale (GADS; 
Goldberg et al., 1988) 
Measurement 9 Recently Yes/no 2 0-9 
Hospital Anxiety and Depression Scale (HADS; 
Zigmond & Snaith, 1983) 
Measurement 7 7 days Likert 4 0-21 
Mental Health Inventory-38 (MHI-38; Veit & 
Ware, 1983) 
Measurement 9 1 month Likert 6 9-54 
Mind Over Mood Anxiety Inventory (MOMAI; 
Greenberger & Padesky, 1995) 
Measurement 24 7 days Likert 4 0-72 
The Penn State Worry Questionnaire (PSWQ; 
Meyer et al., 1990)  
Measurement 16 - Likert 5 16-80 
Self-rating Anxiety Scale (SAS; Zung, 1971) Measurement 20 Several 
days 
Likert 5 20-80 
Short Anxiety Screening Test (SAST; Sinoff et al., Measurement 10 - Likert 4 10-40 
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Scale Type of scale No of anxiety 
items 
Timeframe  Type of response 
option 
No of response 
options 
Score 
range 
1999) 
State-Trait Anxiety Inventory (STAI; Spielberger 
et al., 1983) 
Measurement 20 (state 
anxiety) 
‘Right now’ Likert 4 20-80 
Symptom Checklist-90 (SCL-90; Derogatis et al., 
1973) 
Measurement 10 7 days Likert 5 0-40 
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Scales contained between 7 and 24 anxiety-related items and most scales 
incorporated a Likert-type response set, although the GAI (Pachana et al., 2007) 
and the Goldberg Anxiety and Depression Scale (GADS; Goldberg et al., 1988) 
utilised dichotomous response options. The response sets for Likert-type scales 
ranged from 3 to 6, with a median value of 4. Timeframes varied from 7 days to 
1 month, yet four scales (Cognitive-Somatic Anxiety Questionnaire, CSAQ, 
Schwartz et al., 1978; GADS; Self-rating Anxiety Scale, SAS, Zung, 1971; STAI) 
did not quantify the timeframe and instead used descriptors to guide the 
respondent e.g., ‘recently’ or ‘typically’. 
 
Dizziness, light-headedness, faintness Indigestion 
Dry mouth Flushed face 
Sweating Muscle weakness 
Chills Butterflies in stomach 
Shaking, trembling Choking sensations 
Muscle tension, muscle soreness Frequent urination 
Headaches Swallowing problems, lump in throat 
Back pain, neck pain Numbness, tingling 
Breathlessness Nausea 
Tachycardia, heart palpitations Chest pain 
 
Figure 5.1: Somatic anxiety symptoms identified in extant scales used in 
Phase 1.1 
 
From the fourteen identified scales, 201 anxiety-related items were found. 
Eleven scales (containing 65 items) were found to contain items relating to 
somatic anxiety symptoms e.g., breathlessness, dizziness etc. (see Figure 5.1 for 
178 
 
examples). Three scales – the GAD-7, the Penn State Worry Questionnaire 
(PSWQ; Meyer et al., 1990) and the STAI – contained no somatic items. On 
average, in scales that contained somatic items, 36% of items were somatic (see 
Table 5.2). Eight items from 4 scales were found which related to sleep and 
these were subsequently excluded from the analysis. Two additional items were 
removed for being non-specific – one item from the STAI and another from the 
Symptom Checklist-90 (SCL-90; Derogatis et al., 1973). 
 
 
Table 5.2: Numbers and proportion of somatic items in extant scales used 
in Phase 1.1 
 
Scale Number of somatic items Somatic items as % of total 
BAI 14 67 
CSAQ 7 50 
DASS 8 57 
GAI 4 20 
GADS 2 22 
HADS 1 14 
MHI-38 1 11 
MOMAI 11 46 
SAS 12 60 
SAST 3 30 
SCL-90 2 20 
Mean 6 36 
BAI, Beck Anxiety Inventory; CSAQ, Cognitive-Somatic Anxiety Questionnaire; DASS, Depression 
Anxiety Stress Scales; GAI, Geriatric Anxiety Inventory; GADS, Goldberg Anxiety and Depression 
Scale; HADS, Hospital Anxiety and Depression Scale; MHI-38, Mental Health Inventory-38; 
MOMAI, Mind Over Mood Anxiety Inventory; SAS, Self-Rating Anxiety Scale, SAST, Short Anxiety 
Screening Test; SCL-90, Symptom Checklist-90  
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The final number of non-somatic items subjected to categorisation was 126. 
Items varied in their wording, ranging from short, single-word statements of 
symptoms (e.g., “Restlessness”; Mind Over Mood Anxiety Inventory, MOMAI, 
Greenberger & Padesky, 1995) to more detailed questions relating to anxiety 
symptoms (e.g., “During the past month, how much of the time have you felt 
restless, fidgety, or impatient?”; Mental Health Inventory-38, MHI-38, Veit & 
Ware, 1983). A content analysis of the 126 remaining items was conducted to 
identify common symptom categories across the scales. Four main categories 
were identified: psychic tension, apprehension, panic, and behavioural. Within 
these main categories, 12 specific symptom themes were identified 
representing a range of cognitive and behavioural anxiety symptoms. Table 5.3 
illustrates the 12 symptom themes and the corresponding scales that contained 
items related to each symptom.  
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Table 5.3: Non-somatic symptom themes and corresponding scales used in Phase 1.1 
 
BAI, Beck Anxiety Inventory; CSAQ, Cognitive-Somatic Anxiety Questionnaire; DASS, Depression Anxiety Stress Scales; GAD-7, Generalized Anxiety 
Disorder-7, GAI, Geriatric Anxiety Inventory; GADS, Goldberg Anxiety and Depression Scale; HADS, Hospital Anxiety and Depression Scale; MHI-38, Mental 
Health Inventory-38; MOMAI, Mind Over Mood Anxiety Inventory; PSWQ, Penn State Worry Questionnaire; SAS, Self-Rating Anxiety Scale, SAST, Short 
Anxiety Screening Test; STAI, State-Trait Anxiety Inventory; SCL-90, Symptom Checklist-90 
 
Organising category Theme No of scales 
containing 
theme 
BAI CSAQ DASS GAD-
7 
GAI GADS HADS MHI-
38 
MOMAI PSWQ SAS SAST STAI SCL-
90 
Psychic tension Nervousness 8 X   X X   X X  X X X  
 Tenseness or 
restlessness 
8    X  X X X X  X  X X 
 Irritability 4    X  X   X   X   
 Inability to relax 8 X   X X X X     X X X 
 Difficulty 
concentrating 
3  X   X    X      
Apprehension Fear 11 X X X X X  X  X  X X X X 
 Emotional 4     X   X   X  X  
 General worry 11  X X X X X X X X X  X X  
 General 
anxiousness 
6  X X X X   X   X    
Panic Panic 4   X    X    X   X 
 Fear of losing 
control 
4 X        X  X X   
Behavioural Avoiding anxiety 
inducing 
situations 
1         X      
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Some scales contained more than one item for each symptom theme. For 
example, the MHI-38 contained three items that were grouped under the theme 
nervousness. The most common anxiety symptoms found in extant scales were 
fear and general worry, which were included under the organising theme of 
apprehension. There was some reference to symptoms of panic, although only 
seven scales contained items relating to this theme. Behavioural anxiety 
symptoms were included by just one scale – the MOMAI. This single item 
referred to avoidance of situations that might induce anxiety. 
 
In general, extant scales did not cover the full range of anxiety related 
symptoms. The greatest coverage was found in the MOMAI, which included 
eight of the 12 symptom themes identified in the analysis. With the exception of 
the MOMAI and the PSWQ, scales covered between four and eight of the anxiety 
symptoms. The PSWQ, a scale that focuses specifically on the worry aspect of 
anxiety, contained 16 items, which all fell under the theme of general worry. 
 
5.3.5 KEY FINDINGS 
 
This study identified 14 anxiety scales that are used to assess anxiety in clinical 
settings. Analysis identified 12 anxiety symptoms under the four categories of 
psychic tension, apprehension, panic and behavioural. 
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5.4 PHASE 1.2: INTERVIEWS WITH PATIENTS 
 
5.4.1 INTRODUCTION 
 
In order to understand fully the experiences and manifestations of anxiety 
among patients with COPD, it is important to elicit the stories of individuals 
who have had first-hand experience of anxiety. Phase 1.2 was designed to gain a 
deeper understanding of the experience of anxiety through qualitative 
interviews with patients and, as a result, to enhance theoretical clarity by 
determining whether underlying theoretical positions reflect the patients’ 
experience.  
 
5.4.2 PHASE 1.2 AIMS 
 
The specific aims of Phase 1.2 were: 
 
a) To identify new scale items through mapping reported anxiety 
symptoms in patients with COPD with those identified in Phase 1.1. 
b) To explore experiences of living and coping with anxiety in patients with 
COPD. 
c) To explore the need for a new anxiety scale for use in patients with 
COPD. 
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5.4.3 METHODS 
 
5.4.3.1 Design 
 
An exploratory qualitative approach was utilised to explore patients’ 
experiences of living and coping with symptoms of anxiety alongside their 
COPD. Data were collected through in-depth, semi-structured interviews 
conducted by the author. The author explained the purpose of the research and 
the criteria for inclusion to groups of patients at PR and Breathe Easy 
community support groups in the Greater Manchester region and eligible 
participants were given a Patient Information Sheet (see Appendix 4) and an 
Informed Consent Form (see Appendix 5). The criteria for inclusion were 
individuals who had a documented primary diagnosis of COPD (FEV1 ≤80% 
predicted and an FEV1/ FVC ratio ≤0.7; NICE, 2010), had self-reported 
symptoms of anxiety, and were able to describe their experiences.  
 
Once written informed consent had been obtained, interviews were conducted 
at either the participant’s local outpatient clinic, or at their home, with 
participants free to choose the time and location of the interview. Prior to 
interview, participants were asked to give socio-demographic details and to 
complete the HADS (see Appendix 6). The HADS data was used to help describe 
the severity of anxiety and depression symptoms across the sample. The 
psychometric properties of the HADS have been described in Chapter 2. The 
HADS was chosen for this study as it provides an insight into levels of anxiety 
and depression symptoms. Despite the documented limitations (see section 
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2.1.8.4), the HADS is the most common scale used in research and clinical 
settings relating to COPD. 
 
5.4.3.2 Participants 
 
This study sought to elicit data from people of various age groups and disease 
severities so that a comprehensive picture of experiences could be explored in a 
diverse sample. Data were collected from a purposive nonprobabilistic sample 
of 14 participants with COPD. The participants for this study were recruited 
from PR and Breathe Easy support groups in Greater Manchester. Potential 
participants were approached by the author who attended Breathe Easy group 
meetings and PR classes and explained the purpose of the research and the 
eligibility criteria. Those recruited from PR were all undergoing an 8-week 
programme of rehabilitation incorporating exercise and disease-education 
components. The remaining participants were members of the Breathe Easy 
support network, a regional network of support groups run by the British Lung 
Foundation. Breathe Easy groups are held within local communities and usually 
meet monthly. Typical group activities include social events, fundraising and 
disease education.  
 
Participants’ characteristics are outlined in Table 5.4. The participants were five 
men and nine women and their ages ranged from 43 to 76 years. Four 
participants were living alone at the time of the study, nine lived with their 
spouse and one lived with an elderly parent. On average, participants had been 
diagnosed with COPD for six years and, typically, had a smoking history of 20 
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pack years. A pack year is equal to smoking 20 cigarettes (one pack) per day for 
one year, or 40 cigarettes per day for half a year, and so on.  Five of the 
participants had never smoked. Of the nine who had smoked, none were current 
smokers and had ceased smoking an average of 10 years ago. Of the 14 
participants, three used supplementary oxygen for up to 2 hours a day, 10 used 
no supplementary oxygen, and one was on 24-hr oxygen via a nasal cannula. 
One participant was awaiting a double lung transplant and was attending PR as 
preparation for their surgery. Only one participant was currently employed 
(part-time), the other 13 were retired. All retired participants indicated that 
they had ceased employment prematurely because of their respiratory disease.  
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Table 5.4: Interview participant characteristics in Phase1.2 
 
Age (years) mean (SD) 62.3 (±9.9) 
Sex (n)  
Male 5 
Female 9 
Recruitment site (n)  
PR 6 
Breathe Easy group 8 
Interview location (n)  
Participant’s home 9 
Local hospital 5 
Smoking status (n)  
Never smoked 5 
Previous smoker 9 
Current smoker 0 
Smoking history (pack years)a mean (SD) 19.5 (±18.0) 
Use of supplementary O2 (n)  
None 10 
≤ 2 hrs./day 3 
24 hrs./day 1 
HADS mean (SD)  
Total score  17.8 (±7.7) 
Anxiety score 9.9 (±5.5) 
Depression score 7.9 (±4.2) 
a One pack year = 20 cigarettes/day for 1 year 
PR: pulmonary rehabilitation; HADS: Hospital Anxiety and Depression Scale 
 
 
Five of the participants had a past clinical diagnosis of GAD for which four had 
taken medication. In all cases, medication had been discontinued 6-12 months 
previously. Two participants had received psychological support in the form of 
counselling from a clinical or counselling psychologist; this, too, had been 
discontinued in the previous year. Participants’ mean HADS score was 10 
(range 5-18) for the anxiety subscale and 8 (range 3-17) for the depression 
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subscale. Using a cut-off score of eleven on the anxiety subscale of the HADS 
(Bjelland et al., 2002), six of the participants were identified as having a 
clinically significant symptoms of anxiety. In addition, five participants had 
clinically significant symptoms of depression based on a score of ≥8 on the 
depression subscale of the HADS. Four participants had both clinically 
significant symptoms of anxiety and depression. Six participants had neither 
anxiety or depression. 
 
5.4.3.3 The interview 
 
The interview was conducted in a conversational style and the questions were 
based around a topic guide aimed at eliciting the participant’s experience of 
anxiety, a particular focus upon the symptoms they had experienced, and how 
this had impacted upon their lives. The interview was preceded by a short 
period of scene setting. Following this period, the remaining interview was 
recorded using an Olympus VN713PC voice recorder (Olympus, UK). 
 
Participants were asked to share their story of their respiratory disease and the 
effect this had on their lives. Following this, participants were asked to explore 
the impact that COPD had on their mental health, with a particular focus on 
experiences of anxiety. Participants were asked to recall episodes where they 
had felt anxious and were encouraged to provide examples of significant events 
or experiences. For the focus of the interview, the participants were asked to 
describe their symptoms of anxiety in detail and what they felt were the causes 
or triggers of anxious episodes. Participants were then asked to explore the 
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impact of anxiety on their lives and to discuss any management or coping 
strategies which they had found helpful. Finally, participants were given the 
opportunity to add any additional information that they felt was relevant. 
 
Participants were free to take breaks at any time during the interview, 
particularly if they became breathless or had an episode of prolonged coughing. 
They were also offered the opportunity to stop at any time during an interview 
and if necessary, to proceed at a later date. No participants required this. 
Interviews lasted between 30 and 90 minutes. 
 
5.4.3.4 Data analysis 
 
Interviews were transcribed verbatim and transcripts were coded in NVIVO 
(version 9) qualitative software. Data were subjected first to a thematic analysis 
by the author using a thematic network analysis approach (Attride-Stirling, 
2001), an approach which has been utilised widely within health and social 
science research (e.g., Goodacre & Candy, 2011; Hancock et al., 2006; Marshall 
et al., 2008). Thematic network analysis aims to facilitate and structure the 
development of themes salient within the text. Using web like illustrations that 
summarise the main themes constituting a piece of text, thematic networks are 
able to offer a visual tool for interpretation and exploration by the researcher. 
Thematic networks can also act as a tool for the reader who is able to anchor 
the researcher’s interpretation on the summary provided by the network 
(Attride-Stirling, 2001). 
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The thematic network is developed starting from a basic theme and working 
inwards toward a global theme. The process of analysis constitutes three steps: 
(1) extraction of the lowest order premises evident in the text (basic themes); 
(2) categories of basic themes are grouped together to summarise more 
abstract principles (organising themes); and (3) superordinate themes are 
generated which capture the text as a whole (global themes). 
 
In order to enhance the dependability (reliability) of the findings, coding and 
basic themes were checked by another member of the research team. In 
addition, credibility (validity) was enhanced by checking the findings with 
members of a local Breathe Easy group.  
 
Following the thematic network analysis, the data were examined specifically 
for symptoms of anxiety through content analysis. The four categories and 14 
symptom themes identified in the previous review (Phase 1.1) were used as a 
basis for a focused coding strategy (Saldana, 2009). Additional symptoms that 
were not previously identified were also recorded.  A frequency count of the 
symptoms present among participants was conducted and these were mapped 
against those from the extant scale review (Wiitavaara et al., 2009). Additional 
themes that were not identified in previous scales were also subjected to 
content analysis. The coding and categorisation of anxiety symptoms was 
discussed within the research group as peer review (Creswell, 2007). 
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Data collection was stopped after 14 interviews had been conducted, because it 
was felt that data saturation had been achieved and that no new information 
was forthcoming.  
 
5.4.4 RESULTS 
 
5.4.4.1 Thematic network analysis 
 
Following the first analysis, three thematic networks were developed, each with 
a global theme: relationships with breathing, fighting for control, and panic 
attacks as life changing. Figure 5.2 illustrates the thematic networks which were 
developed during thematic analysis. 
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Figure 5.2: Three thematic networks identified in Phase 1.2 
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5.4.4.1.1 Relationships with breathing 
 
5.4.4.1.1.1 Anxiety-breathlessness relationship 
 
This organising theme pertains to the intricate relationship between breathing 
and anxiety that was identified by participants. The presence of anxiety was 
described as both a symptom and cause of breathlessness. For many, 
breathlessness was treated as a trigger of anxiety or panic, particularly during 
episodes of more severe breathlessness: 
 
“Very often, if you have had a very severe bout of coughing… then you can be short 
of breath again… it can cause you to start to panic, and you think ‘god I have 
cleared all that muck off my lungs, and I still can’t get my breath.’” 
 
For others, episodes of anxiety were often idiopathic and could be triggered by 
a number of situations including social discomfort, such as feeling embarrassed:  
 
“I tend to get panicky when I go out… Because when people are looking at you, 
you start to panic a bit.” 
 
Others found that specific triggers such as misplacing medication caused them 
to become anxious. These individuals reflected on episodes of acute anxiety 
which were initiated by emotional triggers rather than breathlessness:  
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“… and there wasn’t an inhaler. And you think ‘huh, I haven’t got any inhalers,’ and 
you get all worked up. At first when it first happened I was like ‘oh my god!’” 
 
The relationship between anxiety and breathing was described as a vicious 
circle by several participants who experienced a downward spiral of escalating 
breathlessness and anxiety. These events were recalled with fear, partly 
because of their predictable but uncontrollable nature: 
 
“It’s like a vicious circle. Your breathing gets bad so you get anxious, then you get 
afraid, and your breathing gets worse, which makes you more afraid. The COPD 
feeds the anxiety and the anxiety feeds the fear.” 
 
Living with anxiety was seen as a challenge for some, which was further 
complicated by the confusion and overlap of physical symptoms. Although these 
participants were sometimes aware that they were experiencing symptoms of 
anxiety, the overlap between symptoms of COPD, anxiety, and the side effects of 
medication complicated the recognition of such episodes. In addition, this 
confusion of symptoms was often stressful and led to heightened levels of 
anxiety: 
 
“When you are having a panic attack… your breathing quickens, you struggle to 
breathe, your heart rate quickens, you are sweating, you are trembling. Is it 
because you have taken too much salbutamol? Is it because the anxiety has kicked 
off? Has the anxiety kicked off the COPD? Or, has the COPD kicked off the anxiety?” 
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5.4.4.1.1.2 Control of breathing is important 
 
The relationship between breathing and anxiety, combined with the confusion 
of symptoms, resulted in a fear of breathlessness. In turn, this fear of becoming 
breathless led to the avoidance of activities which were treated as potential 
triggers for anxiety. This was a barrier to normal life that also led to a 
downward spiral of deconditioning where reduced exercise tolerance caused by 
activity avoidance resulted in a greater likelihood of, and sensitivity to, 
breathlessness. The disabling nature of breathlessness avoidance was seen as a 
major barrier to living a normal life: 
 
“You think ‘I will get worse if I move,’ so you find your capability to do physical 
things are pushed back… Cleaning windows, doing the gardening, exercising the 
dog, walking a distance or up a hill, it gets eroded bit by bit because you fear of 
being breathless and being caught out and there being no one to help.” 
 
Among the confusion of symptoms and the vicious cycle of breathlessness and 
anxiety, breathing was identified as manageable through regulating activity and 
breathing exercises. Participants who had adjusted to their anxiety were aware 
of the need to break this vicious cycle and therefore utilised a number of 
breathing exercises including pursed lip breathing and breathing pattern 
control: 
 
“You have just got to slow your breathing down completely… train yourself to take 
a deep breath in and then blow it out… sometimes you are out of breath and you 
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start to think ‘oh I can’t do it’ … you have got to really train yourself to be able to 
do this… it doesn’t always work and that is when I feel the panic again. And then 
you have got to stop yourself and think ‘I can do it’. I tend to talk to myself all of 
the time.” 
 
It was through PR or contact with healthcare professionals that individuals 
were made aware of their anxiety and given an explanation of what they were 
experiencing. These clinicians were able to offer advice on the recognition of 
anxiety and recommend effective coping strategies which participants were 
able to implement. 
 
5.4.4.1.2 Fighting for control 
 
5.4.4.1.2.1 Anxiety can be uncontrollable 
 
Participants recalled experiences of acute anxiety and panic as a fight for 
control. This organising theme relates to how participants viewed their life with 
anxiety as a constant battle for control over their situation, often unsuccessfully. 
Panic led to feelings of vulnerability and loss of bodily control, such as 
incontinence or profuse sweating:  
 
“I lost control of my bladder. And you know what you are doing and you think ‘I 
have got to get to the toilet,’ you know? But you can’t.” 
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These experiences were characterised by an acute awareness of the situation, 
but an inability to manage. During episodes of panic, anxiety took over to the 
point that participants felt helpless:  
 
“Sometimes there is nothing that I can do. I try and take control and put my mind 
on other things. I just sit there but I can’t take control.” 
 
5.4.4.1.2.2 Self-management is important 
 
In many cases, participants were able to take control of their situation after a 
short period of helplessness. The point at which control was regained varied 
and was unpredictable. However, the process of taking control was 
characterised by a logical and systematic thought process and helplessness was 
replaced by a conscious effort to regain control through self-talk and focus: 
 
“I have just got to sit down and say to myself ‘stop it’. And look at something and 
focus on it and physically slow my breathing down… you have got to completely 
take control.” 
 
Self-talk was an important management strategy and was a critical part of being 
in control of one’s situation. Through self-talk and reflection on past events, 
patients were able to assess the relative risk of their situation and were able to 
take positive steps toward avoiding a panic attack. This concept of self-
management was important to participants who felt that they had once had 
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little control over their own situation. Self-management had been facilitated by 
healthcare professionals and through engaging with peers: 
 
“I’m not saying I haven’t had any [panic attacks]. I have felt some coming on but I 
can manage them. She [the nurse] said ‘you can’t die from a panic attack, you 
know?’… And I have imprinted that in my mind … ‘you have got to get your 
breathing right, don’t panic’… It’s all to do with just calming yourself down and 
breathing slowly and deeply.” 
 
The battle for control over one’s daily living was seen as a vital part of 
preventing episodes of panic. Planning was a key element in effective self-
management and was seen as a way of preventing situations that might trigger 
panic attacks. Despite this, the constant planning had a negative consequence in 
causing excessive worry. Paradoxically, in aiming to prevent panic attacks, 
participants’ incessant planning led to an increase in levels of anxiety: 
 
“Your whole life revolves around ‘how close will I be able to park?’ I will have to go 
half an hour earlier than everyone else and then I can make sure I get a parking 
space. And ‘how far away from the room are the toilets?’ Things that everybody 
else takes for granted.” 
 
Some participants described their battle to be in control as a potential trigger 
for episodes of panic. Medication was recognised as an aspect of COPD 
management that was controllable and therefore became an integral part of 
everyday life. However, the relationship with medication became one of 
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reliance and patients explained that unexpected and unplanned circumstances 
could cause panic attacks: 
 
“As long as I have got enough inhalers I am alright. I mean if I go out, I wouldn’t 
tell the doctor this, but I do like to have two. One in my handbag because I think if 
I got robbed then, you know? If somebody managed to get my handbag then I have 
to have one in my pocket… I think it is unlikely that both things will go.” 
 
5.4.4.1.3 Panic attacks as life changing 
 
5.4.4.1.3.1 Panic attacks are traumatic experiences 
 
This organising theme relates to the life changing nature of previous panic 
attacks. Participants recalled their previous episodes of panic as significant and 
traumatic life events. Episodes of panic were seen as particularly isolating 
experiences which were characterised by escalating fear: 
 
“I was panting. It wouldn’t calm down and your heart is bursting because it can’t 
keep up with the breathing… it gets more and more frightening… this time I was 
on my own… I was thinking “there is no way out from this, I can’t even crawl.’” 
 
Participants also experienced claustrophobic sensations such as feeling trapped 
or smothered that were often described in relation to their ability to breathe: 
 
“It is as though I am sat there and the room is being sealed off completely, as if no 
air is getting in. The windows and doors would be open but no air is getting in. It’s 
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like the walls are closing in and the closer they get the less you can breathe. It’s 
like it’s closing in. And that’s how it starts.” 
 
Some panic attacks were perceived as near death experiences that there was 
little chance of overcoming. Participants recalled their experiences with great 
clarity and acceptance of their fate. In such cases, there was little desire to fight 
back:  
 
“You just think you are going to die, and you just think you would be better just 
dying and not doing anything about it.” 
 
5.4.4.1.3.2 Panic attacks have a lasting impact 
 
The traumatic nature of panic episodes had a lasting effect in which participants 
had an underlying fear of experiencing similar events. The fear and memories of 
having a panic attack acted as a trigger for further anxiety in some cases: 
 
“And those panic attacks are always on my mind. They are not very nice believe 
me. So sometimes, I worry about these things, and sometimes the worry causes 
your breathing to go bad.” 
 
Participants experienced meta-worry (worry about worry) which sometimes 
led to further anxiety and panic attacks. Fear of experiencing a panic attack was 
also seen as disabling. For some participants the combination of previous 
traumatic experiences and the fear of another episode impacted on daily life:  
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“I found panicking and being out of breath when I was outside very embarrassing 
and in the end I would rather stop in and not put myself in that situation. Now I 
have basically stopped doing everything.” 
 
Fear of anxiety caused some participants to become housebound. For one 
person, the fear of experiencing a panic attack was particularly debilitating: 
 
“I have been in a situation where at bedtime I won’t go upstairs. I have literally 
stayed all night in the armchair because I have been too frightened to go up the 
stairs in case I get one of these panic attacks.” 
 
5.4.4.2 Content analysis of anxiety symptoms 
 
The participants in this study reported a range of somatic, cognitive and 
behavioural anxiety symptoms. As expected, somatic symptoms were common, 
with all but one participant reflecting upon physical anxiety symptoms. The 
most common somatic symptoms were breathlessness, heart palpitations and 
sweating, affecting 86%, 43% and 36% of participants respectively (see Table 
5.5).  
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Table 5.5: Frequency of somatic anxiety symptoms described by 
participants in Phase1.2 
 
Somatic anxiety symptoms Number of patients experiencing symptom n (%)* 
Breathless 12 (86) 
Heart palpitations 6 (43) 
Sweating 5 (36) 
Feeling smothered 3 (22) 
Sleep problems 3 (22) 
Shaking 2 (14) 
Urinary incontinence 2 (14) 
Tingling 2 (14) 
Hot flushes 2 (14) 
Unable to move 2 (14) 
Tiredness 1 (7) 
Chest tightness 1 (7) 
Butterflies in the stomach 1 (7) 
*Please note that several patients reported more than one symptom 
 
Mapping of the non-somatic anxiety symptoms revealed that there was a high 
level of convergence between the cognitive and behavioural symptom themes 
found in the extant scale review and the anxiety symptoms reported by 
interview participants (see Table 5.6).  Participants described symptoms which 
related to all 12 of the themes identified during the literature review 
(Phase1.1).  
 
202 
 
 
Table 5.6: Comparison of themes between Phase 1.1 and 1.2 
 
Theme from 
literature review 
Number of scales 
containing theme 
n (%) 
Symptoms from 
interview 
Number of participants 
experiencing symptom 
n (%) 
Nervousness 8 (57) Feeling nervous 3 (22) 
Tenseness or 
restlessness 
8 (57) 
 
Feeling frustrated 
Experiencing nagging 
thoughts 
7 (50) 
Irritability 4 (29) 
 
Feeling irritable 
Getting easily annoyed 
6 (43) 
Inability to relax 8 (57) 
 
Feeling unable to relax  8 (57) 
Difficulty 
concentrating 
3 (22) 
 
Feeling unable to 
concentrate when 
needed 
2 (14) 
Fear 11 (79) 
 
Feelings of fear, terror 
or impending danger 
11 (79) 
Emotional 4 (29) 
 
Becoming easily upset 
Not being able to 
control emotions 
8 (57) 
General worry 11 (79) 
 
Feeling generally 
worried 
10 (71) 
General 
anxiousness 
6 (43) 
 
Feeling generally 
anxious 
6 (43) 
Panic 4 (29) 
 
Experiencing episodes 
of sudden panic or fear 
12 (86) 
Fear of losing 
control 
4 (29) 
 
Experiencing feelings 
of potentially losing 
control 
2 (14) 
Avoiding anxiety 
inducing situations 
1 (7) Avoiding situations 
that might lead to 
anxiety or panic 
6 (43) 
Additional 
themes 
   
Anticipatory worry  Worry about everyday 
activities 
5 (36) 
Anticipatory panic  Feeling anxious about 
future panic attacks 
6 (43) 
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Symptoms relating to panic and fear were common among the interview 
participants. Eighty six per cent of participants reported symptoms of panic and 
79% of participants reported experiencing feelings of intense fear or impending 
danger. Although fear was a common symptom in extant scales, panic as a 
symptom was only identified by three of the 13 scales.  
 
Behavioural anxiety symptoms such as avoiding situations that cause elevated 
anxiety is an aspect of anxiety that is not covered in the majority of extant 
scales. However, six of the participants in the current study report this as a 
symptom of their anxiety experience. In contrast, nervousness was mentioned 
by three of the participants (22%), yet this was a core anxiety symptom in over 
60% of extant scales.  
 
Other symptoms which were common among participants include general 
worry, difficulty relaxing, feeling frustrated and getting emotional easily. With 
the exception of emotionality, these cognitive symptoms of anxiety were found 
in at least half of the extant scales reviewed. 
 
Table 5.7 presents example quotes from the interviews that relate to the 
symptom themes identified from the literature review.  
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Table 5.7: Example quotes from Phase 1.2 interviews 
 
Theme Example quote 
Nervousness “I was so nervous and shaky” 
Tenseness or restlessness “The COPD can trigger off the anxiety ... 
because you get yourself wound up.” 
“It is very weird and a very tense feeling.” 
Irritability “I am just so bloody useless and frustrated. I 
am annoyed with myself.” 
“It is just that you are annoyed with yourself.” 
Inability to relax “I plan something in my head ... I start to 
worry about it and it would cause a little bit 
of anxiety, you know?” 
Difficulty concentrating “You can’t concentrate. When I am anxious I 
can’t concentrate and I like reading and 
everything but you can’t concentrate on 
anything.” 
“I like to read books but I just can’t 
concentrate.” 
Fear  “Oh I have never felt anything like it at all. I 
don’t know, it was frightening, really, really 
frightening.” 
“Because I would be frightened to death…” 
Emotional “Things upset you like that. It can be 
something trivial sometimes that triggers it 
off.” 
“And you can get yourself worked up over 
things.” 
“I would have got all worked up and then I 
would have got anxious and then the 
breathing starts.” 
“And you are getting yourself so worked up 
about things.” 
“Things upset you and things like that. It can 
be something trivial sometimes that can 
trigger it off.” 
General worry “I am worried at the moment because I am 
thinking ‘am I going to get back to where I 
was 6 or 8 months ago?’ And that is an 
underlying worry at the moment.” 
“Yeah I wonder and I worry about where I 
am going to be. About what the family would 
do if anything happened. I always worry 
what is going to happen. And I have thought 
like that for a while now.” 
“I have worried about what is going to 
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Theme Example quote 
happen.” 
General anxiety  “I could not get to sleep. And that gets you a 
bit anxious, especially when my husband 
needs to sleep.” 
“And you do something and then think I can’t 
do that, and it is like a flashback, and you 
think oh god and that’s that thing when you 
start to feel a bit anxious.” 
Panic “If I had been out and got dropped off at the 
gate… I could be in a panic attack before I 
actually got to the front door.” 
“The more I gasped the more panicky I got 
and the worse it got.” 
“I did get quite panicky then because I was 
thinking what is going to happen?” 
Fear of losing control “The anxiety feeds the fear and then you are 
thinking to yourself – I have got to control 
this, I have got to control it. And I used to feel 
out of control.” 
“Everything was spiralling out of control.” 
“A panic attack is very similar to over doing it 
but you just can’t control it. You can’t 
breathe and you can’t control it.” 
Avoidance of anxiety-inducing situations “I seem to get out of breath. I think ‘oh it’s 
coming on again’, so I stop doing it and I 
wonder sometimes if I should carry on doing 
it.” 
“I found being out of breath when I was 
outside very embarrassing and in the end I 
would rather stop in and not put myself in 
that situation. Now I have basically stopped 
doing everything.” 
 
 
In addition to the 12 symptom themes that were previously identified in 
Phase1.1, the interviews revealed two further domains of non-somatic anxiety 
that are not covered in extant scales: anticipatory worry and anticipatory panic. 
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5.4.4.2.1 Anticipatory worry 
 
The first domain identified through interviews relates to worries about 
everyday tasks, such as going shopping or visiting a friend. This was labelled as 
anticipatory worry. Participants described their fears and worries about 
participating in a range of everyday activities; often well in advance of the 
event:  
 
“Yeah because you are thinking all the time. And it spoils it because you are 
worrying about things before you have actually got there.” 
 
The excessive anticipatory worry that participants described appeared to be 
closely related to a fear of becoming breathless through overexertion. For 
example, one participant described a situation where they became anxious at 
the thought that they might have to walk to a restaurant or up a flight of stairs:  
 
“Also, I would start to worry about doing things. Say I were going out on Saturday 
night, I would be worrying about it now… You would be worrying about whether 
there would be anywhere to park near the entrance, so you didn’t have to walk. 
You would be worrying if it were upstairs.” 
 
For some patients, the anticipatory worry about activities and the prospect of 
becoming breathless caused them to experience a panic attack: 
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“I get them [panic attacks] thinking what could happen I suppose, like if I was 
walking up hills and things.” 
 
Other participants experienced anticipatory worry in relation to their 
medications: 
 
“...and now when we are going out it is like ‘have you got your inhaler? Have you 
taken your tablets? Have you got your spare tablets in case you are ill while we 
are away?’ It is a totally different thing, you can’t just think ‘let’s go here and get 
up and go’, you have got to think ‘have I got my inhaler with me? Have I got these? 
Have I got my tablets?’” 
 
5.4.4.2.2 Anticipatory panic 
 
The second domain that was identified through the qualitative interviews was 
the notion of anticipatory panic, or a worry about experiencing future panic 
attacks. Several participants reported experiencing flashbacks of previous panic 
attacks, which led to an underlying worry about experiencing future panic: 
 
“… you start to get flashbacks and worry.” 
 
“…they [panic attacks] are always on my mind. They are not very nice believe me. 
So sometimes I worry about these things.” 
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Panic attacks were associated with intense fear, near-death experiences, and 
were perceived as serious life events. As a result, participants explained how 
these life-changing events caused considerable distress, which affected daily 
life:  
 
“Well they [panic attacks] are such a big part of your life... Everything revolves 
around it… It is awful. It is the most horrible, horrible place to be.” 
 
“I have been in a situation where at bedtime I won’t go upstairs. I have literally 
stayed all night in the armchair because I have been too frightened to go up the 
stairs in case I got one of these panic attacks.” 
 
5.5 CONCLUSIONS 
 
The results from these two studies provide an insight into key symptoms of 
anxiety from both emic and etic perspectives. In general, the symptoms of 
anxiety experienced by interview participants closely mirror those assessed in 
extant anxiety scales. However, two additional symptoms of anticipatory anxiety 
and anticipatory panic appear to be relevant aspects of anxiety among patients 
with COPD. Furthermore, behavioural anxiety in the form of avoidance of 
anxiety-inducing situations is another aspect of the anxiety construct which may 
be pertinent to patients with COPD and yet is not included within the majority 
of extant scales.   
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Although interview participants experienced the majority of symptoms found in 
the scale review, it is evident that patients with COPD experience panic and 
worry more than some other symptoms of anxiety, such as difficulty in 
concentrating or nervousness. The review of extant scales suggests that not all 
anxiety scales cover aspects of panic, yet this appears to be particularly 
prevalent among patients with COPD. Almost all scales, on the other hand, cover 
worry as an aspect of anxiety. 
 
The experiences of participants in the present study indicate that anxiety, and 
particularly panic attacks, are distressing experiences that have a considerable 
impact upon daily life. In addition, their accounts suggest that although patients 
with COPD experience a high incidence of somatic anxiety symptoms such as 
breathlessness and palpitations, these are readily confused with symptoms of 
respiratory disease and the side effects of medication. This finding supports the 
notion that non-somatic items may be particularly useful in identifying and 
detecting anxiety in patients with COPD, and lends support to the development 
of a non-somatic anxiety scale. 
 
5.6 DEVELOPMENT OF POTENTIAL SCALE ITEMS 
 
The results from emic and etic perspectives acted as a basis for the item writing 
process. Therefore, the 14 symptom themes that were identified were used as a 
guide for item content. In addition to item content and wording, three 
important decisions guided the development of the draft items: 
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1) the overarching syntax of the scale 
2) the response format 
3) The timeframe of the response 
 
The following section outlines the decisions that guided this process. 
 
5.5.1 ITEM FORMAT 
 
It was decided that in order to minimise cognitive load and erroneous 
responding, each statement should contain the same sentence stem (Michalak & 
Murray, 2010). Therefore, each statement began with the sentence stem –‘I 
have...’  
 
A pool of items was written to cover the 14 symptom themes that were 
identified previously (see section 5.4.4.2). Where possible, the words that 
participants used to describe their symptoms were incorporated into the 
statements. For example, words such as ‘wound-up’, ‘annoyed’, ‘worked-up’ and 
‘panicky’ were used in the new items.  
 
A relatively small pool of items was written (Table 5.8) as it was deemed 
important to minimise participant burden, especially in those with acute 
respiratory or anxiety symptoms. Therefore, for most themes a single item was 
written. In keeping with the majority of items from extant scales, a decision was 
made by the author and supervisory team that items would be worded in a 
negative direction. However, it was decided that one positively worded item 
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would be included to explore acquiescence bias. Hence, for the theme ‘inability 
to relax,’ two items were written. 
 
Table 5.8: Items developed for new scale 
 
Themes from 
literature review 
Item 
number 
Item wording Associated DSM-IV-
TR anxiety 
diagnosis 
Nervousness 13 ‘I have felt nervous or on-edge’ GAD 
Tenseness or 
restlessness 
1 ‘I have felt tense, restless or 
wound-up’ 
GAD 
Irritability 2 ‘I have felt irritable and/or easily 
annoyed’ 
GAD 
Inability to relax 9 
16 
‘I have found it hard to relax’ 
‘I have felt relaxed and in control’ 
GAD 
 
GAD 
Difficulty 
concentrating 
3 ‘I have found it difficult to 
concentrate on things, such as 
watching TV or reading’ 
GAD 
Fear 12 ‘I have had thoughts that 
something bad might happen’ 
PD 
Emotional 6 ‘I have felt worked-up and/or 
upset’ 
GAD 
General worry 4 ‘I have had worrying thoughts 
going through my mind’ 
GAD 
General anxiety 11 ‘I have felt generally anxious’ GAD 
Panic 10 
 
5 
‘I have had sudden and intense 
feelings of fear and/or panic’ 
‘I have felt very frightened or 
panicky’ 
PD 
 
PD 
Fear of losing control 7 ‘I have had a fear of losing control 
or falling apart’ 
PD 
Avoidance of anxiety-
inducing situations 
14 ‘I have avoided situations that I felt 
might lead me to panic’ 
PD 
Anticipatory anxiety  15 ‘I have worried about doing 
everyday tasks, such as going 
shopping or visiting a friend’ 
GAD 
Anticipatory panic 8 ‘I have worried about experiencing 
panic’ 
PD 
DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision; 
GAD, generalised anxiety disorder; PD, panic disorder 
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As feelings of panic were the most frequently cited symptom by patients, a 
decision was made to include two items that were designed to reflect this 
symptom theme. One item – ‘I have had sudden and intense feelings of fear 
and/or panic’ was written to reflect PAs, whereas another item – ‘I have felt very 
frightened or panicky’ was written to reflect a state of hyper-arousal, and also to 
closely mirror the words used by patients to describe their experience of panic. 
Six of the items reflect the criteria for a DSM-IV-TR diagnosis for PD, whilst the 
other 10 reflect key symptoms considered in a GAD diagnosis (APA, 2000).  
 
The reading age of the new items was examined to determine if items needed 
re-wording. Items had a Flesch-Kincaid reading level of grade 4.9. This is below 
the minimum reading level of grade 5 that DeVellis (2003) advises for writing 
scales for the adult population. In the UK, grade 5 is the equivalent of Year 6, 
with pupils aged between 10-11 years old. 
 
5.5.2 RESPONSE FORMAT 
 
The choice of response format was guided by the decision that the scale should 
assess the severity of markers of anxiety. Therefore, a response that was 
anchored between experiencing a symptom that occurred almost all of the time, 
to not at all seemed prudent. A 4-point Likert-type response format was chosen 
as it is the best understood response format in psychology, and is 
psychometrically powerful and efficient (Carifio & Perla, 2008). In addition, this 
response format is the most commonly used format in existing anxiety scales 
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(see Table 5.1). Longer alternatives would have the advantage of being more 
continuous levels of measurement, but would add to the response burden. 
 
All statements, therefore, had four possible responses that were scored from 0-
3. These were as follows: 
 
 Not at all (0) 
 Occasionally (1) 
 Frequently (2) 
 Almost all of the time (3) 
 
5.5.3 TIMEFRAME 
 
A decision was made to incorporate a timeframe of 2 weeks because it is 
intuitively familiar, requires minimal recall and will therefore minimise the 
cognitive load (Michalak & Murray, 2010). In addition, this is a similar 
timeframe to that used in other psychiatric instruments such as the GAD-7 and 
the Patient Health Questionnaire (PHQ; Spitzer et al., 1999) so allows direct 
comparison with these scales. Finally, the review of extant scales suggests that a 
timeframe of between 1 week and 1 month is optimal. 
 
The wording of the scale read as follows: 
 
‘Please think back over the past 2 weeks and mark (X) in the box that best 
describes how you have felt. Be sure to only select one response for each item.’ 
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5.5.4 COMPLETION AND LAYOUT 
 
After consulting with an expert reference group (ERG) that included members 
of the Breathe Easy network (n = 4), two physiotherapists, two respiratory 
nurse specialists and a geriatric psychiatrist, it was decided that due to the 
decline in cognitive performance and visual acuity that occurs in older patients 
with COPD (e.g., Hung et al., 2009; Sjöstrand et al., 2011), items should be easy 
to read, and large spaces should be provided for respondents to mark. 
Therefore, each item was designed to have its own shaded area with four clear 
response sections (see Figure 5.3). 
 
 
Figure 5.3: Example item from the 16-item scale 
 
5.5.5 PILOTING 
 
Once the items had been developed and the final scale had been designed, the 
16-item scale was piloted with participants from the ERG to test for usability. It 
was also given to the clinicians from the ERG to test for face and content 
validity. No further amendments were advised. 
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5.7 SUMMARY OF CHAPTER 5 
 
This chapter described the mixed methods approach to scale development in 
which emic and etic perspectives were integrated to develop 16 novel anxiety 
items. These reflect the experiences of patients with COPD and are guided by 
the words used by participants to describe their anxiety. The items generated in 
Phase 1 are, therefore, grounded in the experiences of patients with COPD and 
relevant to this clinical population.  
 
The qualitative interviews also allowed an in-depth exploration of the 
experience of anxiety from the perspectives of patients with COPD. A thematic 
network analysis approach identified three thematic networks, each with a 
global theme: relationships with breathing, fighting for control, and panic 
attacks as life changing.  
 
The following chapter will describe the process of refining the pool of scale 
items into a reliable and valid scale through quantitative analysis based on data 
from clinical samples of patients with COPD. 
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Chapter 6 : PHASES 2 & 3 – SCALE REFINEMENT AND 
VALIDATION 
 
6.1 INTRODUCTION 
 
In the previous chapter (Chapter 5), the development of an initial pool of items 
using a mixed methods approach was described. In this chapter, the 
quantitative processes relating to the reduction of the initial pool of scale items 
into an internally consistent and valid scale are discussed. The chapter contains 
two phases of work: Phase 2 and Phase 3. In Phase 2, the 16 items established in 
the item development phase were reduced, using classical test approaches, to 
produce a shortened scale (the AIR) with strong internal consistency and a clear 
factorial structure. In Phase 3, the psychometric properties and clinical utility of 
the final 10-item AIR were established. 
 
6.2 CHAPTER 6 AIMS 
 
1. To refine items developed in Phase 1 into a short, novel, user-friendly 
and unidimensional anxiety scale that assesses markers of anxiety and 
screens for anxiety disorders in patients with COPD. 
2. To establish psychometric properties, perform initial validation and 
establish clinical screening utility of the new scale in a sample of patients 
with stable COPD. 
 
217 
 
6.3 PHASE 2: SCALE REFINEMENT 
 
6.3.1 PHASE 2 AIM 
 
To reduce the initial 16-item AIR into a scale with high internal consistency and 
a clear factor structure through scale analysis and EFA procedures. 
 
6.3.2 METHOD 
 
6.3.2.1 Procedure 
 
Participants completed the draft AIR (see Appendix 7) which contained the 16 
items developed in Phase 1. Basic demographic data were also recorded. 
 
6.3.2.2 Sample 
 
The sample consisted of both inpatients and outpatients with COPD. 
Outpatients were recruited through convenience sampling by the author from 
two localities. The first location was four PR groups running within the Pennine 
Acute Hospital NHS trust. The second location was four Breathe Easy groups in 
the Greater Manchester area (Bury, Newton Heath, Oldham, and Tameside and 
Glossop). Inpatients were recruited by the author, or with the help of a Trust 
research assistant, from an acute medical ward at Tameside Hospital 
Foundation Trust in Greater Manchester. 
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Patients were eligible for inclusion if they were ≥40 years of age and had a 
documented primary diagnosis of COPD (defined by spirometry: FEV1<80% of 
predicted and FEV1/FVC <70% predicted; NICE, 2010). Inpatients were eligible 
for inclusion if they had been admitted to hospital due to AECOPD.  
 
Patients were excluded if they had a documented cognitive impairment e.g., 
Mini Mental State Examination Score <25 (Iliffe et al., 1990), had another 
primary diagnosis e.g., severe chronic heart failure or unstable angina, or did 
not understand written English. 
 
The author approached all eligible outpatients either at the PR groups or at 
monthly Breathe Easy group meetings. Eligible participants were given 
information packs which contained a Participant Information Sheet (see 
Appendix 8) and an example Informed Consent Form (see Appendix 9). Eligible 
inpatients were given the same research information packs shortly after 
admission to hospital, when their condition had stabilised. All potential 
participants were given 24 hours to consider their involvement in the study and 
were encouraged to ask for clarification if there was any information they did 
not understand. 
 
6.3.2.3 Data analysis 
 
Data were analysed using item and factor analysis with Statistical Package for 
Social Sciences (SPSS; version 19) in order to: (a) refine the item pool and 
establish initial internal reliability, and (b) assess factorial structure. A 
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constructive approach to item reduction was used to remove items based on a 
number of criteria. There are no strict criteria guiding the removal of items but 
based on the recommendations of other scale developers (Al-Shair et al., 2009; 
Bova et al., 2006; Costello & Osbourne, 2005; DeVellis, 2003; Fabrigar et al., 
1999), items were removed for the following reasons:  
 
1. They had an item-total correlation of <.55.  
2. They showed redundancy of measurement defined by a high correlation 
(r≥.9) with another item.  
3. They had a squared multiple correlation (r2 coefficient) of <.5 or >.9.  
4. They had “floor” or “ceiling” effects. This was defined as items that were 
mostly answered with “Not at all” or “Almost all of the time”.  
5. They increased internal consistency (Cronbach’s α) if removed. 
6. Their communalities (or shared variance) were <.5.  
 
After the final item selection, remaining items were subjected to ML EFA. Prior 
to testing, the suitability of the data for ML EFA was assessed using three 
different tests:  
 
1. KMO value. This tests whether the data is likely to factor well. A value ≥.7 
is considered to be good (Hutcheson & Sofroniou, 1999). 
2. Bartlett’s test of sphericity. A significant value disaffirms the null 
hypothesis that the correlation matrix is an identity matrix i.e., that there 
is no relationship between the items (Field, 2005). 
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3. Examining the correlation matrix for the presence of multiple 
coefficients (Williams et al., 2010). 
 
Extraction of factors was based on Kaiser’s criterion for an Eigen value of >1 
and Cattell’s scree test (Field, 2005). Internal consistency was assessed using 
Cronbach’s α and Guttman’s split-half coefficient. 
 
Normal distribution of the final 10-item AIR was assessed by Shapiro-Wilk 
goodness of fit test. Non-normally distributed data was transformed using log to 
base 10 (Field, 2005). The data could not be transformed to normal distribution 
and were therefore analysed using a non-parametric equivalent of the t-test: the 
Mann-Whitney U test. Means of total scores were compared according to patient 
recruitment site (outpatient vs. inpatient) and sex using Chi-square test. 
Significance was set at p<0.05. 
 
6.3.3 RESULTS 
 
6.3.3.1 Sample characteristics 
 
In all, 156 patients with COPD were invited to participate in this study; 91 
inpatients and 65 outpatients. A total of 88 patients participated in this study; 
33 (37.5%) outpatients and 55 (62.5%) inpatients. This resulted in a response 
rate of 56.4% overall (60.4% for inpatients and 53.8% for outpatients). The 
mean (SD) age of the total sample was 70.6 (±11.9) years (66.8 (±9.1) years for 
outpatients and 74.1 (±8.1) years for inpatients). Thirty-two (36.4%) of the 
sample were male (10 (30.3%) outpatients and 22 (40.0%) inpatients). 
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6.3.3.1 Item reduction 
 
Table 6.1 shows mean (SD) values and range of scores for all 16 items. All items 
had reasonable means that were close to mid-values. Using constructive steps, a 
total of six items were excluded from the initial 16 items: 
 
First, item 16 “I have felt relaxed and in control” was removed for having an 
item-total correlation <.55 and a r2 coefficient of <.5. Second, items 2 “I have felt 
irritable and/or easily annoyed”, 14 “I have avoided situations that I felt might 
lead me to panic”, 15 “I have worried about everyday tasks, such as going 
shopping or visiting a friend”, and 3 “I have found it difficult to concentrate on 
things, such as watching TV or reading” were removed as they did not contribute 
strongly to internal consistency (their removal increased Cronbach’s α) and had 
communalities <.5. Finally, item 1 “I have felt tense, restless or wound-up” was 
removed as its removal improved internal consistency, it had a communality of 
<.5, and had a borderline r2 coefficient value (r2=.51). No items demonstrated 
floor or ceiling effects. 
 
Following these steps, a 10-item version of the AIR was produced (see Appendix 
10). Assessment of the scale’s reliability found excellent internal consistency 
(Cronbach’s α = 0.95; 95% CI: 0.94-0.97) and split-half reliability (Guttman’s 
coefficient = 0.95). 
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Table 6.1: Phase 2 item scores 
 
 Item Mean SD Range 
1 I have felt tense, restless or wound-up 1.49 0.97 0-3 
2 I have felt irritable and/or easily annoyed 1.28 0.95 0-3 
3 I have found it difficult to concentrate on things, such as watching 
TV or reading 
1.24 1.07 0-3 
4 I have had worrying thoughts going through my mind 1.21 1.02 0-3 
5 I have felt very frightened or panicky 1.01 0.95 0-3 
6 I have felt worked-up and/or upset 1.23 0.89 0-3 
7 I have had a fear of losing control and/or falling apart 0.85 0.95 0-3 
8 I have worried about experiencing panic 0.86 0.95 0-3 
9 I have found it hard to relax 1.52 1.00 0-3 
10 I have had sudden and intense feelings of fear and/or panic 0.91 0.94 0-3 
11 I have felt generally anxious 1.23 0.86 0-3 
12 I have had thoughts that something bad might happen  1.07 0.91 0-3 
13 I have felt nervous or on-edge 1.21 0.89 0-3 
14 I have avoided situations that I felt might lead me to panic 1.18 1.01 0-3 
15 I have worried about doing everyday tasks, such as going 
shopping or visiting a friend 
1.16 1.08 0-3 
16 I have felt relaxed and in control 1.52 1.02 0-3 
 
 
 
 
6.3.3.2 Factor analysis 
 
Prior to testing, the suitability of the data for EFA was confirmed. The KMO 
value was 0.92, considerably higher than the minimum recommended value 
(Hutcheson & Sofroniou, 1999), and Bartlett’s test of sphericity was significant 
(χ2=1060.61, p<0.001). Finally, inspection of the correlation matrix revealed 
numerous coefficients. 
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Figure 6.1: Scree plot for 10-item AIR 
 
 
EFA revealed a single factor (‘anxiety’) with an eigenvalue of 7.04, which 
accounted for 67.15% of variance. Catell’s scree plot (Figure 6.1) supported the 
existence of a single factor, demonstrating a clear point of inflexion at the 
second factor. The presence of a single factor dictated that no rotation was 
required. Factor loadings were high across all 10 items with a mean loading of 
0.82 ± 0.05 (see Table 6.2). Communalities varied from 0.50-0.77 with a mean 
value of 0.67 ± 0.09. 
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Table 6.2: Factor loadings and communality values for final 10-item AIR 
 
Original item 
number 
New item 
number 
Item Communality Factor 1 
loading 
4 1 I have had worrying thoughts 
going through my mind 
0.65 0.81 
5 2 I have felt very frightened or 
panicky 
0.70 0.84 
6 3 I have felt worked-up and/or 
upset 
0.56 0.75 
7 4 I have had a fear of losing 
control and/or falling apart 
0.65 0.81 
8 5 I have worried about 
experiencing panic 
0.77 0.88 
9 6 I have found it hard to relax 0.50 0.71 
10 7 I have had sudden and intense 
feelings of fear and/or panic 
0.74 0.86 
11 8 I have felt generally anxious 0.70 0.84 
12 9 I have felt nervous or on-edge 0.77 0.88 
13 10 I have had thoughts that 
something bad might happen 
0.67 0.82 
  Mean (SD) 0.67 ± 0.09 0.82 ± 0.05 
 
 
Scores for the 10-item AIR ranged from 0-30 (mean (SD) = 11 ± 7.8; median = 
10) and were positively skewed (Shapiro-Wilk test, p=0.001) (see Figure 6.2). 
There was no difference between median total scores for patients from 
inpatient settings compared with outpatients (U = 766, p= 0.22). Likewise, no 
difference was found between median scores for males compared to females (U 
= 865, p=0.79). 
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Figure 6.2: Distribution of scores for 10-item AIR 
 
6.3.4 PILOTING OF 10-ITEM AIR 
 
Four patients with COPD who were recruited from the Tameside and Glossop 
Breathe Easy group were asked to complete the 10-item AIR prior to filling out 
a feedback form which rated the AIR on ease of completion, content and clarity 
(see Appendix 11). Participants were asked to rate each aspect on a scale of 0-
10, with ten being the highest rating and zero the lowest. They were also 
encouraged to leave comments if they wished. All participants rated the AIR as 
easy to complete (mean score of 10). The mean score for content was 8.8. All 
four patients scored the AIR a 10 for clarity. 
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Participants were generally positive about the AIR. Positive comments included: 
“Really simple and straightforward” (Participant 1), “I found it very easy to read, 
even without my glasses” (Participant 4). One participant commented that the 
AIR could be longer to capture more symptoms: “It was short. Perhaps you could 
add some more questions in as I doubt it would make much difference in how long 
it would take to complete it” (Participant 2). On average, the 10-item AIR took 95 
seconds to complete. 
 
6.3.5 KEY FINDINGS FROM PHASE 2 
 
In Phase 2 of the research the initial 16-item AIR was reduced to a 10-item 
version of the AIR using constructive steps based on scale and factor analysis. 
The final 10-item AIR demonstrated excellent internal consistency and a clear 
single-factor structure. Piloting of the AIR verified that the scale is easy to 
understand and quick to complete. 
 
6.4 PHASE 3: SCALE VALIDATION 
 
6.4.1 PHASE 3 AIMS 
 
 To examine the psychometric properties of the AIR in a sample of 
patients with stable COPD. 
 To explore the ability of the AIR to screen for anxiety disorders and to 
establish a cut-off score for the scale’s clinical utility as a screening tool. 
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 To explore the prevalence of psychiatric diagnoses among a sample of 
stable COPD outpatients. 
 To identify clinical characteristics of patients with clinical anxiety 
disorders. 
 
6.4.2 HYPOTHESES 
 
In order to establish the validity of the AIR, a number of a priori hypotheses 
were generated. The hypotheses for Phase 3 of the research are as follows: 
 
 To establish convergent validity it is hypothesised that the AIR will 
demonstrate strong correlation with the HADS-A. It is also expected that 
the AIR will correlate (but to a lesser extent) with the HADS-D. This will 
reflect the general negative affect which occurs in those patients 
experiencing anxious and depressive symptoms (McDowell, 2006). 
 To establish known groups validity, it is hypothesised that those patients 
with COPD and a clinical anxiety disorder will have significantly higher 
total AIR scores than those without an anxiety disorder. 
 To establish construct validity it is hypothesised that a single factor 
model will provide the best data fit through CFA  
 To establish temporal stability it is hypothesised that scores on the AIR 
will remain stable over a two-week period. 
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6.4.3 METHOD 
 
6.4.3.1 Procedure 
 
Participants completed a battery of self-report instruments, including the AIR; 
the COPD Assessment Tool (CAT); the HADS; the Manchester Respiratory 
Activities of Daily Living questionnaire (MRADL), and the PHQ, and were also 
asked to provide basic demographic details including age, smoking history etc. 
Severity of COPD was established through lung function testing. Participants 
were then sent the same self-report instruments one week later and asked to 
return the completed measures by pre-paid post. Those participants who 
consented also underwent a structured psychiatric interview (the Mini-
International Neuropsychiatric Interview; MINI) at a later date in order to 
establish a ‘gold standard’ diagnosis of psychiatric disorders. 
 
6.4.3.2 Sample 
 
The sample consisted of outpatients with COPD who were recruited from two 
sources: (1) patients attending PR classes running within the Pennine Acute 
Hospital NHS Trust, and (2) community-based patients who were on the patient 
list of the Pennine Acute Hospital NHS Trust Acute Respiratory Assessment 
Service (ARAS); a community nursing service for patients with COPD.  
 
1. Patients with COPD who were attending the PR classes were approached 
by the author during the educational component of the class. All eligible 
patients were given an information pack that contained a Participant 
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Information Sheet (see Appendix 12) and an example Informed Consent 
Form (see Appendix 13). Potential participants were given 48 hours to 
consider their involvement in the study and were encouraged to ask for 
clarification from the author on any information they did not 
understand. 
 
Data were collected during the following PR class (usually between 3 
and 5 days later) where participants were also required to give written 
informed consent. 
 
2. All patients with COPD who were under ARAS care were sent a research 
invitation pack by post. The invitation pack contained a Research 
Invitation Letter (see Appendix 14), Participant Information Sheet and 
an example Informed Consent Form. A detachable ‘interest’ form was 
produced as part of the Research Invitation Letter. Patients who were 
interested in participating were asked to complete the form and return 
by pre-paid post.  
 
All patients who expressed an interest in participating in the research 
were contacted by the author in order to answer any questions and to 
arrange a home visit for data collection. During the home visit, the 
author obtained informed consent and collected the relevant data 
(outcome measures and demographic data).  
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One week later, all participants were sent a follow-up letter (see Appendix 15) 
and the same self-report instruments by post. Participants were requested to 
complete the self-report instruments on delivery and to return them by pre-
paid post. The follow-up letter also asked participants to indicate whether there 
had been any major change in their health status since their initial participation.  
 
Those participants who consented to psychiatric interview were visited at a 
later date by a second researcher (an expert in psychiatric disorders and COPD) 
who was blinded to the previous results. The diagnostic interviews were 
conducted according to the MINI structured format (Sheehan et al., 1998) and, 
typically, lasted 15-30 minutes. Patients also completed the AIR scale prior to 
psychiatric interview. 
 
Patients were eligible for inclusion if they were ≥40 years of age, had a 
documented primary diagnosis of COPD (defined by spirometry: FEV1<80% of 
predicted and FEV1/FVC <70% predicted; NICE, 2010). They were excluded if 
they had a documented cognitive impairment e.g., Mini Mental State 
Examination Score <25 (Illiffe et a., 1990), had another primary diagnosis e.g., 
chronic heart failure or unstable angina, or did not understand written English. 
 
6.4.3.3 Measurements 
 
6.4.3.3.1 COPD Assessment Test (CAT) 
 
The CAT (Jones et al., 2009b) is a disease specific HRQoL tool that measures the 
impact of COPD on a patient’s life (see Appendix 16). The CAT consists of eight 
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items, with each item containing two statements describing the best and worst 
scenarios. Patients are asked to rate on a scale of 0-5 where they believe they 
are on the scale. Scores range from 0-40 with a higher score indicating worse 
health status. Initial findings indicate that the CAT is reliable (Cronbach’s 
α=0.88), valid and sensitive to changes in health status (Jones et al., 2009a; 
Jones et al., 2009b; Jones et al., 2012). 
 
6.4.3.3.2 Hospital Anxiety and Depression Scale (HADS) 
 
The HADS (Zigmund and Snaith, 1983) is described in detail earlier in this 
thesis (see section 2.8.1.4). The HADS (see Appendix 6) was chosen for this 
study as it provides a recognised marker of anxiety and depression symptom 
severity and is recommended internationally for clinical use in patients with 
COPD (GOLD, 2011; Maurer, 2008). The HADS has good reliability and validity 
and is the most common marker of anxiety and depression in COPD-related 
research. 
 
6.4.3.3.3 Manchester Respiratory Activities of Daily Living questionnaire (MRADL) 
 
The MRADL (Yohannes et al., 2000b) is a self-complete respiratory specific 
activities of daily living (ADL) questionnaire (see Appendix 17). The 
questionnaire contains 21 items that assess functional ability across four 
domains: mobility, kitchen activities, domestic activities and leisure activities. 
Patients are asked to indicate their ability to perform activities across four 
possible responses: not at all, with help, alone with difficulty, or alone easily. 
Scores range from 0-21 with a lower score indicating worse functional ability. 
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The MRADL has good documented reliability (Cronbach’s α=0.91) and validity 
(Yohannes et al., 2000b; 2002). 
 
6.4.3.3.4 Patient Health Questionnaire (PHQ) – anxiety screeners  
 
The PHQ (Spitzer et al., 1999) is a self-report questionnaire which acts as a 
diagnostic tool for a variety of mental disorders including depressive, anxiety, 
somatoform, alcohol and eating disorders. The anxiety section of the 
questionnaire (see Appendix 18) contains two sections that screen for PD and 
‘other anxiety disorder’ (typically GAD). The PHQ is an accurate and valid 
screening tool for diagnosing anxiety disorders in clinical populations (Spitzer 
et al., 1999; 2000). Spitzer and colleagues (1999) found that the self-report PHQ 
was comparable to the Primary Care Evaluation of Mental Disorders (PRIME-
MD; Spitzer et al., 1994) diagnostic interview in diagnostic accuracy. Studies 
exploring the accuracy of the PHQ in detecting anxiety disorders indicate that 
when compared to a structured psychiatric interview, the PD specific screener 
has a diagnostic accuracy of 96% in medical patients (Löwe et al., 2003). For 
detecting any anxiety disorder, the ‘other anxiety disorder’ component of the 
PHQ has a diagnostic accuracy of 93% (Diez-Quevedo, 2001). 
 
6.4.3.3.5 The Mini- International Neuropsychiatric Interview (MINI) 
 
The MINI (Sheehan et al., 1998) is a short, structured diagnostic interview 
developed for DSM-IV and ICD-10 psychiatric disorders (see Appendix 19). The 
MINI takes about 15 minutes to complete and has well established validity and 
reliability (Lecrubier et al., 1997; Sheehan et al., 1998). 
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6.4.3.3.6 Spirometry 
 
Spirometry was performed using a Vitalograph 2120 handheld spirometer 
(Vitalograph, Buckingham, England) according to ATS/ERS Standardisation 
Guidelines (Miller et al., 2005). COPD severity was classified as mild, moderate, 
severe or very severe according to GOLD (2011) guidelines (see Table 1.1 in 
Chapter 1). 
 
6.4.3.4 Data analysis 
 
6.4.3.4.1 Tests of normality 
 
All data analyses were performed using SPSS (version 19). Normal distribution 
was assessed by the Shapiro-Wilk goodness of fit test. Non-normally distributed 
data were transformed using transformation to base 10 (Field, 2005). Where 
data could not be transformed, original data were retained and non-parametric 
statistics were used. AIR score, MRADL score and FEV1% predicted were all 
found to have non-normal distributions (see Appendix 20). Transformation of 
data was only successful for FEV1% predicted and therefore non-parametric 
statistics were used for analyses involving non-normally distributed variables. 
Normally distributed variables were analysed using parametric statistical tests 
e.g., t-test or Chi-square. 
 
Data is presented as mean (SD) for normally distributed data and median 
(interquartile range; IQR) for non-normally distributed data. 
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A p-value of 0.05 was selected a priori and was used for all analyses. 
 
6.4.3.4.2 Group comparisons 
 
Kruskall-Wallis H Test, a non-parametric alternative to analysis of variance 
(ANOVA) was used to evaluate the difference between AIR scores for patients 
according to GOLD (2011) classification (mild, moderate, severe and very 
severe) and smoking status (current smoker, previous smoker or never 
smoked). A Mann-Whitney U test was conducted to compare mean rank AIR 
scores for patients according to sex. 
 
T-tests for parametric statistics, and Mann-Whitney U tests and Chi-Square tests 
for non-parametric data were also used to explore any differences in clinical 
characteristics (e.g., Age, Sex, FEV1% predicted, anxiety) between patients who 
completed follow-up and those who did not. 
 
6.4.3.4.3 Reliability of AIR 
 
Reliability was calculated for the first completion of the AIR and also for follow-
up data. Internal consistency reliability was evaluated using Cronbach’s α, and 
Guttman’s split-half coefficient. Test-retest reliability was calculated using ICC 
and Bland-Altman mean difference plots (Bland & Altman, 1986). 
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6.4.3.4.4 Validity 
 
6.4.3.4.4.1Known groups validity 
 
Known groups validity was calculated by comparing total AIR score between 
anxiety cases and non-cases using the Mann-Witney U test. 
 
Independent t-tests and Mann-Whitney U tests were carried out on 
demographic data to compare any differences between anxiety cases and non-
cases. 
 
6.4.3.4.4.2 Convergent validity 
 
To measure convergent validity the AIR scores were compared to the HADS-A 
score using Spearman’s rho correlation coefficients. The associations between 
the AIR and the HADS-D, HADS-T, CAT and MRADL were also assessed using 
Spearman’s rho correlation coefficients. 
 
6.4.3.4.4.3 Construct validity 
 
Construct validity was established by conducting CFA to determine the degree 
of model-fit. All CFAs were undertaken using AMOS (version 19) SEM software. 
The following models were compared: a single-factor model with one factor of 
‘anxiety’ (Figure 6.3a) and a two-factor model with two intercorrelated factors 
of panic and general anxiety (Figure 6.3b). 
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a) 
 
b) 
 
Figure 6.3: Two CFA models: a) single-factor model of anxiety, b) two-
factor model of general anxiety and panic 
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Model fit was determined using six indices to empirically evaluate the models. 
These were the overall model Chi-Square (χ2); the root mean square error of 
approximation (RMSEA); the GFI; the standardised root mean square residual 
(SRMSR);  the NNFI or TLI, and the comparative fit index (CFI). Although there 
are no strict criteria for evaluating these measures, based on current guidelines, 
model fit was considered acceptable if CFI was 0.90 or greater, if RMSEA was 
between 0.08 and 0.10, if SRMSR was between 0.08 and 0.05 and if TLI was 0.80 
or greater. Good fit was indicated if GFI was 0.90 or greater, CFI and TLI were 
0.95 or greater, if RMSEA was less than 0.08, and if SRMSR was less than 0.05. 
For the overall model χ2, non-significant values indicated a good model fit 
(Hooper, 2008; Hu & Bentler, 1999; Kline, 2005; MacCallum et al., 1996; Miles & 
Shevlin, 1998). 
 
Ad hoc improvements to the model were permitted if they fitted within the 
theoretical framework of the model. These were conducted on the 
recommendation of modification indices provided by the SEM software. 
 
6.4.3.4.5 Clinical cut-off value 
 
The sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) were calculated for each score on the AIR. Diagnosis 
according to PHQ screener were used as the criterion standard for the absence 
or presence of anxiety disorders. In order to determine a cut-off point for 
clinical anxiety, ROC curves were constructed. ROC curves were also 
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constructed for the HADS-A to enable direct comparison of the screening 
properties with the AIR. 
 
In addition, data from the psychiatric interviews were used to further explore 
ROC and clinical cut-off values. Patients were grouped into cases or non-cases 
for any clinical anxiety disorder and for specific cases of PD or GAD.   
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6.4.4 RESULTS 
 
Figure 6.4 illustrates the recruitment process for Phase 3. A total of 56 patients 
were recruited to the study including 31 community-based ARAS patients and 
25 outpatients from PR classes. Ten patients did not respond to follow-up; an 
82% follow-up rate. 29 patients originally consented to psychiatric interview 
and a total of 22 underwent the interview. Of the seven patients who originally 
consented but did not undergo psychiatric interview, five withdrew their 
consent and two patients died.  
 
Of the 505 ARAS patients who were invited to participate, 51 (10.1%) 
responded. Following contact from the author, a total of 31 patients consented 
to participate in the study, a final response rate of 6.1%. The response rate for 
patients invited from PR groups was 59.5%. 
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Figure 6.4: Flow chart of Phase 3 recruitment 
 
 
Invitation packs 
sent to ARAS 
patients n=505 
Invitation packs 
distributed to 
outpatients n=42 
 
Patient deceased 
since invitation 
sent n=6 
 
Did not wish to 
participate n=17 
Responded to 
invitation n=51 
Did not wish to 
participate n=20 
Participants 
completing 
follow-up n=46  
 
Total participants 
completing initial 
testing n=56  
ARAS patients 
consented to 
participate n=31 
PR patients 
consented to 
participate n=25 
 
Failed to respond 
to follow-up n=10 
Participants 
consenting to 
interview n=29 
 
Participants 
completing 
interview n=22 
 
Withdrew consent 
or deceased n=7 
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6.4.4.1 Participant characteristics 
 
Table 6.3 shows the characteristics of the study participants. The majority of 
participants (96.2%) had moderate-to-very severe COPD according to GOLD 
(2011) guidelines.  Most participants were current or previous smokers with 
only 6.7% having never smoked. Those participants who currently or 
previously smoked had a mean smoking history of 42 pack years. 
 
Table 6.3: Phase 3 sample characteristics 
 
 N  
Age (years) 56 69.96 (±8.07) 
Sex (% male) 56 48.2 
Recruitment site n (%) 
PR 
Community 
56  
25.0 (44.6) 
31.0 (53.4) 
Height (cm) 56 163.09 (±11.61) 
Lung function 52  
FEV1 (L) median (IQR)  0.87 (0.43) 
FVC (L) median (IQR)  1.68 (0.73) 
FEV1/FVC  53.06 (±11.66) 
FEV1 % predicted median (IQR)  43.50 (23.67) 
COPD severity a (%) 52  
Mild  3.8 
Moderate  25.0 
Severe  42.3 
Very severe  28.8 
Smoking status (%) 45  
Current smoker  26.7 
Previous smoker  66.7 
Never smoked  6.7 
Pack years b 39 42.49 (±21.91) 
Mean values and SDs are shown unless otherwise noted.  
a based on GOLD (2011) criteria, b one pack year = 20 cigarettes/day for 1 year 
PR, pulmonary rehabilitation; FEV1, forced expiratory volume in 1 second; IQR, interquartile 
range; FVC, forced vital capacity 
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According to the PHQ anxiety screener, 15 patients screened positive for an 
anxiety disorder (Table 6.4). All 15 of these patients screened positive for PD, 
with six also screening positive for other anxiety disorders. HADS-A scores 
indicated that 29 patients had mild-to-severe anxiety and 24 patients had mild-
to-moderate depression according to the HADS-D.  
 
Table 6.4: Anxiety disorders and likely cases of anxiety among total Phase 3 
sample 
 
 n (%) 
PHQ anxiety screener  
Any anxiety disorder  
Case 15 (26.8) 
Non-case 41 (73.2) 
Panic disorder  
Case 15 (26.8) 
Non-case 41 (73.2) 
Other anxiety disorder  
Case 6 (10.7) 
Non-case 50 (89.3) 
HADS cut-off scores a  
HADS-Anxiety  
Non case (≤7) 27 (48.2) 
Mild case (8-10) 13 (23.2) 
Moderate case (11-15) 15 (26.8) 
Severe case (≥16) 1 (1.8) 
HADS-Depression  
Non case (≤7) 32 (57.1) 
Mild case (8-10) 14 (25.0) 
Moderate case (11-15) 10 (17.9) 
Severe case (≥16) 0 (0) 
PHQ, Patient Health Questionnaire; HADS, Hospital Anxiety and Depression Scale 
a Values from Snaith and Zigmund (1994) 
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The mean (SD) follow-up gap was 14.7 ± 5.1 (range = 9-34) days. Of the 46 
participants who completed follow-up, 41 indicated that there had been no 
major change in their health status, such as an AECOPD. Table 6.5 shows the 
scores on self-report scales for participants on the first completion and also for 
those participants who completed the follow-up and had no change in their 
health status. 
 
Table 6.5: Summary of self-report scale scores for a) participants’ first 
completion (n=56), and b) participants who followed-up and had no major 
change in their health status (n=41) 
a) 
Scale Minimum Maximum Mean (SD) Median (IQR) 
AIR 0 23 - 7.5 (11.5) 
CAT 5 38 24.6 (±8.1) - 
HADS     
Anxiety 0 16 7.8 (±4.5) - 
Depression 1 15 7.1 (±3.4) - 
Total 2 29 14.9 (±7.3) - 
MRADL 0 21 - 13 .0(12.0) 
b) 
Scale Minimum Maximum Mean (SD) Median (IQR) 
AIR 0 30 - 6.0 (11.0) 
CAT 0 44 23.4 (±10.1) - 
HADS     
Anxiety 0 16 - 7.0 (8.5) 
Depression 1 15 6.3 (±3.6) - 
Total 2 29 13.1 (±7.5) - 
MRADL 0 21 - 12 .0(14.0) 
SD, standard deviation; IQR, interquartile range; AIR, Anxiety Inventory for Respiratory Disease; 
CAT, COPD Assessment Test; HADS, Hospital Anxiety and Depression Scale; MRADL, Manchester 
Respiratory Activities of Daily Living 
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Table 6.6 compares the characteristics of those who completed follow-up and 
those who did not. There were no significant differences in age (t = 0.85, 
p=0.40), sex (χ2 = 0.68, p=0.50), FEV1 % predicted (U = 193, p=0.99), pack year 
smoking history (t = 0.08, p=0.94), and CAT score (U = 229, p=0.97) between 
those participants who completed follow-up and those who did not. However, 
those who did not complete follow-up had higher anxiety scores on the AIR (U = 
137.50, p = 0.047) and HADS-A (t = -2.16, p = 0.04), higher total scores on the 
HADS-T (t = -2.17, p = 0.03) and lower scores on the MRADL (U = 131, p=0.03).  
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Table 6.6: Comparison of sample characteristics between follow up and 
non-follow up patients 
 
 Completed follow up 
(n=46) 
Did not follow up 
(n=10) 
p value 
Age (yrs.) 70.4 (±8.0) 68.0 (±8.6) 0.43c 
Sex (male) 21 (46) 6 (60) 0.50b 
FEV1 % predicted 43.6 (24.9) 39.9 (21.7) 0.99a 
Gold (2011) classification 
Mild 
Moderate 
Severe 
Very severe 
 
1 (2) 
12 (28) 
17 (40) 
13 (30) 
 
1 (11) 
1 (11) 
5 (56) 
2 (22) 
0.42b 
Smoking status  
Current 
Ceased 
Never 
 
9 (24) 
27 (71) 
2 (5) 
 
3 (43) 
3 (43) 
1 (14) 
0.27b 
Pack years 42.6 (± 22.6) 41.8 (±19.2) 0.94c 
AIR score 7.0 (10.3) 14.5 (13.3) 0.047a* 
CAT score 24.2 (±8.1) 23.6 (±11.0) 0.83c 
HADS-A score 7.2 (±4.6) 10.5 (±3.2) 0.04c * 
HADS-D score 6.7 (±3.4) 8.8 (±3.0) 0.08c 
HADS-T score 13.9 (±7.4) 19.3 (±5.6) 0.03c * 
MRADL score 14.5 (11.5) 9.5 (5.8) 0.03a* 
PHQ anxiety disorder 
Case 
Non-case 
 
10 (22) 
36 (78) 
 
5 (50) 
5 (50) 
0.07b 
FEV1, forced expiratory volume in 1 second; AIR, Anxiety Inventory for Respiratory disease; 
CAT, COPD Assessment Test; HADS, Hospital Anxiety and Depression Scale; MRADL, Manchester 
Respiratory Activities of Daily Living questionnaire; PHQ, Patient Health Questionnaire. 
a Data reported as median (IQR) with Mann-Whitney U test, b Data reported as n (%) with Chi-
Squared test, c Data reported as mean (SD) with t-test 
*p<0.05 
 
 
22 patients underwent psychiatric interview at a later date (approximately 3 
months after their original participation). The characteristics of this sub-sample 
are shown in Table 6.7. 
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Table 6.7: Phase 3 sub-sample (psychiatric interview) characteristics 
(n=22) 
  
Age (years) 71.12 (±5.47) 
Sex (% male) 27.3 
FEV1 % predicted  44.85 (18.31) 
COPD severity a (%)  
Mild 9.1 
Moderate 31.8 
Severe 36.4 
Very severe 22.7 
Smoking status (%)  
Current smoker 27.3 
Previous smoker 59.1 
Never smoked 9.1 
Missing data 4.5 
Pack years b 37.63 (±20.55) 
Mean values and SDs are shown unless otherwise noted.  
a based on GOLD (2011) criteria, b one pack year = 20 cigarettes/day for 1 year 
FEV1, forced expiratory volume in 1 second 
 
Table 6.8 illustrates the psychiatric disorders that were diagnosed in this sub-
sample. Ten patients (45%) had an anxiety disorder. The most common anxiety 
disorder was PD with or without agoraphobia, whilst the most common mood 
disorder was current MDD. Nine patients (41%) had more than one psychiatric 
disorder and seven (32%) patients had both a clinical anxiety disorder and a 
mood disorder. 
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Table 6.8: Psychiatric disorders diagnosed from MINI interview 
 n (%) 
Anxiety disorders  
Any anxiety disorder 10 (45) 
GAD 5 (23) 
PD with or without agoraphobia 8 (36) 
Agoraphobia without history of PD 2 (9) 
Social phobia 1 (5) 
Mood disorders  
Any mood disorder 9 (41) 
Current MDD 7 (32) 
Past MDD 1 (5) 
Recurrent MDD 1 (5) 
Both anxiety and mood disorder 7 (32) 
GAD, generalised anxiety disorder; PD, panic disorder; MDD, major depressive disorder 
 
6.4.4.2 Score distribution and group differences 
 
Scores for the AIR ranged from 0-23 (mean (SD) = 9.8 (±6.7); median = 7.5 (IQR 
11.5) and were positively skewed (Shapiro-Wilk Test p=0.003) (see Figure 6.5). 
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Figure 6.5: Frequency of responses for AIR score (first completion n=56) 
 
 
There was no difference in total AIR scores between males and females (U = 
376, p=0.80), according to GOLD classification (H=2.85, p=0.42) and according 
to smoking status (H=3.33, p=0.19).There was no statistically significant 
correlation between AIR score and FEV1% predicted (r=-0.18, p=0.33), age (r=-
0.24, p=0.08) or smoking history in pack years (r=0.18, p=0.28). Likewise, there 
was no difference in HADS-A score between sex (U=386, p=0.93), GOLD 
classification (H=2.41, p=0.49), smoking status (H=2.06, p=0.36), and no 
correlation with FEV1 (r=-0.03, p=0.83), smoking history in pack years (r=0.05, 
p=0.78) and age (r=-0.26 p=0.06).  
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AIR scores obtained during the psychiatric interviews (n=22) ranged from 0-21 
(mean (SD) = 8.8 (±6.6)) and were normally distributed (Shapiro-Wilk Test 
p=0.153). Figure 6.6 presents the distribution of these scores. 
 
 
Figure 6.6: Frequency of responses for AIR score (follow-up psychiatric 
interview sample n=22) 
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6.4.4.3 Reliability 
 
6.4.4.3.1 Internal reliability 
 
The Cronbach’s α of the AIR on first completion was 0.92 (95% CI: 0.89-0.95). 
Cronbach’s α for follow-up data was 0.95 (95% CI: 0.93-0.97). Guttman’s split-
half coefficient was 0.90 on first completion and 0.93 for follow-up.  
 
6.4.4.3.2 Test-retest reliability 
 
ICC test-retest reliability was 0.81 (95% CI; 0.67-0.89, p=<0.001) for the 41 
participants who reported no major change in their health status. ICC test-retest 
reliability was 0.83 (95% CI; 0.70-0.90, p=<0.001) for the HADS-A. Figure 6.7 
shows the Bland-Altman plot for the AIR. All but one (97.56%) participant 
scored within 2 SDs indicating good test-retest reliability. The mean change was 
1.76 with a upper limit of agreement of 9.94 and a lower limit of agreement of 
6.43.  
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Figure 6.7: Bland Altman plot for AIR 
 
 
6.4.4.4 Validity 
 
6.4.4.4.1Known groups validity 
 
Table 6.9 shows the differences in AIR score between anxiety cases and non-
cases as diagnosed by the PHQ screener. There was a significant difference in 
AIR score between these two groups (U = 9, p<0.001). A significant difference in 
AIR score (U = 39, p<0.001) was also found between those participants who 
screened as anxiety cases and non-cases according to the HADS-A (score of 
≥11). There was no significant difference in AIR score between the groups in 
age (t = 0.91, p = 0.37), sex (χ2 = 0.20, p=0.89), FEV1% predicted (U = 253, p = 
0.99), smoking status (χ2 = 0.51, p=0.78) and pack year smoking history (t = -
1.05, p = 0.30). 
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Patients with a PHQ anxiety diagnosis had significantly higher HADS-A scores (t 
=-6.59, p<0.001), HADS-D scores (t =-4.37, p<0.001), HADS-T scores (t = -6.26, 
p<0.001), and CAT scores (t = -4.10, p<0.001), and significantly lower MRADL 
scores (U = 125.5, p=0.001). 
 
Table 6.9: Comparison of AIR scores between anxiety cases and non-cases 
based on PHQ screener 
 
 No anxiety diagnosis 
n=41 
Anxiety diagnosis 
n=15 
Statistical 
difference 
AIR score    
Median 6.00 18.00  
IQR 6.00 4.00  
Range 0-16 11-23 U = 9; p<0.001 
95% CI lower 5.20 16.83  
95% CI upper 7.77 20.50  
AIR, Anxiety Inventory for Respiratory disease; IQR, interquartile range; CI, confidence interval 
 
The differences in AIR score between patients with a diagnosed anxiety 
disorder (diagnoses in psychiatric interview) and those without are shown in 
Table 6.10. A significant difference in AIR score was found between the groups 
(t=-3.94, p=0.001). 
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Table 6.10: Comparison of AIR scores between anxiety cases and non-cases 
according to psychiatric diagnosis 
 No anxiety diagnosis 
n=12 
Anxiety diagnosis 
n=10 
Statistical 
difference 
AIR score    
Mean 5.17 13.50  
SD 3.95 5.93  
Range 0-12 5-21 t =-3.94; p=0.001 
95% CI lower 2.66 9.26  
95% CI upper 7.68 17.74  
AIR, Anxiety Inventory for Respiratory disease; SD, standard deviation; CI, confidence interval 
 
 
6.4.4.4.2 Convergent validity 
 
Table 6.11 shows the correlations between the AIR and the other self-report 
scales. There were significant correlations between the AIR and HADS-A, HADS-
D, HADS-T, CAT and MRADL. 
 
Table 6.11: Spearman’s rho correlation of AIR with other self-report scales 
 
 AIR Total  
HADS-Anxiety 0.91* 
HADS-Depression 0.66* 
HADS-Total 0.87* 
CAT 0.65* 
MRADL 0.52* 
AIR, Anxiety Inventory for Respiratory disease; HADS, Hospital Anxiety and Depression Scale; 
CAT, COPD Assessment Test; MRADL, Manchester Respiratory Activities of Daily Living 
questionnaire. 
*<0.001 
 
 
255 
 
According to values proposed by Domholdt (2005), the AIR correlated very 
highly with the HADS-A (see Figure 6.8), and highly with the HADS-T. There 
were medium correlations between the AIR and the HADS-D, CAT and MRADL. 
 
 
Figure 6.8: Spearman’s rho correlation between scores on the AIR and 
HADS-A 
 
 
6.4.4.4.3 Construct validity 
 
Table 6.12 shows the model fit indices of all three models that were tested.  
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Table 6.12: CFA values for single-factor and two-factor models 
 
Model description df χ2 p value CFI GFI NNFI/TLI RMSEA SRMSR 
Single-factor 35 68.46 0.001 0.90* 0.79 0.88* 0.13 0.05* 
Two-factor (a) 34 52.50 0.022 0.95** 0.83 0.93* 0.10* 0.045** 
Two-factor (b) 33 39.75 0.20** 0.98** 0.88 0.97** 0.06** 0.04** 
df, degrees of freedom; χ2, chi-square; CFI, comparative fit index; GFI, goodness-of-fit index; 
NNFI, non-normed-fit index; TLI, Tucker-Lewis index; RMSEA, root mean square of error 
approximation; SRMSR, standardised root mean square residual.  
*acceptable fit, **good fit (based on recommended criteria) 
 
 
The CFA of the first single-factor model (model 1) tested is shown in Figure 6.9. 
Results indicate that the model did not fit the data well. χ2 value was significant 
indicating poor model fit, GFI, RMSEA and TLI were all outside minimum values 
for acceptable fit, whilst CFI and SRSMR demonstrated acceptable fit. Factor 
loadings were all positive and significant. 
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Figure 6.9: CFA for single-factor anxiety model (model 1) 
 
 
Figure 6.10 shows the CFA for the two-factor model (model 2a). Results show 
that the model appeared to fit the data better than the single factor model. As 
before, χ2 value was significant (p=0.022) and GFI was outside acceptable fit 
values. However, RMSEA and TLI reached acceptable fit values and values for 
CFI and SRMSR indicated good fit to the data. Factor loadings for both factors 
were all positive and significant. 
 
258 
 
 
 
Figure 6.10: CFA for two-factor anxiety model (model 2a) 
 
To determine the areas of misfit in the hypothesised models, modification 
indices were reviewed. Modification indices suggested a minor adjustment to 
the two-factor model that resulted in allowing the error terms of item 1 and 3 to 
covary (Figure 6.11). This fits the conceptualised model as both items reflect a 
common concept of worry. This minor adjustment to the model had a significant 
improvement in data fit. χ2 reached a non-significant value (p=0.20), thus 
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supporting the model. In addition, GFI (0.88) almost reached an acceptable 
value. However, values for CFI, TLI, SRMSR and RMSEA all indicated a good 
model fit. Factor loadings for both factors were all positive and significant. 
 
The two-factor model indicates that there may be two latent variables 
underlying the AIR that might screen separately for both GAD (general anxiety 
factor) and PD (panic factor). Therefore, the scores for items 1, 3, 6, 8 and 9 can 
be totalled to produce a score for general anxiety, and the scores for items 2, 4, 
5, 7 and 10 can be totalled to produce a score for panic. Scores for general 
anxiety range between 0-15 and scores for panic range from 0-15. 
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Figure 6.11: CFA for modified two-factor anxiety model (model 2b) 
 
 
6.4.4.5 Clinical cut-off values 
 
6.4.4.5.1 Total AIR score 
 
 
ROC analysis was performed on total AIR scores using the PHQ screener as an 
indication of anxiety case or non-case (see Figure 6.12). AUC for the AIR was 
0.96 (95% CI; 0.96-1.00).  
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Figure 6.12: ROC curve for AIR (PHQ anxiety screener) 
 
 
Optimal cut-off value for the AIR (see dashed reference line in Figure 6.12) was 
14.5 (a score of 15), which yielded a sensitivity of 0.93, a specificity of 0.98, a 
PPV of 93% and a NPV of 98% (see Table 6.13). The AUC for PD was 0.96 (95% 
CI; 0.96-1.00) and for ‘other anxiety disorder’ was 0.93 (95% CI; 0.86-1.00). The 
optimal cut-off points for both PD and ‘other anxiety disorder’ were 14.5. This 
resulted in a sensitivity of 0.93 and a specificity of 0.98 for the detection of PD 
and a sensitivity of 1.00 and a specificity of 0.82 for the detection of ‘other 
anxiety disorder.’ 
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Table 6.13: Cut-off scores for AIR (PHQ anxiety screener) 
 
Cut-off score Sensitivity Specificity PPV (%) NPV (%) 
10.5 1.00 0.81 65 100 
11.5 0.93 0.83 78 97 
12.5 0.93 0.90 78 97 
13.5 0.93 0.93 82 97 
14.5 0.93 0.98 93 98 
15.5 0.87 0.98 93 95 
16.5 0.80 1.00 100 93 
PPV, positive predictive value; NPV, negative predictive value 
 
 
A ROC curve was also calculated for the HADS-A (see Figure 6.13). AUC for the 
HADS-A was 0.93 (95% CI; 0.85-1.00).  
 
 
Figure 6.13: ROC curve for HADS-A and AIR (PHQ anxiety screener) 
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Table 6.14 shows the optimal cut-off value for the HADS-A as an anxiety 
screener. The optimal cut-off score was 10.5 (a score of 11) which yielded a 
sensitivity of 0.87, a specificity of 0.92, a PPV of 76% and a NPV of 95%. 
 
Table 6.14: Cut-off scores for HADS-A (PHQ anxiety screener) 
 
Cut-off score Sensitivity Specificity PPV (%) NPV (%) 
4.5 1.00 0.34 36 100 
5.5 0.93 0.42 37 94 
6.5 0.93 0.51 41 95 
7.5 0.93 0.63 48 96 
8.5 0.93 0.78 61 97 
9.5 0.93 0.85 70 97 
10.5 0.87 0.92 76 95 
11.5 0.80 0.92 75 93 
12.5 0.67 0.95 83 89 
13.5 0.47 1.00 100 84 
PPV, positive predictive value; NPV, negative predictive value 
 
ROC analyses were also conducted on data collected from psychiatric 
interviews (n=22). Figure 6.14 shows the ROC curve for clinical anxiety 
disorders. AUC for the AIR was 0.88 (95% CI; 0.75-1.00). 
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Figure 6.14: ROC curve for AIR (diagnosed anxiety disorder) 
 
A cut-off value of 7.5 (a score of 8) achieved an optimal balance between 
sensitivity and specificity. This yielded a sensitivity of 0.80, a specificity of 0.75, 
a PPV of 67% and a NPV of 81% (see Table 6.15). A cut-off value of 8.5 (a score 
of 9) achieved a higher PPV (78%) with only a slight decrease in NPV (77%). 
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Table 6.15: Cut-off scores for AIR (diagnosed anxiety disorder) 
Cut-off score Sensitivity Specificity PPV (%) NPV (%) 
4.5 1.00 0.50 63 100 
5.5 0.90 0.58 64 88 
6.5 0.90 0.58 64 88 
7.5 0.80 0.75 67 81 
8.5 0.70 0.83 78 77 
9.5 0.60 0.83 75 71 
10.5 0.60 0.83 75 71 
11.5 0.60 0.83 75 71 
12.5 0.60 1.00 100 75 
PPV, positive predictive value; NPV, negative predictive value 
 
6.4.4.5.1 Screening properties of AIR sub-categories  
 
ROC analyses were performed on the two sub-scores of the AIR (panic and 
general anxiety) using the PHQ anxiety screeners as an indication of anxiety 
case or non-case. The PD screener of PHQ was used to indicate cases and non-
cases of PD and the ‘other anxiety disorder’ screener of the PHQ was used to 
screen for cases of other anxiety disorders, primarily GAD. AUC for the AIR-
panic score (see Figure 6.15) was 0.95 (95% CI; 0.89-1.00). A cut-off score of 5.5 
(≥6) yielded a sensitivity of 1.00 and a specificity of 0.93 for detecting PD. AUC 
for the AIR-general anxiety score (See Figure 6.16) was 0.90 (95 % CI; 0.81-
0.99). A cut-off score of 8.5 (≥9) yielded a sensitivity of 1.00 and a specificity of 
0.82 for detecting ‘other anxiety disorder’. 
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Figure 6.15: ROC curve for AIR-panic (PHQ PD screener) 
 
Figure 6.16: ROC curve for AIR-general anxiety (PHQ ‘other anxiety 
disorder’ screener) 
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Due to the small sample in the psychiatric interview follow-up phase, a ROC 
analysis was unable to be performed for specific anxiety disorders. 
 
6.4.5 KEY FINDINGS OF PHASE 3 
 
In phase 3, the psychometric properties of the 10-item AIR were established. 
Reliability was confirmed with data indicating excellent internal consistency 
and split half reliability. In addition, the scale demonstrated excellent test-retest 
ICC and Bland-Altman values. Validity was also established in this phase of 
research. Very high correlations with the HADS-A support the convergent 
validity of the AIR, whilst significant differences in AIR score between anxiety 
cases and non-cases confirm discriminant validity. CFA results indicate that the 
data did not fit the hypothesised single-factor model which was proposed in 
Phase 2. However, with minor refinements, the data showed a good fit to the 
two-factor model which contains two sub-scores: panic and general anxiety.  
Finally, the ROC curve demonstrates that the AIR has excellent clinical utility as 
a screening tool for clinical anxiety disorders, specifically for PD and GAD based 
on the two sub-scores.  
 
6.5 SUMMARY OF CHAPTER 6 
 
This chapter outlined Phases 2 and 3 of the research which were concerned 
with modifying the initial pool of items into an internally consistent scale and 
subsequent validation of the 10-item scale in a clinical population. Results from 
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Phase 2 indicate that a 10-item version of the AIR is both internally consistent 
and factorially valid. Phase 3 results provide further support for the reliability 
and validity of the scale and suggest that the AIR can be used to screen anxiety 
disorders accurately, including PD and GAD in patients with COPD. Although 
CFA in Phase 3 did not support the concept of a single-factor model, a modified 
two-factor model appears to fit the data well and is consistent with a second 
hypothesised conceptual model. 
 
In the next chapter, the results from the three phases of research outlined in 
Chapters 5 and 6 will be discussed in detail and the strengths and limitations of 
this research will be examined. 
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Chapter 7 : DISCUSSION 
7.1 INTRODUCTION 
 
The results of Phases 1-3 of this research have been presented in Chapters 5 
and 6. In the current chapter, these findings will be discussed in relation to the 
research aim and objectives that were set out at the onset of this thesis (see 
sections 1.2 and 1.3). The overall aim of this research was to develop a non-
somatic anxiety scale that can be used to measure and screen anxiety in patients 
with COPD. The focus of this discussion, therefore, will be on the psychometric 
properties and clinical utility of the newly developed AIR. However, the 
research also explored the experiences of anxiety in patients with COPD and 
these insights will also be discussed in the current chapter. 
 
In order to address the aim and objectives of this research, the key findings 
from Phases 1-3 are discussed under the following subheadings: 
 
1. Experiences of anxiety in patients with COPD. 
2. Development and refinement of the AIR. 
3. Validity, reliability and clinical utility of the AIR 
 
Following the discussion of the research findings, the strengths and limitations 
of the three phases of research are explored. 
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7.1.1 EXPERIENCES OF ANXIETY IN PATIENTS WITH COPD 
 
The primary focus of this thesis was to develop a novel anxiety scale that is 
designed specifically for use in patients with COPD. Phase 1.2 of the research 
enabled a thorough exploration of the experience of anxiety from the COPD 
patients’ perspective and, in addition to exploring the symptoms of anxiety in 
patients with COPD, the qualitative interviews permitted an in-depth insight 
into these first hand experiences of anxiety. The following section discusses 
some of the key findings from this rich qualitative data. 
 
One important issue arising finding from this qualitative research is that 
patients with COPD and anxiety report considerable confusion regarding their 
symptoms. Some participants described how they had lived with the physical 
symptoms of anxiety for many years without realising that these were due to 
anxiety. These accounts indicate that many of the physical symptoms of anxiety 
are readily confused by patients. For example, participants highlighted that it 
was sometimes difficult to know whether the physical symptoms they 
experienced were a result of anxiety, their COPD, or the side-effects of COPD-
related medications. These findings support Coffman’s (2002) assertion that 
focussing upon somatic symptoms may be misleading during screening. 
However, this is the first qualitative study (to the author’s knowledge) that 
explores the patients’ perspective of this potential confusion. Symptoms such as 
breathlessness, tachycardia, sweating and trembling were all highlighted as 
potentially confusing symptoms. These findings therefore provide some 
additional support for the argument underlying this thesis – that a 
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measurement/screening tool designed for patients with COPD should focus on 
the non-somatic symptoms of anxiety whilst omitting potentially confounding 
somatic symptoms. 
 
Although these qualitative findings support the theoretical model that somatic 
symptoms may confound the screening of anxiety in patients with COPD, there 
is some evidence to contradict this stance. A recent study by Fergusson et al. 
(2006) explored the ability of the somatic items in the BAI to assess anxiety and 
found that they were valid indicators of anxiety in patients with COPD. 
Fergusson and co-worker’s (2006) study of the BAI was limited by their failure 
to include a psychiatric diagnosis in screening their sample for anxiety and by 
including a predominately male sample. The authors posit that patients with 
COPD may be more sensitive to their somatic symptoms and may therefore 
report these more accurately. However, it is evident from the current research 
that this is not always the case and that patients with COPD readily confuse 
their somatic symptoms. 
 
Kirmayer and Robbins (1991) argue that the majority of patients who present 
in primary care with depressive or anxiety disorders present exclusively with 
somatic symptoms, thus providing additional support for the inclusion of 
somatic items in screening scales.  However, others assert that this is not 
sufficient reason to ignore the non-somatic symptoms of anxiety. For example, 
Kroenke (2003) suggests that most patients with an anxiety disorder will admit 
to psychological symptoms if asked about them, whilst Kunik et al. (2005) 
affirms that the stigma of mental health causes patients to initially focus on the 
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somatic symptoms of anxiety, rather than acknowledge their emotional 
symptoms. Though the participants in the current research gave detailed 
accounts regarding their somatic symptoms of anxiety, they also readily 
acknowledged emotional symptoms of anxiety, worry and fear. The elevated 
risk of false positives when including somatic items (Hill et al., 2008; McDowell, 
2006; Steer et al., 1994) and the fact that non-somatic items of anxiety are valid 
and readily acknowledged by patients supports the non-somatic focus of the 
current scale. 
 
In addition to supporting the conceptualised non-somatic focus of the new 
anxiety scale, participants’ detailed accounts also provide an insight into the 
experience, impact and management of anxiety in patients with COPD. Although 
there are some studies exploring the qualitative accounts of patients with COPD 
(e.g., Bailey, 2001; 2004; Barnett et al., 2005; Shackell et al., 2007), none have 
specifically focussed upon experiences of anxiety, particularly in patients with 
stable COPD. Phase 1.2 explored the detailed experiences of anxiety and builds 
upon previous research which briefly discuss issues relating to anxiety, 
predominantly in relation to breathlessness and sleep (Bailey, 2001; 2004; 
Barnett et al., 2005; Shackell et al., 2007). 
 
Findings from the qualitative phase of this research emphasised the substantial 
impact that co-morbid anxiety had upon patients’ lives. PAs appeared to be 
particularly disabling with participants describing intense fear, which 
sometimes cumulated in ‘near-death’ experiences and resulted in avoidance 
behaviours. These accounts closely mirror the ‘shadow-of-death’ stories that 
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Bailey (2001) reports in her study of patients experiencing AECOPD. However, 
the current findings indicate that these traumatic ‘near-death’ experiences can 
occur outside of AECOPD, often in seemingly ‘safe’ situations. The distressing 
nature of these experiences had a lasting legacy and in some cases became 
pivotal moments that dominated patients’ lives. As a result, patients would 
avoid situations that they felt would cause them to panic, such as situations that 
resulted in breathlessness, or states in which the patient would feel 
embarrassed (such as shopping in the supermarket or visiting friends). These 
experiences indicate that participants in the current study had high levels of 
anxiety sensitivity, or a fear of anxiety-related sensations (Reiss, 1991). 
Heightened anxiety sensitivity often arises from beliefs about the harmful 
consequences of somatic, social or cognitive symptoms of anxiety. Kristensen et 
al. (2009) assert that people with anxiety disorders exhibit fears about 
respiratory-related sensations (e.g., dyspnoea) and fears about the occurrence 
of physical catastrophe (e.g., AECOPD). The fear of anxiety and subsequent 
avoidance of physical and social situations reported by the participants in this 
study may help to explain why anxiety has such a deleterious effect upon 
quality of life and reduced physical capacity among patients with COPD (e.g., 
Cully et al., 2006; Eisner et al., 2010; Giardino et al., 2010; Kim et al., 2000).  
 
A key finding from this phase of the research was the bidirectional and complex 
relationship between anxiety and breathlessness. Participants in this study 
reflected on periods of anxiety through reference to the severity of their 
breathlessness. Research on the affective dimensions of dyspnoea has found 
that patients with chronic breathlessness describe their sensations as anxious 
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thoughts, panic and worry (Carrieri & Janson-Bjerklie, 1986; Coffman, 2002). 
This might explain the interchangeable nature of terms such as “breathlessness”, 
“anxious” and “panicky” in these narratives. Recent brain imaging studies have 
shown that the affective dimension of dyspnoea is processed in areas of the 
brain that are also activated by the sensations of fear and anxiety, thus 
supporting the argument that dyspnoea and anxiety might share a common 
aetiology (Carrieri-Kohlman et al., 2010; LeDoux, 2003; von Leupoldt et al., 
2009). The patients in the current research were asked to reflect on their 
experiences of anxiety and it is possible that some patients, particularly those 
who had experienced intense dyspnoea reflected upon the affective dimension 
of their respiratory distress, including dyspnoea-related anxiety. 
 
Some participants in this research used the term ‘vicious cycle’ to describe the 
complex and escalating relationship between anxiety and breathlessness that 
they experienced. This cycle of heightening symptoms has been outlined 
previously and suggest that breathlessness causes a person to become anxious, 
which in turn leads to further breathlessness, and so on (Bailey, 2004; Coen, 
2008; Smoller et al., 1996). One theory that seeks to explain this relationship 
between anxiety and dyspnoea in patients with COPD has been posited by 
Bailey (2004), who suggests that anxiety is not a cause of distressing dyspnoea 
but a sign of longstanding respiratory failure. This relationship, labelled the 
‘dyspnoea-anxiety-dyspnoea cycle’, proposes that the presence of anxiety in 
patients with COPD is a sign that a patient is breathless. The qualitative 
accounts of the current research provide some support for this theory. Some 
participants reflected that they became anxious because they were breathless, 
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particularly if they had been experiencing a period of worsening COPD 
symptoms e.g., an AECOPD. Breathlessness was also considered to be a trigger 
for anxiety. Participants described situations where overexertion (e.g., walking 
up a steep hill) had caused them to become breathless and anxious or “panicky”. 
This often triggered the vicious cycle of escalating anxiety and breathlessness.  
 
According to Bailey’s theory, anxiety is secondary to dyspnoea in patients with 
COPD, perhaps an affective response to dyspnoea (Carrieri-Kolhman et al., 
2010). Bailey et al. (2004) also asserts that anxiety is rarely a cause of dyspnoea 
in patients with respiratory disease. However, some of the accounts in the 
present study challenge this assertion. A number of participants reported 
episodes of acute anxiety and PAs at times when they were not breathless, yet 
these anxious cognitions often resulted in severe breathlessness and in some 
extreme cases, led to hospitalisations. In these situations, anxiety might be 
considered to be a direct cause of dyspnoea rather than a simply a sign of it. 
 
An amended theoretical model is therefore proposed in which anxiety and 
breathlessness are both considered to be triggers of the ‘vicious cycle’ of 
anxiety-breathlessness in patients with COPD. This model (see Figure 7.1) 
posits that anxiety may also be a cause of breathlessness in these patients, 
rather than merely a sign as Bailey (2004) hypothesises. This was particularly 
evident among those patients who experienced anxiety which was idiopathic, 
was caused by external influences (e.g., social discomfort, misplacing 
medication) and among those who worried about worrying (meta-worry) or 
had high anxiety sensitivity. In such cases, anxiety should not be considered 
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solely as a sign of breathlessness. Rather, breathlessness might be considered to 
be a sign of anxiety.   
 
Contrary to Bailey’s (2004) assertions, the findings from the current research 
indicate that two distinct types of anxiety relationship may exist in patients 
with COPD: one group who experience anxiety that is a direct result of 
dyspnoea and the associated affective sensations (Carrieri-Kohlman et al., 2010; 
von Leoupoldt et al., 2009) and another group who become breathless because 
of anxious thoughts. The levels of breathlessness were not measured in the 
current research, but it is postulated that those patients experiencing more 
severe breathlessness or catastrophic misinterpretations of their symptoms 
(Clark, 1986) are more likely to experience dyspnoea-related anxiety and 
respiratory-dominated panic (Kircanski et al., 2009). In contrast, patients who 
experience milder breathlessness are more likely to be affected by anxiety that 
precedes the breathlessness response and panic which is dominated by 
cognitive symptoms (Kircanski et al., 2009).  
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Figure 7.1: Cyclical breathless-anxiety model 
 
 
The current research also provides a novel qualitative insight into the anxiety 
management strategies utilised by patients with COPD. Whilst it is unclear if 
participants had a clinical anxiety diagnosis, or what specific management 
interventions (if any) they had received, it appears that simple strategies such 
as self-talk and breathing control were effective management approaches. For 
example, some participants explained how they would talk themselves through 
episodes of panic: “I have just got to sit down and say to myself ‘stop it.’” or “I was 
telling myself to calm down.” This verbal self-regulation approach is 
representative of skills based CBT (Brewin, 1996). It is not clear whether these 
self-talk strategies were taught by clinicians, or whether, as Carrieri and Janson-
Bjerklie (1986) assert that they were self-developed though living with a 
Breathlessness trigger e.g., from 
exertion or exacerbation 
Anxiety trigger e.g., social 
embarrassment, flashback or 
misplacing medication 
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chronic illness. Nevertheless, the accounts from the present study support 
previous findings advocating the role that self-talk coping strategies and CBT 
can have in patients with anxiety (Barankiak & Sheffield, 2011; Hynninen et al., 
2010; Kemppainen et al., 2003). 
 
7.1.2 DEVELOPMENT AND REFINEMENT OF THE AIR 
 
The AIR covers a range of anxiety symptoms using items which were developed 
using both emic and etic perspectives. The original 16 items were written 
specifically to reflect both the anxiety symptoms reported by patients with 
COPD and the markers of anxiety in existing anxiety scales. This approach 
allowed a pool of items to be developed which represented the full coverage of 
non-somatic anxiety symptoms and to identify whether any symptoms were not 
included in extant scales (Rowan & Wulff, 2007). This mixed-methods design 
enhanced scale fidelity by allowing the words of patients to guide the writing of 
new scale items (Collins et al., 2006; Yorke et al., 2010). The involvement of an 
ERG throughout the scale development process is consistent with guidelines on 
scale development (FDA, 2009) and allowed content validity, face validity and 
usability to be maximised. 
 
Although there was a high level of convergence between patient-reported 
symptoms and those contained within extant scales, mapping of symptoms 
demonstrated that two pertinent themes highlighted in the qualitative 
interviews were not sufficiently covered in existing anxiety self-report scales: 
anticipatory worry and anticipatory panic. Anticipatory worry about daily 
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activities was frequently cited by participants and was often due to catastrophic 
predictions about future events i.e., a fear of becoming breathless or 
embarrassed. It is not clear whether any of the participants who were 
interviewed in the current study had a clinical anxiety disorder, but symptoms 
of anticipatory worry are commonly found in a number of anxiety disorders 
including GAD and phobias (APA, 2000). Anticipatory panic on the other hand, 
is a common symptom of PD and often occurs when patients experience 
significant anxiety over the prospect of experiencing a future PA (APA, 2000). 
Anticipatory panic may be particularly relevant to patients with COPD because 
their repetitive exposure to breathlessness can lead to a higher sensitivity to 
PAs and thus a higher frequency of distressing panic events (Harvey et al., 
2008). 
 
It is generally accepted that PD, PAs and subclinical panic are common in 
patients with COPD. Alongside the expected somatic symptoms, the qualitative 
accounts in the current research contained frequent references to cognitive 
symptoms of panic including intense fear and sudden panic episodes. Yet, the 
majority of extant scales identified in this study have only limited reference to 
non-somatic symptoms of panic. This may be because the diagnosis of PA and 
PD is dominated by somatic symptoms (APA, 2000) which is reflected in the 
content of extant scales. The conceptual model of the AIR supported the need 
for panic symptoms to be included within the item pool but also required 
somatic items to be omitted. Therefore, several non-somatic items specific to PD 
were developed including symptoms relating to PAs (e.g., frightened, panicky, 
losing control) and anticipatory panic (e.g., thoughts of something bad 
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happening, worry about panic). At a conceptual level, the AIR is therefore able 
to assess symptoms of panic without the inclusion of potentially confounding 
somatic items. 
 
Although the original 16 items developed in Phase 1 covered the key symptoms 
of non-somatic anxiety highlighted through both emic and etic perspectives, the 
goal was to develop a shorter scale with a high internal consistency. In Phase 2 
of the current research, the 16 items developed in Phase 1 were subjected to 
item and factor analysis. The criteria used for item retention in the current 
research were comparable to those used by other scale developers (e.g., Al-
Shair et al., 2009; Delamere et al., 2001), but they were also more robust, thus 
ensuring that only the best performing items were retained. For example, 
Delamere et al. (2001) advocates retaining items with item-total correlation of 
>0.3 whereas the current research employed a more robust cut-off of 0.55. Such 
robust statistical procedures support the claim that the AIR contains a group of 
highly intercorrelated items. 
 
The pool of items developed in Phase 1 deliberately included a single positively 
worded item to identify if response bias was present. Subsequent statistical 
analysis revealed that this item was not a reliable item (having particularly low 
item-total correlation and communality values). This finding indicates that a 
response bias, or ‘careless responding’ (Magazine et al., 1996) may have indeed 
been present amongst this sample. The single positively worded item appeared 
at the end of the scale so it is possible that respondents did not read each 
question clearly and instead responded to the item in a similar fashion to the 
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previous 15 items. Alternatively, the poor performance of this item during item 
analysis and EFA may instead reflect the fact that positively and negatively 
worded items measure different underlying variables (Weems et al., 2003). For 
example, research exploring the factor structure of the STAI indicates that 
distinct negative-worded and positive-worded factors can exist in anxiety scales 
(Mook et al., 1991). Although some scale developers recommend that a mix of 
positively and negatively worded items are included in a scale (e.g., Nardi, 
2003), there is growing acceptance that this practice is often flawed (Weems et 
al., 2003). There is evidence to suggest that respondents may process negatively 
and positively worded items differently or that they may not always identify 
changes in positive/negative wording (Weems et al., 2003). This supports the 
decision to use negatively worded items in the final version of the AIR. 
 
Some scale developers choose to retain items that do not fit the pre-determined 
statistical criteria. This is usually done when it is felt that an item taps into a 
particularly important aspect of the construct that is not covered by other items 
(DeVellis, 2003). The strategy used in the current research was characterised by 
a ‘maximisation of internal consistency’ approach, which produced a scale with 
diverse symptom coverage and a high level of internal consistency. Some items 
that were developed in Phase 1 were removed during Phase 2 because their 
performance in a larger sample of COPD patients demonstrated that they were 
not statistically robust for inclusion in the final scale. The final 10-item AIR 
achieved an excellent internal consistency (Cronbach’s α = 0.95) and analysis 
indicated that the removal of further items would both lower consistency and 
reduce symptom coverage. Therefore, the 10-item AIR produced the optimal 
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balance of reliability and item coverage. Although a shorter version of the scale 
may have reduced item redundancy, it would have also reduced symptom 
coverage. A shorter version may have also reduced respondent burden, but ERG 
feedback supported the AIR’s face validity and indicated that the scale was 
quick and easy to complete. Respondents in the pilot study took an average of 
95 seconds to complete the AIR, which is quicker than other extant scales used 
to assess markers of anxiety patients with COPD. For example, the HADS takes 
between 2 and 5 minutes to complete, whilst the BAI takes approximately 5 
minutes (McDowell, 2006). 
 
Score variability of the AIR was inconsistent across Phases 2 and 3. For 
example, Phase 2 and initial Phase 3 data demonstrated that scores on the AIR 
were positively skewed. In contrast, data from the Phase 3 psychiatric follow-up 
sample showed normal distribution of scores. It is not clear whether this 
variability was due to the design of the AIR (e.g., an inadequate response set) or 
whether this was due to sampling deficiencies. The use of the HADS-A in Phase 
3 test-retest data (which was also positive skewed) demonstrate that this 
follow-up sample did not have good variability in anxiety symptoms, 
particularly towards the severe end of the anxiety spectrum. Other researchers 
suggest that positive skew on anxiety scales is not uncommon and may simply 
be because extreme levels of anxiety are rare (Bruzzese et al., 2011). This is 
certainly a possibility in such small samples and is supported to some extent by 
the fact that maximum recorded HADS-A score was 16 out of a possible 21. 
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Although further confirmation of score variability is needed in considerably 
larger clinical samples, these initial findings indicate that the response set for 
the AIR may need to be reconsidered in future studies. It appears that the 
response options representing the milder symptoms of anxiety (i.e., ‘Not at all’ 
and ‘Occasionally’) may need to be re-worded, or extended. For example, a fifth 
response option such as ‘Very rarely’ may be added between these two options. 
Alternatively, ‘Almost all of the time may’ be too extreme a response, which is 
unlikely to be endorsed by respondents. Although ERG input during scale 
development did not highlight any problems with the response set, only four 
patients were involved. Participants were also restricted in their feedback to 
issues relating to user-friendliness of the scale and not specifically to suitability 
of response sets. A cognitive debriefing approach, such as that described by 
Ploughman et al. (2010) may have been a more appropriate strategy for 
exploring the suitability of the response set. Cognitive debriefing is a qualitative 
method which assesses respondents interpretation of a scale in terms of 
comprehension, retrieval, judgement, response set and respondent burden 
(Ploughman et al., 2010). 
 
Initial EFA in Phase 2 revealed a strong single-factor solution, suggesting that 
there is a clear latent variable (‘anxiety’) underlying the AIR. The items 
contained within the AIR are to some extent specific to both GAD and PD (see 
Table 5.8 in section 5.5.1), so it was anticipated that the scale might contain two 
intercorrelated factors that represent each of these disorders. The single-factor 
solution found in Phase 2 suggested that the AIR measured a global construct of 
anxiety, as opposed to differentiating between panic and general anxiety. The 
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high communalities and factor loadings found in Phase 2 indicate that EFA was 
likely to be reliable even on a relatively small sample (Fabrigar et al., 1999; 
MacCallum et al., 1999). 
 
Boyle (1985) asserts that clinicians generally require outcome measures that 
measure the severity of a disorder, rather than a specific element of that 
condition. An important strength of the AIR is that it demonstrates broad 
symptom coverage and includes items from three of the four symptom themes 
identified in Phase 1. Although the item related to behavioural anxiety was 
removed during the item analysis stage (as it was not endorsed by the 
respondents), the scale covers a comprehensive range of anxiety symptoms that 
include psychic tension, apprehension and panic and, therefore, provides a 
measure of the general severity of anxiety as Boyle recommends. The broad 
symptom coverage should also enhance the AIR’s clinical utility as a screening 
tool by heightening sensitivity, which, according to Jain and Lolak (2009) is the 
most important feature of an anxiety screening tool. McDowell (2006) asserts 
that other self-report scales which measure both anxiety and depression (e.g., 
DASS and HADS) may sacrifice sensitivity at the price of specificity by focussing 
on symptoms that discriminate between the two disorders rather than 
measuring the whole construct.  
 
7.1.3 VALIDITY, RELIABILITY AND CLINICAL UTILITY OF THE AIR 
 
In Phase 3, the psychometric properties of the AIR were established in a clinical 
population of community-dwelling patients with stable COPD. The following 
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section discusses the validity and reliability of the AIR for assessing the severity 
of anxiety, and the clinical utility of the AIR to screen for anxiety disorders. 
Other key findings from Phase 3 of the research are also discussed within this 
section, namely the prevalence of anxiety disorders among this sample and 
their corresponding characteristics. 
 
7.1.3.1 Validity 
 
The validity of the AIR was demonstrated by testing a number of a priori 
hypotheses relating to convergent and construct validity. 
 
The very high correlation between the AIR and the HADS-A demonstrates that 
the AIR has excellent convergent validity with the most widely utilised marker 
of anxiety in patients with COPD. This high correlation compares favourably 
with other studies exploring convergent validity of anxiety markers. For 
example, studies exploring the convergent validity of the BAI with the STAI 
have found correlation coefficients of between 0.44 and 0.68 (McDowell, 2006). 
As hypothesised, the AIR also correlated moderately with the HADS-D. This is 
consistent with the postulated overlap between anxiety and depression (Clark, 
1989; Clark & Watson, 1991; Hirschfeld, 2001). The AIR was designed to assess 
markers of anxiety, rather than distinguish between anxiety and depression as 
other scales have been designed to do (e.g., BAI). Therefore, it contains a broad 
spectrum of symptoms including feeling upset and feelings of anxiety that may 
relate to both anxiety and depression (APA, 2000). However, the enhanced 
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correlation of the AIR with the HADS-A compared to the HADS-D supports the 
construct validity of the AIR as primarily an anxiety outcome measure. 
 
The AIR also demonstrated excellent known groups validity. Significantly 
different total scores were found between patients with a clinical anxiety 
disorder and those without based on both PHQ screening and psychiatric 
interview. This provides further support for the scale’s construct validity and 
demonstrates that scores for the AIR distinguish between anxiety cases and 
non-cases as hypothesised. 
 
The factorial validity of the AIR was less clear. Although the results from Phase 
2 suggested that a single factor underlies the AIR, it was also hypothesised that 
two factors representing the conceptualised model of intercorrelated general 
anxiety and panic may provide the best fit. The original design of the items 
demonstrated that symptoms covering both GAD and PD were present in both 
the 16-item and 10-item versions of the scale. CFA demonstrated that the 
single-factor model (a single ‘anxiety’ factor) showed poor fit to the data with 
only the CFI, TLI and SRMSR indicating acceptable fit. In contrast, the modified 
two-factor model of ‘general anxiety’ and ‘panic’ demonstrated good fit on five of 
the six model fit indices and borderline fit on the remaining index (the GFI). The 
modification to the two-factor model fitted the original conceptual model of the 
AIR as items 1 and 3 both reflect cognitive worry. The two-factor model 
produces three scores: a panic score (five items on the AIR-panic factor), a 
general anxiety score (five items on the AIR-general anxiety factor), and a total 
score (all 10 items).  
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Although the CFA demonstrated a good fit to the two-factor model, it is 
important to consider the impact that sample size may have had on this study. 
General issues relating to sample size for CFA are discussed in greater detail in 
the limitations section of this chapter (section 7.3.3). However, sample size may 
also have had a specific impact upon fit indices. For example, both the GFI and 
SRMSR are sensitive to sample size with larger samples reporting poorer fit 
values (Miles & Shevlin, 1998). In contrast, it has been suggested that the CFI 
demonstrates stable patterns across a range of sample sizes (Tanguma, 2001). 
This may explain why the GFI values were all below acceptable ranges, whilst 
the CFI values were acceptable or good for all models. The results of the current 
CFA show that even in small sample, the modified two-factor model 
demonstrated good fit to the data.  
 
7.1.3.2 Reliability 
 
The internal consistency of the AIR in Phase 3 was found to be very high, 
ranging from an α value of 0.92 in the initial sample to 0.95 in the 2-week 
follow-up sample. This is consistent with data exploring the reliability of other 
anxiety scales. For example, internal consistency of the HADS-A has been 
reported to range from α =0.76-0.93 in a range of clinical settings, whilst 
reported values for the BAI range between α =0.86 and α =0.94 (Bjelland et al., 
2002; McDowell, 2006). Although high internal consistency (>0.90) may 
indicate item redundancy in some circumstances (Streiner and Norman, 2003), 
the internal consistency values reported for the AIR achieve the minimum value 
of 0.90 recommended by Kline (2000) for scales that are designed for clinical 
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use. Boyle (1985) argues that items in scales with high internal consistency are 
often just paraphrases of each other, but it is clear from the content of items 
that each item relates to a unique symptom of the overall anxiety construct and 
has a specific role in assessing markers of either general anxiety or panic. Boyle 
(1985) also contends that high internal consistencies are likely to result in 
narrow syndrome measurement and poor symptom coverage, leading to poor 
validity in recognising psychiatric diagnosis. However, the results of this study 
show that despite high internal consistency, the AIR has excellent known 
groups validity (see section 7.2.4.1) and screening properties (see section 
7.2.4.3). The AIR, therefore, achieves good item coverage, whilst maximising 
internal consistency. 
 
In addition to high internal consistency, the AIR demonstrated excellent 
temporal stability over a 2-week test-retest period. The ICC of 0.81 found in this 
study demonstrates that the AIR is relatively stable over this period. 
Comparable 1-week test-retest reliabilities have been found in a large study 
exploring the validity of HADS-A (0.80) and BAI (0.77) in patients with 
Parkinson’s disease (Leentjens et al., 2008). As the AIR is designed to assess 
markers of state anxiety and uses a 2-week timeframe, the test-retest scores 
might be expected to be slightly lower than those reported for shorter time-
periods. Boyle (1985) asserts that a paradox of high test-retest values is that the 
scale might actually be insensitive to changes in symptoms. However, the 
current research also found a similar 2-week ICC test-retest reliability for the 
validated HADS-A (ICC = 0.83) suggesting that anxiety symptoms remained 
relatively constant over the time-period. The transient nature of state anxiety 
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means that although temporal stability for the AIR was good over a 2-week 
period, it would be expected to decrease as the time gap increases.   
 
An interesting finding in Phase 3 was that patients with higher levels of anxiety 
(assessed using both the AIR and the HADS-A) and worse functional status 
(measured on the MRADL) were less likely to complete the follow-up. Although 
it is not clear why this might be, it is possible that patients who are anxious 
and/or have impaired function in daily activities are less motivated or less able 
to participate in research. One possibility is that patients were unable to follow-
up if they had experienced an AECOPD or hospitalisation. There is some 
evidence to suggest that patients with anxiety are at increased risk of 
exacerbations and hospitalisations (Eisner et al., 2010; Yohannes et al., 2000a) 
but without detailed follow-up data, this assertion cannot by confirmed.  
 
7.1.3.3 Clinical utility as a screening tool 
 
Data from Phase 3 demonstrated that the AIR was able to accurately screen for 
anxiety disorders in patients with COPD. Using the PHQ anxiety screeners as a 
case-finder for anxiety disorders, the AIR demonstrated an AUC of 0.96. Follow-
up diagnostic data found a similarly high AUC of 0.88 in a smaller sample of 22 
patients who underwent psychiatric interview. These results suggest that the 
AIR has excellent clinical utility as a screening tool for detecting patients with 
clinical anxiety. However, the optimal cut-off score for clinically relevant 
symptoms differed between the two tests. Initial data in Phase 3 suggested that 
a cut-off score of ≥15 provided the optimal balance between sensitivity and 
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specificity. In comparison, when formal diagnostic interviews were undertaken 
during follow-up, an optimal cut-off score of ≥8 was found to provide the best 
balance between sensitivity and specificity. This variation in cut-off scores may 
have been due to the small sample size that was included in the second data set. 
This is reflected in the wider CIs that were found in the second data set 
compared to the first (0.75-1.00 vs. 0.96-1.00).  
 
Although this research found differences in optimal cut-off score depending on 
the sample, the ability of the AIR to screen for patients with anxiety disorders 
remains excellent. When the gold standard psychiatric diagnosis was utilised, 
the AIR provided improved screening properties in comparison to existing 
scales. For example, a recent study exploring the clinical utility of the HADS-A 
and GAI to screen for anxiety in patients with COPD (based on MINI diagnosis) 
found an AUC of 0.79 and 0.83 respectively (Cheung et al., 2012). A cut-off score 
of ≥8 on the AIR (based on psychiatric diagnosis of an anxiety disorder) yielded 
a sensitivity of 0.80, a specificity of 0.75, a PPV of 67% and a NPV of 81%. In 
comparison, Cheung and colleagues (2012) report a sensitivity of 0.79, a 
specificity of 0.71, a PPV of 47.8% and a NPV of 90.6% for the optimal cut-off 
score on the HADS-A. Sensitivity and specificity of the AIR were similar to that 
found for the GAI (0.86 and 0.78), and whilst NPV was elevated for the GAI 
(94%), the PPV of the GAI was considerably lower than that found for the AIR in 
the current research (57%).  
 
This research also explored the utility of the HADS-A to screen for anxiety 
disorders in patients with COPD. When the PHQ anxiety screeners were used to 
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indicate cases or non-cases of clinical anxiety, the AIR performed marginally 
better than the HADS-A, demonstrating a slightly larger AUC (0.96 vs. 0.93). 
Although both scales had excellent screening properties, the sensitivity, 
specificity, PPV and NPV of the HADS-A were all lower when compared to the 
AIR. The most important screening property for an anxiety scale is sensitivity as 
it is important to recognise as many patients as possible who may have an 
anxiety disorder so that further diagnosis can be undertaken (Jain & Lolak, 
2009; Vodermaier & Millman, 2011). Findings from the current research 
indicate that the AIR has a higher sensitivity for screening anxiety disorders 
than the HADS-A (0.93 vs. 0.87).  
 
The high prevalence of both PD and GAD reported in Phase 3 of the current 
study support the conceptual framework underpinning the AIR; that the scale 
should be able to screen for both PD and GAD in patients with COPD. ROC 
analyses in Phase 3 indicate that the AIR is able to accurately identify patients 
with both disorders. Data from the 22 patients who underwent psychiatric 
interview suggest that the AUC for cases and non-cases of PD is 0.85 (95% CI: 
0.68-1.00), whilst for GAD it was 0.79 (95% CI: 0.61-0.98). Similarly, ROC 
analyses of the larger sample (n=56) who completed the PHQ anxiety screeners 
found excellent AUCs for PD (AUC = 0.96; 95% CI: 0.96-1.00) and ‘other anxiety 
disorders’ (AUC = 0.93; 95% CI: 0.86-1.00), which include GAD. The sensitivity 
of the AIR for the detection of PD and ‘other anxiety disorders’ was 0.93 and 
1.00 respectively. These findings indicate that the AIR is able to identify 
correctly the majority of patients with PD and GAD, thus supporting its clinical 
utility as an anxiety screener for patients with COPD. 
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The CFA undertaken in Phase 3 identified that the AIR measured two sub-
factors: panic and general anxiety. Although it was not practical to perform ROC 
analyses on the subcategories of AIR-panic and AIR-general anxiety based on 
psychiatric diagnosis (due to the small sample size), analyses were performed 
using the PHQ screeners for both PD and ‘other anxiety disorder’. The 
performance of the AIR-panic subscale in screening for PD according to PHQ 
was excellent (AUC = 0.95). A score of ≥6 (out of 15) yielded a sensitivity of 1.00 
and specificity of 0.93 indicating that the AIR-panic is able to maximise true 
positives and identify almost all true negatives. The performance of AIR-general 
anxiety in detecting ‘other anxiety disorder’ was also excellent (AUC = 0.90) 
with a score of ≥9 (out of 15) on the AIR-general anxiety yielding a sensitivity of 
1.00 and a specificity of 0.82. Although the ‘other anxiety disorder’ screener in 
the PHQ screens for both GAD and anxiety not otherwise specified, there is 
empirical evidence to suggest that it primarily identifies patients with GAD (e.g., 
Hahn et al, 2004; Spitzer et al., 1999). Though the screening utility of the two 
sub-scores requires further exploration in larger populations with confirmed 
psychiatric diagnoses, these initial findings indicate that the AIR might be used 
to accurately screen for both PD and GAD. 
 
7.1.3.4 Prevalence of anxiety and mood disorders 
 
A cut-off score of ≥8 on the HADS-A indicated that over half (51.8%) of the 
patients in the initial Phase 3 sample had clinically relevant symptoms of 
anxiety. Using a more rigorous cut-off, a score of ≥11 identified that 28.6% of 
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patients had moderate-to-severe anxiety (Snaith and Zigmund ,1994). The PHQ 
screener identified a similar proportion of patients with a clinical anxiety 
disorder (26.8%). Recent studies report comparable prevalence of likely 
anxiety, ranging from 10% to 57% depending upon the type of screening tool 
used, choice of cut-off score and study population. For example, a large (n=406) 
multi-centre epidemiological study by Gudmundsson et al. (2005) found that 
41% of patients had mild-to-severe symptoms of anxiety based on a cut-off 
score of ≥8 on the HADS. Similarly Cleland and co-workers (2007) report a 
prevalence of likely anxiety (based on HADS-A score ≥11) of 32.7% in a sample 
of 170 community COPD patients. 
 
The prevalence of clinical anxiety disorders (diagnosed through psychiatric 
interview) in patients with COPD is reported to be 10-55% (Aghanwa & 
Erhabor, 2001; Vögele & von Leupoldt, 2008). The findings from the current 
research suggest that 45% of patients had a clinical anxiety disorder based on 
psychiatric diagnosis. Whilst the sample in this study is small (n=22) it is 
comparable in size to two frequently cited studies from Nigeria and Germany 
who report prevalence based on samples of 20-30 subjects (Aghanwa & 
Erhabor, 2001; Vögele & von Leupoldt, 2008). The prevalence of anxiety 
reported in the current study is in line with data from a large Canadian sample 
of outpatients that report a prevalence of 46% (Laurin et al., 2007).  
 
To the author’s knowledge, the current study is one of only two studies to 
report the prevalence of anxiety in COPD outpatients in the UK, and the only 
study to incorporate a recognised DSM or ICD diagnosis. Another study by 
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Yohannes and colleagues (2000a) report a prevalence of clinical anxiety of 18% 
within a sample of 137 older (mean age = 73 years) COPD outpatients based on 
the Automatic Geriatric Examination for Computer Assisted Taxonomy 
(AGECAT; Copeland et al., 1986), a syndromal rather than a strict nosological 
classification system such as the DSM-IV-TR or ICD-10. Although Yohannes and 
colleagues do not report the severity of COPD among their sample, they indicate 
that their subjects had an FEV1 of 0.89 (SD 0.3) litres, a similar level of lung 
function to the subjects in the current research (median = 0.87 litres).  
 
In the current study, PD was diagnosed in 36% of patients making it the most 
prevalent disorder among the sample. In addition, 23% of patients were 
diagnosed with GAD. These findings are in line with previous studies which 
suggest that PD and GAD are the most common anxiety disorders in patients 
with COPD. Prior studies exploring the prevalence of PD indicate that it is the 
most common co-morbid anxiety disorder in COPD. For example, a study by 
Dowson et al. (2004) found that 41% of inpatients with COPD had PD. In 
contrast, Laurin and colleagues report the prevalence of PD in a large outpatient 
sample (n=116) to be 21%. Findings from the current study indicate that PD 
may be more prevalent in outpatients than previously reported.  
 
The prevalence of GAD in patients with COPD appears to be higher in inpatients 
than outpatients. Previous studies report the prevalence of GAD among 
inpatients with COPD to be 10-33%, whilst studies in outpatients suggest a 
prevalence of 6-19% (Dowson et al., 2004; Kühl et al., 2008; Laurin et al., 2007; 
Yellowlees et al., 1987). As is the case with PD, findings from the current study 
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suggest that the prevalence of GAD among patients with COPD may be higher 
than previously thought. It is not clear why a higher prevalence was found in 
this research. Although the small sample size is likely a key factor, another 
influence may be the recruitment and sampling strategy used in this research. 
Patients were invited to participate in a study exploring anxiety, so it is possible 
that self-selection bias influenced recruitment (Nilsen et al., 2009). For instance, 
patients who had experienced anxiety may have been more likely to participate 
than those who had not.  
 
Psychiatric interviews also indicated that one patient (5%) in the follow-up 
sample had a diagnosis of social phobia and two patients (9%) had a diagnosis 
of agoraphobia without a history of PD. The prevalence of social phobia in the 
current study is the same as found by Vögele and von Leupoldt in a sample of 20 
inpatients with COPD. However, this is a lower figure than that reported by 
Laurin et al. (2007) who found a prevalence of social phobia of 11% in a 
demographically similar sample of outpatients from Canada. Again, the small 
sample size in the current research may be responsible for this discrepancy in 
findings. Laurin et al. (2007) included 116 patients in their study, whilst the 
current sample incorporated only 22 participants.  
 
To the author’s knowledge, this is the first study to report on the prevalence of 
agoraphobia without a history of PD in patients with COPD. This DSM-IV-TR 
diagnosis is characterised by agoraphobia and a focus of fear on the occurrence 
of incapacitating or extremely embarrassing panic-like symptoms or limited-
symptom attacks rather than full PAs (APA, 2000). The APA (2000) suggests 
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that agoraphobia without a history of PD is relatively unknown and uncommon, 
and affects less than 2% of the general population (Andrews & Slade, 2002). A 
key diagnostic feature of this anxiety disorder that might explain the elevated 
prevalence in this sample is that individuals suffering from agoraphobia 
without a history of PD commonly have an associated medical condition and 
experience a fear of being incapacitated or embarrassed by the development of 
symptoms and not being able to get help (APA, 2000). Another factor that might 
explain the high prevalence in this sample is that this anxiety disorder is also 
more prevalent in older patients (Andrews & Slade, 2002). 
 
Data from the psychiatric interviews also suggest that mood disorders were 
common among this sample of patients with COPD. A total of 41% (n=9) of the 
sample had a mood disorder with 32 % (n=7) diagnosed with current major 
depressive disorder. These findings are consistent with previous studies which 
report the prevalence of clinical depression to be 17-37% (Barr et al., 2009; 
Kunik et al., 2005; Laurin et al., 2007). The findings also support the assertion 
that clinical anxiety and mood disorders frequently co-occur. In the current 
research, 32% of patients had both an anxiety and a mood disorder. This is 
higher than that reported by both Kunik et al. (2005) and Laurin et al. (2007) 
who found a prevalence of co-morbid anxiety and mood disorders in patients 
with COPD to be 26% and 14% respectively.  
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7.1.3.5 Characteristics of anxious patients 
 
Previous research exploring the influence of COPD severity on anxiety are 
contradictory, with some studies finding no relationship (e.g., Gudmundsson et 
al., 2006; Wagena et al., 2005) and others suggesting that patients with 
decreased lung function (especially those towards the very severe end of the 
spectrum) are at greater risk of anxious symptoms (Downson et al., 2001; 
Felker et al., 2010). Findings from the current research indicate that there was 
no difference in anxiety severity (both AIR and HADS-A score) when compared 
with COPD severity, as measured by GOLD criteria. In addition, there was no 
significant difference in COPD severity between cases and non-cases of clinical 
anxiety in patients screened with the PHQ. 
 
It is generally accepted that sex has an influence on anxiety, both in the general 
population and among patients with COPD. For example, several studies have 
demonstrated that women with COPD are significantly more likely to have 
clinically relevant symptoms of anxiety than their male counterparts (DiMarco 
et al., 2006; Gudmundsson et al. 2006). However, findings from the current 
research challenge these findings. No difference in AIR and HADS-A scores were 
found between males and females, and men were equally as likely as women to 
have a clinical anxiety disorder. 
 
The current findings also fail to support previous findings suggesting that COPD 
patients with anxiety are more likely to be younger (Cleland et al., 2007) and 
are more likely to be current smokers (Gudmundsson et al., 2006). In the 
298 
 
current study, patients with clinical anxiety disorders did not differ in age, 
smoking status and pack year smoking history. In addition, there was no 
difference in AIR and HADS-A scores according to smoking status and no 
correlation between pack year smoking history and both anxiety scales. 
 
The current results identified an obvious negative relationship between anxiety 
and HRQoL and ADL function. Patients who screened positive for an anxiety 
disorder on the PHQ had significantly higher CAT score and significantly lower 
MRADL. These findings are similar to those previously reported by Cully et al. 
(2006) and Giardino and colleagues (2010) who suggest that anxiety is 
inversely associated with scores on respiratory-specific HRQoL scales. 
 
Although it has been demonstrated that anxiety leads to worse exercise 
performance (Eisner et al., 2010) and worse functional ability (Kim et al., 2000) 
in patients with COPD, this is the first study to explore the relationship between 
anxiety and ADL in patients with COPD with a disease-specific scale. In the 
current research, scores on the MRADL, which provides an indication of 
functional impairment in patients with respiratory disease, were significantly 
lower among patients with an anxiety disorder than those without. 
 
7.2 STUDY STRENGTHS AND LIMITATIONS 
 
As several studies were undertaken as part of this thesis, the strengths and 
limitations of the research are discussed under three sections, each addressing 
a single phase of the research. 
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7.2.1 PHASE 1 
 
The main strength of this phase of the research was that both emic and etic 
perspectives were integrated to develop a novel pool of items. Previous studies 
have developed potential scale items by replicating items from existing scales 
(e.g., Zhang & Yu, 1998) or by generating new items through qualitative 
interviews (e.g., Rushton et al., 2011) and thus focus solely upon emic or etic 
perspectives. The items developed in this research were developed using both 
existing theory and the accounts of individuals who had experienced the 
phenomena in question. This development strategy, therefore, achieved one of 
the key goals in scale development set out by Rowan and Wulff (2007) in that 
the validity of the quantitative data was enhanced by being grounded in theory 
and real life situations.  
 
Another strength of the qualitative study was that the purposive sampling 
strategy enabled the recruitment of participants with a variety of 
characteristics, including both males and females, and a range of ages, COPD 
severities and anxiety symptom severities. An associated limitation of this 
strategy is that the respondents were homogenous in terms of geographical 
location (i.e., they were residents in one part of Greater Manchester) and were 
mostly retired and engaging with COPD-related services such as Breath Easy 
support groups or PR classes. Also, the patients recruited in Phase 1 had self-
reported symptoms of anxiety rather than a confirmed diagnosis. This may be 
considered as a limitation as it is not clear whether the participants had 
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experienced clinical levels of anxiety. However, scores on the HADS-A indicated 
that 50% of the sample had clinically significant levels of anxiety and 36% had a 
previously diagnosed anxiety disorder. The range of scores recorded on the 
HADS-A (5-18) suggest that this sample had a range of anxiety severities that 
may enhance the range of experiences that were discussed. Although this 
sample is relatively small compared to other studies who utilise emic 
perspectives in item development (e.g., Jones et al., 2009b; Michalak et al., 
2010), data saturation was achieved, indicating that the sample was adequate 
and that participants in this sample experienced somewhat similar experiences 
of anxiety. 
 
A further limitation of the non-probabilistic sampling strategy used in this 
qualitative research is that self-selection bias may have occurred. However, the 
aims of the current study were to elicit the experiences of individuals who had 
experienced anxiety and were willing to discuss their experiences. As a 
particularly emotive issue such as anxiety was being explored, it was felt that 
any participants who were willing to share their story should be given an 
opportunity to participate in this study. In addition, the high prevalence of 
undiagnosed COPD and anxiety, the stigma around mental health, the older age 
of patients, and the fact that the majority of patients with COPD are treated in 
the community setting are all potential barriers to recruitment, which indicate 
that this patient group could be considered what Daly and Lumley (2002) label 
a ‘hard-to-reach group’. The relatively diversified nature of the sample and the 
efforts that were made to establish trust between the researcher and 
participants adds to the trustworthiness of this data. The credibility of the 
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findings was also enhanced by allowing the research team to engage in peer 
review and also by the use of member checking to enhance respondent 
validation.  
 
A possible limitation of the literature review undertaken in Phase 1 is that not 
all anxiety scales were identified and reviewed. Although every effort was made 
to identify all relevant anxiety scales including extensive literature searching 
and checking with expert clinicians, it is possible that some (particularly those 
lesser-known) scales were missed. Additionally, scales that were not available 
in English were also omitted which may have excluded important instruments. 
Despite these potential limitations, the final pool of items was extensive (over 
200 items) and covered a range of anxiety-related symptoms.  
 
The involvement of patients and clinicians in the scale development process is 
an increasingly important aspect in the development of outcome measures and 
is a fundamental component of the FDA’s guidelines on the development of 
PROMs (FDA, 2009). The involvement of the ERG throughout the scale 
development process is an important strength of this research. The ERG 
allowed the content and face validity of the AIR to be enhanced and also 
ensured that the scale was user-friendly in patients with COPD. The ERG 
feedback had a direct influence on the final design of the AIR, including the 
decision to use large and clear shaded boxes, the use of simple wording and 
consistent response options. This ensures that the scale can be completed by 
patients with varying visual acuity and by those who may be experiencing 
tremor or shaking (e.g., as a side-effect of COPD medication or AECOPD), or 
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those patients with limited dexterity. For example, some inpatients in this study 
were able to use bingo daubers to mark the relevant response.  
 
The decision to develop a small pool of potential scale items in Phase 1 might be 
regarded as a limitation of this research. Other scale developers have 
incorporated significantly larger item pools. For example, Michalak and Murray 
established a pool of 210 items in their development of a new HRQoL measure 
for people with bipolar disorder. However, the size of item pool will likely have 
an impact upon the sample size recruited for subsequent item reduction 
processes. Within this research, it was felt that respondent burden should be 
minimised as much as possible, particularly as patients would be recruited from 
acute hospital settings as well as outpatient settings. A larger pool of items 
would have allowed items with varying wording to be tested; however, it was 
felt that a small item pool would allow a larger sample to be targeted in Phase 2, 
as the time burden for completion would be minimised. Also, issues regarding 
item wording and structure were resolved using the input of the ERG and pilot 
respondents.  
 
7.2.2 PHASE 2 
 
Perhaps the most obvious limitation in Phase 2 of this research is the size of the 
sample. As has been discussed in sections 3.5.3.1 and 3.5.3.2 on statistical tests 
for scale development, minimum sample sizes for both item and factor analysis 
are a contentious issue. However, it is generally accepted that although 
successful analysis can be undertaken on smaller samples, at least 100 
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participants are recommended (Costello & Osbourne, 2005; Fabrigar et al., 
1999; MacCallum et al., 1999). Although the current sample of 88 respondents 
is below the recommended minimum according to most guidelines, there are 
several indicators that the sample size for Phase 2 was acceptable. According to 
Fabrigar et al. (1999) and MacCallum and co-workers (1999), successful EFA 
can be conducted on smaller samples providing they demonstrate certain 
characteristics including overdeterminned factors (>4:1), high ratios of 
respondents to variable (>5:1) and high communalities (mean >0.7). 
In the current study the two tests exploring the suitability of the data for EFA 
(KMO and Bartlett’s test of sphericity) were favourable. Also, factors were 
overdeterminned at a ratio of 16:1 and ratio of respondents to variable were 
5.5:1. Finally, although communalities for the final 10-items did not quite meet 
recommended levels (averaging 0.67), they were still high suggesting a high 
degree of shared variance between the items.  
 
Another potential limitation of Phase 2 is that the response rate was relatively 
low (56.4% overall). The representativeness of the sample may have been 
limited as almost half of the sample approached were not sufficiently motivated 
to participate in the research. In addition, demographic characteristics of the 
sample were not recorded in any detail due to time and data confidentiality 
constraints. Therefore, it is difficult to establish whether the sample is 
representative, or whether sampling bias occurred. Nevertheless, the sample 
did include a mix of both acutely ill inpatients and stable outpatients, roughly 
equal numbers of males and females, and participants with a range of ages.  
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The inclusion and exclusion criteria may have also had an impact upon the 
representativeness of the sample. For example, patients with other major co-
morbidities were not eligible to participate, which may have excluded a large 
proportion of patients. Recent findings that have explored the prevalence of co-
morbidities among hospitalised patients with COPD indicate that 77% may have 
an additional significant medical condition (Royal College of Physicians, British 
Thoracic Society & British Lung Foundation, 2008). Therefore, it is likely that a 
significant number of patients were ineligible to participate in this research. 
 
Finally, a key strength of Phase 2 is that robust item and factor analytical 
procedures were utilised during scale refinement. Firstly, EFA was undertaken 
as opposed to PCA. Costello and Osbourne (2005) assert that EFA is a preferred 
procedure to PCA as it explores the latent structure of the data rather than 
merely reducing the data into manageable groups. PCA is also thought to 
overestimate values of variance when compared to EFA. Phase 2 also utilised 
ML extraction, which is suggested to be the most reliable factor extraction 
method (Costello & Osbourne, 2005; Fabrigar et al., 1999). Finally, the number 
of factors retained was determined using two different approaches to ensure an 
unambiguous factor solution. Although, eigenvalues >1 are often the preferred 
option for many researchers, the current research utilised this approach in 
combination with the more robust scree test as recommended in current EFA 
guidelines (Costello & Osbourne, 2005). 
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7.2.3 PHASE 3 
 
As is the case in Phase 2, a limitation of Phase 3 may be the representativeness 
of the sample. Alongside the potential for patients to be excluded due to 
ineligibility, this study had a very low response rate among patients under the 
care of the ARAS nursing team. There is no clear reason why this may have 
occurred; however, a number of factors may have played a part. First, the 
patients were approached by an invitation letter, which was sent according to 
database records. It was evident from the high number of letters returned by 
Royal Mail (6%) that many of the addresses were out of date. Second, it is 
possible that many patients simply did not wish to engage in COPD-related 
research, particularly if they believed that their lung disease was not a key 
factor in their lives (i.e., other co-morbidities or life events may be prioritised 
above COPD). Third, there is the potential that the stigma associated with 
mental health resulted in patients not wishing to participate in anxiety-related 
research (Woodall et al. 2010). Finally, although the author was informed that 
several of the patients on the records had deceased since the database had last 
been updated, it is possible that other records were out of date. 
 
Although a number of factors may have influenced the response rate of this 
study to some extent, such a low response rate indicates that the vast majority 
of potential participants were not motivated to take part in this research. One 
additional factor that may have played a key role in participant motivation is 
the fact that there was no incentive to participate in this research. Anecdotal 
evidence collected by the author suggests that patients who had participated in 
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previous research had received compensation for their time and effort (usually 
money or vouchers). Providing incentives has been shown to increase 
participant rates in research (e.g., Onwuegbuzie, 2000) and may also enhance 
the care and attention that participants put into their responses (Weems et al., 
2003). Therefore, the lack of incentives in the current research might help to 
explain the extremely low response rates in this particular sample of patients. It 
is worth noting, however, that incentives may have a detrimental effect in terms 
of biasing responses and should be carefully selected to avoid the possibility of 
any coercion (Grant & Sugarman, 2004; Weems et al., 2003) 
 
In contrast to the ARAS sample, the response rate for participants from PR 
classes was considerably higher. Once again, it is unclear why this might be. 
Some insight is provided by Halding and colleagues (2010) who suggest that 
patients attending PR have a collective sense of belonging that promotes 
engagement, confidence and motivation. This feeling of belonging may have 
influenced patients’ willingness to participate in this research. Alternatively, the 
presence of clinicians during the PR classes may have had a ‘white coat’ effect 
on patients which motivated them to participate (Merz et al., 2002).  
 
An important strength of Phase 3 was that psychiatric assessment was 
undertaken by a blinded researcher to establish caseness of clinical anxiety 
disorders. This allowed the screening properties of the AIR to be compared 
against the gold standard diagnostic criteria. Other studies have established the 
clinical utility of screening tools through comparison with other screeners or 
scales. For example, Kunik et al. (2007) explored the screening properties of the 
307 
 
shortened PRIME-MD by comparing it with the BAI. Although this allows large 
samples to be incorporated (due to reduced participant burden), the validity of 
this approach is severely limited by not incorporating a criterion diagnostic 
measures such as DSM-IV-TR and ICD-10. Although the current research 
incorporated a psychiatric diagnosis, it also utilised the PHQ as a second 
criterion measure. Although the PHQ has excellent documented accuracy as a 
screener for anxiety disorders (Diez-Quevedo, 2001; Löwe et al., 2003), the 
dependence upon this scale for establishing aspects of the AIR’s clinical utility 
may be seen as a potential limitation of the current research. 
 
Whilst there is some disagreement as to which of the two psychiatric 
classification systems is preferred, the DSM-IV (which is virtually identical to 
DSM-IV-TR in terms of anxiety classification) appears to be more popular 
among mental health professionals worldwide (Andrews et al., 1999). This may 
be because although the ICD-10 is a global classification system, the DSM-IV-TR 
(originating in the USA) contains additional detail which is unlikely to ever be 
included in future versions of the ICD (American Psychological Association, 
2009). Thus, the current research is strengthened by the potential for findings 
to be interpreted globally.  
 
One drawback of incorporating a psychiatric assessment is that it is often 
difficult to recruit large numbers of participants. In the current study, less than 
half of the original participants underwent psychiatric interview. Many 
participants did not originally consent to psychiatric assessment and others 
withdrew their consent. Although it is not possible to determine the reasons for 
308 
 
this low consent rate, it is possible that this is due to the stigma associated with 
mental health and psychiatry in particular, and the time-consuming nature of 
the interview. There is also the potential for a sampling bias to be present as 
participants were consenting volunteers rather than chosen randomly from a 
wider sample. In other words, those patients who experienced anxiety may 
have been more likely to volunteer to participant compared to patients without 
anxiety. 
 
As has been discussed in the previous section (7.3.2), sample size can have a 
important effect on the accuracy of CFA procedures. The sample of 56 patients 
recruited in Phase 3 is significantly lower than the recommended minimum of 
100 participants endorsed by Kline (2005) to ensure reliable CFA can be 
undertaken. However, the ratio of participants to parameters (5.6:1) exceeded 
that recommended by Worthington & Whittaker (2006), indicating that the 
sample may be adequate for CFA. As discussed previously in relation to the 
validity of the AIR (section 7.2.3.1), a larger sample would have also had the 
advantage of minimising the negative influence that sample size can have on 
some indices of fit (Miles & Shevlin, 1998). 
 
Although there was little missing data for outcome measures in Phase 3, data 
were unavailable for several participant characteristics. In particular, there 
were missing data for both smoking status and smoking history, which may 
limit findings relating to the relationship between smoking and anxiety. Several 
participants did not wish to disclose whether they were current smokers and 
some individuals could not recall, or chose not to disclose their pack year 
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smoking history. It is therefore likely that the smoking status and smoking 
history figures may be distorted, presumably underreporting both the 
prevalence and history of smokers.  
 
A potential limitation and ethical issue of this study is that in completing a self-
report measure which asks questions about anxiety, there is the possibility that 
this induced anxiety by prompting memory of past anxiety experiences. 
Although, it was not possible to assess objectively whether the AIR induced 
anxiety in the current study, a recent study by Humphris et al. (2006) exploring 
whether completing a questionnaire about dental anxiety increased anxiety 
found that completion of the questionnaire had no significant effect on state 
anxiety. The potential for the AIR to induce anxiety in this study was 
acknowledged as a potential ethical issue. However, anecdotal evidence 
indicated that patients reported that taking part in both interviews and scale 
completion was a positive experience and that they appreciated the opportunity 
to have their voice heard, even if it involved recalling difficult experiences. This 
finding is supported by work by Humphris and co-workers who assert that the 
completion of an anxiety scale can decrease the state anxiety of dental patients 
(Humphris et al. 2006). In order to minimise the distress experienced by the 
participants in the current study, it was emphasised that clinical support (via a 
GP or recruiting clinician) would be available after the study should any 
participants wish to discuss distress experiences as a result of the study. 
 
Although this research incorporated several well-validated outcome measures 
including the CAT, PHQ and MRADL, it is possible that these somewhat brief 
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self-report scales do not provide a comprehensive assessment of these 
outcomes. Of particular note is the use of the CAT which contains only eight 
items relating to HRQoL. In comparison, a more traditional scale such as the 
SGRQ contains 76 HRQoL-related items covering three domains: symptoms, 
activity and impacts. Although the CAT is certainly less detailed than the SGRQ, 
recent data indicate that the CAT is a comparable outcome measure. Ringbaek 
et al. (2012) report a high correlation (r=0.73) between the two measures 
within a sample of 90 COPD patients who were undergoing PR. The authors also 
suggest that in addition to speed of completion, the CAT is considerably easier 
to complete. A total of 86.5% of patients in Ringbaek and colleague’s study 
needed assistance in completing the SGRQ compared to 53.9% completing the 
CAT.  
 
A further limitation of the current research is although the reliability and 
validity of the AIR were examined in detail, the sensitivity to change was not 
explored and therefore it is difficult to recommend the AIR for use as an a 
temporal measure in research settings. Recommendations regarding future 
research (section 8.4) discuss this in more detail. 
 
In light of the cognitive theories of anxiety discussed in Chapter 2, it is 
important to note that this thesis did not explore the coping styles of the 
research participants. As Lewis et al. (2012) assert, if defensiveness measures 
are not included when measuring self-reported anxiety, then repressors will be 
classed as low-anxious and defensive high-anxious patients will be classed as 
high-anxious. This may have important implications on both the identification 
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of patients with clinically relevant levels of anxiety and the subsequent 
management of these individuals. 
 
In terms of detecting PD and GAD, it is possible that patients who might be 
classed as repressors were not identified in this study as high anxious, as their 
self-reported anxiety may not reflect their true anxiety (i.e., they might be 
considered self-deceivers). Previous research suggests that the repressive 
coping style is common in patients with chronic disease, particularly among 
chronic respiratory diseases such as asthma and lung cancer (Prasertsri et al. 
2011, Gonzalez-Freire et al. 2010). Approximately one quarter of patients in the 
studies by Gonzalez-Freire and colleagues (2010) and Prasertsri and co-
workers (2011) were identified as repressors. Although no studies have 
specifically explored the prevalence of the repressive coping style in patients 
with COPD, the clinical and demographic characteristics of Prasertsri and co-
workers’ sample of patients with lung cancer were very similar to those found 
in the current research. This would suggest that approximately 25% of patients 
in the current research might be considered as repressors and thus not 
identified as highly anxious by the AIR. It is important to remember that these 
individuals are not merely in denial, but genuinely believe that they are well-
adjusted, self-controlled, and content and are likely to seem healthy on all self-
report measures of mental health (Weinberger, 1990).  
 
Although it is difficult to predict whether patients in this study were repressors 
(high-defensiveness and low anxiety), the narratives of interview respondents 
suggest that at least one group of research participants had high levels of self-
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reported anxiety. Myers and Brewin (1996) assert that when asked of their life 
experiences, repressors are likely to report more positive events and fewer 
negative events as compared to nonrepressors. The narratives of the patients 
interviewed (during the qualitative phase of research) in the current study 
indicate that they were highly anxious and so might be classed as defensive high 
anxious (high anxiety and high defensiveness) or high anxious (Weinberger, 
Schwartz and Davidson, 1979). Other studies have found high proportions of 
defensive high anxious patients in populations of patients with chronic lower 
back pain and chronic fatigue syndrome (Creswell & Chalder, 2001; Lewis et al. 
2012). It is important to consider that this research utilised three separate 
samples of patients, so the experiences of the qualitative sample do not indicate 
that all patients in sample 2 and 3 were high anxious. Conversely, it is possible 
that Phase 2 and 3 samples had a low number of repressors due to self-selection 
bias. For example, Lewis and colleagues (2012) suggest that the low numbers of 
repressors identified in their study of patients with lower back pain may be 
because repressors are less willing to seek or accept treatment and participate 
in research studies. In order to fully understand the coping styles of individuals 
with COPD, a validated instrument such as the Marlow-Crowne Social 
Desirability Scale (Crowne & Marlowe, 1964) could be utilised, and this may be 
an important future direction of further research.  
 
Identification of coping style within COPD populations may have important 
implications for the management of anxiety as this will enable clinicians to put 
in place appropriate management strategies for patient with this condition. 
Repressors, for example, may respond better to interventions where they 
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maintain a greater feeling of personal control; they may also be reluctant to 
engage in psychotherapy (Phipps & Steele, 2002). This group may also be more 
comfortable with low levels of information about their disease, as higher levels 
result in information overload and increases in arousal. However, high anxious 
individuals may do better when provided with additional information that may 
act to lower an individual’s anxiety (Shaw et al. 1986). Thus, the management of 
PD or GAD in patients with a repressive coping style may need to be tailored 
accordingly. In the context of the vigilance-avoidance theory which explains the 
cognitive biases around the repressive coping style, it is understood that 
avoidance maintains anxiety as it prevents an individual from evaluating non-
threatening stimuli sufficiently to perceive that they are not threatening and 
therefore exposure to the stimulus is insufficient to allow habituation 
(Derakshan et al. 2007). To support modification of these cognitive biases, there 
is growing evidence to support the role of cognitive therapies such as CBT in 
supporting changes in attentional biases and ameliorating anxiety (Derryberry 
& Reed, 2002; Amir & Taylor, 2011 ; Emmelkamp, 2012). 
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Chapter 8 : SUMMARY, IMPLICATIONS, 
RECOMMENDATIONS AND CONCLUSIONS 
 
8.1 INTRODUCTION 
 
The following chapter presents a summary of findings from the current 
research. Following this, the potential implications of these findings for both 
theory and practice are explored and, finally, considerations for further study 
will be discussed. 
 
8.2 SUMMARY 
 
The overall aim of this research was to develop a non-somatic anxiety scale that 
can be used as a marker of anxiety in patients with COPD and screen for the two 
common anxiety disorders of GAD and PD. In the following section a summary 
of the research findings related to the objectives outlined in section 1.6 are 
presented. 
 
8.2.1 FINDINGS RELATING TO RESEARCH OBJECTIVES 
 
1. The experiences of anxiety in patients with COPD were explored in a 
sample of 14 participants. The findings suggest that symptoms of anxiety 
were often confused with those of COPD and the side-effects of 
medications. The findings also enhanced the understanding of the 
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relationships between anxiety and breathlessness. Patient-reported non-
somatic symptoms of anxiety were compared with those in extant scales 
and 16 novel items were developed that reflected symptoms of GAD and 
PD.   
2. ERG involvement guided the development of a draft version of the AIR, 
which had a clear layout, a consistent response set and good face 
validity. 88 patients with COPD completed the draft AIR and six items 
were excluded from the draft AIR based on strict item and factor 
analytical procedures. The final version of the AIR had a clear single-
factor structure and excellent internal consistency.  
3. The AIR was completed by a clinical sample of outpatients with COPD. 
The findings suggest that the scale has excellent temporal stability and 
provide further evidence to support the excellent internal consistency of 
the AIR. The findings demonstrated that the AIR had high convergent 
validity with the HADS-A and was able to discriminate between patients 
with and without clinical anxiety disorders, thus demonstrating known-
groups validity. CFA indicated that the best model fit for the AIR was a 
two-factor solution of panic and general anxiety. Three scores can be 
calculated from the AIR: a panic score (5 items) and a general anxiety 
score (5 items) and a total anxiety score. The AIR was able to accurately 
screen for anxiety disorders and sub-scores for the AIR-panic and AIR-
general anxiety demonstrated clinical utility in screening specifically for 
PD and GAD.  
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8.3 IMPLICATIONS OF FINDINGS 
 
Findings from this research have implications for both theory and practice. 
First, these findings demonstrate that the AIR is a short, user-friendly, reliable 
and valid self-report scale that can be used as a marker of anxiety and to screen 
for anxiety disorders in patients with COPD. Existing COPD guidelines have 
highlighted the need for a disease-specific anxiety scale which can be used to 
screen for anxiety disorders in clinical practice. The AIR is the first COPD-
specific scale which reliably assess markers of anxiety in this population and 
can therefore be recommended for use in clinical and research settings.  
 
Co-morbid anxiety disorders are common in patients with COPD, yet are often 
unrecognised. The AIR demonstrates excellent screening properties for the two 
most common anxiety disorders in COPD patients: PD and GAD. Although 
further research is needed to confirm the screening utility of the AIR for specific 
PD and GAD diagnoses, there is promising evidence that the sub-scores of the 
scale may be used as additional screening indicators for the two anxiety 
disorders. In the meantime, it is recommended that the total score of the AIR be 
used to screen for the presence of clinical anxiety disorders. 
 
This study also compared the screening properties of the AIR and the HADS-A 
(the most commonly used anxiety scale in COPD research and practice) and 
found that the AIR had superior clinical utility for the detection of anxiety 
disorders, particularly PD. Therefore, these findings indicate that the AIR is a 
valid (and potentially superior) alternative to the HADS-A for screening anxiety 
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in this population. Unlike other extant scales used in patients with COPD, the 
AIR was also designed in collaboration with patients and clinicians, which 
supports its validity and usability in COPD-related clinical practice. The 
development and validation of the AIR is in accord with recommendations set 
out by the FDA (2009) which ensure that the scale is also a valid outcome 
measure for research settings. Its brief completion time and clear format 
further support the efficacy of the AIR for use in patients with COPD. 
 
Findings from the qualitative phase of this research compliment current 
understanding on co-morbid anxiety in patients with COPD. Alongside exploring 
the most relevant anxiety symptoms, which helped to conceptualise the AIR, the 
accounts of patients with COPD also provide the first in-depth insight into their 
experiences of anxiety. These findings provide additional evidence for the 
confusion that exists between somatic symptoms of anxiety and those of COPD. 
In particular, the accounts of these participants suggest that symptoms such as 
breathlessness, palpitations and shaking are readily confused by patients who 
may consider them to be side-effects of their medication or merely a symptom 
of their COPD. This has implications on practice and suggests that a focus on 
non-somatic symptoms might be employed by clinicians. It also indicates that 
patients may require additional time and support in learning to recognise and 
manage their own symptoms.  
 
These findings also add to the emerging theory exploring the relationships 
between dyspnoea and anxiety. Specifically, they suggest that anxiety might be 
both a sign and a cause of breathlessness in patients with COPD. This may have 
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implications on the management of co-morbid anxiety in this patient group. For 
example, strategies for managing PD, PA or sub-clinical symptoms of panic may 
be more suitable if focussed on the cognitive aspects of panic, rather than 
primarily addressing the somatic symptoms. This provides support for the role 
of CBT and other psychotherapies in managing anxiety in patients with COPD. 
In addition, these qualitative data also indicate that self-management, 
particularly self-talk strategies are simple yet effective cognitive management 
techniques that, to date, have received little focus within the COPD literature.  
 
8.4 RECOMMENDATIONS FOR FUTURE RESEARCH 
 
Scale development is an on-going process, particularly in terms of establishing 
validity, which depends on the collation of empirical evidence to support the 
conceptual model of a scale (Robins et al., 2001). At the heart of these 
recommendations is the need to continue to establish and confirm the 
psychometric properties of the AIR in clinical populations. Therefore, this 
research should be replicated across samples with different ages, cultures and 
geographical locations, with a particular focus upon the utility of the AIR to 
screen for clinical anxiety disorders. The importance of a gold standard 
criterion measure cannot be underestimated and future studies should 
endeavour to incorporate psychiatric diagnoses in larger patient samples. The 
inconsistent cut-off scores found in the current research indicate that further 
research is warranted to establish the optimal cut-off score in patients with 
COPD. Furthermore, in light of the cognitive theories of anxiety discussed 
previously, particularly the role of defensiveness in confounding the 
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identification of patients with high anxiety, it is recommended that a validated 
social desirability measure such as the Marlow-Crowne Social Desirability Scale 
(Crowne & Marlowe, 1964) is use in future studies to fully understand the 
prevalence of repressive coping within this population. This may give an 
important insight into the true ability of the AIR to detect anxiety in patients 
with COPD. 
 
Further research should also be undertaken to translate and validate the AIR in 
languages other than English. The ability to be transferable across different 
languages is an important goal for an outcome measure, particularly in research 
settings. However, Keedwell and Snaith (1996) highlight that this may prove to 
be problematic for anxiety scales as anxiety has a variety of meanings and 
manifestations in different languages. For example, although the terms derive 
from a common root, the English term anxiety does not cover the same 
semantic space as the French anxiété or the Spanish ansiedad. The French term 
angoisse or anguish emphasises physical symptoms, whilst the German term 
angst is a more general emotion (Keedwell and Snaith, 1996).  
 
Another recommendation is to examine and re-affirm other aspects of the AIR’s 
reliability and validity. In particular, further research should be conducted to 
investigate the sensitivity of the AIR to detect change in anxiety severity. This 
can be achieved by incorporating the AIR as an outcome measure for anxiety in 
trials exploring management interventions for anxiety (e.g., PR programmes or 
CBT interventions). This will also allow the minimum important difference of 
the AIR to be calculated by comparing scores over time between treatment 
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groups. This would enhance the utility of the AIR as an outcome measure for 
clinical research (FDA, 2009). Also, the inconsistency in factor structure 
between Phase 2 and 3 in the current research emphasises the need for further 
CFA on larger clinical samples. The influence of sample size on fit indices means 
that it is difficult to reach firm conclusions on the factor structure of the AIR 
based on findings from the current research. Therefore, further analyses in 
samples of >200 patients are worthy of endeavour. Finally, although this 
research established the temporal stability of the AIR over a 2-week period, 
future studies should be undertaken to explore the test-retest reliability of the 
scale at longer intervals e.g., 3 months, 6 months and 1 year. 
 
Future research might also explore the utility and psychometric properties of 
the AIR in other clinical populations. Although the AIR was designed specifically 
for patients with COPD, the conceptual non-somatic nature of the scale indicates 
potential validity in patients with other respiratory diseases and even in other 
chronic diseases that are characterised by an emphasis on somatic symptoms. 
Of course, instruments developed for a particular population may not be valid 
in other groups and therefore specific validation, including item analysis and FA 
is recommended (FDA, 2009; National Institute of Health, 1998). 
 
Additional studies are also needed to confirm the variability of scores on the 
AIR. The findings in the current research indicate that scores might be 
positively skewed, which questions the ability of the AIR to distinguish between 
patients with a full spectrum of anxiety severities. Therefore, studies should be 
undertaken to establish whether this is the case in larger representative 
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samples. If non-normal distribution of scores remains, then the response set of 
the AIR may need to be widened or the wording amended. Studies that 
incorporate cognitive debriefing may aid in this process. 
 
Finally, further research should be undertaken to explore the experiences of 
patients with COPD and anxiety in more detail. In particular, qualitative studies 
exploring the experiences of patients with diagnosed anxiety disorders are 
worthy of endeavour. It is likely that patients with PD, GAD and other anxiety 
disorders have differing experiences and these accounts may aid our 
understanding of why patients with COPD experience an elevated prevalence of 
anxiety and help to optimise or tailor the management of these co-morbid 
disorders. 
 
8.5 CONCLUSIONS 
 
This thesis aimed to develop a novel non-somatic anxiety scale which can be 
used as a marker of anxiety and screener for anxiety disorders in patients with 
COPD. The results of the current research affirm the need for a non-somatic 
scale and provide strong evidence for the reliability and validity of the newly 
developed AIR.  
 
The qualitative findings from this research provide the first insight into the 
unique experience of anxiety from the COPD patients perspective and suggest 
that anxiety and panic can have a profound impact emotionally. The accounts of 
participants with COPD confirm that somatic symptoms of anxiety are readily 
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confused with those of the disease and medications and support the 
conceptualisation of a non-somatic anxiety scale. The findings also aid our 
understanding of the complex relationships between breathlessness and 
anxiety and highlight patients’ anxiety management strategies.  
 
The three phases of research presented in this thesis demonstrate the robust 
development of the novel AIR scale which has been specifically designed for use 
in patients with COPD. The synthesis of emic and etic perspectives and the 
integration of an ERG ensure that the AIR has good content and face validity, 
and is user-friendly by being quick to complete, easy to understand and 
complete, and meaningful to patients. 
 
Although further validation is certainly required, these findings indicate that 
the AIR is able to accurately identify patients with clinical anxiety disorders, 
particularly the two common disorders of PD and GAD. The scale appears to 
perform as well, if not better, than the HADS-A as a screening tool for anxiety in 
patients with COPD and the high sensitivity values indicate that the AIR is able 
to maximise false positives and minimise false negatives. 
 
The AIR can be recommended as an accurate and user-friendly screening tool 
for anxiety disorders and reliable and valid outcome measure for anxiety 
severity in patients with COPD. Future study should further explore the 
reliability and validity of the AIR in larger representative samples and confirm 
the ability of the AIR to specifically screen for GAD and PD. Further assessment 
of coping styles within this population is also warranted in order to fully 
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understand the accuracy of this tool in identifying anxiety using self-report. 
Finally, the utility of the AIR in other chronic respiratory populations and 
possibly other chronic diseases is also worthy of further research.  
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Appendix 3: Example GP information sheet 
                                
                                         
                                                                          
Department of Health Professions 
Manchester Metropolitan University 
Elizabeth Gaskell Campus 
Hathersage Road 
Manchester 
M13 0JA 
Tel: 0161 247 2610 
Thomas.g.willgoss@stu.mmu.ac.uk 
 
Date:  
 
GP INFORMATION SHEET- Phase 2 Item analysis (Version 1.1 20/04/10)  
 
Title of project: The development and validation of a novel scale to screen and 
measure anxiety syndrome in patients with Chronic Obstructive Pulmonary 
Disease (COPD) 
 
Principal researcher:   Thomas Willgoss 
Your patient:    
Address:    
D.O.B:     
 
Has participated in the above research study. 
 
This research has three objectives:  
1. To investigate how people with COPD experience anxiety and anxious 
symptoms. 
2. To design a new COPD-specific anxiety scale which is simple to administer 
and complete. 
3. To test if the new scale is reliable and valid. 
Participants completed a draft version of the COPD anxiety scale so that statistical 
analysis can be carried out to refine scale items.  
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We wish to inform you that your patient has completed the draft scale on [date]. 
Although the scale is yet to be validated, their responses indicate that they may 
have been experiencing high levels of anxiety. Your patient has consented for us to 
contact you if we feel that their anxiety levels are high. We hope that this 
information will enable you to explore this matter as you see fit. 
 
If you have any questions about this research please do not hesitate to contact me. 
 
Kind regards, 
 
 
 
Thomas Willgoss 
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Appendix 4: Phase 1.2 Patient Information Sheet 
 
 
 
Department of Health Professions 
Manchester Metropolitan University 
Elizabeth Gaskell Campus 
Hathersage Road 
Manchester 
M13 0JA 
 
Date: 
PARTICIPANT INFORMATION SHEET- Phase 1 Interviews (Version 2.1, 02/06/10) 
Title of project: The development and validation of a novel scale to screen and 
measure anxiety syndrome in patients with Chronic Obstructive Pulmonary 
Disease (COPD) 
You are being invited to take part in a research study which is being undertaken as 
part of the researcher’s PhD. Before you decide if you wish to take part it is 
important for you to understand why the research is being done and what it will 
involve. Please read this information carefully and talk it through with someone 
else if you wish. Also, please ask us if there is anything that is not clear or if you 
would like more information. 
Thank you for reading this. 
What is the purpose of the study? 
Previous research has found that patients with COPD often suffer with anxiety 
which can lead to a poorer quality of life and increased hospital visits. However, we 
do not know how common this problem is. One of the problems with detecting 
anxiety in patients with COPD is that at the moment, there is no specific tool to 
identify anxiety. Existing scales are designed for the general public and therefore do 
not take into account how people with COPD experience anxiety. Research has 
found that many of the symptoms of anxiety overlap with symptoms of COPD, 
making it difficult to tell the difference between the two. We are planning to design 
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a new scale to detect anxiety specifically in patients with COPD. This scale will be 
easy to complete and may help medical professionals identify people who may 
need further help. 
This research has three objectives:  
4. To investigate how people with COPD experience anxiety. 
5. To design a new anxiety scale which is simple to complete. 
6. To test if the new scale is reliable and valid. 
 
Why have I been chosen? 
We are hoping to recruit and interview 18 patients in Greater Manchester with 
COPD who can help us to understand what it is like to live with COPD and anxiety. 
Do I have to take part? 
No, taking part is voluntary. This is a research study and it is up to you to decide 
whether or not to take part. If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. If you take part you 
are still free to stop at any time without giving reason. This will not affect the 
standard of care you receive. 
What will happen to me if I take part? 
You will be asked to complete an interview (taking up to 1 hour) at a time that is 
convenient to you. Interviews will be carried out at your home but another location 
can be arranged if you wish e.g. at the hospital. The interview will be conducted by 
the researcher (Thomas Willgoss) who will ask questions about your experiences of 
living with COPD and anxiety. The interviewer will also ask you a few questions 
about you and your lifestyle (age, if you are a smoker etc). You are free to stop the 
interview and recording at any time you wish. Also, if you feel out of breath during 
the interview and require a break then this can be arranged. If you become very 
breathless then the interviewer will be happy to return on another occasion and 
resume the interview. We will also ask you to complete the Hospital Anxiety and 
Depression Scale (HADS) so that we can record your level of anxiety. If we are 
concerned about your anxiety then we will contact your GP with your permission.  
The interview will be recorded on a digital recorder and then transcribed by the 
interviewer. Your name or details will not be used on the transcripts and a code will 
be allocated to your interview which is only known to the interviewer. Therefore, all 
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responses will be anonymous. We will send you a copy of the transcript for your 
reference and to see if you wish to add any further comments. 
What do I have to do? 
If you agree to take part in this research then please let the researcher or the 
physiotherapist know. The researcher will then contact you to arrange the 
interview. On the day of the interview the researcher will ask you to sign an 
informed consent form (a copy is included) before starting the interview. 
What are the possible disadvantages of taking part? 
We do not feel that there are any disadvantages in taking part in this study. 
What are the possible benefits of taking part? 
There are no direct benefits in participating in this study. However, information we 
get from this study may be used to improve the treatment of people with COPD. 
What if something goes wrong? 
If you are harmed by taking part in this research project there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, then 
you may have grounds for legal action but you may have to pay for it. The normal 
National Health Service complaints service will still be available to you. If you are 
worried about any aspect of this study, you should ask to speak to the researcher or 
academic supervisor who will do their best to answer your questions (please see 
contact details at end of sheet). If you are still unhappy and wish to complain 
formally, you can do this through the NHS Complaints Procedure. Details can be 
obtained from the hospital. 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will 
be kept strictly confidential. Any information about you which leaves the university 
or hospital will have your name and address removed so that you cannot be 
recognised from it. All interview data will be allocated a code and will be kept in a 
locked room which can only be accessed by people directly involved in the 
research. The data collected will only be used for this research project. The data will 
be kept for 5 years and after this time it will be deleted. 
Will my GP be informed? 
Your GP will be told that you are taking part in this research. Also, if we are 
concerned about your anxiety then we will contact your GP with your permission. 
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What will happen if I don’t wish to carry on with the study? 
You are free to stop taking part in the study at any time. Any information and 
interview data collected up to this point will be destroyed and your personal details 
removed from the study. This will not affect the care that you receive. 
What will happen to the results of the research study? 
The findings of the study will be used by the researcher in order to gain a PhD. It is 
also hoped that findings from the research will be published in scientific journals. 
We will let you know of any work which is published as a result of this research. 
However, you will not be identified in any report or publication. 
Who is organising and funding the research? 
The Manchester Metropolitan University Research Institute of Health, Psychology 
and Social Care. 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed and given a favourable opinion by Lancaster Research 
Ethics Committee. This study has also been reviewed and given a favourable 
opinion by the Manchester Metropolitan University Research Ethics Committee. 
Who do I contact for further information? 
For general information about research, specific information about this research 
project, or if you are unhappy with the study, please contact: 
Thomas Willgoss 
Department of Health Professions 
Manchester Metropolitan University 
Elizabeth Gaskell Campus 
Hathersage Road 
Manchester 
M13 0JA 
Tel: 07951727110 
Email: Thomas.g.willgoss@stu.mmu.ac.uk 
 
If you wish to make a complaint about this research, please contact the academic 
supervisor: 
Dr Abebaw Yohannes 
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Department of Health Professions 
Manchester Metropolitan University 
Elizabeth Gaskell Campus 
Hathersage Road 
Manchester 
M13 0JA 
Tel: 0161 247 2943 
Email: A.Yohannes@mmu.ac.uk 
 
For advice as to whether you should participate in this research please contact: 
 
Janet Severn 
Pulmonary Rehabilitation Co-ordinator 
Royal Oldham Hospital 
Oldham 
OL1 2JH 
Email: Janet.Severn@pat.nhs.uk 
 
Or 
 
Paula Baker 
Acute Physiotherapy Site Lead 
Royal Oldham Hospital 
Oldham 
OL1 2JH 
Tel: 0161 656 1377 
Email: Paula.Baker@pat.nhs.uk 
 
You will be given a copy of this information sheet and a signed consent form to 
keep. 
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Appendix 5: Phase 1.2 Informed consent form 
 
 
 
Centre Number:  
Participant Identification Number for this trial: 
 
CONSENT FORM Phase 1 Interviews (Version 2.1 02/06/10) 
 
Title of Project: The development and validation of a novel scale to screen and measure anxiety 
syndrome in patients with Chronic Obstructive Pulmonary Disease (COPD) 
 
Name of researcher: Thomas Willgoss 
Please initial box 
 
1. I confirm that I have read and understand the information sheet dated………..  
for the above study.  I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily.   
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my medical care or legal rights 
being affected. 
 
3. I agree to my interview being recorded, transcribed and used for research 
purposes. I understand that any data is confidential and anonymous. I agree to 
the researcher sending me a copy of the interview transcript for my reference. 
 
 
4. I agree to my GP being informed of my participation in the study. 
 
5. I agree to take part in the above study. 
 
 
_______________________  ____________        ____________________ 
Name of participant  Date   Signature 
 
_______________________ ____________         ____________________ 
Name of person               Date   Signature 
taking consent 
 
 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical notes.  
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Appendix 6: Hospital Anxiety and Depression Scale (HADS; Zigmund & 
Snaith, 1983) 
 
This questionnaire will help your physician to know how you are feeling. Read every sentence. Place 
an “X” on the answer that best describes how you have been feeling during the LAST WEEK. You do 
not have to think too much to answer. In this questionnaire, spontaneous answers are more 
important. 
 
1 I feel tense or wound up: 
Most of the time 
A lot of the time 
Time to time, occasionally 
Not at all 
 
2  I still enjoy the things I used to enjoy: 
Definitely as much 
Not quite so much 
Only a little  
Hardly at all           
 
3  I get a sort of frightened feeling as if 
something awful is about to happen: 
Very definitely and quite badly 
Yes, but not too badly 
A little, but it doesn’t worry me 
Not at all   
 
4  I can laugh and see the funny side of 
things: 
As much as I always could 
Not quite so much now 
Definitely not so much now 
Not at all             
 
5  Worrying thoughts go through my mind: 
A great deal of the time               
A lot of the time 
From time to time bur not too often 
Only occasionally 
 
6  I feel cheerful 
Not at all 
Not often 
Sometimes 
Most of the time 
 
 
7  I can sit at ease and feel relaxed: 
Definitely 
Usually 
Not often 
Not at all 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8  I feel as if I am slowed down: 
Nearly all the time 
Very often 
Sometimes 
Not at all 
 
9  I get a sort of frightened feeling like 
“butterflies” in the stomach: 
Not at all 
Occasionally 
Quite often 
Very often  
 
10  I have lost interest in my appearance: 
Definitely 
I don’t take so much care as I should 
I may not take quite as much care  
I take just as much care as ever 
 
11 I feel restless as if I have to be on the 
move: 
Very much indeed 
Quite a lot 
Not very much 
Not at all 
 
12 I look forward with enjoyment to things: 
As much as I ever did 
Rather less than I used to  
Definitely less than I used to  
Hardly at all 
 
13 I get sudden feelings of panic: 
Very often indeed 
Quite often 
Not very often 
Not at all 
 
14 I can enjoy a good book or radio or TV 
programme: 
Often 
Sometimes 
Not often 
Very seldom 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
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Appendix 7: Draft 16-item Anxiety Inventory for Respiratory disease (AIR) 
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Appendix 8: Phase 2 Participant Information Sheet 
 
 
 
 
Department of Health Professions 
Manchester Metropolitan University 
Elizabeth Gaskell Campus 
Hathersage Road 
Manchester 
M13 0JA 
 
Date: 
PARTICIPANT INFORMATION SHEET- Phase 2 Item analysis (Version 2.1, 02/06/10) 
Title of project: The development and validation of a novel scale to screen and 
measure anxiety syndrome in patients with Chronic Obstructive Pulmonary 
Disease (COPD) 
You are being invited to take part in a research study which is being undertaken as 
part of the researcher’s PhD. Before you decide if you wish to take part it is 
important for you to understand why the research is being done and what it will 
involve. Please read this information carefully and talk it through with someone 
else if you wish. Also, please ask us if there is anything that is not clear or if you 
would like more information. 
Thank you for reading this. 
What is the purpose of the study? 
Previous research has found that patients with COPD often suffer with anxiety 
which can lead to a poorer quality of life and an increased hospital visits. However, 
we do not know how common this problem is. One of the problems with detecting 
anxiety in patients with COPD is that at the moment, there is no specific tool to 
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identify anxiety. Existing scales are designed for the general public and therefore do 
not take into account how people with COPD experience anxiety. Research has 
found that many of the symptoms of anxiety overlap with symptoms of COPD, 
making it difficult to tell the difference between the two. We are planning to design 
a new scale to detect anxiety specifically in patients with COPD. This scale will be 
easy to complete and may help medical professionals identify people who may 
need further help. 
This research has three objectives:  
1. To investigate how people with COPD experience anxiety. 
2. To design a new anxiety scale which is simple to complete. 
3. To test if the new scale is reliable and valid. 
Why have I been chosen? 
We are hoping to recruit 200 patients in Greater Manchester with COPD who can 
help us to develop a new scale to measure symptoms of anxiety. 
Do I have to take part? 
No, taking part is voluntary. This is a research study and it is up to you to decide 
whether or not to take part. If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. If you take part you 
are still free to stop at any time without giving reason. This will not affect the 
standard of care you receive. 
What will happen to me if I take part? 
You will be asked to fill out a questionnaire (taking about 2-3 minutes) during your 
visit. The questionnaire will ask you about any anxiety symptoms that you may have 
had in recent weeks.  
What do I have to do? 
The researcher will contact you and answer any questions you might have. You can 
then decide whether or not you would like to take part in this research. If you do 
decide to take part then we will ask you to sign an informed consent form (a copy is 
included) before giving you the questionnaire. 
What are the possible disadvantages of taking part? 
We do not feel that there are any disadvantages in taking part in this study. 
What are the possible benefits of taking part? 
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There are no direct benefits in participating in this study. However, information we 
get from this study may be used to improve the treatment of people with COPD. 
What if something goes wrong? 
If you are harmed by taking part in this research project there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, then 
you may have grounds for legal action but you may have to pay for it. The normal 
National Health Service complaints service will still be available to you. If you are 
worried about any aspect of this study, you should ask to speak to the researcher or 
academic supervisor who will do their best to answer your questions (please see 
contact details at end of sheet). If you are still unhappy and wish to complain 
formally, you can do this through the NHS Complaints Procedure. Details are 
available from the hospital. 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will 
be kept strictly confidential. Any information about you which leaves the university 
or hospital will have your name and address removed so that you cannot be 
recognised from it. To ensure anonymity, all information you provide will be 
allocated a code. All data will be kept in a locked room which can only be accessed 
by people directly involved in the research. The data collected will only be used for 
this research project. The data will be kept for 5 years and after this time it will be 
deleted. 
Will my GP be informed? 
Your GP will be told that you are taking part in this research. Also, if we are 
concerned about your anxiety then we will contact your GP with your permission. 
What will happen if I don’t wish to carry on with the study? 
You are free to stop taking part in the study at any time. Any information collected 
up to this point will be destroyed and your personal details removed from the 
study. This will not affect the care that you receive. 
What will happen to the results of the research study? 
The findings of the study will be used by the researcher in order to gain a PhD. It is 
also hoped that findings from the research will be published in scientific journals. 
We will let you know of any work which is published as a result of this research. 
However, you will not be identified in any report or publication. 
Who is organising and funding the research? 
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The Manchester Metropolitan University Research Institute of Health, Psychology 
and Social Care. 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed and given a favourable opinion by Lancaster Research 
Ethics Committee. This study has also been reviewed and given a favourable 
opinion by the Manchester Metropolitan University Research Ethics Committee. 
Who do I contact for further information? 
For general information about research, specific information about this research 
project, or if you are unhappy with the study, please contact: 
 
Thomas Willgoss 
Department of Health Professions 
Manchester Metropolitan University 
Elizabeth Gaskell Campus 
Hathersage Road 
Manchester 
M13 0JA 
Tel: 07951727110 
Email: Thomas.g.willgoss@stu.mmu.ac.uk 
 
If you wish to make a complaint about this research, please contact the academic 
supervisor: 
 
Dr Abebaw Yohannes 
Department of Health Professions 
Manchester Metropolitan University 
Elizabeth Gaskell Campus 
Hathersage Road 
Manchester 
M13 0JA 
Tel: 0161 247 2943 
Email: A.Yohannes@mmu.ac.uk 
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Appendix 9: Phase 2 Informed Consent Form 
 
 
 
 
 
Centre Number:  
Patient Identification Number for this study: 
 
CONSENT FORM Phase 2 Item analysis (Version 2.1 02/06/10) 
 
Title of Project: The development and validation of a novel scale to screen and measure 
anxiety syndrome in patients with Chronic Obstructive Pulmonary Disease (COPD) 
 
Name of researcher: Thomas Willgoss 
Please initial box 
 
1. I confirm that I understand the purpose of this study.  I have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily.   
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical 
care or legal rights being affected. 
 
3. I agree to my GP being informed of my participation in the study. 
 
4. I agree to take part in the above study. 
 
______________________  ____________        ____________________ 
Name of participant   Date   Signature 
 
 
_______________________ ____________         ____________________ 
Name of person   Date   Signature 
taking consent 
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Appendix 10: Anxiety Inventory for Respiratory disease (AIR) 
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Appendix 11: Phase 2 Patient feedback form 
AIR (Anxiety Inventory for Respiratory disease) Feedback 
 
1) Please rate with a score of 0-10 how easy the scale was to complete.  
0= not easy at all 
10= extremely easy 
 
2) Please rate with a score of 0-10 how helpful you feel the scale is in reflecting 
your experiences of anxiety. 
0= not helpful at all 
10= extremely helpful 
 
3) Please rate with a score of 0-10 how easy the scale was to understand. 
0= not easy at all 
10= extremely easy 
 
Please use the space below to add any additional comments you might have about 
the scale and your experience of completing it. 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
________________________________ 
 
Thank you for your feedback. 
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Appendix 12: Phase 3 Participant Information Sheet 
 
 
 
Department of Health Professions 
Manchester Metropolitan University 
Elizabeth Gaskell Campus 
Hathersage Road 
Manchester 
M13 0JA 
 
Date: 
PARTICIPANT INFORMATION SHEET- Phase 3 Scale validation (Version 3.2, 
17/03/11) 
Title of project: The development and validation of a novel scale to screen and 
measure anxiety syndrome in patients with Chronic Obstructive Pulmonary 
Disease (COPD) 
You are being invited to take part in a research study which is being undertaken as 
part of the researcher’s PhD. Before you decide if you wish to take part, it is 
important for you to understand why the research is being done and what it will 
involve. Please read this following information carefully and talk it through with 
someone else if you wish. Also, please ask us if there is anything that is not clear or 
if you would like more information. 
Thank you for reading this. 
What is the purpose of the study? 
Previous research has found that patients with COPD often suffer with anxiety 
which can lead to a poorer quality of life and an increased hospital visits. However, 
we do not know how common this problem is. One of the problems with detecting 
anxiety in patients with COPD is that at the moment, there is no specific tool to 
identify anxiety. Existing scales are designed for the general public and therefore do 
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not take into account how people with COPD experience anxiety. Research has 
found that many of the symptoms of anxiety overlap with symptoms of COPD, 
making it difficult to tell the difference between the two. We are planning to design 
a new scale to detect anxiety, specifically in patients with COPD. This scale will be 
easy to complete and may help medical professionals identify people who may 
need further help. 
This research has three objectives:  
1. To investigate how people with COPD experience anxiety. 
2. To design a new anxiety scale which is simple to complete. 
3. To test if the new scale is reliable and valid. 
 
Why have I been chosen? 
We are hoping to recruit 100 patients in Greater Manchester with COPD who can 
help us to test the validity and reliability of a new scale to measure symptoms of 
anxiety. 
Do I have to take part? 
No, taking part is voluntary. This is a research study and it is up to you to decide 
whether or not to take part. If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. If you take part you 
are still free to stop at any time without giving reason. This will not affect the 
standard of care you receive. 
What will happen to me if I take part? 
You will be asked to complete four short questionnaires (taking about 10 minutes). 
The questionnaires will ask about your quality of life, day-to-day activities and 
about any feelings of anxiety that you may have had in recent weeks. The 
interviewer will also ask you a few questions about you and your lifestyle (age, if 
you are a smoker etc). After 2 weeks we will send you a copy of the questionnaires 
for you to complete again. If there has been a change in your health during this 
time then you do not need to complete the questionnaires. 
In addition, we will be selecting a number of participants at random to undergo a 
short clinical interview (taking about 20 minutes) during which a clinician will ask 
you more detailed questions about any symptoms of anxiety that you may have 
experienced. Participation in this part of the research is completely optional and 
you are free to withdraw at any time without giving reason. 
403 
 
What do I have to do? 
The researcher will contact you and answer any questions you might have. You can 
then decide whether or not you would like to take part in this research. If you do 
decide to take part then we will ask you to sign an informed consent form (a copy is 
included) before giving you the questionnaires. 
What are the possible disadvantages of taking part? 
We do not feel that there are any disadvantages in taking part in this study. 
What are the possible benefits of taking part? 
There are no direct benefits in participating in this study. However, information we 
get from this study may be used to improve the treatment of people with COPD. 
What if something goes wrong? 
If you are harmed by taking part in this research project there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, then 
you may have grounds for legal action but you may have to pay for it. The normal 
National Health Service complaints service will still be available to you. If you are 
worried about any aspect of this study, you should ask to speak to the researcher or 
academic supervisor who will do their best to answer your questions (please see 
contact details at end of sheet). If you are still unhappy and wish to complain 
formally, you can do this through the NHS Complaints Procedure. Details are 
available from the hospital. 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will 
be kept strictly confidential. Any information about you which leaves the university 
or hospital will have your name and address removed so that you cannot be 
recognised from it. To ensure anonymity, all information you provide will be 
allocated a code. All data will be kept in a locked room which can only be accessed 
by people directly involved in the research. The data collected will only be used for 
this research project. The data will be kept for 5 years and after this time it will be 
deleted. 
Will my GP be informed? 
Your GP will be told that you are taking part in this research. Also, if we are 
concerned about your anxiety then we will contact your GP with your permission. 
What will happen if I don’t wish to carry on with the study? 
404 
 
You are free to stop taking part in the study at any time. Any information collected 
up to this point will be destroyed and your personal details removed from the 
study.  This will not affect the care that you receive. 
What will happen to the results of the research study? 
The findings of the study will be used by the researcher in order to gain a PhD. It is 
also hoped that findings from the research will be published in scientific journals. 
We will let you know of any work which is published as a result of this research. 
However, you will not be identified in any report or publication. 
Who is organising and funding the research? 
The Manchester Metropolitan University Research Institute of Health, Psychology 
and Social Care. 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed and given a favourable opinion by Lancaster Research 
Ethics Committee. This study has also been reviewed and given a favourable 
opinion by the Manchester Metropolitan University Research Ethics Committee. 
Who do I contact for further information? 
For general information about research, specific information about this research 
project, or if you are unhappy with the study, please contact: 
 
Thomas Willgoss 
Department of Health Professions 
Manchester Metropolitan University 
Elizabeth Gaskell Campus 
Hathersage Road 
Manchester 
M13 0JA 
Tel: 07951727110 
Email: Thomas.g.willgoss@stu.mmu.ac.uk 
 
If you wish to make a complaint about this research, please contact the academic 
supervisor: 
 
Dr Abebaw Yohannes 
Department of Health Professions 
Manchester Metropolitan University 
Elizabeth Gaskell Campus 
Hathersage Road 
405 
 
Manchester 
M13 0JA 
Tel: 0161 247 2943 
Email: A.Yohannes@mmu.ac.uk 
For advice as to whether you should participate in this research please contact: 
Catharine Thomas 
Consultant Physiotherapist 
Tameside Hospital NHS Foundation Trust 
Fountain Street 
Ashton-under-Lyne 
OL6 9RW 
Tel: 0161 922 4123 
Email: Catharine.Thomas@tgh.nhs.uk 
 
 
 
 
You will be given a copy of this information sheet and a signed consent form to 
keep. 
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Appendix 13: Phase 3 Informed Consent Form 
 
 
 
 
Centre Number:  
Patient Identification Number for this trial: 
 
CONSENT FORM Phase 3 Scale validation (Version 3.2 17/03/11) 
 
Title of Project: The development and validation of a novel scale to screen and measure anxiety 
syndrome in patients with Chronic Obstructive Pulmonary Disease (COPD) 
 
Name of researcher: Thomas Willgoss 
Please initial box 
 
6. I confirm that I have read and understand the information sheet dated………..  
for the above study.  I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily.   
 
7. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my medical care or legal rights 
being affected. 
 
8. I agree to my GP being informed of my participation in the study. 
 
 
9. I agree to participate in a clinical interview if selected (optional). 
 
 
10. I agree to take part in the above study. 
 
_______________________  ____________        ____________________ 
Name of participant  Date   Signature 
 
_______________________ ____________         ____________________ 
Name of person               Date   Signature 
taking consent 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical notes.  
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Appendix 14: Phase 3 Invitation letter 
 
 
 
Acute Respiratory Support Service  
(COPD support team) 
 
Invitation to participate in a research project 
Would you like to be involved in a short research project that might 
help improve the treatment of COPD in the future? 
We are inviting people with COPD to complete several brief questionnaires. 
The questionnaires have been designed to explore how COPD affects 
everyday life and to help us understand the relationships between COPD 
and anxiety. 
The questionnaires will take approximately 10 minutes to complete. 
Before you decide whether you wish to take part, please read the enclosed 
information sheet.  
If you are interested in participating, please complete the slip below and 
return in the pre-paid envelope. Alternatively, you can contact the researcher 
directly on: 
Telephone:  07951727110  
or 
  0161 247 2610 
Email: Thomas.g.willgoss@stu.mmu.ac.uk 
Thank you for your cooperation. 
--------------------------------------------------------------------------------------------------- 
Please fill in your details and return in the pre-paid envelope to Thomas 
Willgoss, Manchester Metropolitan University, Department of Health 
Professions, Elizabeth Gaskell Campus, Hathersage Road, Manchester, 
M13 0JA. 
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Name_____________________________________Gender___________ 
D.O.B._____________ 
Adress_______________________________________________________
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________ 
Telephone 
number______________________________________________________ 
Email________________________________________________________ 
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Appendix 15: Phase 3 follow-up letter 
 
 
 
 
Dear [Name], 
Re. Anxiety questionnaire for COPD research project 
Thank you for participating in this research project on [Date]. Your help in filling out 
the questionnaires is much appreciated. 
As discussed during my visit, I am sending out the same questionnaires to be 
completed a second time. This will allow us to test how reliable the questionnaires 
are over time. Therefore, please could you complete the enclosed questionnaires 
and return them in the pre-paid envelope. 
In addition, it is important for us to know if there has been any major change in 
your health status (e.g., an exacerbation of COPD), so please tick one of the boxes 
below: 
 
There has not been a major change in my health status since [Date]  
  
 
There has been a major change in my health status since [Date]   
  
 
Once you have completed the questionnaires, please return them along with this 
letter in the envelope provided. 
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If you have any questions regarding this research or the completion of the 
questionnaires then please do not hesitate to contact me: 
Telephone: 0161 247 2610 or 07951727110 
Email: Thomas.g.willgoss@stu.mmu.ac.uk 
Thank you for your time and participation. 
Yours sincerely, 
 
Thomas Willgoss (Principal Investigator) 
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Appendix 16: COPD Assessment Tool (CAT; Jones et al., 2009) 
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Appendix 17: Manchester Respiratory Activities of Daily Living 
questionnaire (MRADL; Yohannes et al., 2000b) 
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Appendix 18: Patient Health Questionnaire anxiety and panic screening 
sections (Spitzer et al., 1999) 
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Appendix 19: MINI Sections A, E-I and O (major depressive and anxiety 
disorders) 
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417 
 
 
418 
 
 
419 
 
 
420 
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Appendix 20: Tests of normality for Phase 3 data using Shapiro-Wilk test 
 P value 
Age 
 
0.158 
Height 
 
0.074 
FEV1 
 
<0.001* 
FVC 
 
<0.001* 
FEV1/FVC 
 
0.168 
FEV1 predicted 
 
0.071 
FVC predicted 
 
0.033* 
FEV1 % predicted 
 
0.035* 
Pack years 
 
0.157 
AIR score 
Initial data 
Follow-up data 
 
 
0.003* 
0.001* 
CAT score 
Initial data 
Follow-up data 
 
 
0.095 
0.867 
HADS-A score 
Initial data 
Follow-up data 
 
 
0.053 
0.021* 
HADS-D score 
Initial data 
Follow-up data 
 
 
0.397 
0.089 
HADS-T score 
Initial data 
Follow-up data 
 
 
0.068 
0.389 
MRADL score 
Initial data 
Follow-up data 
 
0.002* 
<0.001* 
*Statistically significant at <0.05 indicating non-normal distribution for data 
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Appendix 21: Journal article published in International Journal of 
Geriatric Psychiatry 
 
Yohannes, A.M., Willgoss, T.G., Baldwin, R.C., Connolly, M.J. (2010) Depression 
and anxiety in chronic heart failure and chronic obstructive pulmonary disease: 
prevalence, relevance, clinical implications and management principles. 
International Journal of Geriatric Psychiatry, Vol. 12, no. 12, pp. 1209-1221. 
 
Abstract 
 
Objective 
To review evidence regarding the prevalence, causation, clinical implications, 
aspects of healthcare utilisation and management of depression and anxiety in 
chronic heart failure and chronic obstructive pulmonary disease. 
 
Design 
A critical review of the literature (1994–2009). 
 
Findings 
The prevalence of depression and anxiety is high in both chronic obstructive 
pulmonary disease (8–80% depression; 6–74% anxiety) and chronic heart 
failure (10–60% depression; 11–45% anxiety). However, methodological 
weaknesses and the use of a wide range of diagnostic tools make it difficult to 
reach a consensus on rates of prevalence. Co-morbid depression and anxiety are 
associated with increased mortality and healthcare utilisation and impact upon 
functional disability and quality of life. Despite these negative consequences, the 
identification and management of co-morbid depression and anxiety in these 
two diseases is inadequate. There is some evidence for the positive role of 
pulmonary/cardiac rehabilitation and psychotherapy in the management of co-
morbid depression and anxiety, however, this is insufficient to guide 
recommendations. 
 
Conclusions 
The high prevalence and associated increase in morbidity and mortality justifies 
future research regarding the management of anxiety and depression in both 
chronic heart failure and chronic obstructive pulmonary disease. Current 
evidence suggests that multi-faceted interventions such as pulmonary and 
cardiac rehabilitation may offer the best hope for improving outcomes for 
depression and anxiety.  
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Appendix 22: Journal article published in Nursing Times 
 
Willgoss, T.G., Yohannes, A.M., Goldbart, J., Fatoye, F. (2011) COPD and anxiety: 
its impact on patients’ lives. Nursing Times, Vol. 107, no. 15-16, pp. 16-19. 
 
Abstract 
 
Background 
Anxiety is a common comorbidity in people with chronic obstructive pulmonary 
disease (COPD) but its identification and management are often insufficient. 
 
Aim 
To explore the experience of living with and managing comorbid anxiety and 
COPD from a patient’s perspective. 
 
Method 
The study followed a qualitative approach. In-depth interviews were carried out 
with 14 patients who had COPD. 
 
Results 
Participants believed anxiety had a significant impact on their quality of life. It 
made them feel isolated and caused them to avoid social occasions and daily 
activities. Identifying anxiety was a challenge because of the overlap in the 
symptoms of anxiety and those of COPD, and the side-effects of medication. 
 
Conclusion 
Nurses can play a vital role in screening and managing anxiety, and educating 
people in strategies to prevent episodes of panic. 
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Appendix 23: Abstract presented at the British Thoracic Society Winter 
Meeting, London, UK. December 2011, and published in Thorax: 
 
Willgoss, T.G., Yohannes, A.M., Goldbart, J., Fatoye, F. (2011) The development of 
a novel scale to screen and measure anxiety in patients with chronic obstructive 
pulmonary disease (COPD). Thorax, Vol. 66, Suppl. 4, pp. A44. 
 
Introduction and objectives 
Comorbid anxiety disorders are common among patients with COPD, affecting 
up to half of all patients. Comorbid anxiety may be a significant factor in 
predicting quality of life, yet recognition and management of anxiety among this 
patient group is poor. Screening and measuring symptoms of anxiety can be 
challenging due to the overlap of physical symptoms and the lack of a validated 
disease-specific tool. The aim of this study was to develop a novel non-somatic 
scale (Anxiety Inventory for Respiratory disease (AIR)) to screen and measure 
anxiety in patients with COPD. 
 
Methods 
This study utilised a multi-method approach to scale development 
incorporating both qualitative and quantitative methods. An item pool was 
developed using in-depth interviews with COPD patients who exhibited 
symptoms of anxiety (n=14), and the analysis of existing anxiety scales. Item 
wording, content and user-friendliness were checked by an expert reference 
group (ERG) that included clinicians and patients. This item pool was tested on 
a group of COPD patients (n=82). The Likert-type scale has four consistent 
responses to statements (Not at all, Occasionally, Frequently, Almost all of the 
time) that are scored from 0 to 3. Item and factor analysis were carried out to 
aid in item reduction and to explore the factor structure. 
 
Results 
Sixteen items were selected for inclusion following development and approval 
from the ERG. Items were retained based on item-to-total correlation analysis 
and a-if-item-deleted analysis. One item was discarded as it had a corrected-
item-to-total correlation of <0.55. Exploratory principal component factor 
analysis was performed and three further items were removed due to low 
communalities (<0.50). Secondary analysis indicated a single factor solution 
accounting for 66.67% of total variance with a mean communality of 0.67. The 
12-item scale had a mean total score of 13.55 (SD=9.41, range=0-36), and a 
Cronbach’s α of 0.95. 
 
Conclusions 
The AIR is a short self-report non-somatic anxiety scale with a clear uni-
dimensional factor solution and high internal consistency. Additional studies 
are warranted to further explore the scale’s psychometric properties and to 
establish its ability to screen for clinical anxiety disorders. 
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Appendix 24: Journal article published in Respiratory Care 
 
Willgoss, T.G., Yohannes, A.M. (2012) Anxiety disorders in patients with chronic 
obstructive pulmonary disease: a systematic review. Respiratory Care, [Epub 
ahead of print] 
 
Abstract 
 
Background   
There is a growing interest in the role of co-morbid anxiety in patients with 
chronic obstructive pulmonary disease (COPD). Co-morbid anxiety has major 
impact on physical functioning, health-related quality of life and healthcare 
utilisation. However, the prevalence of clinical anxiety, particularly specific 
anxiety diagnoses, in patients with COPD remains unclear. 
 
Objective 
We performed a systematic review of studies which report the prevalence of 
clinical anxiety and specific anxiety disorders in patients with COPD. 
 
Method 
We searched for articles in CINAHL, EMBASE, Medline and PsycINFO from 1966 
to 31st January 2012, with a focus upon studies which utilised a clinical 
interview for a robust psychiatric diagnosis.  
 
Results 
Of 410 studies identified, ten met the inclusion criteria for review. Studies had 
small or modest sample sizes (n=20-204) and included mainly male 
participants (71% male). The prevalence of clinical anxiety ranged from 10-
55% amongst inpatients and 13-46% amongst outpatients. Reported 
prevalence of specific anxiety disorders ranged considerably and included 
generalised anxiety disorder (6-33%), panic disorder (with and without 
agoraphobia) (0-41%), specific phobia (10-27%) and social phobia (5-11%). 
Women were significantly more likely to have a clinical anxiety disorder, 
particularly specific phobia and panic disorder.  
 
Conclusions 
There is a high prevalence of a clinical anxiety in patients with COPD. Social 
phobia and specific phobia appear to be particularly prevalent, yet they have 
received little attention within existing literature. Further research into 
effective management and screening for clinical anxiety disorders is warranted. 
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Appendix 25: Journal article published in Heart & Lung 
 
Findings also presented at:  
 
Chartered Society of Physiotherapists Annual Conference, Liverpool, September 
2011  
 
IV World Asthma and COPD Forum, Paris, April 2011. 
 
Abstract 
 
Willgoss, T.G., Yohannes, A.M., Goldbart, J., Fatoye, F. (2012) 'Everything was 
Spiralling out of Control': Experiences of Anxiety in People With Chronic 
Obstructive Pulmonary Disease. Heart & Lung, Vol. 41, no. 6, pp. 562-571. 
 
Objective  
This study sought to elicit and describe the first hand experiences of anxiety in 
community patients with stable chronic obstructive pulmonary disease (COPD). 
 
Background 
Anxiety is common among patients with COPD. Clinical anxiety affects up to two 
thirds of patients leading to reduced quality of life and physical functioning.  
There has been little research exploring the experiences of anxiety in patients 
with COPD, particularly in individuals with stable respiratory symptoms.  
 
Methods 
We interviewed 14 community patients with stable COPD and self-reported 
symptoms of anxiety. Data were analysed using thematic network analysis to 
develop basic, organising and global themes.  
 
Results 
Patients reported intense thoughts of fear, hopelessness and confusion that 
were associated with the anxiety and panic attacks. Self-management was 
important, particularly self-talk coping strategies. 
 
Conclusions 
Unmanaged anxiety appears to be particularly distressing for patients with 
COPD. Taught self-management strategies can be highly effective in preventing 
and managing anxiety. 
 
